The following law book contains the current "unofficial" pharmacy law and rules.

* The permanent statutes of the Kansas State Board of Pharmacy have been codified in Chapter 65 of the Kansas Statutes Annotated. The KSAs are published by the Secretary of State’s Office and contain all of the “official” agency laws. Chapter 68 of the Kansas Administrative Rules (KARS) contains all "official" agency rules and is published by the Secretary of State’s Office.

This document is provided as a courtesy by the Kansas State Board of Pharmacy; and is not a final, exhaustive source that stringently defines and delineates all professional responsibilities. The inclusion or omission of any statute or regulation within this work cannot be used as a basis for comparison on compliance with applicable local, state, or federal laws/regulations. No part of this document shall constitute legal advice or offer relief from any professional duty.

Guide for selected content in this document:

* * * Indicates redacted text that may not be of interest to pharmacists.
KSA Kansas Statutes Annotated
KAR Kansas Administrative Rules (Regulations)
# Table of Contents

Table of Contents ........................................................................................................................... 3

I. Pharmacy Practice Act - Statutes ................................................................................................. 25

65-1601. .............................................................................................................................................. 25
65-1602. .............................................................................................................................................. 25
65-1603. .............................................................................................................................................. 25
65-1604. .............................................................................................................................................. 25
65-1605, 65-1606. ............................................................................................................................... 25
65-1607. .............................................................................................................................................. 25
65-1608. .............................................................................................................................................. 25
65-1609. .............................................................................................................................................. 25
65-1610, 65-1611. ............................................................................................................................... 25
65-1612, 65-1613. ............................................................................................................................... 25
65-1614. .............................................................................................................................................. 25
65-1615, 65-1616. ............................................................................................................................... 25
65-1617 .............................................................................................................................................. 25
65-1618. .............................................................................................................................................. 25
65-1619. .............................................................................................................................................. 25
65-1620. .............................................................................................................................................. 25
65-1621 to 65-1623. ............................................................................................................................ 25
65-1624. .............................................................................................................................................. 25
65-1625. Title of act. ............................................................................................................................ 26
65-1626. Definitions............................................................................................................................ 26
65-1626a. Practice of pharmacy defined; persons engaged as pharmacists. .................................... 34
65-1626b. ............................................................................................................................................. 35
65-1626c. ............................................................................................................................................. 35
65-1626d. ............................................................................................................................................. 35
65-1627. Grounds for revocation, suspension, placement in probationary status, denial, temporary suspension or temporary limitation of license for pharmacist, permit for retail dealer or registration
for pharmacy, manufacturer, distributor or logistics provider; emergency proceedings, procedure.

65-1627a. Same; jurisdiction of board; petition, who may file; stipulation, order based thereon....39
65-1627b. Same; direction by board to file petition or to prosecute.................................39
65-1627c. Same; form of petition, rules.............................................................................40
65-1627d. ..............................................................................................................................40
65-1627e. ..............................................................................................................................40
65-1627f. Same; powers of board; term of suspension, probation or revocation; hearing; orders. .40
65-1627g. ..............................................................................................................................40
65-1627h. Costs of proceedings..............................................................................................41
65-1627i. ..............................................................................................................................41
65-1627j. Subpoenas..................................................................................................................41
65-1627k. Certain records of board of pharmacy confidential; exceptions. .........................41
65-1627l. Conditions of probation or disciplinary action; compliance inspections and audits; payment of costs..............................................................................................42
65-1628. Order; judicial review. ..............................................................................................42
65-1628a. Review bond. ...........................................................................................................43
65-1628b. ..............................................................................................................................43
65-1629. Inspection of drugs by board; samples; analyses; publication of results..................43
65-1630. Rules and regulations. ..............................................................................................43
65-1631. Licensure required of pharmacists; qualification of applicants; application for licensure by examination; reciprocal licensure; fees; applicants from schools outside the United States...........43
65-1632. Renewal of license; fee; denial; conditions; continuing education; inactive status license; reinstatement after nonrenewal; penalty fee. .................................................................................45
65-1633. Change of address of pharmacist. ...........................................................................46
65-1634. Responsibility for quality of drugs sold; adulteration or mislabeling unlawful.........47
65-1635. Dispensing and administering of drugs by duly licensed practitioners, nurses and other persons.................................................................47
65-1635a. Administration of vaccine; education and reporting requirements; delegation of authority prohibited; "pharmacist" defined.................................................................47
65-1636. Sale of drugs limited to pharmacies; violations; exceptions. .................................48
65-1637. Prescription orders; requirements; compounding, filling and refilling of prescriptions; refusal to fill; brand exchange; interchangeable biological products............................................48
65-1637a. Institutional drug rooms; supervision and record-keeping; rules and regulations.......... 51
65-1637b. Transmission of prescription drug orders; filling and refilling of prescriptions; refusal to fill; brand exchange................................................................. 51
65-1637c. Pharmacist required to be in charge of pharmacy; filling of certain prescriptions; refusal to fill; brand exchange. [See Revisor's Note] ................................................................. 52
65-1637d. Automated prescription drug dispensing systems; pharmacist required to supervise; rules and regulations................................................................. 52
65-1637e. Compounding of drugs and distribution of compounded drugs; rules and regulations... 52
65-1638. Sale of drugs and poisons by registered pharmacist.................................................. 52
65-1639. ........................................................................................................................................ 52
65-1640. Act not applicable to manufacture or to certain sales of poisons................................. 53
65-1641. Display of pharmacist license; when unlawful. ......................................................... 53
65-1642. Equipment of pharmacy; records of prescription orders; medication profile record system; electronic transmission of prescription drug orders ................................................. 53
65-1643. Registration or permit required; pharmacies, manufacturers, wholesale distributors, third-party logistics providers, automated dispensing systems, auctions, sales, distribution or dispensing of samples, retailers, institutional drug rooms, veterinary medical teaching hospital pharmacies; certain acts declared unlawful................................................................. 54
65-1643a. ........................................................................................................................................ 56
65-1643b. ........................................................................................................................................ 56
65-1643c. ........................................................................................................................................ 56
65-1643d. Registration as manufacturer or virtual manufacturer; information required in application; criteria for grant or denial; state board of pharmacy rules and regulations; inspections; registration of manufacturer or virtual manufacturer licensed or registered in another state........ 56
65-1644. Duplicate licenses, registrations and permits; fees.................................................... 58
65-1645. Applications for registrations and permits; renewals; forms; establishment of fees; establishment of retail dealer classes; display of registrations and permits; expiration dates; penalty fee for renewal after lapse; proration of fees .................................................................................. 58
65-1646. Violations of act or rules and regulations; penalty; revocation or suspension of registration or permit; notice and hearing. ............................................................................. 60
65-1647. Repeated violations of act or rules and regulations may be enjoined........................... 60
65-1648. Distribution and control of prescription medications by a medical care facility pharmacy, health department, indigent health care clinic, federally qualified health center or family planning clinic; maintenance and use of emergency medication kit by adult care home; rules and regulations. ........................................................................................................... 61
65-1649. Invalidity of part

65-1650. Regulation of advertising of prescription-only drugs; exceptions and exclusions

65-1651. Sections part of and supplemental to pharmacy act

65-1651a. Study of regulating wholesale prescription drug distributors; pedigrees for prescription drugs

65-1652. Immunity from liability in civil actions for reporting, communicating and investigating certain information concerning alleged malpractice incidents and other information; conditions

65-1653. References to registered pharmacists deemed to apply to licensed pharmacists

65-1654. Privileged communications

65-1655. Information required of applicant for registration to distribute at wholesale any drugs; factors in reviewing qualifications of applicants; denial of application if not in public interest; qualifications of personnel; inspection by the board; rules and regulations

65-1655a. Information required of applicant for registration as third-party logistics provider; factors for reviewing qualifications of applicants; denial of application if not in public interest; inspection by the board; rules and regulations

65-1655b. Information required of applicant for registration as outsourcing facility; factors for reviewing qualifications of applicants; denial of application if not in public interest; inspection by the board; rules and regulations

65-1656. Filling transferred prescriptions; exceptions and conditions; common electronic prescription files authorized; rules and regulations

65-1657. Nonresident pharmacy registration; information required; civil fine; regulatory requirements; drug product selection rules; interstate delivery guidelines; disciplinary action; pharmacies prohibited from advertising unless registered; penalties for violations; injunctive relief; rules and regulations

65-1658. Civil fines for violations

65-1659. Pharmacies authorized to place certain drugs with home health agencies and hospices; protocols for drug handling and storage; review and inspection; definitions

65-1660. Dialysates, devices or drugs designated by board for treatment of persons with chronic kidney failure; inapplicability of pharmacy act; rules and regulations

65-1661

65-1662. Veterinary medical teaching hospital pharmacy; distribution and control of prescription-only drugs; pharmacist in charge

65-1663. Registration of pharmacy technicians; applications; registration fee; qualifications for registration; expiration and renewal of registration; grounds for denial of application or registration; revocation, suspension or limitation of registration; responsibilities of pharmacists and pharmacies; rules and regulations
65-1693 Same; penalties............................................................................................................................... 88
65-1694 Same; veterinary prescription monitoring program task force; study; members; report. .. 88
65-1695. Continuous quality improvement program; purpose; confidential peer review documents; rules and regulations. ......................................................................................................................... 89
65-1696. State board of pharmacy; fingerprinting and criminal history .................................................. 90
65-1697 to 65-16,100. Reserved. .................................................................................................................. 91
65-16, 101. Statewide electronic logging system for sale of methamphetamine precursor act; definitions. .................................................................................................................................................... 91
65-16, 102. Same; maintenance of program by the board of pharmacy; rules and regulations; waiver and liability. ........................................................................................................................................................................... 91
65-16,103. Same; no cost charged to pharmacies; funding of program ................................................ 92
65-16,104. Same; confidential information; authorized access to data in the log ................................. 93
65-16,105. Same; another agency or private vendor as contractor; maintenance and destruction of records; educational program for pharmacies; annual report ................................................................. 93
65-16, 106. Same; rules and regulations. ................................................................................................. 94
65-16, 107. Same; penalties....................................................................................................................... 94
65-16, 108. Same; short title .................................................................................................................... 94
65-16,121. Pharmacy audit integrity act .................................................................................................. 94
65-16,122. Same; definitions .................................................................................................................. 94
65-16,123. Same; procedural requirements. .......................................................................................... 95
65-16,124. Same; audit reports; recoupment and repayment of funds; access to audit information ........................................................................................................................................................................... 95
65-16,125. Same; final report; availability ............................................................................................... 96
65-16,126. Same; application of the act ................................................................................................. 96
65-16,127. Emergency opioid antagonists; dispensing, storing and administering; duties of the state board of pharmacy and first responder agencies; rules and regulations ......................................................... 96
65-16,128. Electronic transmission of prescription orders required, when; exceptions ........................ 98
65-16,129. Pharmacists authorized to administer drugs, when; exceptions .......................................... 99
65-16,130. Telepharmacy; definitions; requirements for operation; state board of pharmacy rules and regulations ........................................................................................................................................................................... 99
65-16,131. Pharmacist-initiated therapy for certain health conditions; requirements; establishment of protocols by collaborative drug therapy management advisory committee; penalty for violation. ........................................................................................................................................................................... 100
II. Pharmacy Practice Act - Regulations .................................................................................................. 101
68-2-16 Branches, agents and pickup stations. .......................................................... 109
68-2-17 ..................................................................................................................... 109
68-2-18 ..................................................................................................................... 109
68-2-19 Prescription copies. ....................................................................................... 109
68-2-20 Pharmacist's function in filling a prescription. ............................................. 109
68-2-21 ..................................................................................................................... 111
68-2-22 Electronic transmission of a prescription. ..................................................... 111
68-2-23 Notification to board; disciplinary action. .................................................... 112

Article 3: Retail Dealers Permit ............................................................................. 113
68-3-1 ..................................................................................................................... 113
68-3-2 ..................................................................................................................... 113
68-3-3 and 68-3-4 ................................................................................................. 113
68-3-5 Retail dealer permit required. ..................................................................... 113
68-3-6 Minimum required information for permit. ................................................. 113

Article 4: Manufacturers ....................................................................................... 114
68-4-1 to 68-4-4 ..................................................................................................... 114
68-4-5 ..................................................................................................................... 114

Article 5: General Rules ....................................................................................... 114
68-5-1 Definitions. ................................................................................................. 114
68-5-2 ..................................................................................................................... 114
68-5-3 to 68-5-5 ..................................................................................................... 114
68-5-6 ..................................................................................................................... 114
68-5-7 and 68-5-8 ................................................................................................. 114
68-5-9 ..................................................................................................................... 115
68-5-10 ................................................................................................................. 115
68-5-11 ................................................................................................................. 115
68-5-12 and 68-5-13 ............................................................................................. 115
68-5-14 .................................................................................................................. 115
68-5-15 Training of pharmacy technicians. ............................................................. 115
68-5-16 Ratio of pharmacy technicians to pharmacists. ....................................... 116
68-5-17 Pharmacy technicians; certification examination; request for extension. 116
68-5-18 Pharmacy technicians; continuing education ........................................... 117
Article 6: Poisons, Additions and Deletions to Statutory List ............................................................... 119
  68-6-1 ................................................................................................................................................ 119
  68-6-2 ................................................................................................................................................ 119

Article 7: Miscellaneous Provisions....................................................................................................... 119
  68-7-1 to 68-7-6 ................................................................................................................................ 119
  68-7-7 ................................................................................................................................................ 119
  68-7-8 Records. ................................................................................................................................. 119
  68-7-9 ................................................................................................................................................ 121
  68-7-10. Pharmacy based drug distribution systems in long-term care facilities; emergency
          medication kits................................................................................................................................. 121
  68-7-11. Medical care facility pharmacy .......................................................................................... 123
  68-7-12 Responsibility of pharmacist-in-charge in other than a medical care facility pharmacy .... 125
  68-7-12a Nonresident pharmacies .................................................................................................. 125
  68-7-12b Incident reports ................................................................................................................ 127
  68-7-13 Pharmacist in charge of more than one location. ................................................................. 127
  68-7-14 Prescription labels. .............................................................................................................. 127
  68-7-15 Prepackaging of drugs or devices in advance of immediate need. .................................... 128
  68-7-16 Labels of drugs or devices packaged in advance of immediate need. ............................. 129
  68-7-17 .............................................................................................................................................. 129
  68-7-18 Health departments and private not-for-profit family planning clinics. ............................ 129
  68-7-19 Transfer of a refillable prescription between pharmacies ................................................. 131
  68-7-20 Shared services ................................................................................................................... 133
  68-7-21 Institutional Drug Rooms .................................................................................................... 134
  68-7-22. Collaborative Practice ......................................................................................................... 135
  68-7-23. Dispensing and administration of emergency opioid antagonist without a prescription. 137
  68-7-25 Notification to board; pharmacist, pharmacy technician, or pharmacy intern. ............... 138

Article 8: Advertising ............................................................................................................................. 139
  68-8-1 Advertising. ............................................................................................................................ 139

Article 9: Automated Prescription Systems .......................................................................................... 139
  68-9-1 Electronic data storage systems ............................................................................................ 139
  68-9-2 Automated drug delivery systems in pharmacies ............................................................... 140
  68-9-3 Automated drug delivery system to supply drugs for administration in certain facilities. ... 141
Article 10: Nuclear Pharmacies

68-10-1 to 68-10-3 Not in active use.

Article 11: Fees

68-11-1 Fees for examination and licensure as a pharmacist.
68-11-2 Fees for premises registrations and permits.
68-11-3. Fees for registration as a pharmacy technician or pharmacy intern.

Article 12: Resale of Medication

68-12-1 Not in active use.
68-12-2 Resale of dispensed prescription drugs.

Article 13: Compounding Sterile and Nonsterile Preparations

68-13-1 REVOKED

68-13-2 Definitions.
68-13-3 Nonsterile Preparations.
68-13-4 Sterile Preparations.

Article 14: Wholesale Distributors

68-14-1 REVOKED

68-14-2 Definitions.
68-14-3 REVOKED

68-14-4 Minimum required information for registration.
68-14-5 Personnel.
68-14-6 Violations and penalties.

68-14-7 Wholesale distributors; minimum requirements for the storage and handling of prescription-only drugs and devices and for the establishment and maintenance of prescription-only drug and device distribution records.

68-14-7a. Third-party logistics providers; minimum requirements for operation and maintenance of records.
68-14-7b. Outsourcing facilities; minimum requirements for operation and maintenance of records.

68-14-8 Wholesale distributors transaction.

Article 15: Nonprescription Wholesale Distributors

68-15-1 Nonprescription wholesale distributors.
68-15-2 Nonprescription wholesale distributor registration required.
68-15-4 Minimum requirements for storage.
Article 18.—Utilization of Unused Medications ................................................................. 176
  68-18-1. Transferring unused medications ................................................................. 176
  68-18-2. Accepting unused medications ................................................................. 176
  68-18-3. Recall of unused medications ................................................................. 177

Article 19.—Continuous Quality Assurance Programs ............................................... 178
  68-19-1. Minimum program requirements ............................................................. 178

Article 22. — Electronic Supervision of Medical Care Facility’s Pharmacy Personnel ... 179
  68-22-1. Definitions ................................................................................................. 179
  68-22-2. Application for approval to utilize electronic supervision ......................... 179
  68-22-3. Prior approval and training required .......................................................... 179
  68-22-4. Electronic supervision ............................................................................. 180
  68-22-5. Minimum operating requirements ............................................................ 180

III. Controlled Substances Act - Statutes ................................................................. 182
  65-4101. Definitions ................................................................................................. 182
  65-4101a. ................................................................................................................. 186
  65-4101b. ................................................................................................................. 186
  65-4101c. ................................................................................................................. 186
  65-4101d. ................................................................................................................. 186
  65-4102. Board of pharmacy to administer act; authority to control; report to speaker of house and president of senate on substances proposed for scheduling, rescheduling or deletion; scheduling of the controlled substance analog. ........................................ 186
  65-4103. Nomenclature ........................................................................................... 187
  65-4104. ................................................................................................................. 187
  65-4105. Substances included in schedule I .............................................................. 188
  65-4105a. ................................................................................................................. 194
  65-4105b. ................................................................................................................. 194
  65-4106. ................................................................................................................. 195
  65-4107. Substances included in schedule II ............................................................ 195
  65-4108. ................................................................................................................. 197
  65-4109. Substances included in schedule III ........................................................... 197
  65-4110. ................................................................................................................. 201
  65-4111. Substances included in schedule IV ........................................................... 201
65-4111a. ................................................................................................................................................. 204
65-4112. .................................................................................................................................................. 204
65-4113.   Substances included in schedule V. ..................................................................................... 204
65-4114. .................................................................................................................................................. 205
65-4115   Fees. .......................................................................................................................................... 205
65-4116.   Registration requirements, exceptions; termination of registration. ............................... 205
65-4117.   Registration.......................................................................................................................... 207
65-4118.   Revocation and suspension of registration. ................................................................. 207
65-4119.   Denial, suspension, revocation or refusal to renew registration; order to show cause. 208
65-4120.   Judicial review of board's actions. ..................................................................................... 208
65-4121.   Registrants to keep records and inventories. ...................................................................... 208
65-4122.   Order forms for distribution of substances in schedules I and II........................................ 209
65-4123.   Dispensing of controlled substances; oral, written or electronic prescriptions; limitations on refilling; prescription recordkeeping requirements. ................................................. 209
65-4123a. Gratuitous distribution of certain controlled substances prohibited. ................................. 209
65-4124 to 65-4126.............................................................................................................................. 209
65-4127 ................................................................................................................................................ 210
65-4127a. .............................................................................................................................................. 210
65-4127b. .............................................................................................................................................. 210
65-4127c.   General penalties; criminal penalties not applicable to violations of regulations............. 210
65-4127d. .............................................................................................................................................. 210
65-4127e.   Sentencing under 65-4127a and 65-4127b; substances and quantities; crimes committed prior to July 1, 1993.......................................................... 210
65-4127f. .............................................................................................................................................. 211
65-4127g. .............................................................................................................................................. 211
65-4128.   Penalties in addition to remedies under other laws............................................................. 212
65-4129. .............................................................................................................................................. 212
65-4130.   Enforcement ......................................................................................................................... 212
65-4131.   Inspection ............................................................................................................................. 212
65-4132.   Injunctions ............................................................................................................................ 212
65-4133.   Search warrant procedure ................................................................................................... 212
65-4134.   Identity of patient or research subject of practitioner confidential............................. 212
65-4135. ............................................................................................................................................ 213
65-4136. ............................................................................................................................................ 213
65-4137. Pending proceedings. ....................................................................................................... 213
65-4138. Medical care facility exemption. ...................................................................................... 213
65-4139. Citation of act. .................................................................................................................. 213
65-4140. Severability. ...................................................................................................................... 213
65-4141. ............................................................................................................................................ 214
65-4142. ............................................................................................................................................ 214
65-4143 to 65-4149. Reserved. ....................................................................................................... 214
65-4150. ............................................................................................................................................ 214
65-4151. ............................................................................................................................................ 214
65-4152. ............................................................................................................................................ 214
65-4153. ............................................................................................................................................ 214
65-4154. ............................................................................................................................................ 214
65-4155. ............................................................................................................................................ 214
65-4156. ............................................................................................................................................ 214
65-4157. Severability of provisions of act. ...................................................................................... 214
65-4158. ............................................................................................................................................ 214
65-4159. ............................................................................................................................................ 215
65-4159a. .......................................................................................................................................... 215
65-4160. ............................................................................................................................................ 215
65-4161. ............................................................................................................................................ 215
65-4162. ............................................................................................................................................ 215
65-4163. ............................................................................................................................................ 215
65-4164. ............................................................................................................................................ 215
65-4165. ............................................................................................................................................ 215
65-4166. ............................................................................................................................................ 215
65-4167. Trafficking in counterfeit drugs. ....................................................................................... 215
65-4168. ............................................................................................................................................ 215
65-4168a. .......................................................................................................................................... 216
65-4169. Severability clause. .......................................................................................................... 216
65-4170. Reserved. ......................................................................................................................... 216
IV. Controlled Substances Act - Regulations .......................................................... 217

Article 20: Controlled Substances ........................................................................ 217

68-20-1 Definitions. ............................................................................................. 217
68-20-2 to 68-20-4 Revoked. ............................................................................. 218
68-20-5 Revoked. ............................................................................................... 218
68-20-6 Revoked. ............................................................................................... 218
68-20-7 Revoked. ............................................................................................... 218
68-20-8 Revoked. ............................................................................................... 218
68-20-8a Revoked. ............................................................................................. 218
68-20-8b and 68-20-8c Revoked. ...................................................................... 219
68-20-9 Fees for registration and reregistration. ............................................. 219
68-20-10 Requirements of registration. ............................................................. 220
68-20-10a Electronic transmission of a controlled substance prescription. .... 224
68-20-11 Applications for registration. ............................................................... 224
68-20-12 Revoked. ............................................................................................. 225
68-20-13 Hearings generally. ............................................................................ 225
68-20-14 Modification, transfer and termination of registration. .................. 226
68-20-15 Revoked. ............................................................................................. 227
68-20-15a Security requirements. ....................................................................... 227
68-20-15b Notification to board; suspected diversion, theft, or loss of controlled substances. ...... 228
68-20-16 Records and inventories of registrants. ............................................. 228
68-20-17 Order forms. ....................................................................................... 229
68-20-18 Information concerning prescriptions. ............................................. 229
68-20-18a Information concerning prescriptions; recordkeeping; pharmacy prescription application. ................................................................. 231
68-20-19 Controlled substances listed in schedule II. .................................... 232
68-20-20 Controlled substances listed in schedules III, IV, and V. ............... 234
68-20-21 Revoked. ............................................................................................. 235
65-660. Same; adulterated or misbranded food, drug, device or cosmetic; detaining or embargoing; condemnation proceedings; consolidation, when; samples and analyses of seized articles; destruction of certain perishable food 249
65-662. Same; minor violations; notice or warning 249
65-668. Same; drugs or devices deemed adulterated, when 250
65-669. Same; drugs or devices deemed misbranded, when 250
65-669a. New drugs; selling, offering or giving away, restrictions; investigational uses 254
65-670. Same; cosmetic deemed adulterated, when 254
65-671. Same; cosmetic deemed misbranded, when 255
65-672. Same; advertisements of food, drugs, devices or cosmetics deemed false, when 255
65-674. Same; free access to establishments and vehicles for inspections and samples 256
65-675. Same; reports and dissemination of information 256
65-678. Same; cooperation with federal food and drug administration 256
65-679. Same; act not to limit authority established under certain other acts 256
65-679a. Dimethyl sulfoxide; labeling and information requirements if sold other than by prescription 257

VI. Chemical Control Act- Statutes 259

Article 70.—Chemical Control 259
65-7001. Citation of act 259
65-7002. Purpose of act 259
65-7003. Definitions 259
65-7004. Application of act 261
65-7005. Secretary; powers and duties; director; powers and duties 261
65-7007. Regulated chemical distributor and retailer; submissions to bureau 262
65-7008. Information program for retailers 263
65-7009. Orders subject to Kansas administrative procedure act; final action subject to Kansas judicial review act 263
65-7010. Civil penalties 263
65-7011. Liability; cleanup 263
65-7012. Chemical control fund; revenues; expenditures 264
65-7013. Secretary; investigation and cleanup; liability; inspections 265
65-7014. Seizure and forfeiture 267

VII. Drug Crimes-Statutes 268
<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>21-5701</td>
<td>Definitions</td>
</tr>
<tr>
<td>21-5701b</td>
<td></td>
</tr>
<tr>
<td>21-5702</td>
<td>Effective date; scope of act.</td>
</tr>
<tr>
<td>21-5703</td>
<td>Unlawful manufacturing of controlled substances.</td>
</tr>
<tr>
<td>21-5704</td>
<td>Same; costs and expenses.</td>
</tr>
<tr>
<td>21-5705</td>
<td>Unlawful cultivation or distribution of controlled substances.</td>
</tr>
<tr>
<td>21-5706</td>
<td>Unlawful possession of controlled substances.</td>
</tr>
<tr>
<td>21-5707</td>
<td>Unlawful manufacture, distribution, cultivation or possession of controlled substances using a communication facility.</td>
</tr>
<tr>
<td>21-5708</td>
<td>Unlawfully obtaining or selling a prescription-only drug.</td>
</tr>
<tr>
<td>21-5709</td>
<td>Unlawful possession of certain drug precursors and drug paraphernalia.</td>
</tr>
<tr>
<td>21-5710</td>
<td>Unlawful distribution of certain drug precursors and drug paraphernalia.</td>
</tr>
<tr>
<td>21-5711</td>
<td>Factors to consider when determining what is drug paraphernalia.</td>
</tr>
<tr>
<td>21-5712</td>
<td>Unlawful abuse of toxic vapors.</td>
</tr>
<tr>
<td>21-5713</td>
<td>Unlawful distribution or possession of a simulated controlled substance.</td>
</tr>
<tr>
<td>21-5714</td>
<td>Unlawful representation that noncontrolled substance is controlled substance.</td>
</tr>
<tr>
<td>21-5715</td>
<td>Treatment of a controlled substance analog.</td>
</tr>
<tr>
<td>21-5716</td>
<td>Unlawful acts involving proceeds derived from violations of 21-5701 through 21-5717.</td>
</tr>
<tr>
<td>21-5717</td>
<td>Uniformity of act.</td>
</tr>
</tbody>
</table>

VIII. Kansas State Board of Pharmacy

Article 16.—Board of Pharmacy.

<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>74-1601</td>
<td></td>
</tr>
<tr>
<td>74-1602</td>
<td></td>
</tr>
<tr>
<td>74-1603</td>
<td>State board of pharmacy; creation, membership; vacancies; number of terms limited.</td>
</tr>
<tr>
<td>74-1604</td>
<td>Same; appointment; terms; qualifications.</td>
</tr>
<tr>
<td>74-1605</td>
<td>Same; names submitted by state pharmaceutical association for consideration; oaths.</td>
</tr>
<tr>
<td>74-1606</td>
<td>Officers of board; executive secretary; compensation; employees.</td>
</tr>
<tr>
<td>74-1607</td>
<td>Same; compensation and expenses of board members.</td>
</tr>
<tr>
<td>74-1608</td>
<td>Same; meetings, notice; reports.</td>
</tr>
<tr>
<td>74-1609</td>
<td>Same; executive secretary, duties; disposition of moneys received; pharmacy fee fund.</td>
</tr>
<tr>
<td>74-1610</td>
<td>Same; administration of oaths by president and executive secretary.</td>
</tr>
<tr>
<td>74-1611</td>
<td>Same; records admissible in evidence.</td>
</tr>
</tbody>
</table>
IX. Related Laws/Useful Information ........................................................................................................ 287

ANIMALS – SELECTED STATUTES ........................................................................................................ 287

21-1213. Unlawful sale, purchase or injection of certain animal vaccines ................................ 287
21-1214. Same; penalties ............................................................................................................... 287

SCHOOLS – SELECTED STATUTES .......................................................................................................... 287

72-6283. Epinephrine kits; requirements ...................................................................................... 287

MEDICAL CARE FACILITIES – SELECTED STATUTES ...........................................................................288

65-443. Termination of human pregnancy; performance, referral for, or participation in medical procedures not required; prescription or administration of any device or drug not required .......... 288
65-444. Same; medical care facility refusal to permit; establishment of criteria and procedures ... 288

CONTACT LENS PRESCRIPTIONS - SELECTED STATUTES ........................................................................ 288

65-4966. Patient entitled to receive copy of contact lens prescription; disclosures; prescription limitations ........................................................................................................ 288
65-4967. Definition of person dispensing contact lenses for purposes of section; persons mailing or delivering contact lenses to patients in Kansas; registration requirements; fees; temporary suspension or limitation of registration; emergency proceedings; moneys remitted to state board of healing arts ........................................................................ 288

SOCIAL WELFARE - DRUG FORMULARY - SELECTED STATUTES ............................................................ 290

39-7,121e. Limitation of reimbursement to multisource generic equivalent drugs, when; pharmacists not required to dispense certain drugs ............................................................................ 290

LICENSE OF ADULT CARE HOMES - SELECTED REGULATIONS .......................................................... 290

28-39-156. Pharmacy services ......................................................................................................... 290

HOSPITAL PHARMACY SERVICES - SELECTED REGULATIONS .......................................................... 292

28-34-10a. Pharmacy services ........................................................................................................... 292

EMERGENCY MEDICAL SERVICES – SELECTED STATUTES ............................................................... 293

65-6149a. Automated external defibrillator; use by qualified persons and other entities, .......... 293

KANSAS RETAILERS’ SALES TAX - SELECTED STATUTES .............................................................. 294

79-3606. Exempt sales. The following shall be exempt from the tax imposed by this act: *** .... 294

KANSAS TELEMEDICINE ACT - SELECTED STATUTES ................................................................. 296

40-2,211. Kansas telemedicine act; definitions .................................................................................. 296
40-2,212. Same; confidentiality ......................................................................................................... 296

INSURANCE, REGULATION OF ADMINISTRATORS - SELECTED STATUTES ...................................... 297
40-3821. Pharmacy benefits manager registration act; citation of act; licensure required; applicability. ........................................................................................................................................297
40-3822. Same; definitions. ..................................................................................................................................................................................297
40-3823. Same; licensure; application; required information; fee; material changes in information; confidentiality of documents. ........................................................................................................................................298
40-3824. Same; renewal of license, application; fees. ........................................................................................................................................299
40-3825. Same; rules and regulations. .................................................................................................................................................................299
40-3826. Same; statement of charges, hearing; violation; penalty. .................................................................................................................300
40-3827. Same; pharmacy benefits manager licensure fund. ........................................................................................................................................300
40-3828. Same; severability. .............................................................................................................................................................................300
40-3828a. Pharmacy benefits manager licensure act; denial, revocation or limitation of license. .................................................................301
40-3829. Pharmacy benefits managers; maximum allowable cost pricing; definitions. ........................................................................................................................................301
40-3830. Same; MAC list requirements; frequency of updates; appeals process. ........................................................................................301
40-3831. Kansas Pharmacy Patients Fair Practices Act.................................................................................................................................303

HEALTHCARE PROVIDER INSURANCE - SELECTED STATUTES ........................................................................................................303
40-3401. Definitions. ..................................................................................................................................................................................303
40-3402. Professional liability insurance to be maintained by health care providers as condition of active licensure to render services in state, exception, limits of coverage; information to be furnished by insurer; termination of coverage, notice; contents of policies issued in state; duties of certain insurance companies; surcharge and information required of certain health care providers; occurrence form policy as alternative to required claims made policy for certain persons. ............................................................306

TRANSIENT MERCHANT LICENSING ACT - SELECTED STATUTES ........................................................................................................309
19-2243. Flea markets; prohibition of sale of certain baby products or drugs. .................................................................................................309

JURORS - SELECTED STATUTES .................................................................................................................................................................309
43-159. Same; exclusions from jury service by court. In addition to the persons excused from jury service in K.S.A. 43-158, and amendments thereto, the following persons may be excused from jury service by the court: (a) Persons so physically or mentally infirm as to be unequal to the task of ordinary jury duty; ........................................................................................................................................309

X. Other Healthcare Provider Statutes and Regulations ........................................................................................................................................310

HEALING ARTS - SELECTED STATUTES ..................................................................................................................................................310
65-2837a. Restrictions on prescribing, ordering, dispensing, administering, selling, supplying or giving certain amphetamine or sympathomimetic amine controlled substances; unprofessional conduct. ........................................................................................................................................310
65-2869. Persons deemed engaged in practice of medicine and surgery. ........................................................................................................310
65-2870. Persons deemed engaged in practice of osteopathy ................................................................. 311
65-2871. Persons deemed engaged in practice of chiropractic ............................................................... 311
65-2872. Persons not engaged in the practice of the healing arts .......................................................... 311
65-2872b. Same; administration of epinephrine; limitation of liability ................................................... 313
65-28,127. Licensees who direct, supervise, order, refer, accept responsibility for, enter into practice protocols with or delegate acts which constitute practice of healing arts to others; requirements and limitations; construction of section ................................................................. 313
65-28,135. Telemedicine; out-of-state physician practice; requirements and limitations; waiver application and fee; other healthcare professionals ................................................................. 314

HEALTHCARE PROVIDERS - SELECTED STATUTES ................................................................................. 317
65-4909. Limited liability for certain associations of health care providers, review organizations, committee members and individuals or entities acting at request thereof; good faith requirement; "health care provider" defined ........................................................................................................... 317
65-4915. Peer review; healthcare providers, services and costs; definitions; authority of peer review officer or committee; records and testimony of information contained therein privileged; licensing agency disciplinary proceedings; exceptions ................................................................. 318
65-4921. Definitions ................................................................................................................................ 320
65-4922. Medical care facilities; risk management program required; submission of plan; inspections and investigations; approval of plan; reports and records confidential ................................................................. 321
65-4923. Reporting requirements ............................................................................................................. 322
65-4924. Reports relating to impaired providers; procedures ...................................................................... 323
65-4926. Immunity from civil liability for report or investigation, limits .................................................. 324
65-4977. Persons suffering from pain; use of controlled substances for pain treatment .......................... 325

DENTAL ACT - SELECTED STATUTES ................................................................................................. 325
65-1422. Persons deemed to be practicing dentistry .............................................................................. 325
65-1438. Using services of unlicensed person; written prescription; misdemeanors; suspension or revocation of license ................................................................................................................. 326
65-1444. Drugs; surgery; anesthetics; appliances; qualifications for administering intravenous sedation and general anesthetics; sedation permits; rules and regulations; assistant administering and monitoring nitrous oxide or oxygen, requirements; denial, revocation, suspension or limitation of sedation permit ................................................................................................................. 327

OPTOMETRY ACT - SELECTED STATUTES ......................................................................................... 327
65-1501. Practice of optometry defined; exclusions; standard of care in diagnosis and treatment of glaucoma; low vision rehabilitation services ........................................................................... 327
65-1501a. Definitions ............................................................................................................................... 328
100-28a-13. Prescription-only drugs. ................................................................. 342
100-28a-14. Different practice location................................................................. 344

INDEPENDENT PRACTICE OF MIDWIFERY ACT - SELECTED STATUTES .................. 344
65-28b02. Definitions............................................................................................... 344
65-28b07. Same; rules and regulations; standards of care. ................................. 344
65-28b10. Same; abortion not authorized.............................................................. 345

MIDWIFE - SELECTED REGULATIONS ..................................................................... 345
100-28b-1. Definitions. ......................................................................................... 345

VETERINARY MEDICINE - SELECTED REGULATIONS............................................. 346
70-7-1. The practice of veterinary medicine......................................................... 346
I. Pharmacy Practice Act - Statutes

Chapter 65.—Public Health
Article 16.—Regulation of Pharmacists

65-1601.
History: L. 1885, ch. 150, § 1; R.S. 1923, 65-1601; Repealed, L. 1953, ch. 290, § 37; Aug. 1.

65-1602.
History: L. 1885, ch. 150, § 3; R.S. 1923, 65-1602; Repealed, L. 1953, ch. 290, § 38; July 1.

65-1603.
History: L. 1887, ch. 174, § 5; L. 1921, ch. 268, § 1; R.S. 1923, 65-1603; Repealed, L. 1953, ch. 290, § 38; July 1.

65-1604.
History: L. 1921, ch. 269, § 1; R.S. 1923, 65-1604; Repealed, L. 1953, ch. 290, § 38; July 1.

65-1605, 65-1606.
History: L. 1921, ch. 269, §§ 2, 3; R.S. 1923, 65-1605, 65-1606; Repealed, L. 1953, ch. 290, § 38; July 1.

65-1607.
History: L. 1913, ch. 186, § 2; L. 1921, ch. 268, § 2; R.S. 1923, 65-1607; L. 1929, ch. 216, § 1; Repealed, L. 1953, ch. 290, § 38; July 1.

65-1608.
History: L. 1921, ch. 268, § 3; R.S. 1923, 65-1608; L. 1929, ch. 216, § 2; Repealed, L. 1953, ch. 290, § 38; July 1.

65-1609.
History: L. 1913, ch. 186, § 3; R.S. 1923, 65-1609; Repealed, L. 1953, ch. 290, § 37; Aug. 1.

65-1610, 65-1611.

65-1612, 65-1613.
History: L. 1913, ch. 186, §§ 6, 7; R.S. 1923, 65-1612, 65-1613; Repealed, L. 1953, ch. 290, § 38; July 1.

65-1614.
History: L. 1913, ch. 186, § 8; R.S. 1923, 65-1614; Repealed, L. 1953, ch. 290, § 37; Aug. 1.

65-1615, 65-1616.

65-1617.
History: L. 1887, ch. 174, § 8; R.S. 1923, 65-1617; Repealed, L. 1943, ch. 269, § 28; June 30.

65-1618.

65-1619.
History: L. 1885, ch. 150, § 13; R.S. 1923, 65-1619; Repealed, L. 1953, ch. 290, § 38; July 1.

65-1620.
History: L. 1897, ch. 164, § 1; L. 1921, ch. 270, § 1; R.S. 1923, 65-1620; Repealed, L. 1953, ch. 290, § 38; July 1.

65-1621 to 65-1623.
History: L. 1933, ch. 87, §§ 1 to 3 (Special Session); Repealed, L. 1953, ch. 290, § 38; July 1.

65-1624.
History: L. 1953, ch. 290, § 1; Repealed, L. 1975, ch. 319, § 47; July 1.
65-1625. Title of act.
This act shall be known and may be cited as the pharmacy act of the state of Kansas.

History: L. 1953, ch. 290, § 2; L. 1975, ch. 319, § 1; July 1.

65-1626. Definitions.
As used in the pharmacy act of the state of Kansas:

(a) "Address" means, with respect to prescriptions, the physical address where a patient resides, including street address, city and state.

(b) "Administer" means the direct application of a drug, whether by injection, inhalation, ingestion or any other means, to the body of a patient or research subject by:
   (1) A practitioner or pursuant to the lawful direction of a practitioner;
   (2) the patient or research subject at the direction and in the presence of the practitioner; or
   (3) a pharmacist as authorized in K.S.A. 65-1635a., and amendments thereto, or K.S.A. 2022 Supp. 65-16,129, and amendments thereto.

(c) "Agent" means an authorized person who acts on behalf of or at the direction of a manufacturer, repackager, wholesale distributor, third-party logistics provider or dispenser but does not include a common carrier, public warehouseman or employee of the carrier or warehouseman when acting in the usual and lawful course of the carrier's or warehouseman's business.

(d) "Automated dispensing system" means a robotic or mechanical system controlled by a computer that:
   (1) Performs operations or activities, other than compounding or administration, relative to the storage, packaging, labeling, dispensing or distribution of drugs;
   (2) collects, controls and maintains all transaction information; and
   (3) operates in accordance with the board's rules and regulations.

(e) "Biological product" means the same as defined in 42 U.S.C. § 262(i), as in effect on January 1, 2017.

(f) "Board" means the state board of pharmacy created by K.S.A. 74-1603, and amendments thereto.

(g) "Brand exchange," in the case of a drug prescribed, means the dispensing of a different drug product of the same dosage form and strength and of the same generic name as the brand name drug product prescribed, and in the case of a biological product prescribed, means the dispensing of an interchangeable biological product.

(h) "Brand name" means the registered trademark name given to a drug product by its manufacturer, labeler or distributor.

(i) "Co-licensed partner" means a person or pharmaceutical manufacturer that has entered into an agreement with another pharmaceutical manufacturer or an affiliate of the manufacturer to engage in a business activity or occupation related to the manufacture or distribution of a product.

(j) "Common carrier" means any person who undertakes, whether directly or by any other arrangement, to transport property, including drugs, for compensation.

(k) (1) "Compounding" means the combining of components into a compounded preparation under either of the following conditions:
   (A) As the result of a practitioner's prescription drug order or initiative based on the practitioner-patient-pharmacist relationship in the course of professional practice to meet the specialized medical need of an individual patient of the practitioner that cannot be filled by an FDA-approved drug; or
   (B) for the purpose of, or incidental to, research, teaching or chemical analysis, and not for sale or dispensing.
(2) Compounding includes the preparation of drugs or devices in anticipation of receiving prescription drug orders based on routine, regularly observed prescribing patterns.

(3) Compounding does not include reconstituting any mixed drug according to the FDA-approved labeling for the drug.

(i) "Current good manufacturing practices" or "CGMP" means the requirements for ensuring that drugs and drug products are consistently manufactured, repackaged, produced, stored and dispensed in accordance with 21 C.F.R. §§ 207, 210 and 211.

(m) "DEA" means the United States department of justice, drug enforcement administration.

(n) "Deliver" or "delivery" means the actual, constructive or attempted transfer from one person to another of any drug whether or not an agency relationship exists.

(o) "Device" means an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent or other similar or related article, including a component part or accessory that:

1. (A) Is recognized in the official national formulary, or the United States pharmacopoeia, or any supplement thereof;
2. (B) is intended for use in the diagnosis of disease or other conditions;
3. (C) is used for the cure, mitigation, treatment or prevention of disease in human or other animals; or
4. (D) is intended to affect the structure or any function of the body of human or other animals; and

5. (A) does not achieve its primary intended purposes through chemical action within or on the body of human or other animals; and
6. (B) is not dependent upon being metabolized for the achievement of any of its primary intended purposes.

(p) "Direct supervision" means the process by which the responsible pharmacist shall observe and direct the activities of a pharmacist intern or pharmacy technician, be readily and immediately available at all time activities are performed, provide personal assistance, direction and approval throughout the time the activities are performed and complete the final check before dispensing.

(q) "Dispense" or "dispensing" means to deliver prescription medication to the ultimate user or research subject by or pursuant to the lawful order of a practitioner or pursuant to the prescription of a mid-level practitioner, including, but not limited to, delivering prescription medication to a patient by mail, common carrier, personal delivery or third-party delivery to any location requested by the patient.

(r) "Dispenser" means:

1. A practitioner or pharmacist who dispenses prescription drugs or devices or a physician assistant who has authority to dispense prescription-only drugs in accordance with K.S.A. 65-28a08(b), and amendments thereto; or
2. a retail pharmacy, hospital pharmacy or group of pharmacies under common ownership and control that do not act as a wholesale distributor.

(s) "Distribute" or "distribution" means to deliver, offer to deliver, sell, offer to sell, purchase, trade, transfer, broker, give away, handle, store or receive, other than by administering or dispensing, any product, but does not include dispensing a product pursuant to a prescription executed in accordance with 21 U.S.C. § 353 or the dispensing of a product approved under 21 U.S.C. § 360b.

(t) "Distributor" means a person or entity that distributes a drug or device.

(u) "Diversion" means the transfer of a controlled substance from a lawful to an unlawful channel of distribution or use.

(v) "Drop shipment" means the sale, by a manufacturer, repackager or exclusive distributor, of the manufacturer's prescription drug to a wholesale distributor whereby the wholesale distributor takes title but not possession of such prescription drug and the wholesale distributor invoices the dispenser,
and the dispenser receives delivery of the prescription drug directly from the manufacturer, repackager, third-party logistics provider or exclusive distributor, of such prescription drug.

(w) "Drug" means articles:

1. Recognized in the official United States pharmacopeia, or other such official compendiums of the United States, or official national formulary, or any supplement to any of them;
2. intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease in human or other animals;
3. other than food, intended to affect the structure or any function of the body of human or other animals; and
4. intended for use as a component of any articles specified in paragraph (1), (2) or (3); but does not include devices or their components, parts or accessories, except that the term "drug" does not include amygdalin (laetrile) or any livestock remedy, if such livestock remedy had been registered in accordance with the provisions of article 5 of chapter 47 of the Kansas Statutes Annotated, prior to its repeal.

(x) "Durable medical equipment" means equipment that:
1. Provides therapeutic benefits or enables an individual to perform certain tasks that the individual is unable to otherwise undertake due to certain medical conditions or illnesses;
2. is primarily and customarily used to serve a medical purpose;
3. generally is not useful to a person in the absence of an illness or injury;
4. can withstand repeated use;
5. is appropriate for use in the home, long-term care facility or medical care facility, but may be transported to other locations to allow the individual to complete instrumental activities of daily living that are more complex tasks required for independent living; and
6. may include devices and medical supplies or other similar equipment determined by the board in rules and regulations adopted by the board.

(y) "Electronic prescription" means an electronically prepared prescription that is authorized and transmitted from the prescriber to the pharmacy by means of electronic transmission.

(z) "Electronic prescription application" means software that is used to create electronic prescriptions and that is intended to be installed on the prescriber's computers and servers where access and records are controlled by the prescriber.

(aa) "Electronic signature" means a confidential personalized digital key, code, number or other method for secure electronic data transmissions that identifies a particular person as the source of the message, authenticates the signatory of the message and indicates the person's approval of the information contained in the transmission.

(bb) "Electronic transmission" means the transmission of an electronic prescription, formatted as an electronic data file, from a prescriber's electronic prescription application to a pharmacy's computer, where the data file is imported into the pharmacy prescription application.

(cc) "Electronically prepared prescription" means a prescription that is generated using an electronic prescription application.

(dd) "Exclusive distributor" means the wholesale distributor that directly purchased the product from the manufacturer and is the sole distributor of that manufacturer's product to a subsequent repackager, wholesale distributor or dispenser.

(ee) "FDA" means the United States department of health and human services, food and drug administration.

(ff) "Facsimile transmission" or "fax transmission" means the transmission of a digital image of a prescription from the prescriber or the prescriber's agent to the pharmacy. "Facsimile transmission" includes, but is not limited to, transmission of a written prescription between the prescriber's fax
machine and the pharmacy's fax machine; transmission of an electronically prepared prescription from the prescriber's electronic prescription application to the pharmacy's fax machine, computer or printer; or transmission of an electronically prepared prescription from the prescriber's fax machine to the pharmacy's fax machine, computer or printer.

(gg) "Generic name" means the established chemical name or official name of a drug or drug product.

(hh) "Healthcare entity" means any person that provides diagnostic, medical, surgical or dental treatment or rehabilitative care but does not include any retail pharmacy or wholesale distributor.

(ii) (1) "Institutional drug room" means any location where prescription-only drugs are stored and from which prescription-only drugs are administered or dispensed and that is maintained or operated for the purpose of providing the drug needs of:

(A) Inmates of a jail or correctional institution or facility;
(B) residents of a juvenile correctional facility or juvenile detention facility, as defined in K.S.A. 38-2302, and amendments thereto;
(C) students of a public or private university or college, a community college or any other institution of higher learning that is located in Kansas;
(D) employees of a business or other employer; or
(E) persons receiving inpatient hospice services.
(2) "Institutional drug room" does not include:

(A) Any registered pharmacy;
(B) any office of a practitioner; or
(C) a location where no prescription-only drugs are dispensed and no prescription-only drugs other than individual prescriptions are stored or administered.

(jj) "Interchangeable biological product" means a biological product that the FDA has identified in the "purple book: lists of licensed biological products with reference product exclusivity and biosimilarity or interchangeability evaluations" as meeting the standards for "interchangeability" as defined in 42 U.S.C. § 262(k), as in effect on January 1, 2017.

(kk) "Intracompany transaction" means any transaction or transfer between any division, subsidiary, parent or affiliated or related company under common ownership or control of a corporate entity, or any transaction or transfer between co-licensed partners.

(ll) "Label" means a display of written, printed or graphic matter upon the immediate container of any drug.

(mm) "Labeling" means the process of preparing and affixing a label to any drug container, exclusive of the labeling by a manufacturer, packer or distributor of a non-prescription drug or commercially packaged legend drug.

(nn) "Long-term care facility" means "nursing facility," as defined in K.S.A. 39-923, and amendments thereto.

(oo) "Medical care facility" means the same as defined in K.S.A. 65-425, and amendments thereto, and also includes psychiatric hospitals and psychiatric residential treatment facilities as defined by K.S.A. 39-2002, and amendments thereto.

(pp) "Manufacture" means the production, preparation, propagation, compounding, conversion or processing of a drug either directly or indirectly by extraction from substances of natural origin, independently by means of chemical or biological synthesis or by a combination of extraction and chemical or biological synthesis or the packaging or repackaging of the drug or labeling or relabeling of its container, except that this term does not include the preparation or compounding of a drug by an individual for the individual's own use or the preparation, compounding, packaging or labeling of a drug by:
(1) A practitioner or a practitioner's authorized agent incident to such practitioner's administering or dispensing of a drug in the course of the practitioner's professional practice;

(2) a practitioner, by a practitioner's authorized agent or under a practitioner's supervision for the purpose of, or as an incident to, research, teaching or chemical analysis and not for sale; or

(3) a pharmacist or the pharmacist's authorized agent acting under the direct supervision of the pharmacist for the purpose of, or incident to, the dispensing of a drug by the pharmacist.

(qq) "Manufacturer" means:

(1) A person that holds an application approved under section 505 of the federal food, drug and cosmetic act or a license issued under section 351 of the federal public health service act for such drug or, if such drug is not the subject of an approved application or license, the person who manufactured the drug;

(2) a co-licensed partner of the person described in paragraph (1) that obtains the drug directly from a person described in paragraph (1) or (3); or

(3) an affiliate of a person described in paragraph (1) or (2) that receives the product directly from a person described in paragraph (1) or (2).

(rr) "Medication order" means a written or oral order by a prescriber or the prescriber's authorized agent for administration of a drug or device to a patient in a Kansas licensed medical care facility or in a Kansas licensed nursing facility or nursing facility for mental health, as such terms are defined by K.S.A. 39-923, and amendments thereto.

(ss) "Mid-level practitioner" means a certified nurse-midwife engaging in the independent practice of midwifery under the independent practice of midwifery act, an advanced practice registered nurse issued a license pursuant to K.S.A. 65-1131, and amendments thereto, who has authority to prescribe drugs under K.S.A. 65-1130, and amendments thereto, or a physician assistant licensed pursuant to the physician assistant licensure act who has authority to prescribe drugs pursuant to a written agreement with a supervising physician under K.S.A. 65-28a08, and amendments thereto.

(tt) "Nonresident pharmacy" means a pharmacy located outside of Kansas.

(uu) "Outsourcing facility" means a facility at one geographic location or address that is engaged in the compounding of sterile drugs and has registered with the FDA as an outsourcing facility pursuant to 21 U.S.C. § 353b.

(vv) "Person" means individual, corporation, government, governmental subdivision or agency, partnership, association or any other legal entity.

(ww) "Pharmacist" means any natural person licensed under this act to practice pharmacy.

(xx) "Pharmacist-in-charge" means the pharmacist who is responsible to the board for a registered establishment's compliance with the laws and regulations of this state pertaining to the practice of pharmacy, manufacturing of drugs and the distribution of drugs. The pharmacist-in-charge shall supervise such establishment on a full-time or a part-time basis and perform such other duties relating to supervision of a registered establishment as may be prescribed by the board by rules and regulations. Nothing in this definition shall relieve other pharmacists or persons from their responsibility to comply with state and federal laws and regulations.

(yy) "Pharmacist intern" or "intern" means:

(1) A student currently enrolled in and in good standing with an accredited pharmacy program;

(2) a graduate of an accredited pharmacy program serving an internship; or

(3) a graduate of a pharmacy program located outside of the United States that is not accredited and who has successfully passed equivalency examinations approved by the board.

(zz) "Pharmacy," "drugstore" or "apothecary" means premises, laboratory, area or other place, including any electronic medium:
(1) Where drugs are offered for sale where the profession of pharmacy is practiced and where prescriptions are compounded and dispensed;
(2) that has displayed upon it or within it the words "pharmacist," "pharmaceutical chemist," "pharmacy," "apothecary," "drugstore," "druggist," "drugs," "drug sundries" or any of these words or combinations of these words or words of similar import in any language or on any sign containing any of these words as used in the context of health, medical or pharmaceutical care or services; or
(3) where the characteristic symbols of pharmacy or the characteristic prescription sign "Rx" may be exhibited in the context of health, medical or pharmaceutical care or services. As used in this subsection, premises refers only to the portion of any building or structure leased, used or controlled by the licensee in the conduct of the business registered by the board at the address for which the registration was issued.

(aaa) "Pharmacy prescription application" means software that is used to process prescription information and is either installed on a pharmacy's computers or servers and is controlled by the pharmacy or is maintained on the servers of an entity that sells electronic pharmacy prescription applications as a hosted service where the entity controls access to the application and maintains the software and records on its server.

(bbb) "Pharmacy technician" means an individual who, under the direct supervision and control of a pharmacist, may perform packaging, manipulative, repetitive or other nondiscretionary tasks related to the processing of a prescription or medication order and who assists the pharmacist in the performance of pharmacy-related duties, but who does not perform duties restricted to a pharmacist.

(ccc) "Practitioner" means a person licensed to practice medicine and surgery, dentist, podiatrist, veterinarian, optometrist or scientific investigator or other person authorized by law to use a prescription-only drug in teaching or chemical analysis or to conduct research with respect to a prescription-only drug.

(ddd) "Preceptor" means a licensed pharmacist who possesses at least two years' experience as a pharmacist and who supervises and is responsible for the actions of pharmacist interns obtaining pharmaceutical experience.

(eee) "Prescriber" means a practitioner or a mid-level practitioner.

(ff) "Prescription" or "prescription order" means the front and back of a lawful written, electronic or facsimile order from a prescriber or an oral order from a prescriber or the prescriber's authorized agent that communicates the prescriber's instructions for a prescription drug or device to be dispensed.

(ggg) "Prescription medication" means any drug, including label and container according to context, that is dispensed pursuant to a prescription order.

(hhh) "Prescription-only drug" means any drug whether intended for use by human or animal, required by federal or state law, including 21 U.S.C. § 353, to be dispensed only pursuant to a written or oral prescription or order of a practitioner or is restricted to use by practitioners only.

(iii) "Probation" means the practice or operation under a temporary license, registration or permit or a conditional license, registration or permit of a business or profession for which a license, registration or permit is granted by the board under the provisions of the pharmacy act of the state of Kansas requiring certain actions to be accomplished or certain actions not to occur before a regular license, registration or permit is issued.


(III) "Professional incompetency" means:
(1) One or more instances involving failure to adhere to the applicable standard of pharmaceutical care to a degree that constitutes gross negligence, as determined by the board;
(2) repeated instances involving failure to adhere to the applicable standard of pharmaceutical care to a degree that constitutes ordinary negligence, as determined by the board; or

(3) a pattern of pharmacy practice or other behavior that demonstrates a manifest incapacity or incompetence to practice pharmacy.

(mmm) "Readily retrievable" or "readily available" means that records kept in hard copy or by automatic data processing applications or other electronic or mechanized record-keeping systems can be separated out from all other records quickly and easily during an inspection or investigation, or within a reasonable time not to exceed 48 hours of a written request from the board or other authorized agent.

(nnn) "Repackage" means changing the container, wrapper, quantity or label of a drug to further the distribution of the drug.

(ooo) "Repackager" means a person who owns or operates a facility that repackages.

(PPP) "Retail dealer" means a person selling at retail nonprescription drugs that are prepackaged, fully prepared by the manufacturer or distributor for use by the consumer and labeled in accordance with the requirements of the state and federal food, drug and cosmetic acts. Such nonprescription drugs shall not include: (1) A controlled substance; (2) a prescription-only drug; or (3) a drug intended for human use by hypodermic injection.

(qqq) "Reverse distributor" means a person who owns or operates an establishment that disposes of or otherwise processes saleable or nonsaleable products received from an authorized trading partner such that the product may be processed for credit to the purchaser, manufacturer or seller or disposed of for no further distribution.

(rrr) "Secretary" means the executive secretary of the board.

(sss) "Third-party logistics provider" means an entity that provides or coordinates warehousing or other logistic services of a product in interstate commerce on behalf of a manufacturer, wholesale distributor or dispenser, but does not take ownership of the product or have responsibility to direct the sale or disposition of the product.

(ttt) "Trading partner" means:

(1) A manufacturer, repackager, wholesale distributor or dispenser from whom a manufacturer, repackager, wholesale distributor or dispenser accepts direct ownership of a product or to whom a manufacturer, repackager, wholesale distributor or dispenser transfers direct ownership of a product; or

(2) a third-party logistics provider from whom a manufacturer, repackager, wholesale distributor or dispenser accepts direct possession of a product or to whom a manufacturer, repackager, wholesale distributor or dispenser transfers direct possession of a product.

(uuu) "Transaction" means the transfer of product between persons in which a change of ownership occurs.

(vvv) "Unprofessional conduct" means:

(1) Fraud in securing a registration or permit;

(2) intentional adulteration or mislabeling of any drug, medicine, chemical or poison;

(3) causing any drug, medicine, chemical or poison to be adulterated or mislabeled, knowing the same to be adulterated or mislabeled;

(4) intentionally falsifying or altering records or prescriptions;

(5) unlawful possession of drugs and unlawful diversion of drugs to others;

(6) willful betrayal of confidential information under K.S.A. 65-1654, and amendments thereto;

(7) conduct likely to deceive, defraud or harm the public;

(8) making a false or misleading statement regarding the licensee's professional practice or the efficacy or value of a drug;
(9) commission of any act of sexual abuse, misconduct or exploitation related to the licensee's professional practice; or
(10) performing unnecessary tests, examinations or services that have no legitimate pharmaceutical purpose.

(www) "Vaccination protocol" means a written protocol, agreed to and signed by a pharmacist and a person licensed to practice medicine and surgery by the state board of healing arts, that establishes procedures and recordkeeping and reporting requirements for administering a vaccine by the pharmacist for a period of time specified therein, not to exceed two years.

(xxx) "Valid prescription order" means a prescription that is issued for a legitimate medical purpose by an individual prescriber licensed by law to administer and prescribe drugs and acting in the usual course of such prescriber's professional practice. A prescription issued solely on the basis of an internet-based questionnaire or consultation without an appropriate prescriber-patient relationship is not a valid prescription order.

(yyy) "Veterinary medical teaching hospital pharmacy" means any location where prescription-only drugs are stored as part of an accredited college of veterinary medicine and from which prescription-only drugs are distributed for use in treatment of or administration to a nonhuman.

(zzz) "Virtual manufacturer" means an entity that engages in the manufacture of a drug or device for which it:
(1) Owns the new drug application or abbreviated new drug application number, if a prescription drug;
(2) owns the unique device identification number, as available, for a prescription device;
(3) contracts with a contract manufacturing organization for the physical manufacture of the drug or device;
(4) is not involved in the physical manufacture of the drug or device; and
(5) does not store or take physical possession of the drug or device.

(aaaa) "Virtual wholesale distributor" means a wholesale distributor that sells, brokers or transfers a drug or device but never physically possesses the product.

(bbbb) "Wholesale distributor" means any person engaged in wholesale distribution or reverse distribution of drugs or devices, other than a manufacturer, co-licensed partner or third-party logistics provider.

(cccc) "Wholesale distribution" means the distribution or receipt of drugs or devices to or by persons other than consumers or patients, in which a change of ownership occurs. "Wholesale distribution" does not include:
(1) The dispensing of a drug or device pursuant to a prescription;
(2) the distribution of a drug or device or an offer to distribute a drug or device for emergency medical reasons, including a public health emergency declaration pursuant to section 319 of the public health service act, except that, for purposes of this paragraph, a drug or device shortage not caused by a public health emergency shall not constitute an emergency medical reason;
(3) intracompany distribution;
(4) the distribution of a drug or device, or an offer to distribute a drug or device, among hospitals or other healthcare entities under common control;
(5) the distribution of a drug or device, or the offer to distribute a drug or device, by a charitable organization described in section 501(c)(3) of the internal revenue code of 1986 to a nonprofit affiliate of the organization to the extent otherwise permitted by law;
(6) the distribution of an intravenous drug used to maintain the equilibrium of water and minerals in the body, such as dialysis solutions; or
(7) the sale or transfer from a retail pharmacy of expired, damaged, returned or recalled prescription drugs to the original manufacturer, originating wholesale distributor or to a reverse distributor registered in accordance with the board's rules and regulations.


65-1626a. Practice of pharmacy defined; persons engaged as pharmacists.

(a) For the purpose of the pharmacy act of the state of Kansas, the following individuals shall be deemed to be engaged in the practice of pharmacy:

(1) Individuals who publicly profess to be a pharmacist, or publicly profess to assume the duties incident to being a pharmacist and their knowledge of drugs or drug actions, or both; and

(2) individuals who attach to their name any words or abbreviation indicating that they are a pharmacist licensed to practice pharmacy in Kansas.

(b) As used in this section:

(1) "Practice of pharmacy" means:

(A) The interpretation and evaluation of prescription orders;

(B) the compounding, dispensing and labeling of drugs and devices pursuant to prescription orders;

(C) the administering of vaccine pursuant to a vaccination protocol;

(D) the participation in drug selection according to state law and participation in drug utilization reviews;

(E) the proper and safe storage of prescription drugs and prescription devices and the maintenance of proper records thereof in accordance with law;

(F) consultation with patients and other health care practitioners about the safe and effective use of prescription drugs and prescription devices;

(G) performance of collaborative drug therapy management pursuant to a written collaborative practice agreement with one or more physicians who have an established physician-patient relationship;

(H) participation in the offering or performing of those acts, services, operations or transactions necessary in the conduct, operation, management and control of a pharmacy; and

(I) initiation of therapy for the conditions specified in K.S.A. 2022 Supp. 65-16,131, and amendments thereto.

(2) "Collaborative drug therapy management" means a practice of pharmacy where a pharmacist performs certain pharmaceutical-related patient care functions for a specific patient which have been delegated to the pharmacist by a physician through a collaborative practice agreement. A physician who enters into a collaborative practice agreement is responsible for the care of the patient following initial diagnosis and assessment and for the direction and supervision of the pharmacist throughout the collaborative drug therapy management process. Nothing in this subsection shall be construed to permit a pharmacist to alter a physician's orders or directions, diagnose or treat any disease, independently prescribe drugs or independently practice medicine and surgery.
(3) "Collaborative practice agreement" means a written agreement or protocol between one or more pharmacists and one or more physicians that provides for collaborative drug therapy management. Such collaborative practice agreement shall contain certain specified conditions or limitations pursuant to the collaborating physician's order, standing order, delegation or protocol. A collaborative practice agreement shall be: (A) Consistent with the normal and customary specialty, competence and lawful practice of the physician; and (B) appropriate to the pharmacist's training and experience.

(4) "Physician" means a person licensed to practice medicine and surgery in this state.

(c) Nothing in this section shall be construed to:

(1) Add any additional requirements for registration or for a permit under the pharmacy act of the state of Kansas or for approval under K.S.A. 65-1643(g), and amendments thereto;

(2) prevent persons other than pharmacists from engaging in drug utilization review;

(3) require persons lawfully in possession of prescription drugs or prescription devices to meet any storage or record keeping requirements except such storage and record keeping requirements as may be otherwise provided by law; or

(4) affect any person consulting with a healthcare practitioner about the safe and effective use of prescription drugs or prescription devices.


65-1626b.


65-1626c.


65-1626d.

65-1627. Grounds for revocation, suspension, placement in probationary status, denial, temporary suspension or temporary limitation of license for pharmacist, permit for retail dealer or registration for pharmacy, manufacturer, distributor or logistics provider; emergency proceedings, procedure.

(a) The board may deny an application or renewal, limit, condition, revoke, suspend or place in a probationary status the license of any pharmacist upon a finding that:

(1) The licensee has obtained, renewed or reinstated, or attempted to obtain, renew or reinstate, a license by false or fraudulent means, including misrepresentation of a material fact;
(2) the licensee has been convicted of a misdemeanor involving moral turpitude or gross immorality or any felony and the licensee fails to show that the licensee has been sufficiently rehabilitated to warrant the public trust;
(3) the licensee is found by the board to be guilty of unprofessional conduct or professional incompetency;
(4) the licensee is addicted to the liquor or drug habit to such a degree as to render the licensee unfit to practice the profession of pharmacy;
(5) the licensee has violated a provision of the federal or state food, drug and cosmetic act, the federal or state uniform controlled substances act, or any rule and regulation adopted under any such act;
(6) the licensee is found by the board to have filled a prescription not in strict accordance with the directions of the practitioner or a mid-level practitioner;
(7) the licensee is found to be mentally or physically incapacitated to such a degree as to render the licensee unfit to practice the profession of pharmacy;
(8) the licensee has violated any of the provisions of the pharmacy act of the state of Kansas or any rule and regulation adopted by the board pursuant to the provisions of such pharmacy act;
(9) the licensee has failed to comply with the continuing education requirements of the board for license renewal;
(10) the licensee as a "pharmacist-in-charge" or consultant pharmacist under the provisions of K.S.A. 65-1648 (c) or (d), and amendments thereto, has failed to comply with the requirements of K.S.A. 65-1648 (c) or (d), and amendments thereto;
(11) the licensee has knowingly submitted a misleading, deceptive, untrue or fraudulent misrepresentation on a claim form, bill or statement;
(12) the licensee has had a license to practice pharmacy revoked, suspended or limited, has been censured or has had other disciplinary action taken, or voluntarily surrendered the license after formal proceedings have been commenced, or has had an application for license denied, by the proper licensing authority of another state, territory, District of Columbia or other country, a certified copy of the record of the action of the other jurisdiction being conclusive evidence thereof;
(13) the licensee has self-administered any controlled substance without a practitioner's prescription order or a mid-level practitioner's prescription order;
(14) the licensee has assisted suicide in violation of K.S.A. 21-3406, prior to its repeal, or K.S.A. 2021 Supp. 21-5407, and amendments thereto, as established by any of the following:
   (A) A copy of the record of criminal conviction or plea of guilty for a felony in violation of K.S.A. 21-3406, prior to its repeal, or K.S.A. 2021 Supp. 21-5407, and amendments thereto;
   (B) a copy of the record of a judgment of contempt of court for violating an injunction issued under K.S.A. 60-4404, and amendments thereto; or
   (C) a copy of the record of a judgment assessing damages under K.S.A. 60-4405, and amendments thereto;
(15) the licensee has failed to furnish the board, its investigators or its representatives any information legally requested by the board;
(16) the licensee has violated or failed to comply with any lawful order or directive of the board;
(17) the licensee has violated any of the provisions of the prescription monitoring program act of the
state of Kansas or any rule and regulation of the board pursuant to the provisions of the prescription
monitoring program act; or
(18) the licensee has failed to keep, has failed to file with the board or has falsified records required to
be kept or filed by the provisions of the pharmacy act of the state of Kansas, the federal or state uniform
controlled substances act or rules and regulations adopted by the board.

(b) In determining whether or not the licensee has violated subsection (a)(3), (a)(4), (a)(7) or (a)(13),
the board upon reasonable suspicion of such violation has authority to compel a licensee to submit to
mental or physical examination or drug screen, or any combination thereof, by such persons as the
board may designate. To determine whether reasonable suspicion of such violation exists, the
investigative information shall be presented to the board as a whole. Information submitted to the board
as a whole and all reports, findings and other records shall be confidential and not subject to discovery
by or release to any person or entity. The licensee shall submit to the board a release of information
authorizing the board to obtain a report of such examination or drug screen, or both. A person affected
by this subsection shall be offered, at reasonable intervals, an opportunity to demonstrate that such
person can resume the competent practice of pharmacy with reasonable skill and safety to patients. For
the purpose of this subsection, every person licensed to practice pharmacy and who shall accept the
privilege to practice pharmacy in this state by so practicing or by the making and filing of a renewal
application to practice pharmacy in this state shall be deemed to have consented to submit to a mental
or physical examination or a drug screen, or any combination thereof, when directed in writing by the
board and further to have waived all objections to the admissibility of the testimony, drug screen or
examination report of the person conducting such examination or drug screen, or both, at any
proceeding or hearing before the board on the ground that such testimony or examination or drug screen
report constitutes a privileged communication. In any proceeding by the board pursuant to the
provisions of this subsection, the record of such board proceedings involving the mental and physical
examination or drug screen, or any combination thereof, shall not be used in any other administrative
or judicial proceeding.

(c) The board may temporarily suspend or temporarily limit the license of any licensee in accordance
with the emergency adjudicative proceedings under the Kansas administrative procedure act if the
board determines that there is cause to believe that grounds exist for disciplinary action under
subsection (a) against the licensee and that the licensee's continuation in practice would constitute an
imminent danger to the public health and safety.

(d) The board may suspend, revoke, place in a probationary status or deny an application or renewal
of any retail dealer's permit issued by the board when information in possession of the board discloses
that such operations for which the permit was or may be issued are not being conducted according to
law or the rules and regulations of the board. When the board determines that action under this
subsection requires the immediate protection of the public interest, the board shall conduct an
emergency proceeding in accordance with K.S.A. 77-536, and amendments thereto, under the Kansas
administrative procedure act.

(e) The board may deny an application or renewal, limit, condition, revoke, suspend or place in a
probationary status the registration of any pharmacy upon a finding that:
(1) Such pharmacy has been operated in such manner that violations of the provisions of the pharmacy
act of the state of Kansas or of the rules and regulations of the board have occurred in connection therewith;
(2) the owner, pharmacy or any pharmacist employed at such pharmacy is convicted, subsequent to
such owner's acquisition of or such employee's employment at such pharmacy, of a violation of the
pharmacy act of the state of Kansas, the federal or state uniform controlled substances act or the federal or state food, drug and cosmetic act;
(3) the owner, pharmacy or any pharmacist employed by such pharmacy has fraudulently claimed money for pharmaceutical services;
(4) the registrant has had a registration revoked, suspended or limited, has been censured or has had other disciplinary action taken, or an application for registration denied, by the proper registering authority of another state, territory, District of Columbia or other country, a certified copy of the record of the action of the other jurisdiction being conclusive evidence thereof. When the board determines that action under this subsection requires the immediate protection of the public interest, the board shall conduct an emergency proceeding in accordance with K.S.A. 77-536, and amendments thereto, under the Kansas administrative procedure act;
(5) the registrant has obtained, renewed or attempted to obtain or renew a registration by false or fraudulent means, including misrepresentation of a material fact or falsification of any application;
(6) the registrant has refused to permit the board or its duly authorized agents to inspect the registrant's establishment in accordance with the provisions of the pharmacy act of the state of Kansas, federal or state uniform controlled substances act or the federal or state food, drug and cosmetic act;
(7) the registrant has failed to keep, has failed to file with the board or has falsified records required to be kept or filed by the provisions of the pharmacy act of the state of Kansas, the federal or state uniform controlled substances act or rules and regulations adopted by the board;
(8) such pharmacy has been operated in such manner that violations of the provisions of the federal or state food, drug and cosmetic act, the federal or state uniform controlled substances act, or any rule and regulation adopted under any such act have occurred in connection therewith;
(9) such pharmacy has been operated in such manner that the violations of the provisions of the prescription monitoring program act of the state of Kansas or any rule and regulation of the board have occurred in connection therewith;
(10) the registrant has failed to furnish the board, its investigators or its representatives any information legally requested by the board; or
(11) the registrant has violated or failed to comply with any lawful order or directive of the board.
(f) A registration to manufacture or repackage drugs or devices, to operate as a wholesale distributor, third-party logistics provider, outsourcing facility, institutional drug room or automated dispensing system, or to sell durable medical equipment, or a registration for the place of business where any such operation is conducted, may be limited, conditioned, suspended, revoked or placed in a probationary status or the application for or renewal of such registration may be denied by the board upon a finding that the registrant or the registrant's agent:
(1) Has obtained, renewed or attempted to obtain or renew a registration by false or fraudulent means, including misrepresentation of a material fact or falsification of any application;
(2) has been convicted of a felony under any federal or state law relating to the manufacture, compounding, dispensing or distribution of drugs or devices;
(3) has had any federal registration for the manufacture, compounding, dispensing or distribution of drugs or devices suspended, limited, denied, disciplined, censured or revoked;
(4) has refused to permit the board or its duly authorized agents to inspect the registrant's establishment in accordance with the provisions of the pharmacy act of the state of Kansas, the federal or state uniform controlled substances act or the federal or state food, drug and cosmetic act;
(5) has failed to keep, has failed to file with the board or has falsified records required to be kept or filed by the provisions of the pharmacy act of the state of Kansas, the federal or state uniform controlled substances act or rules and regulations adopted by the board;
(6) has violated the pharmacy act of the state of Kansas or rules and regulations adopted by the state board of pharmacy under the pharmacy act of the state of Kansas, has violated the uniform controlled substances act or rules and regulations adopted by the state board of pharmacy under the uniform controlled substances act, has violated the federal uniform controlled substances act, has violated the federal or state food, drug and cosmetic act or any rules and regulations adopted under any such act, or has violated a provision of the federal drug supply chain security act or any rule or regulation adopted under such act. When the board determines that action under this subsection requires the immediate protection of the public interest, the board shall conduct an emergency proceeding in accordance with K.S.A. 77-536, and amendments thereto, under the Kansas administrative procedure act;

(7) the registrant has had a registration revoked, suspended or limited, has been censured or has had other disciplinary action taken, or an application for registration denied, by the proper registering authority of another state, territory, District of Columbia or other country, a certified copy of the record of the action of the other jurisdiction being conclusive evidence thereof. When the board determines that action under this subsection requires the immediate protection of the public interest, the board shall conduct an emergency proceeding in accordance with K.S.A. 77-536, and amendments thereto, under the Kansas administrative procedure act;

(8) has failed to furnish the board, its investigators or its representatives any information legally requested by the board; or

(9) the registrant has violated or failed to comply with any lawful order or directive of the board.

(g) Orders under this section, and proceedings thereon, shall be subject to the provisions of the Kansas administrative procedure act.


65-1627a. Same; jurisdiction of board; petition, who may file; stipulation, order based thereon.

The board shall have jurisdiction of the proceedings to revoke, suspend, place in a probationary status or deny a renewal of any license, registration or permit issued by the board under the provision of the pharmacy act of the state of Kansas. The petition for the revocation, suspension, placing in a probationary status or denial of a renewal of a license, registration or permit may be filed: (a) By the attorney general in all cases; (b) by the district or county attorney of the county in which the licensee, or permit holder resides or in which a place of business or place of professional practice of such person is located; or (c) by a regularly employed attorney of the board. The petition shall be filed in the office of the executive secretary of the board.

The board and the person holding the license permit or registration may enter into a stipulation which shall be binding upon the board and such person entering into the stipulation, and the board may enter its enforcement order based upon such stipulation without the necessity of filing any formal charges or holding hearings in the proceedings.


65-1627b. Same; direction by board to file petition or to prosecute.

(a) The board may direct the attorney general, the district or county attorney or its regularly employed attorney to file such petition against the licensee, registrant or permit holder upon its own motion, or it may give such direction upon the sworn statement of some person who resides
in the county in which a place of business or place of professional practice of such person is located.
(b) The attorney general shall comply with such directions of the board and prosecute the action on behalf of the state, but the district or county attorney of any county where the licensee, registrant or permit holder has operated a place of business or place of professional practice, at the request of the attorney general or the board, shall appear and prosecute such action.

**History:** L. 1975, ch. 319, § 5; L. 1986, ch. 231, § 12; June 1.

**65-1627c. Same; form of petition, rules.**

The following rules shall govern the form of the petition in such cases:
(a) The board shall be named as plaintiff and the person who holds the license, registration or permit as defendant. (b) The charges against the person who holds the license, registration or permit shall be stated with reasonable definiteness. (c) Amendments may be made as in ordinary actions in the district court. (d) All allegations shall be deemed denied, but the person who holds the license, registration or permit may plead to the petition if such person so desires.

**History:** L. 1975, ch. 319, § 6; L. 1986, ch. 231, § 13; June 1.

**65-1627d.**

**History:** L. 1975, ch. 319, § 7; Repealed, L. 2005, ch. 26, § 1; July 1.

**65-1627e.**


**65-1627f. Same; powers of board; term of suspension, probation or revocation; hearing; orders.**

(a) Depositions may be used by either party. Upon the completion of any hearing held hereunder, the board shall have the power to enter an order of revocation, suspension, probation or denial of the renewal of a license, registration or permit. The license, registrant or permit holder shall not engage in the activity authorized by such license, registration or permit after a license, registration or permit is revoked or the renewal thereof denied or during the time for which it is suspended. If a license, registration or permit is suspended or placed on probation, the suspension or probation shall be for a definite period of time to be fixed by the board, and the license, registration or permit shall be reinstated and any limitations or conditions thereon removed upon the expiration of such period if all renewal fees have been paid. If such license, registration or permit is revoked, such revocation shall be for all time, except that at any time after the expiration of one year, application may be made for reinstatement of any license, registrant or permit holder whose license, registration or permit shall have been revoked, and such application shall be addressed to the executive secretary of the board. Such application shall be processed in accordance with the provisions of the Kansas administrative procedure act. (b) All final orders entered in any proceeding shall be the action of the board with a quorum present at such meeting.

**History:** L. 1975, ch. 319, § 9; L. 1986, ch. 231, § 15; L. 1988, ch. 356, § 197; L. 1998, ch. 98, § 2; Apr. 16.

**65-1627g.**

**History:** L. 1975, ch. 319, § 10; L. 1986, ch. 231, § 16; Repealed, L. 2005, ch. 26, § 1; July 1.
65-1627h. Costs of proceedings.
(a) If the order is adverse to the licensee, registrant or permit holder, the costs shall be charged to such person as in ordinary civil actions in the district court, but if the board is the unsuccessful party, the costs shall be paid out of any money in the state board of pharmacy fee fund. Witness fees and costs may be taxed according to the statutes applicable in the district courts.
(b) All costs accrued at the instance of the state, when it is the successful party, and which the attorney general certifies cannot be collected from the licensee, registrant or permit holder, shall be paid out of any available funds in the state treasury to the credit of the board.
(c) The board may consider nonpayment of costs which have been assessed against a person under this section when considering a motion for reinstatement of a license or registration by such person, or as a condition of probation.


65-1627i.

65-1627j. Subpoenas.
(a) In all investigative and disciplinary matters pending before the board, the board shall have the power to issue subpoenas and compel the attendance of witnesses and the production of all necessary papers, books and records, documentary evidence and materials. Any person failing or refusing to appear or testify regarding any matter about which such person may be lawfully questioned or to produce any papers, books, records, documentary evidence or materials in the matter to be heard, after having been required by order of the board or by a subpoena of the board to do so, upon application to any district judge of the state of Kansas, may be ordered to comply with such subpoena, and upon failure to comply with the order of the district judge, the court may compel obedience by attachment as for contempt as in the case of disobedience of a similar order or subpoena issued by the court. A subpoena may be served upon any person named therein, anywhere within the state of Kansas with the same fees and mileage by any officer authorized to serve subpoenas in civil actions in the same manner as is prescribed by the code of civil procedure for subpoenas issued out of the district courts of this state.
(b) This section shall be part of and supplemental to the pharmacy act of the state of Kansas.

History: L. 1999, ch. 38, § 2; July 1.

65-1627k. Certain records of board of pharmacy confidential; exceptions.
(a) Any complaint, investigation, report, record or other information relating to a complaint or investigation that is received, obtained or maintained by the board shall be confidential and shall not be disclosed by the board or its employees in a manner that identifies or enables identification of the person who is the subject or source of the information, except the information may be disclosed:
(1) In any proceeding conducted by the board under the law or in an appeal of an order of the board entered in a proceeding, or to any party to a proceeding or appeal or the party's attorney;
(2) to the person who is the subject of the information or to any person or entity when requested by the person who is the subject of the information, but the board may require disclosure in such a manner that will prevent identification of any other person who is the subject or source of the information; or
(3) to a state or federal licensing, regulatory or enforcement agency with jurisdiction over the subject of the information or to an agency with jurisdiction over acts or conduct similar to acts or conduct that would constitute grounds for action under this act. Any confidential complaint or report, record or other information disclosed by the board as authorized by this section shall not be disclosed by the receiving agency except as otherwise authorized by law.

(b) Except as provided in subsection (a), no applicant, registrant or individual shall have access to any complaint, investigation, report, record or information concerning a complaint or investigation in progress until the investigation and any enforcement action is completed. This section shall not be construed to authorize the release of records, reports or other information that are subject to other specific state or federal laws concerning their disclosure.

(c) This section shall be a part of and supplemental to the pharmacy act of the state of Kansas.

History: L. 2021, ch. 106, § 1; June 3.

65-1627l. Conditions of probation or disciplinary action; compliance inspections and audits; payment of costs.

(a) (1) As a condition of probation or other disciplinary action under K.S.A. 65-1627 or 65-1657, and amendments thereto, the board may require that a licensee or registrant be subject to additional compliance inspections or audits and pay the actual costs of such inspections and audits.

(2) If a licensee or registrant fails to comply with a board order regarding the costs of additional inspections and audits, the board may impose additional disciplinary action against the licensee or registrant for failure to comply with a lawful order of the board under K.S.A. 65-1627, and amendments thereto.

(b) Actual costs under this section include, but are not limited to:

(1) Salaries and wages;
(2) travel, mileage and lodging;
(3) subsistence allowances;
(4) document storage, shipping and handling; or
(5) other expenses deemed reasonable and necessary by the board.

(c) All moneys assessed and collected under this section shall be remitted to the state treasurer in accordance with the provisions of K.S.A. 75-4215, and amendments thereto, and deposited in the state treasury to the credit of the state board of pharmacy fee fund.

(d) This section shall be a part of and supplemental to the pharmacy act of the state of Kansas.

History: L. 2021, ch. 106, § 2; June 3.

65-1628. Order; judicial review.

(a) If any application for any license, registration or permit is refused or the renewal thereof denied or if any license, registration or permit is suspended, revoked or placed on probation, the board shall notify the person affected in writing of its decision and order and the reasons therefor.

(b) Any action of the board pursuant to K.S.A. 65-1627f, and amendments thereto, is subject to review in accordance with the Kansas judicial review act.

If the licensee, registrant or permit holder petitions for review, the only bond required shall be one running to the state, in an amount to be fixed by the court for the payment of the costs both before the board and in the district court. Such bond shall be approved by the judge of the district court. The giving of such a bond by the licensee, registrant or permit holder shall not operate to stay the order of the board or restore the right of the licensee, registrant or permit holder to engage in the profession or business for which the license, registration or permit was issued or remove any condition upon engaging therein pending review, but a stay may be granted in accordance with K.S.A 77-616, and amendments thereto.


65-1628b.

65-1629. Inspection of drugs by board; samples; analyses; publication of results.
The board and its duly authorized agents and employees may inspect in a lawful manner the drugs kept for sale, offered for sale or for dispensing, or sold in the state of Kansas by any pharmacist, or kept in stock by any duly licensed practitioner or institutional drug room in the state, or when such inspection is required by the secretary of health and environment the drugs kept in stock by any medical care facility; and for this purpose shall have the right to enter and inspect during business hours any institutional drug room or any pharmacy or any other place in the state of Kansas where drugs are manufactured, packed, packaged, made, sold, offered for sale or kept for sale and may collect samples of such drugs upon payment therefor. The samples thus collected may be submitted for analysis to the office of laboratory services of the department of health and environment and the results of the analysis may be published by the state department of health and environment.


The board may adopt and promulgate such reasonable rules and regulations, not inconsistent with law, as may be necessary to carry out the purposes and enforce the provisions of this act, which rules and regulations shall be filed in the office of the secretary of state as required by article 4 of chapter 77 of the Kansas Statutes Annotated and amendments thereto.


65-1631. Licensure required of pharmacists; qualification of applicants; application for licensure by examination; reciprocal licensure; fees; applicants from schools outside the United States.
(a) It shall be unlawful for any individual to practice as a pharmacist in this state unless such individual is licensed by the board as a pharmacist. Except as otherwise provided in subsection (d), every applicant for licensure as a pharmacist shall be at least 18 years of age, shall be a graduate of a school or college of pharmacy or department of a university recognized and approved by the board, shall file proof satisfactory to the board, substantiated by proper affidavits, of a minimum of one year of pharmaceutical experience, acceptable to the board, under the supervision of a preceptor and shall pass an examination approved by the board. Pharmaceutical experience as required in this section shall be under the supervision of a preceptor and shall be predominantly related to the dispensing of prescription
medication, compounding prescriptions, preparing pharmaceutical preparations and keeping records and making reports required under state and federal statutes. A school or college of pharmacy or department of a university recognized and approved by the board under this subsection shall have a standard of education not below that of the university of Kansas school of pharmacy. The board shall adopt rules and regulations establishing the criteria that a school or college of pharmacy or department of a university shall satisfy in meeting the standard of education established under this subsection.

(b) All applications for licensure by examination shall be made on a form to be prescribed and furnished by the board. Each application for a new license by examination shall be accompanied by a license fee fixed by the board as provided in K.S.A. 65-1645, and amendments thereto.

(c) The board is authorized to adopt rules and regulations relating to the score that an applicant must receive in order to pass the examinations required for licensure. The board shall only accept a passing score on an examination required for licensure from an applicant's first five attempts taking such examination.

(d) Notwithstanding the preceding provisions of this section, the board may in its discretion license as a pharmacist, without examination, any individual who is duly registered or licensed by examination in some other state, except that the board may require that such individual take the multi-state jurisprudence examination approved by the board. The board is authorized to adopt rules and regulations relating to the score that such individual shall be required to receive in order to pass the multi-state jurisprudence examination. The board shall only accept a passing score on an examination required for licensure from an applicant's first five attempts taking such examination. Such individual shall file proof satisfactory to the board of having the education and training required of applicants for licensure under the provisions of the pharmacy act of this state. Individuals who are registered or licensed as pharmacists by examination in other states shall be required to satisfy only the requirements that existed in this state at the time they become registered or licensed in such other states. The provisions of this subsection shall apply only if the state in which the individual is registered or licensed grants, under like conditions, reciprocal registrations or licenses as pharmacists, without examination, to pharmacists duly licensed by examination in this state. Reciprocal licensure shall not be denied to any applicant otherwise qualified for reciprocal licensure under this section who has met the internship requirements of the state from which the applicant is reciprocating or who has at least one year of practice as a licensed pharmacist. A reciprocal licensure may be denied for any of the reasons set forth in K.S.A. 65-1627(a)(1) through (a)(13), and amendments thereto.

(e) In the event that an applicant for reciprocal licensure has not been subject to laws requiring continuing education as a condition for renewal of a registration or license, such applicant shall be required to satisfy the board through a competency examination that the applicant has the knowledge and ability to meet Kansas standards for licensure as a pharmacist.

(f) All applicants for reciprocal licensure shall file their applications on a form to be prescribed and furnished by the board and such application shall be accompanied by a reciprocal licensure fee fixed by the board as provided in K.S.A. 65-1645, and amendments thereto. The reciprocal licensure fee established by this section immediately prior to the effective date of this act shall continue in effect until a different reciprocal licensure fee is fixed by the board by rules and regulations as provided in K.S.A. 65-1645, and amendments thereto.

(g) The board shall take into consideration any felony conviction of such individual, but such conviction shall not automatically operate as a bar to licensure.

(h) All applicants for licensure who graduate from a school or college of pharmacy outside the United States or who graduate from a school or college of pharmacy not approved by the board shall submit information to the board, as specified by rules and regulations, and this information shall be accompanied by an evaluation fee fixed by the board as provided in K.S.A. 65-1645, and amendments thereto, that shall be in addition to any other fee paid by the applicant under the pharmacy act of the
state of Kansas. The evaluation fee fixed by the board under this section immediately prior to the effective date of this act shall continue in effect until a different evaluation fee is fixed by the board by rules and regulations as provided in K.S.A. 65-1645, and amendments thereto. The board may contract with investigative agencies, commissions or consultants to assist the board in obtaining information about such schools or colleges of pharmacy. In entering such contracts the authority to approve schools or colleges of pharmacy shall remain solely with the board.

(i) All applicants for licensure who graduate from a school or college of pharmacy outside the United States or who are not citizens of the United States shall provide proof to the board that the applicant has a reasonable ability to communicate with the general public in English. The board may require such applicant to take the test of English as a foreign language and to attain the grade for passing such test as established by the board by rules and regulations.

(j) Every registered pharmacist holding a valid registration as a pharmacist in effect on the day preceding the effective date of this act shall be deemed to be a licensed pharmacist under this act, and such individual shall not be required to file an original application hereunder for a license.

65-1632. Renewal of license; fee; denial; conditions; continuing education; inactive status license; reinstatement after nonrenewal; penalty fee.

(a) Except as otherwise provided in this section, each license to practice as a pharmacist issued by the board, shall expire every two years. The expiration date shall be established by rules and regulations adopted by the board. Each application for renewal of a license as a pharmacist shall be made on a form prescribed and furnished by the board. Each application, when accompanied by the renewal fee and received by the executive secretary of the board on or before the date of expiration of the license, shall have the effect of temporarily renewing the applicant’s license until actual issuance or denial of the renewal. If at the time of filing a proceeding is pending before the board which may result in the suspension, probation, revocation or denial of the applicant’s license, the board may by emergency order declare that the application for renewal shall not have the effect of temporarily renewing such applicant’s license. Every licensed pharmacist shall pay to the secretary of the board a renewal fee fixed by the board as provided in K.S.A. 65-1645, and amendments thereto.

(b) To provide for a system of biennial renewal of licenses, the board may provide by rules and regulations that licenses issued or renewed may expire less than two years from the date of issuance or renewal. License fees may be prorated for licensure periods which are less than biennial in accordance with rules and regulations of the board.

(c) The board may deny renewal of any license of a pharmacist on any ground which would authorize the board to deny an initial application for licensure or on any ground which would authorize the board to suspend, revoke or place on probation a license previously granted. Orders under this section, and proceedings thereon, shall be subject to the provisions of the Kansas administrative procedure act.

(d) The payment of the renewal fee by a person who is a holder of a license as a pharmacist shall entitle the person to renewal of license if no grounds exist for denying the renewal of the license and if the person has furnished satisfactory evidence to the board that the person has successfully complied with the rules and regulations of the board relating to continuing professional education. These educational requirements shall be fixed by the board at not less than 20 clock
hours nor more than 40 clock hours biennially of a program of continuing education approved by
the board. Continuing education hours may be prorated for licensure periods which are less than
biennial in accordance with rules and regulations of the board. The maximum number of
continuing education hours required by the board to meet the requirements for cancellation of
inactive status licensure and renewal of license under subsection (e) or reinstatement of license
because of nonpayment of fees under subsection (f) shall not exceed 60.
(e) The payment of the renewal fee by the person who is a holder of a license as a pharmacist but
who has not complied with the continuing education requirements fixed by the board, if no
grounds exist for denying the renewal of the license other than that the person has not complied
with the continuing education requirements fixed by the board, shall entitle the person to inactive
status licensure by the board. No person holding an inactive status license from the board shall
engage in the practice of pharmacy in this state. Upon furnishing satisfactory evidence to the
board of compliance with the continuing education requirements fixed by the board and upon the
payment to the board of all applicable fees, a person holding an inactive status license from the
board shall be entitled to cancellation of the inactive status license and to renewal of licensure as
a pharmacist.
(f) If the renewal fee for any pharmacist’s license has not been paid prior to the expiration of the
license of the renewal year, the license is hereby declared void, and no license shall be reinstated
except upon payment of any unpaid renewal fee plus a penalty fee fixed by the board as provided
in K.S.A. 65-1645, and amendments thereto, and proof satisfactory to the board of compliance
with the continuing education requirements fixed by the board. The penalty fee established by
this section immediately prior to the effective date of the act shall continue in effect until a
different penalty fee is fixed by the board by rules and regulations as provided in K.S.A. 65-
1645, and amendments thereto. Payment of any unpaid renewal fee plus a penalty fee and the
submission of proof satisfactory to the board of compliance with the continuing education
requirements fixed by the board shall entitle the license to be reinstated. The nonpayment of
renewal fees by a previously licensed pharmacist for a period exceeding three years shall not
deprive the previously licensed pharmacist of the right to reinstate the license upon the payment
of any unpaid fees and penalties and upon compliance with the continuing education
requirements fixed by the board, except that the board may require such previously licensed
pharmacist to take and pass an examination approved by the board for reinstatement as a
pharmacist and to pay any applicable application fee.

History: L. 1953, ch. 290, § 18; L. 1962, ch. 37, § 2; L. 1967, ch. 342, § 2; L. 1974, ch. 252, § 2;

65-1633. Change of address of pharmacist.
Every pharmacist who changes residential address or email address shall within 30 days thereof
notify the secretary of such change on a form prescribed and furnished by the board, and upon
receipt of the notice the secretary shall make the proper alterations in the record kept for that
purpose.

History: L. 1953, ch. 290, § 19; L. 1962, ch. 37, § 3; L. 1975, ch. 319, § 19; L. 1982, ch. 263, §
3; L. 1986, ch. 231, § 22; L. 2017, ch. 34, § 3; April 20.
65-1634. Responsibility for quality of drugs sold; adulteration or mislabeling unlawful.
Every person holding a license, registration or permit under the pharmacy act of the state of Kansas who engages in the sale of drugs, medicines, chemicals and poisons shall be responsible for the quality of all such drugs, medicines, chemicals and poisons which such person may sell, compound or put up except when sold in the original and unbroken pack, package, box or other container of the manufacturer. If any person intentionally adulterates or mislabels any drugs, medicines, chemicals or poisons, or causes the same to be adulterated or mislabeled or exposed for sale knowing the same to be adulterated or mislabeled, such person shall be guilty of a class A misdemeanor.


65-1635. Dispensing and administering of drugs by duly licensed practitioners, nurses and other persons.
(a) Nothing contained in the pharmacy act of the state of Kansas shall prohibit any duly licensed practitioner from purchasing and keeping drugs, from compounding prescriptions or from administering, supplying or dispensing to such practitioner's patients such drugs as may be fit, proper and necessary. Except as provided in subsection (b) or (c), such drugs shall be dispensed by such practitioner and shall comply with the Kansas food, drug and cosmetic act and be subject to inspection as provided by law.
(b) Nothing contained in the pharmacy act of the state of Kansas shall be construed to prohibit any nurse or other person, acting under the direction of a duly licensed practitioner, from administering drugs to a patient.
(c) Nothing contained in the pharmacy act of the state of Kansas shall be construed to prohibit any registered nurse, acting under the supervision of a person who is licensed to practice medicine and surgery as of July 1, 1982, from dispensing drugs to patients of such person so long as the principal office of such person is, and as of July 1, 1982, was, located in a city not having a registered pharmacy within its boundaries. For the purposes of this subsection (c), "supervision" means guidance and direction of the dispensing of drugs by the person licensed to practice medicine and surgery who shall be physically present in the general location at which the drugs are being dispensed.
(d) Nothing contained in the pharmacy act of the state of Kansas shall be construed to prohibit a duly registered wholesale distributor from distributing a prescription-only drug pursuant to a veterinarian practitioner's written prescription or order, where a valid veterinarian-client-patient relationship, VCPR, as defined in K.S.A. 47-816, and amendments thereto, exists, to the layman responsible for the control of the animal.
(e) Nothing contained in the pharmacy act of the state of Kansas shall require an in-person examination or encounter between a person licensed to practice medicine and surgery and the patient prior to a pharmacist filling or refilling any prescription.


65-1635a. Administration of vaccine; education and reporting requirements; delegation of authority prohibited; "pharmacist" defined.
(a) A pharmacist or a pharmacy student, intern or pharmacy technician who is 18 years of age or older and working under the direct supervision and control of a pharmacist may administer influenza vaccine to a person six years of age or older and may administer vaccine, other than
influenza vaccine, to a person 12 years of age or older pursuant to a vaccination protocol if the
pharmacist, pharmacy student, intern or pharmacy technician has successfully completed a
course of study and training, approved by the accreditation council for pharmacy or the board, in
vaccination storage, protocols, injection technique, emergency procedures and recordkeeping and
has taken a course in cardiopulmonary resuscitation (CPR) and has a current CPR certificate
when administering vaccine. A pharmacist, pharmacy student, intern or pharmacy technician
who successfully completes such a course of study and training shall maintain proof of
completion and, upon request, provide a copy of such proof to the board.
(b) All vaccinees will be given a written immunization record for their personal files. The
administering pharmacist or pharmacist supervising an administering pharmacy student, intern or
pharmacy technician shall promptly report a record of the immunization to the vaccinee’s
primary care provider by mail, electronic facsimile, email or other electronic means. If the
vaccinee does not have a primary care provider, then the administering pharmacist or pharmacist
supervising an administering pharmacy student, intern or pharmacy technician shall promptly
report a record of the immunization to the person licensed to practice medicine and surgery by
the state board of healing arts who has entered into the vaccination protocol with the pharmacist.
The immunization will also be reported to appropriate county or state immunization registries,
except that if the person vaccinated or, if the person is a minor, the parent or guardian of the
minor, objects to the report, the report shall not be made.
(c) A pharmacist, pharmacy student, intern or pharmacy technician shall not delegate to any
person the authority granted under this act to administer a vaccine.
(d) As used in this section, “pharmacist” means a pharmacist as defined in K.S.A. 65-1626, and
amendments thereto, who has:
(1) Successfully completed a course of study and training, approved by the accreditation council
for pharmacy or the board, in vaccination storage, protocols, injection technique, emergency
procedures and recordkeeping;
(2) taken a course in cardiopulmonary resuscitation (CPR); and
(3) a current CPR certificate.
(e) This section shall be a part of and supplemental to the pharmacy act of the state of Kansas.
History: L. 2000, ch. 118, § 3; L. 2006, ch. 41, § 1; L. 2007, ch. 177, § 32; L. 2010, ch 43, § 1;
L. 2023, ch. 90, § 3, July 1.

65-1636. Sale of drugs limited to pharmacies; violations; exceptions.
(a) Except as otherwise provided in this act, the sale and dispensing of drugs shall be limited to
pharmacies operating under registrations as required by this act, and the actual sale or dispensing
of drugs shall be made by a pharmacist or other persons acting under the immediate personal
direction and supervision of the pharmacist.
(b) The donation, acceptance, transfer, distribution or dispensing of any drug in compliance with
the provisions of the utilization of unused medications act and any rules and regulations
promulgated thereunder shall not constitute a violation of this section.
1; L. 2013, ch. 114, § 7; L. 2017, ch. 34, § 5; April 20.

65-1637. Prescription orders; requirements; compounding, filling and refilling of
prescriptions; refusal to fill; brand exchange; interchangeable biological products.
(a) The pharmacist shall exercise professional judgment regarding the accuracy, validity and
authenticity of any prescription order consistent with federal and state laws and rules and regulations.
Except as provided in K.S.A. 65-1635 (e), and amendments thereto, and as may otherwise be provided by law, a pharmacist shall not dispense a prescription drug if the pharmacist, in the exercise of professional judgment, determines that the prescription is not a valid prescription order.

(b) The prescriber may authorize an agent to transmit to the pharmacy a prescription order orally, by facsimile transmission or by electronic transmission, provided that the first and last names of the transmitting agent are included in the order.

c) (1) A new written or electronically prepared and transmitted prescription order shall be manually or electronically signed by the prescriber. If transmitted by the prescriber's agent, the first and last names of the transmitting agent shall be included in the order.

(2) If the prescription is for a controlled substance and is written or printed from an electronic prescription application, the prescription shall be manually signed by the prescriber prior to delivery of the prescription to the patient or prior to facsimile transmission of the prescription to the pharmacy.

(3) An electronically prepared prescription shall not be electronically transmitted to the pharmacy if the prescription has been printed prior to electronic transmission. An electronically prepared and transmitted prescription that is printed following electronic transmission shall be clearly labeled as a copy, not valid for dispensing.

(4) The board is hereby authorized to conduct pilot projects related to any new technology implementation when deemed necessary and practicable, except that no state moneys shall be expended for such purpose.

(d) An authorization to refill a prescription order or to renew or continue an existing drug therapy may be transmitted to a pharmacist through oral communication, in writing, by facsimile transmission or by electronic transmission initiated by or directed by the prescriber.

(1) If the transmission is completed by the prescriber's agent, and the first and last names of the transmitting agent are included in the order, the prescriber's signature is not required on the fax or alternate electronic transmission.

(2) If the refill order or renewal order differs in any manner from the original order, such as a change of the drug strength, dosage form or directions for use, the prescriber shall sign the order as provided by subsection (c)(1).

e) Regardless of the means of transmission to a pharmacy, a pharmacist or a pharmacist intern shall be authorized to receive a new prescription order or a refill or renewal order from a prescriber or transmitting agent. A registered pharmacy technician may receive a refill, renewal or order for continuation of therapy that contains no changes from the original prescription from a prescriber or transmitting agent if such registered pharmacy technician's supervising pharmacist has authorized that function.

(f) A refill is one or more dispensings of a prescription drug or device that results in the patient's receipt of the quantity authorized by the prescriber for a single fill as indicated on the prescription order. A prescription for a schedule III, IV or V controlled substance may authorize no more than five refills within six months following the date on which the prescription is issued.

(g) All prescriptions shall be filled or refilled in strict conformity with any directions of the prescriber, except that:

(1) A pharmacist who receives a prescription order for a brand name drug product may exercise brand exchange with a view toward achieving a lesser cost to the purchaser unless:

(A) The prescriber indicates "dispense as written" on the prescription or when communicating a prescription by oral order;

(B) the FDA has determined that a biological product is not an interchangeable biological product for the prescribed biological product; or
(C) the FDA has determined that a drug product of the same generic name is not bioequivalent to the prescribed brand name prescription medication;

(2) a pharmacist may provide up to a three-month supply of a prescription drug that is not a controlled substance or psychotherapeutic drug when a practitioner has written a drug order to be filled with a smaller supply but included sufficient numbers of refills for a three-month supply; or

(3) except for a prescription for a controlled substance, a pharmacist may use professional judgment to make the following adaptations to a prescription order if a patient consents, the prescriber has not indicated "dispense as written" on the prescription, the pharmacist documents the adaptation on the patient's prescription record and the pharmacist notifies the prescriber:

(A) Change the prescribed quantity if:
   (i) The prescribed quantity or package size is not commercially available;
   (ii) the change in quantity is related to a change in dosage form; or
   (iii) the change extends a maintenance drug for the limited quantity necessary to coordinate a patient's refills in a medication synchronization program;

(B) change the prescribed dosage form, strength or directions for use if it is in the best interest of the patient and the change achieves the intent of the prescriber; or

(C) complete missing information on the prescription order if there is evidence to support the change.

(h) A pharmacist who selects an interchangeable biological product shall inform the patient or the patient's representative that an interchangeable biological product has been substituted for the prescribed biological product.

(i) If a prescription order contains a statement that during any particular time the prescription may be refilled at will, there shall be no limitation as to the number of times that such prescription may be refilled, except that it may not be refilled after the expiration of the time specified or one year after the prescription was originally issued, whichever occurs first.

(j) Prescription orders shall be recorded in writing by the pharmacist and the record so made by the pharmacist shall constitute the original prescription to be dispensed by the pharmacist. This record, if telephoned by other than the prescriber, shall bear the full name of the individual so telephoning. Nothing in this section shall be construed as altering or affecting in any way laws of this state or any federal act requiring a written prescription order.

(k) (1) Except as provided in paragraph (2), no prescription shall be refilled unless authorized by the prescriber either in the original prescription or by oral order that is reduced promptly to writing and filled by the pharmacist.

(2) A pharmacist may refill a prescription order issued on or after the effective date of this act for any prescription drug, except a drug listed on schedule II of the uniform controlled substances act or a narcotic drug listed on any schedule of the uniform controlled substances act, without the prescriber's authorization when all reasonable efforts to contact the prescriber have failed and when, in the pharmacist's professional judgment, continuation of the medication is necessary for the patient's health, safety and welfare. Such prescription refill shall only be in an amount judged by the pharmacist to be sufficient to maintain the patient until the prescriber can be contacted, but in no event shall a refill under this paragraph be more than a 30-day supply or one package of the drug. However, if the prescriber states on a prescription that there shall be no emergency refilling of that prescription, then the pharmacist shall not dispense any emergency medication pursuant to that prescription. A pharmacist who refills a prescription order under this paragraph shall contact the prescriber of the prescription order on the next business day subsequent to the refill or as soon thereafter as possible. No pharmacist shall be required to refill any prescription order under this paragraph. A prescriber shall not be subject to liability for any damages resulting from the refilling of a prescription order by a
Any pharmacist who exercises brand exchange and dispenses a less expensive drug product shall not charge the purchaser more than the regular and customary retail price for the dispensed drug.

(n) Except as provided in K.S.A. 65-1635(e), and amendments thereto, and as may otherwise be provided by law, nothing contained in this section shall be construed as preventing a pharmacist from refusing to fill or refill any prescription if, in the pharmacist's professional judgment and discretion, such pharmacist is of the opinion that it should not be filled or refilled.

(o) Within five business days following the dispensing of a biological product, the dispensing pharmacist or the pharmacist's designee shall make an entry of the specific product provided to the patient, including the name of the product and the manufacturer. The communication shall be conveyed by making an entry that is electronically accessible to the prescriber through:
   (1) an interoperable electronic medical records system;
   (2) an electronic prescribing technology;
   (3) a pharmacy benefits management system; or
   (4) a pharmacy record.

(p) Entry into an electronic records system as described in subsection (o) shall be presumed to provide notice to the prescriber. Otherwise, the pharmacist shall communicate the biological product dispensed to the prescriber using facsimile, telephone, electronic transmission or other prevailing means, provided that communication shall not be required where:
   (1) There is no FDA-approved interchangeable biological product for the product prescribed; or
   (2) a refill prescription is not changed from the product dispensed on the prior filling of the prescription.

(q) A pharmacist shall maintain a record of any biological product dispensed for at least five years.

(r) The board shall maintain a link on its website to the current lists of all biological products that the FDA has determined to be interchangeable biological products.


65-1637a. Institutional drug rooms; supervision and record-keeping; rules and regulations.
(a) An institutional drug room shall be under the supervision of a pharmacist or a practitioner, who may be retained on a part-time basis and who shall be responsible for recordkeeping and storage of drugs by such drug room. For the purposes of this section, "practitioner" means any person licensed to practice medicine and surgery.

(b) The board shall adopt such rules and regulations relating to record-keeping and storage of drugs by institutional drug rooms as necessary for proper control of drugs by such drug rooms.

(c) This section shall be part of and supplemental to the pharmacy act of the state of Kansas.

History: L. 1979, ch. 193, § 5; L. 1986, ch. 231, § 26; June 1.

65-1637b. Transmission of prescription drug orders; filling and refilling of prescriptions; refusal to fill; brand exchange.

65-1637c. Pharmacist required to be in charge of pharmacy; filling of certain prescriptions; refusal to fill; brand exchange. [See Revisor's Note]
(a) In every store, shop or other place defined in this act as a “pharmacy” there shall be a pharmacist-in-charge and, except as otherwise provided by law, the compounding and dispensing of prescriptions shall be limited to pharmacists only.
(b) Except as otherwise provided by the pharmacy act of this state, when a pharmacist is not in attendance at a pharmacy, the premises shall be enclosed and secured.


65-1637d. Automated prescription drug dispensing systems; pharmacist required to supervise; rules and regulations.
(a) An automated dispensing system shall be under the supervision of a pharmacist licensed in Kansas, who may be retained on a part-time basis and who shall be responsible for recordkeeping and storage of all drugs and verifying and documenting each prescription drug prepared or dispensed by such system.
(b) The board shall adopt such rules and regulations relating to automated dispensing systems as necessary for proper control and operation.
(c) This section shall be part of and supplemental to the pharmacy act of the state of Kansas.

History: L. 2017, ch. 34, § 7; April 20.

65-1637e. Compounding of drugs and distribution of compounded drugs; rules and regulations.
(a) The board shall adopt rules and regulations governing proper compounding practices and distribution of compounded drugs by pharmacists and pharmacies.
(b) This section shall be part of and supplemental to the pharmacy act of the state of Kansas.

History: L. 2017, ch. 34, § 17; April 20.

65-1638. Sale of drugs and poisons by registered pharmacist.
A pharmacist shall have the right to keep and sell, subject to such restrictions as may be provided by law, all drugs and poisons listed in the national formulary, the United States Pharmacopeia and other standard pharmaceutical and medical works of recognized utility, but nothing in the pharmacy act of the state of Kansas shall be construed to protect any pharmacist who violates or in any way abuses this trust from the penalties for violations of the laws relating to the sale or distribution of drugs.
Nothing in the pharmacy act of the state of Kansas shall prohibit pharmacists from repackaging poisons according to applicable state and federal packaging and labeling laws. The sale of poisons shall conform to applicable state and federal laws.


65-1639.
65-1640. Act not applicable to manufacture or to certain sales of poisons.
Nothing contained in the pharmacy act of the state of Kansas shall prevent the manufacture by
any person of any poisons, nor shall anything in such act prevent the sale by any person of any
poisons when the poison is sold in unbroken packages and is labeled as required by law.

65-1641. Display of pharmacist license; when unlawful.
A person holding a license as a pharmacist shall display conspicuously such license in that part
of the place of business in which such person is engaged in the profession of pharmacy, and
which is usually occupied by the public or which is visible to the public. It shall be unlawful for
any licensed pharmacist to permit such license to be displayed in any place of business unless
such pharmacist is actively engaged in the profession of pharmacy in such place of business.

65-1642. Equipment of pharmacy; records of prescription orders; medication profile
record system; electronic transmission of prescription drug orders.
(a) Each pharmacy shall be equipped with proper pharmaceutical utensils, in order that
prescriptions can be properly filled and United States pharmacopeia and national formulary
preparations properly compounded, and with proper sanitary appliances that shall be kept in a
clean and orderly manner. The board shall prescribe the minimum of such professional and
technical equipment which a pharmacy shall at all times possess.
(b) Each pharmacy shall keep a suitable book or file that records every prescription order filled at
the pharmacy and a medication profile record system as provided under subsection (d). The book
or file of prescription orders shall be kept for a period of not less than five years. The book or file
of prescription orders shall at all times be open to inspection by members of the board, the
secretary of health and environment, the duly authorized agents or employees of such board or
secretary and other proper authorities.
(c) (1) A medication profile record system shall be maintained in all pharmacies for persons for
whom prescriptions are dispensed. The following information shall be recorded:
   (A) The name and address of the patient for whom the medication is intended;
   (B) the prescriber's name, the original date the prescription is dispensed and the number
      or designation identifying the prescription;
   (C) the name, strength and quantity of the drug dispensed and the name of the dispensing
      pharmacist; and
   (D) drug allergies and sensitivities.
(2) Upon receipt of a prescription order, the pharmacist shall examine the patient's
medication profile record before dispensing the medication to determine the possibility of a
harmful drug interaction or reaction to medication. Upon recognizing a potential harmful
drug interaction or reaction to the medication, the pharmacist shall take appropriate action to
avoid or minimize the problem that shall, if necessary, include consultation with the
prescriber with documentation of actions taken on the prescription record.
(3) A medication profile record shall be maintained for a period of not less than five years
from the date of the last entry in the record.
(4) All prescription drug orders communicated by way of electronic transmission shall
conform to federal and state laws and the provisions of the board's rules and regulations.
(d) No registration shall be issued or continued for the conduct of a pharmacy until or unless the provisions of this section have been complied with.
(e) Each pharmacy shall comply with the requirements of the federal drug supply chain security act, 21 USC 351 et seq.


**65-1643. Registration or permit required; pharmacies, manufacturers, wholesale distributors, third-party logistics providers, automated dispensing systems, auctions, sales, distribution or dispensing of samples, retailers, institutional drug rooms, veterinary medical teaching hospital pharmacies; certain acts declared unlawful.**

It shall be unlawful:
(a) For any person to operate, maintain, open or establish any pharmacy within this state without first having obtained a registration from the board. Each application for registration of a pharmacy shall indicate the person or persons desiring the registration, including the pharmacist-in-charge, as well as the location, including the street name and number, and such other information as may be required by the board to establish the identity and exact location of the pharmacy. The issuance of a registration for any pharmacy shall also have the effect of permitting such pharmacy to operate as a retail dealer without requiring such pharmacy to obtain a retail dealer's permit. On evidence satisfactory to the board: (1) That the pharmacy for which the registration is sought will be conducted in full compliance with the law and the rules and regulations of the board; (2) that the location and appointments of the pharmacy are such that it can be operated and maintained without endangering the public health or safety; and (3) that the pharmacy will be under the supervision of a pharmacist, a registration shall be issued to such persons as the board shall deem qualified to conduct such a pharmacy.
(b) For any person to violate the federal drug supply chain security act, 21 U.S.C. § 351 et seq.
(c) For any person to distribute at wholesale any drugs or devices without first obtaining a registration as a wholesale distributor from the board.
(d) For any person to operate as a third-party logistics provider within this state without having first obtained a registration from the board.
(e) For any person to in any manner distribute or dispense samples of any drugs or devices without first having obtained a permit from the board so to do, and it shall be necessary to obtain permission from the board in every instance where the samples are to be distributed or dispensed. Nothing in this subsection shall be held to regulate or in any manner interfere with the furnishing of samples of drugs to duly licensed practitioners, to mid-level practitioners, to pharmacists or to medical care facilities.
(f) Except as otherwise provided in this subsection, for any person operating a store or place of business to sell, offer for sale or distribute any drugs to the public without first having obtained a registration or permit from the board authorizing such person so to do. No retail dealer who sells 12 or fewer different nonprescription drug products shall be required to obtain a retail dealer's permit under the pharmacy act of the state of Kansas or to pay a retail dealer new permit or permit renewal fee under such act. It shall be lawful for a retail dealer who is the holder of a valid retail dealer's permit issued by the board or for a retail dealer who sells 12 or fewer different nonprescription drug products to sell and distribute nonprescription drugs that are prepackaged, fully prepared by the manufacturer or distributor for use by the consumer and labeled in accordance with the requirements of the state and federal food, drug and cosmetic acts. Such nonprescription drugs shall not include: (1) A controlled substance; (2) a prescription-only drug; or (3) a drug product intended for human use by hypodermic injection; but such
a retail dealer shall not be authorized to display any of the words listed in K.S.A. 65-1626 (zz), and amendments thereto, for the designation of a pharmacy or drugstore.

(g) For any person to manufacture within this state any drugs or devices except under the personal and immediate supervision of a pharmacist or such other individual as may be approved by the board after an investigation and a determination by the board that such individual is qualified by scientific or technical training or experience to perform such duties of supervision as may be necessary to protect the public health and safety, and no individual shall manufacture any drugs or devices without first obtaining a registration to do so from the board.

(h) For any person to operate an institutional drug room without first having obtained a registration to do so from the board. Such registration shall be subject to the provisions of K.S.A. 65-1637a, and amendments thereto, and any rules and regulations adopted pursuant thereto.

(i) For any person to operate a veterinary medical teaching hospital pharmacy without first having obtained a registration to do so from the board. Such registration shall be subject to the provisions of K.S.A. 65-1662, and amendments thereto, and any rules and regulations adopted pursuant thereto.

(j) For any person to sell or distribute in a pharmacy a controlled substance designated in K.S.A. 65-4113 (d) or (e), and amendments thereto, unless:
   (1) (A) Such controlled substance is sold or distributed by a licensed pharmacist, or by a registered pharmacy technician, pharmacist intern or clerk supervised by a licensed pharmacist;
   (B) any individual purchasing, receiving or otherwise acquiring any such controlled substance produces a valid photo identification showing the date of birth of the individual and signs a log and enters in the log, or allows the seller to enter in the log, such individual's address and the date and time of sale or allows the seller to enter such information into an electronic logging system pursuant to K.S.A. 65-16,102, and amendments thereto. The log or database required by the board shall be available for inspection during regular business hours to the board of pharmacy and any law enforcement officer;
   (C) the seller determines that the name entered in the log corresponds to the name provided on such identification and that the date and time entered are correct; and
   (D) the seller enters in the log the name of the controlled substance and the quantity sold; or
   (2) there is a lawful prescription.

(k) For any pharmacy to allow customers to have direct access to any controlled substance designated in K.S.A. 65-4113 (d) or (e), and amendments thereto. Such controlled substance shall be placed behind the counter or stored in a locked cabinet that is located in an area of the pharmacy to which customers do not have direct access.

(l) A seller who in good faith releases information in a log pursuant to subsection (j) to any law enforcement officer is immune from civil liability for such release unless the release constitutes gross negligence or intentional, wanton or willful misconduct.

(m) For any person to sell or lease or offer for sale or lease durable medical equipment or to supply medical grade oxygen to an end user without first obtaining a registration from the board, in accordance with rules and regulations adopted by the board, except that this subsection shall not apply to:
   (1) Sales not made in the regular course of the person's business; or
   (2) sales by charitable organizations exempt from federal income taxation pursuant to the internal revenue code of 1986.

(n) For any person to operate as an outsourcing facility within this state, or operate as an outsourcing facility outside of Kansas and ship, mail or deliver drugs into this state, without having first obtained a registration from the board.

(o) For any person to operate an automated dispensing system within this state without having first obtained a registration from the board.
(p) For any person to distribute drugs or devices into Kansas as an out-of-state manufacturer of such
drugs or devices without first obtaining a registration as a manufacturer from the board.

History: L. 1953, ch. 290, § 29; L. 1967, ch. 342, § 3; L. 1975, ch. 319, § 29; L. 1979, ch. 193, § 3; L.
ch. 169, § 11; L. 2009, ch. 131, § 9; L. 2014, ch. 49, § 4; L. 2017, ch. 34, § 9; L. 2021, ch. 106, § 10;
June 3.

65-1643a.
History: L. 1953, ch. 290, § 29; L. 1967, ch. 342, § 3; L. 1975, ch. 319, § 29; L. 1979, ch. 193, §
3; L. 1982, ch. 262, § 3; Repealed, L. 1983, ch. 210, § 3; April 14.

65-1643b.
History: L. 1953, ch. 290, § 29; L. 1967, ch. 342, § 3; L. 1975, ch. 319, § 29; L. 1979, ch. 193, §
3; L. 1982, ch. 263, § 7; L. 1983, ch. 210, § 2; L. 1986, ch. 231, § 29; L. 1997, ch. 112, § 3; L.
153, § 1; L. 2007, ch. 177, § 33; Repealed, L. 2009, ch. 131, § 14; Repealed, L. 2009, ch. 143, §
37; July 1.

65-1643c.
3; L. 1997, ch. 184, § 2; L. 1999, ch. 38, § 5; L. 1999, ch. 149, § 8; L. 2000, ch. 89, § 2; L.
155; June 3.

65-1643d. Registration as manufacturer or virtual manufacturer; information required in
application; criteria for grant or denial; state board of pharmacy rules and regulations;
inspections; registration of manufacturer or virtual manufacturer licensed or registered in
another state.

(a) The board shall require an applicant for registration as a manufacturer or virtual manufacturer under
K.S.A. 65-1643, and amendments thereto, or an applicant for renewal of such a registration, to provide
the following information:

(1) The name, full business address and telephone number of the applicant;
(2) all trade or business names used by the applicant;
(3) all addresses, telephone numbers and the names of contact individuals for all facilities used by the
applicant for the storage, handling and distribution of prescription drugs or devices;
(4) the type of ownership or operation of the applicant;
(5) the name of the owner or operator of the applicant, including:
(A) if an individual, the name of the individual;
(B) if a partnership, the name of each partner and the name of the partnership;
(C) if a corporation, the name and title of each corporate officer and director of the corporation and the
name of the state of incorporation; or
(D) if a sole proprietorship, the full name of the sole proprietor and the name of the business entity; and
(6) any other information as the board deems appropriate.
Changes in any information in this subsection shall be submitted to the board in a form and manner prescribed by the board.

(b) In reviewing the qualifications for applicants for initial registration or renewal of registration as a manufacturer or virtual manufacturer, the board shall consider the following factors:

(1) Any convictions of the applicant under any federal, state or local laws relating to drug samples, manufacture of drugs or devices, wholesale or retail drug distribution or distribution of controlled substances;

(2) any felony convictions of the applicant under federal or state laws;

(3) the applicant's past experience in the manufacture or distribution of prescription drugs including controlled substances;

(4) the furnishing by the applicant of false or fraudulent material in any application made in connection with drug manufacturing or distribution;

(5) discipline, censure, warning, suspension or revocation by federal, state or local government of any license or registration currently or previously held by the applicant for the manufacture or distribution of any drugs including controlled substances;

(6) compliance with registration requirements under previously granted registrations, if any;

(7) compliance with requirements to maintain or make available to the board or to the federal, state or local law enforcement officials those records required by the federal food, drug and cosmetic act, and rules and regulations adopted pursuant thereto; and

(8) any other factors or qualifications deemed by the board to be relevant to and consistent with the public health and safety.

(c) After consideration of the qualifications for applicants for registration as a manufacturer or virtual manufacturer, the board may deny an initial application for registration or application for renewal of a registration if the board determines that the granting of such registration would not be in the public interest. The authority of the board under this subsection to deny a registration as a manufacturer or virtual manufacturer shall be in addition to the authority of the board under K.S.A. 65-1627(f) and 65-1645(e), and amendments thereto.

(d) The board by rules and regulations shall require that personnel employed by persons registered as a manufacturer or virtual manufacturer have appropriate education or experience to assume responsibility for positions related to compliance with state registration requirements.

(e) The board by rules and regulations may implement this section to conform to any requirements of the federal drug supply chain security act, 21 U.S.C. § 351 et seq., in effect on July 1, 2021.

(f) Each facility that manufactures drugs or devices shall undergo an inspection by the board or a third party recognized by the board prior to initial registration and periodically thereafter in accordance with a schedule to be determined by the board but not less than once every three years. The board shall adopt rules and regulations not later than July 1, 2022, to establish standards and requirements for the issuance and maintenance of a manufacturer and virtual manufacturer registration, including inspections.

(g) The board may register a manufacturer or virtual manufacturer that is licensed or registered under the laws of another state if:

(1) The requirements of that state are deemed by the board to be substantially equivalent to the requirements of this state; or

(2) the applicant is inspected by a third party recognized and approved by the board.

(h) The board by rule and regulation shall establish standards and requirements for the issuance and maintenance of a manufacturer and virtual manufacturer registration, including, but not limited to, requirements regarding the following:

(1) An application and renewal fee;
(2) a surety bond;
(3) registration and periodic inspections;
(4) certification of a designated representative;
(5) designation of a registered agent;
(6) storage of drugs and devices;
(7) handling, transportation and shipment of drugs and devices;
(8) security;
(9) examination of drugs and devices and treatment of those found to be unacceptable as defined by
the board;
(10) due diligence regarding other trading partners;
(11) creation and maintenance of records, including transaction records;
(12) procedures for operation; and
(13) procedures for compliance with the requirements of the federal drug supply chain security act, 21
U.S.C. § 351 et seq.
(i) This section shall be a part of and supplemental to the pharmacy act of the state of Kansas.

**History:** L. 2021, ch. 106, § 4; June 3.

### 65-1644. Duplicate licenses, registrations and permits; fees.
The board may issue duplicate licenses, registrations or permits upon return of the original, or
upon a sworn statement that the original has been lost or destroyed, and has not been given away
or disposed of to some other person. Applications for such duplicate licenses, registrations and
permits and the affidavits required by this section shall be made on forms furnished by the board.
The fee for the issuance of a duplicate registration or permit shall not exceed $1.25 for permits,
and $10 for certificates of registration.

**History:** L. 1953, ch. 290, § 30; L. 1962, ch. 37, § 4; L. 1974, ch. 252, § 3; L. 1975, ch. 319, §

### 65-1645. Applications for registrations and permits; renewals; forms; establishment of fees;
establishment of retail dealer classes; display of registrations and permits; expiration
dates; penalty fee for renewal after lapse; proration of fees.
(a) Application for registrations or permits under K.S.A. 65-1643, and amendments thereto, shall be
made on a form prescribed and furnished by the board. Applications for registration shall contain such
information as may be required by the board in accordance with the provisions of K.S.A. 65-1655, 65-
1655a and 65-1655b, and amendments thereto. The application shall be accompanied by the fee
prescribed by the board under the provisions of this section. When such application and fees are
received by the secretary on or before the due date, such application shall have the effect of temporarily
renewing the applicant's registration or permit until actual issuance or denial of the renewal. If, at the
time of filing, a proceeding is pending before the board that may result in the suspension, probation,
revocation or denial of the applicant's registration or permit, the board may declare, by emergency
order, that such application for renewal shall not have the effect of temporarily renewing such
applicant's registration or permit. Separate applications shall be made and separate registrations or
permits issued for each separate place where there is carried on any of the operations for which a
registration or permit is required by K.S.A. 65-1643, and amendments thereto.
(b) An application for a registration or permit under K.S.A. 65-1643, and amendments thereto,
submitted for a facility physically located outside of the state of Kansas shall be accompanied by an
additional non-resident fee prescribed by the board by rules and regulations pursuant to this section. Such fee shall not exceed $350 for a new registration and $250 for a renewal.

(c) The nonrefundable fees required for the issuing of the licenses, registrations or permits under the pharmacy act of the state of Kansas shall be fixed by the board as provided in this section, subject to the following:

(1) Pharmacy, new registration not more than $150, renewal not more than $125;
(2) pharmacist, new license by examination not more than $350;
(3) pharmacist, reinstatement application fee not more than $250;
(4) pharmacist, biennial renewal fee not more than $200;
(5) pharmacist, evaluation fee not more than $250;
(6) pharmacist, reciprocal licensure fee not more than $250;
(7) pharmacist, penalty fee, not more than $500;
(8) manufacturer, new registration not more than $500, renewal not more than $400;
(9) wholesale distributor, new registration not more than $500, renewal not more than $400, except that a wholesale distributor dealing exclusively in nonprescription drugs, the manufacturing, distributing or dispensing of which does not require registration under the uniform controlled substances act, shall be assessed a fee for registration and re-registration not to exceed $50;
(10) special auction not more than $50;
(11) samples distribution not more than $50, renewal not more than $50;
(12) institutional drug room, new registration not more than $40, renewal not more than $35;
(13) retail dealer selling more than 12 different nonprescription drug products, new permit not more than $12, renewal not more than $12;
(14) certification of grades for each applicant for examination and registration not more than $25;
(15) veterinary medical teaching hospital pharmacy, new registration not more than $40, renewal not more than $35;
(16) durable medical equipment registration fee, not more than $300, renewal not more than $300;
(17) third-party logistics provider, new registration not more than $500, renewal not more than $400, except that a third-party logistics provider exclusively providing nonprescription drugs, the manufacturing, distributing or dispensing of which does not require registration under the uniform controlled substances act, shall be assessed a fee for registration and re-registration not to exceed $50;
(18) outsourcing facility, new registration not more than $500, renewal not more than $400;
(19) repackager, new registration not more than $500, renewal not more than $400; or
(20) automated dispensing system registration fee, not more than $40, renewal not more than $35.

(d) For the purpose of fixing fees, the board may establish classes of retail dealers' permits for retail dealers selling more than 12 different nonprescription drug products, and the board may fix a different fee for each such class of permit.

(e) The board shall determine annually the amount necessary to carry out and enforce the provisions of this act for the next ensuing fiscal year and shall fix by rules and regulations the fees authorized for such year at the sum deemed necessary for such purposes. The fees fixed by the board under this section immediately prior to the effective date of this act shall continue in effect until different fees are fixed by the board by rules and regulations as provided under this section.

(f) The board may deny renewal of any registration or permit required by K.S.A. 65-1643, and amendments thereto, on any ground that would authorize the board to suspend, revoke or place on probation a registration or permit previously granted pursuant to the provisions of K.S.A. 65-1643, and amendments thereto. Registrations and permits issued under the provisions of K.S.A. 65-1643 and 65-1644, and amendments thereto, shall be conspicuously displayed in the place for which the registration
or permit was granted. Such registrations or permits shall not be transferable. All such registrations and permits shall expire every year. The expiration date shall be established by rules and regulations adopted by the board. All registrations and permits shall be renewed annually. Notice of renewal of registrations and permits shall be sent by the board to each registrant or permittee at least 30 days prior to expiration of the registration or permit. If application for renewal is not made prior to expiration, the existing registration or permit shall lapse and become null and void on the date of its expiration, and no new registration or permit shall be granted except upon payment of the required renewal fee plus a penalty equal to the renewal fee. Failure of any registrant or permittee to receive such notice of renewal shall not relieve the registrant or permittee from the penalty hereby imposed if the renewal is not made as prescribed.

(g) In each case in which a license of a pharmacist is issued or renewed for a period of time less than two years, the board shall prorate to the nearest whole month the license or renewal fee established pursuant to this section.

(h) The board may require that fees paid for any examination under the pharmacy act of the state of Kansas be paid directly to the examination service by the person taking the examination.


65-1646. Violations of act or rules and regulations; penalty; revocation or suspension of registration or permit; notice and hearing.

Any person violating any of the provisions of this act or any valid rule and regulation made under the authority conferred by this act shall be guilty of a misdemeanor. Upon conviction, any person holding a registration or permit under the provisions of K.S.A. 65-1643 and amendments thereto may have such registration or permit revoked or suspended. No registration or permit shall be suspended or revoked without first giving the registrant or permittee notice and opportunity for a hearing in accordance with the provisions of the Kansas administrative procedure act.


65-1647. Repeated violations of act or rules and regulations may be enjoined.

The board may in its discretion, in addition to the remedies set forth in the preceding section, apply to the court having jurisdiction over the parties and subject matter for a writ of injunction to restrain repetitious violations of the provisions of the pharmacy act of the state of Kansas or violations of any valid rule and regulation made under the authority conferred by such act.

History: L. 1953, ch. 290, § 33; L. 1975, ch. 319, § 33; July 1.
65-1648. Distribution and control of prescription medications by a medical care facility pharmacy, health department, indigent health care clinic, federally qualified health center or family planning clinic; maintenance and use of emergency medication kit by adult care home; rules and regulations.

(a) Any medical care facility pharmacy registered by the board may keep drugs in such facility and may supply drugs to its inpatients and outpatients. Distribution and control of prescription medications in a medical care facility pharmacy shall be under the supervision of a pharmacist in charge. A designated registered nurse or nurses or a licensed physician assistant approved by the pharmacist in charge and under the supervision of the pharmacist in charge shall be in charge of the distribution and control of drugs of a medical care facility pharmacy when a pharmacist is not on the premises. Drugs supplied to outpatients when a pharmacist is not on the premises shall be limited to the quantity necessary until a prescription can be filled.

(b) Nothing contained in this act shall be construed as prohibiting an adult care home that utilizes the services of a pharmacist, from maintaining an emergency medication kit approved by the adult care home's medical staff composed of a duly licensed practitioner and a pharmacist. The emergency medication kit shall be used only in emergency cases under the supervision and direction of a duly licensed practitioner, and a pharmacist shall have supervisory responsibility of maintaining said emergency medication kit.

(c) Every adult care home that maintains an emergency medication kit under subsection (b) shall comply with the following requirements:

(1) Drugs in an emergency medication kit shall be maintained under the control of the pharmacist in charge of the pharmacy from which the kit came until administered to the patient upon the proper order of a practitioner.

(2) Drugs contained within the emergency medication kit may include controlled substances, but in such case a pharmaceutical services committee shall be responsible for specifically limiting the type and quantity of controlled substance to be placed in each emergency kit.

(3) Administration of controlled substances contained within the emergency medication kit shall be in compliance with the provisions of the uniform controlled substances act.

(4) The consultant pharmacist of the adult care home shall be responsible for developing procedures, proper control and accountability for the emergency medication kit and shall maintain complete and accurate records of the controlled substances, if any, placed in the emergency kit. Periodic physical inventory of the kit shall be required.

(d) (1) The department of health and environment, any county, city-county or multicounty health department, indigent health care clinic, federally qualified health center and any private not-for-profit family planning clinic, when registered by the board, may keep drugs for the purpose of distributing drugs to patients being treated by that health department, indigent health care clinic, federally qualified health center or family planning clinic. Distribution and control of prescription medications in a health department, indigent health care clinic, federally qualified health center or family planning clinic shall be under the supervision of a pharmacist in charge. A designated registered nurse or nurses or a licensed physician assistant approved by the pharmacist in charge shall be in charge of distribution and control of drugs in the health department, indigent health care clinic, federally qualified health center or family planning clinic under the supervision of the pharmacist in charge when a pharmacist is not on the premises. Drugs supplied to patients when a pharmacist is not on the premises shall be limited to the quantity necessary to complete a course of treatment as ordered by the practitioner supervising such treatment.
(2) The board shall adopt rules and regulations relating to specific drugs to be used, to recordkeeping and to storage of drugs by a health department, indigent health care clinic, federally qualified health center or family planning clinic as are necessary for proper control of drugs.

(3) Any medical care facility pharmacy registered by the board shall comply with the applicable requirements of the federal drug supply chain security act, 21 U.S.C. § 351 et seq.


**65-1649. Invalidity of part.**
If any clause, sentence, paragraph, section or part of the pharmacy act of the state of Kansas or the application thereof to any person or circumstances shall for any reason be adjudged by any court of competent jurisdiction to be unconstitutional or invalid, such judgment shall not affect, impair or invalidate the remainder thereof, and the application thereof to other persons or circumstances, but shall be confined in its operation to the clause, sentence or paragraph, section or part thereof involved in the controversy, in which such judgment shall have been rendered and to the person or circumstances involved. It is hereby declared to be the legislative intent that such act would have been enacted had such unconstitutional or invalid provisions not been included.


**65-1650. Regulation of advertising of prescription-only drugs; exceptions and exclusions.**
The board of pharmacy is hereby authorized to regulate the advertising, but not the prices or discounts, of prescription-only drugs. The provisions of this section shall not be construed to: (1) Authorize the state board of pharmacy to require, regulate or prohibit the posting within a pharmacy of the current charges by such pharmacy for prescription-only drugs and services, nor, (2) restrict the offering of discounts on prescription-only drugs.

**History:** L. 1974, ch. 252, § 5; L. 1975, ch. 319, § 35; July 1.

**65-1651. Sections part of and supplemental to pharmacy act.**
The provisions of K.S.A. 65-1627a to 65-1627h, inclusive, 65-1628a, 65-1628b and 65-1650, are hereby declared to be a part of and supplemental to the pharmacy act of the state of Kansas.

**History:** L. 1975, ch. 319, § 46; July 1.

**65-1651a. Study of regulating wholesale prescription drug distributors; pedigrees for prescription drugs.**

**History:** L. 2006, ch. 177, § 2; July 1. Repealed, L. 2017, ch. 34; April 20.

**65-1652. Immunity from liability in civil actions for reporting, communicating and investigating certain information concerning alleged malpractice incidents and other information; conditions.**
(a) No person reporting to the board of pharmacy under oath and in good faith any information such person may have relating to alleged incidents of malpractice or the qualifications, fitness or character or a pharmacist shall be subject to a civil action for damages as a result of reporting such information.

(b) Any state, regional or local association of pharmacists and the individual members of any committee thereof, which in good faith investigates or communicates information pertaining to
the alleged incidents of malpractice or the qualifications, fitness or character of any pharmacist to the board of pharmacy or to any committee or agent thereof, shall be immune from liability in any civil action, that is based upon such information or transmittal of information if the investigation and communication was made in good faith and did not represent as true any matter not reasonably believed to be true.

(c) This section shall be a part of and supplemental to the pharmacy act of the state of Kansas.


65-1653. References to registered pharmacists deemed to apply to licensed pharmacists.
(a) Whenever registered pharmacist, or words of like effect, is referred to or designated by a statute, rule and regulation, contract or other document in reference to a pharmacist registered under the pharmacy act of the state of Kansas, such reference or designation shall be deemed to apply to a licensed pharmacist under this act.

(b) This section shall be part of and supplemental to the pharmacy act of the state of Kansas.

History: L. 1986, ch. 231, § 38; June 1.

65-1654. Privileged communications.
(a) The confidential communications between a licensed pharmacist and the pharmacist's patient and records of prescription orders filled by the pharmacist are placed on the same basis of confidentiality as provided by law for communications between a physician and the physician's patient and records of prescriptions dispensed by a physician. Nothing in this subsection shall limit the authority of the board or other persons, as provided by law, from inspecting the book or file of prescription orders kept by a pharmacy or firm performing any duty or exercising any authority as otherwise provided by law.

(b) This section shall be part of and supplemental to the pharmacy act of the state of Kansas.

History: L. 1989, ch. 193, § 3; July 1.

65-1655. Information required of applicant for registration to distribute at wholesale any drugs; factors in reviewing qualifications of applicants; denial of application if not in public interest; qualifications of personnel; inspection by the board; rules and regulations.
(a) The board shall require an applicant for registration as a wholesale distributor under K.S.A. 65-1643 and amendments thereto, or an applicant for renewal of such a registration, to provide the following information:
   (1) The name, full business address and telephone number of the applicant;
   (2) all trade or business names used by the applicant;
   (3) addresses, telephone numbers, and the names of contact persons for all facilities used by the applicant for the storage, handling and distribution of prescription drugs;
   (4) the type of ownership or operation of the applicant;
   (5) the name of the owner or operator, or both, of the applicant, including:
      (A) If a person, the name of the person;
      (B) if a partnership, the name of each partner, and the name of the partnership;
      (C) if a corporation, the name and title of each corporate officer and director, the corporate names and the name of the state of incorporation;
      (D) if a sole proprietorship, the full name of the sole proprietor and the name of the business entity; and
(6) such other information as the board deems appropriate. Changes in any information in this subsection shall be submitted to the board as required by the board.

(b) In reviewing the qualifications for applicants for initial registration or renewal of registration as a wholesale distributor, the board shall consider the following factors:

(1) Any convictions of the applicant under any federal, state or local laws relating to drug samples, wholesale or retail drug distribution or distribution of controlled substances;
(2) any felony convictions of the applicant under federal or state laws;
(3) the applicant's past experience in the manufacture or distribution of prescription drugs, including controlled substances;
(4) the furnishing by the applicant of false or fraudulent material in any application made in connection with drug manufacturing or distribution;
(5) suspension or revocation by federal, state or local government of any license or registration currently or previously held by the applicant for the manufacture or distribution of any drugs, including controlled substances;
(6) compliance with registration requirements under previously granted registrations, if any;
(7) compliance with requirements to maintain or make available to the board or to federal state or local law enforcement officials those records required by federal food, drug and cosmetic act, and rules and regulations adopted pursuant thereto; and
(8) any other factors or qualifications the board considers relevant to and consistent with the public health and safety.

(c) After consideration of the qualifications for applicants for registration as a wholesale distributor, the board may deny an initial application for registration or application for renewal of a registration if the board determines that the granting of such registration would not be in the public interest. The authority of the board under this subsection to deny a registration as a wholesale distributor shall be in addition to the authority of the board under K.S.A. 65-1627(e), and amendments thereto, or K.S.A. 65-1645(e), and amendments thereto.

(d) The board by rules and regulations shall require that personnel employed by persons registered as a wholesale distributor have appropriate education or experience, or both, to assume responsibility for positions related to compliance with state registration requirements.

(e) The board by rules and regulations may implement this section to conform to any requirements of the federal drug supply chain security act, 21 U.S.C. 351 et seq., in effect on the effective date of this act.

(f) Each facility that engages in wholesale distribution must undergo an inspection by the board or a third party recognized by the board to inspect wholesale distributors for the purpose of inspecting the wholesale distribution operations prior to initial registration and periodically thereafter in accordance with a schedule to be determined by the board but not less than once every three years. The board shall adopt rules and regulations to establish standards and requirements for the issuance and maintenance of a wholesale distributor registration, including inspections of wholesale distributor facilities domiciled in the state.

(1) Individual or third party inspectors must demonstrate to the board that they have received training or demonstrate familiarity with the inspection standards. Evidence such as a letter of certification from a training program, notice from the inspector's employing third party organization or other means recognized by the board shall be accepted as meeting the requirement.

(2) The board may register a wholesale distributor that is licensed or registered under the laws of another state if:
(A) The requirements of that state are deemed by the board to be substantially equivalent; or
(B) the applicant is inspected by a third party recognized and approved by the board.

(g) A person licensed or approved by the FDA to engage in wholesale distribution need only satisfy the minimum federal requirements for licensure provided in FDA regulations 21 C.F.R. Part 205 to provide wholesale distribution services.

(h) The board by rule and regulation shall establish standards and requirements for the issuance and maintenance of a wholesale distributor registration, including, but not limited to, requirements regarding the following:
   (1) An application and renewal fee;
   (2) a surety bond;
   (3) registration and periodic inspections;
   (4) certification of a designated representative;
   (5) designation of a registered agent;
   (6) storage of drugs and devices;
   (7) handling, transportation and shipment of drugs and devices;
   (8) security;
   (9) examination of drugs and devices and treatment of those found to be unacceptable as defined by the board;
   (10) due diligence regarding other trading partners;
   (11) creation and maintenance of records, including transaction records;
   (12) procedures for operation; and
   (13) procedures for compliance with the requirements of the federal drug supply chain security act, 21 USC 351 et seq.

(i) This section shall be part of and supplemental to the pharmacy act of the state of Kansas.


65-1655a. Information required of applicant for registration as third-party logistics provider; factors for reviewing qualifications of applicants; denial of application if not in public interest; inspection by the board; rules and regulations.

(a) The board shall require an applicant for registration to operate as a third-party logistics provider under K.S.A. 65-1643, and amendments thereto, or an applicant for renewal of such a registration, to provide the following information:
   (1) The name, full business address and telephone number of the applicant;
   (2) all trade or business names used by the applicant;
   (3) addresses, telephone numbers, and the names of contact persons for all facilities used by the applicant for the storage, handling and distribution of prescription drugs;
   (4) the type of ownership or operation of the applicant;
   (5) the name of the owner or operator, or both, of the applicant, including:
      (A) If a person, the name of the person;
      (B) if a partnership, the name of each partner, and the name of the partnership;
      (C) if a corporation, the name and title of each corporate officer and director, the corporate names and the name of the state of incorporation;
      (D) if a sole proprietorship, the full name of the sole proprietor and the name of the business entity; and

(6) such other information as the board deems appropriate. Changes in any information in this subsection shall be submitted to the board as required by the board.

(b) In reviewing the qualifications for applicants for initial registration or renewal of registration to operate as a third-party logistics provider, the board shall consider the following factors:

1. Any convictions of the applicant under any federal, state or local laws relating to drug samples, wholesale or retail drug distribution or distribution of controlled substances;
2. Any felony convictions of the applicant under federal or state laws;
3. The applicant’s past experience in the manufacture or distribution of prescription drugs, including controlled substances;
4. The furnishing by the applicant of false or fraudulent material in any application made in connection with drug manufacturing or distribution;
5. Suspension or revocation by any federal, state or local government of any license or registration currently or previously held by the applicant for the manufacture or distribution of any drugs, including controlled substances;
6. Compliance with registration requirements under previously granted registrations, if any;
7. Compliance with requirements to maintain or make available to the board or to federal state or local law enforcement officials those records required by the federal food, drug and cosmetic act, and rules and regulations adopted pursuant thereto; and
8. Any other factors or qualifications the board considers relevant to and consistent with the public health and safety.

(c) After consideration of the qualifications for applicants for registration to operate as a third-party logistics provider, the board may deny an initial application for registration or application for renewal of a registration if the board determines that the granting of such registration would not be in the public interest. The authority of the board under this subsection to deny a registration to operate a third-party logistics provider shall be in addition to the authority of the board under K.S.A. 65-1627(e) or 65-1645(e), and amendments thereto.

(d) The board by rules and regulations shall require that personnel employed by persons registered to operate as a third-party logistics provider have appropriate education or experience, or both, to assume responsibility for positions related to compliance with state registration requirements.

(e) The board by rules and regulations may implement this section to conform to any requirements of the federal drug supply chain security act, 21 U.S.C. § 351 et seq., in effect on the effective date of this act.

(f) Each facility that operates as a third-party logistics provider must undergo an inspection by the board or a third party recognized by the board to inspect third-party logistics provider operations prior to initial registration and periodically thereafter in accordance with a schedule to be determined by the board, but not less than once every three years. The board shall adopt rules and regulations to establish standards and requirements for the issuance and maintenance of a third-party logistics provider registration, including inspections of third-party logistics provider facilities domiciled in the state.

(1) Individual or third-party inspectors must demonstrate to the board that they have received training or demonstrate familiarity with the inspection standards. Evidence, such as a letter of certification from a training program, notice from the inspector’s employing third-party organization or other means recognized by the board shall be accepted as meeting the requirement.
(2) The board may register a third-party logistics provider that is licensed or registered under the laws of another state if:
(A) The requirements of that state are deemed by the board to be substantially equivalent; or
(B) the applicant is inspected by a third party recognized and approved by the board.
(g) A person licensed or approved by the FDA to engage in third-party logistics need only satisfy the minimum federal requirements for licensure provided in FDA regulations 21 C.F.R. part 205 to provide third-party logistics services.
(h) The board by rules and regulations shall establish standards and requirements for the issuance and maintenance of a third-party logistics provider registration, including, but not limited to, requirements regarding the following:
(1) An application and renewal fee;
(2) a surety bond;
(3) registration and periodic inspections;
(4) certification of a designated representative;
(5) designation of a registered agent;
(6) storage of drugs and devices;
(7) handling, transportation and shipment of drugs and devices;
(8) security;
(9) examination of drugs and devices and treatment of those found to be unacceptable as defined by the board;
(10) due diligence regarding other trading partners;
(11) creation and maintenance of records, including transaction records;
(12) procedures for operation; and
(13) procedures for compliance with the requirements of the federal drug supply chain security act, 21 U.S.C. § 351 et seq.
(i) This section shall be part of and supplemental to the pharmacy act of the state of Kansas.

History: L. 2017, ch. 34, § 13; April 20.

65-1655b. Information required of applicant for registration as outsourcing facility; factors for reviewing qualifications of applicants; denial of application if not in public interest; inspection by the board; rules and regulations.
(a) The board shall require an applicant for registration as an outsourcing facility under K.S.A. 65-1643, and amendments thereto, or an applicant for renewal of such a registration, to provide the following information:
(1) The name, full business address and telephone number of the applicant;
(2) all trade or business names used by the applicant;
(3) the type of ownership or operation of the applicant;
(4) the name of the owner or operator, or both, of the applicant, including:
(A) If a person, the name of the person;
(B) if a partnership, the name of each partner, and the name of the partnership;
(C) if a corporation, the name and title of each corporate officer and director, the corporate names and the name of the state of incorporation;
(D) if a sole proprietorship, the full name of the sole proprietor and the name of the business entity;
(5) a copy of the valid FDA registration as an outsourcing facility as required by 21 U.S.C. § 353b;
(6) the name and license number of the pharmacist who is designated as the pharmacist-in-charge of the outsourcing facility;
(7) a copy of a current inspection report resulting from an FDA inspection that indicates compliance with the requirements of the federal food, drug and cosmetic act, including guidance documents and current good manufacturing practices established by the FDA, or if no FDA inspection has been conducted within the prior two-year period, the outsourcing facility must undergo an inspection pursuant to subsection (e); and
(8) such other information as the board deems appropriate.
Changes in any information in this subsection shall be submitted to the board as required by the board.
(b) In reviewing the qualifications for applicants for initial registration or renewal of registration as an outsourcing facility, the board shall consider the following factors:
(1) Any convictions of the applicant under any federal, state or local laws relating to drug samples, wholesale or retail drug distribution or distribution of controlled substances;
(2) any felony convictions of the applicant under federal or state laws;
(3) the applicant’s past experience in the manufacture or distribution of prescription drugs, including controlled substances;
(4) the furnishing by the applicant of false or fraudulent material in any application made in connection with drug manufacturing or distribution;
(5) suspension or revocation by any federal, state or local government of any license or registration currently or previously held by the applicant for the manufacture or distribution of any drugs, including controlled substances;
(6) compliance with registration requirements under previously granted registrations, if any;
(7) compliance with requirements to maintain or make available to the board or to federal, state or local law enforcement officials those records required by the federal food, drug and cosmetic act, and rules and regulations adopted pursuant thereto; and
(8) any other factors or qualifications the board considers relevant to and consistent with the public health and safety.
(c) After consideration of the qualifications for applicants for registration as an outsourcing facility, the board may deny an initial application for registration or application for renewal of a registration if the board determines that the granting of such registration would not be in the public interest. The authority of the board under this subsection to deny a registration to operate as an outsourcing facility shall be in addition to the authority of the board under K.S.A. 65-1627(e) or 65-1645(e), and amendments thereto.
(d) The board by rules and regulations shall require that personnel employed by persons registered as an outsourcing facility have appropriate education or experience, or both, to assume responsibility for positions related to compliance with state registration requirements.
(e) Each outsourcing facility must undergo an inspection by the board or a third party recognized by the board for the purpose of inspecting operations prior to initial registration and periodically thereafter in accordance with a schedule to be determined by the board, but not less than once every three years. The board shall adopt rules and regulations to establish standards and requirements for the issuance and maintenance of an outsourcing facility registration, including inspections of facilities domiciled in the state.
(f) The board by rules and regulations shall establish standards and requirements for the issuance and maintenance of an outsourcing facility registration, including, but not limited to, requirements regarding the following:
(1) An application and renewal fee;
(2) a surety bond;
(3) registration and periodic inspections;
(4) certification of a designated representative;
(5) designation of a registered agent;
(6) storage of drugs and devices;
(7) handling, transportation and shipment of drugs and devices;
(8) security;
(9) examination of drugs and devices and treatment of those found to be unacceptable as defined by the board;
(10) due diligence regarding other trading partners;
(11) creation and maintenance of records, including transaction records; and
(12) procedures for operation.

(g) Notwithstanding any other provision, no outsourcing facility may distribute or dispense any drug to any person pursuant to a prescription unless it is also registered as a pharmacy in this state and meets all other applicable requirements of federal and state law.

(h) This section shall be part of and supplemental to the pharmacy act of the state of Kansas.

History: L. 2017, ch. 34, § 14; April 20.

65-1656. Filling transferred prescriptions; exceptions and conditions; common electronic prescription files authorized; rules and regulations.

(a) Nothing contained in the pharmacy act of the state of Kansas shall prohibit a pharmacist licensed in this state from filling or refilling a valid prescription for prescription drugs not listed in schedule II of the uniform controlled substances act, that is on file in a pharmacy licensed or registered in any state and has been transferred from one pharmacy to another upon the following conditions and exceptions:

(1) Prior to dispensing pursuant to any such prescription, the dispensing pharmacist shall:
   (A) Ensure records and notifications are in compliance with rules and regulations adopted by the board; and
   (B) obtain the consent of the prescriber to the refilling of the prescription when the prescription, in the professional judgment of the dispensing pharmacist, so requires. Any interference with the professional judgment of the dispensing pharmacist by any other licensed pharmacist, agents of the licensed pharmacist or employees shall be grounds for revocation or suspension of the registration issued to the pharmacy.

(2) Upon receipt of a request for the transfer of a prescription record, if the requested pharmacist is satisfied in the professional judgment of the pharmacist that such request is valid and legal, the requested pharmacy shall:
   (A) Provide such information accurately and completely;
   (B) ensure records and notifications are made in compliance with rules and regulations adopted by the board; and
   (C) provide information in a timely manner to avoid interruption in the medication therapy of the patient.

(3) When filling or refilling a valid prescription on file in another state, the dispensing pharmacist shall be required to follow all the requirements of Kansas law that apply to the dispensing of prescription drugs. If anything in Kansas law prevents the filling or refilling of the original prescription it shall be unlawful to dispense pursuant to this section.
(4) In addition to any other requirement of this section, the transfer of original prescription information for a controlled substance listed in schedules III, IV and V for the purposes of refill dispensing shall be made in accordance with the requirements of 21 C.F.R. § 1306.25.

(b) Two or more pharmacies may establish and use a common electronic file to maintain required dispensing information. Pharmacies using such a common electronic file are not required to physically transfer prescriptions or information for dispensing purposes between or among pharmacies participating in the same common prescription file, except that any such common file must contain complete and adequate records of such prescription and refill dispensed as required by the pharmacy act of the state of Kansas.

(c) The board may adopt such rules and regulations, not inconsistent with law, as may be necessary to carry out the purposes of and to enforce the provisions of this section except that the board shall not impose greater requirements on either common electronic files or a hard copy record system.

(d) Nothing in this section shall prevent a pharmacy from forwarding to another pharmacy an original, unfilled prescription for a noncontrolled substance or electronically forwarding an original, unfilled, electronic prescription for a controlled substance, at the request of the patient, in compliance with the provisions of the federal or state uniform controlled substances act.

(e) This section shall be a part of and supplemental to the pharmacy act of the state of Kansas.


65-1657. Nonresident pharmacy registration; information required; civil fine; regulatory requirements; drug product selection rules; interstate delivery guidelines; disciplinary action; pharmacies prohibited from advertising unless registered; penalties for violations; injunctive relief; rules and regulations.

(a) No nonresident pharmacy shall ship, mail or deliver, in any manner, prescription drugs or devices to a patient, patient's agent or prescriber's office in this state unless registered under this section as a nonresident pharmacy. Applications for a nonresident pharmacy registration under this section shall be made on a form furnished by the board. A nonresident pharmacy registration shall be granted for a period of one year upon compliance by the nonresident pharmacy with the provisions of this section and rules and regulations adopted pursuant to this section and upon payment of the registration fee established under K.S.A. 65-1645, and amendments thereto, for a pharmacy registration. A nonresident pharmacy registration shall be renewed annually on forms provided by the board, upon compliance by the nonresident pharmacy with the provisions of this section and rules and regulations adopted pursuant to this section and upon payment of the renewal fee established under K.S.A. 65-1645, and amendments thereto, for the renewal of a pharmacy registration.

(b) As conditions for the granting of a registration and for the renewal of a registration for a nonresident pharmacy, the nonresident pharmacy shall comply with the following:

(1) Provide information to the board to indicate the person or persons applying for the registration, the location of the pharmacy from which the prescription drugs will be dispensed, the names and titles of all principal owners and corporate officers, if any, and the names of all pharmacists dispensing prescription drugs to residents of Kansas;

(2) be registered and in good standing in the state in which such pharmacy is located;

(3) maintain, in readily retrievable form, records of prescription drugs dispensed to Kansas patients;

(4) supply upon request, all information needed by the board to carry out the board's responsibilities under this section and rules and regulations adopted pursuant to this section;
(5) maintain pharmacy hours that permit the timely dispensing of drugs to Kansas patients and provide reasonable access for the patients to consult with a licensed pharmacist about such patients' medications;

(6) provide toll-free telephone communication consultation between a Kansas patient and a pharmacist at the pharmacy who has access to the patient's records, and ensure that the telephone number will be placed upon the label affixed to each prescription drug container dispensed in Kansas; and

(7) provide to the board such other information as the board may reasonably request to administer the provisions of this section.

c) Each nonresident pharmacy shall comply with the following unless compliance would be in conflict with specific laws or rules and regulations of the state in which the pharmacy is located:

(1) All statutory and regulatory requirements of Kansas for controlled substances, including those that are different from federal law;

(2) labeling of all prescriptions dispensed, to include, but not be limited to, identification of the product and quantity dispensed;

(3) all the statutory and regulatory requirements of Kansas for dispensing prescriptions in accordance with the quantities indicated by the prescriber; and

(4) the Kansas law regarding the maintenance and use of the patient medication profile record system.

d) In addition to the requirements of subsection (c), each nonresident pharmacy shall comply with all the statutory and regulatory requirements of Kansas regarding drug product selection laws whether or not such compliance would be in conflict with specific laws or rules and regulations of the state in which the pharmacy is located, except that compliance that constitutes only a minor conflict with specific laws or rules and regulations of the state in which the pharmacy is located would not be required under this subsection.

e) Each nonresident pharmacy shall develop and provide the board with a policy and procedure manual that sets forth:

(1) Normal delivery protocols and times;

(2) the procedure to be followed if the patient's medication is not available at the nonresident pharmacy, or if delivery will be delayed beyond the normal delivery time;

(3) the procedure to be followed upon receipt of a prescription for an acute illness. Such policy shall include a procedure for delivery of the medication to the patient from the nonresident pharmacy at the earliest possible time, or an alternative that assures the patient the opportunity to obtain the medication at the earliest possible time; and

(4) the procedure to be followed when the nonresident pharmacy is advised that the patient's medication has not been received within the normal delivery time and that the patient is out of medication and requires interim dosage until mailed prescription drugs become available.

(f) The board may limit, condition, revoke, suspend or place in a probationary status a registration or deny an application for issuance or renewal of any registration on any ground that would authorize the board to take action against the registration of a pharmacy under K.S.A. 65-1627, and amendments thereto.

(g) The board shall adopt rules and regulations that make exceptions to the requirement of registration by a nonresident pharmacy when the out-of-state pharmacy supplies lawful refills to a patient from a prescription that was originally filled and delivered to a patient within the state in which the nonresident pharmacy is located, or when the prescriptions being mailed into the state of Kansas by a nonresident pharmacy occurs only in isolated transactions. In determining whether the prescriptions being mailed into the state of Kansas by a nonresident pharmacy are isolated transactions, the board shall consider whether the pharmacy has promoted its services in this state and whether the pharmacy has a contract
with any employer or organization to provide pharmacy services to employees or other beneficiaries in this state.

(h) It is unlawful for any nonresident pharmacy that is not registered under this act to advertise its services in this state, or for any person who is a resident of this state to advertise the pharmacy services of a nonresident pharmacy that has not registered with the board, with the knowledge that the advertisement will or is likely to induce members of the public in this state to use the pharmacy to fill prescriptions.

(i) Upon request of the board, the attorney general may bring an action in a court of competent jurisdiction for injunctive relief to restrain a violation of the provisions of this section or any rules and regulations adopted by the board under authority of this section. The remedy provided under this subsection shall be in addition to any other remedy provided under this section or under the pharmacy act of the state of Kansas.

(j) The board may adopt rules and regulations as necessary and as are consistent with this section to carry out the provisions of this section.

(k) A violation of this section is a severity level 10, nonperson felony.

(l) This section shall be a part of and supplemental to the pharmacy act of the state of Kansas.


65-1658. Civil fines for violations.
The state board of pharmacy, in addition to any other penalty prescribed under the pharmacy act of the state of Kansas, may assess a civil fine, after notice and an opportunity to be heard in accordance with the Kansas administrative procedure act, against any licensee or registrant under K.S.A. 65-1627(a), (c), (d), (e) and (f), 65-1643, 65-1657, 65-1663 and 65-1676, and amendments thereto, for violation of the pharmacy act of the state of Kansas, rules and regulations of the state board of pharmacy adopted under the pharmacy act of the state of Kansas or for violation of the federal or state uniform controlled substances act or rules and regulations of the state board of pharmacy adopted under the federal or state uniform controlled substances act or for violation of the federal or state food, drug and cosmetic act or any rules and regulations adopted under any such act in an amount not to exceed $5,000 for each violation. All fines assessed and collected under this section shall be remitted to the state treasurer in accordance with the provisions of K.S.A. 75-4215, and amendments thereto, credited to the state board of pharmacy fee fund.


65-1659. Pharmacies authorized to place certain drugs with home health agencies and hospices; protocols for drug handling and storage; review and inspection; definitions.

(a) A pharmacy will be allowed to place certain drugs with a home health agency's authorized employees and with a hospice's authorized employees for the betterment of public health. The pharmacy shall remain the legal owner of the drugs. A written agreement between the pharmacy and home health agency or hospice shall document the protocol for handling and storage of these drugs by authorized employees and shall be approved by the pharmacist in charge. The pharmacist in charge shall review the protocol to assure that safe, secure and accountable handling of legend drugs is maintained under the protocol before giving approval. The pharmacist in charge or a pharmacist designee shall physically inspect and review the drug storage and handling at the home health agency and the hospice at least quarterly during the year.
(b) The home health agency protocol and the hospice protocol shall include, but not be limited to, the following:
(1) Safe and secure storage of drugs;
(2) access to drugs limited to authorized employees;
(3) records of drugs checked out to authorized employees and records of drugs, amounts, to whom and by whom administered;
(4) prompt notification of the pharmacy when a drug is used, including the prescriber, patient, drug, dosage form, directions for use and other pertinent information;
(5) billing information;
(6) procedures for handling drugs beyond their expiration date; and
(7) inventory control.

(c) The following legend drugs shall be allowed under these agreements:
(1) Sterile water for injection or irrigation;
(2) sterile saline solution for injection or irrigation;
(3) heparin flush solution;
(4) diphenhydramine injectable; and
(5) epinephrine injectable.

(d) As used in this section:
(1) "Authorized employee" means any employee of a home health agency or hospice who, in the course of the employee's duties, is licensed by the employee's appropriate licensing agency to administer legend drugs;
(2) "home health agency" means an entity required to be licensed under K.S.A. 65-5102 and amendments thereto; and
(3) hospice means an entity authorized to hold itself out to the public as a hospice or as a licensed hospice under K.S.A. 65-6202 and amendments thereto.

(e) This section shall be part of and supplemental to the pharmacy act of the state of Kansas.

History: L. 1996, ch. 132, § 1; Apr. 11.

65-1660. Dialysates, devices or drugs designated by board for treatment of persons with chronic kidney failure; inapplicability of pharmacy act; rules and regulations.
(a) Except as otherwise provided in this section, the provisions of the pharmacy act of the state of Kansas shall not apply to dialysates, devices or drugs which are designated by the board for the purposes of this section relating to treatment of a person with chronic kidney failure receiving dialysis and which are prescribed or ordered by a physician or a mid-level practitioner for administration or delivery to a person with chronic kidney failure if:
(1) The wholesale distributor is registered with the board and lawfully holds the drug or device; and
(2) the wholesale distributor
   (A) delivers the drug or device to:
      (i) A person with chronic kidney failure for self-administration at the person's home or specified address;
      (ii) a physician for administration or delivery to a person with chronic kidney failure; or
      (iii) a medicare approved renal dialysis facility for administering or delivering to a person with chronic kidney failure; and
   (B) has sufficient and qualified supervision to adequately protect the public health.
(b) The wholesale distributor pursuant to subsection (a) shall be supervised by a pharmacist consultant pursuant to rules and regulations adopted by the board.
(c) The board shall adopt such rules or regulations as are necessary to effectuate the provisions of this section.
(d) As used in this section, "physician" means a person licensed to practice medicine and surgery; "mid-level practitioner" means mid-level practitioner as such term is defined in K.S.A. 65-1626 and amendments thereto.
(e) This section shall be part of and supplemental to the pharmacy act of the state of Kansas.


65-1661.
History: L. 1998, ch. 91, § 2; Repealed, L. 2006, ch. 34, § 1; July 1.

65-1662. Veterinary medical teaching hospital pharmacy; distribution and control of prescription-only drugs; pharmacist in charge.
(a) Distribution and control of prescription-only drugs in a veterinary medical teaching hospital pharmacy shall be under the supervision of a pharmacist in charge. The pharmacist in charge shall also be responsible for establishing and maintaining adequate policies and procedures for training of personnel; storage and maintenance of prescription-only drugs and equipment; quality assurance, labeling, packaging and distribution of prescription-only drugs; recordkeeping and security.
(b) The board shall adopt such rules and regulations relating to the policies and procedures for veterinary medical teaching hospital pharmacies as necessary for proper control of prescription-only drugs by such veterinary medical teaching hospital pharmacies and adequate safety.
(c) This section shall be part of and supplemental to the pharmacy act of the state of Kansas.

History: L. 2000, ch. 89, § 4; Apr. 27.

65-1663. Registration of pharmacy technicians; applications; registration fee; qualifications for registration; expiration and renewal of registration; grounds for denial of application or registration; revocation, suspension or limitation of registration; responsibilities of pharmacists and pharmacies; rules and regulations.
(a) It shall be unlawful for any person to function as a pharmacy technician in this state unless such person is registered with the board as a pharmacy technician. Every person registered as a pharmacy technician shall have graduated from an accredited high school or its equivalent, obtained a graduate equivalent diploma (GED) or be enrolled and in good standing in a high school education program. Every person registered as a pharmacy technician shall pass one or more examinations identified and approved by the board within the period or periods of time specified by the board after becoming registered. The board shall adopt rules and regulations identifying the required examinations, when they must be passed and establishing the criteria for the required examinations and passing scores. The board may include as a required examination any national pharmacy technician certification examination. The board shall adopt rules and regulations restricting the tasks a pharmacy technician may perform prior to passing any required examinations.
(b) All applications for registration shall be made on a form to be prescribed and furnished by the board. Each application for registration shall be accompanied by a registration fee fixed by the board by rule and regulation not to exceed $50.
(c) The board shall take into consideration any felony conviction of an applicant, but such conviction shall not automatically operate as a bar to registration.

(d) Except as otherwise provided in this subsection, each pharmacy technician registration issued by the board shall expire every two years. The expiration date shall be established by rules and regulations adopted by the board. To provide for a system of biennial renewal of pharmacy technician registrations, the board may provide by rules and regulations that registrations issued or renewed may expire less than two years from the date of issuance or renewal. Each applicant for renewal of a pharmacy technician registration shall be made on a form prescribed and furnished by the board and shall be accompanied by a renewal fee fixed by the board by rule and regulation not to exceed $25. Pharmacy technician registration renewal fees may be prorated for registration periods which are less than biennial in accordance with rules and regulations of the board. Except as otherwise provided in this subsection, the application for registration renewal, when accompanied by the renewal fee and evidence satisfactory to the board that the person has successfully complied with the rules and regulations of the board establishing the requirements for a program of continuing pharmacy technician education and received by the secretary on or before the date of expiration of the registration, shall have the effect of temporarily renewing the applicant’s registration until actual issuance or denial of the renewal registration. If at the time of filing a proceeding is pending before the board which may result in the suspension, probation, revocation or denial of the applicant’s registration, the board may by emergency order declare that the application for renewal shall not have the effect of temporarily renewing such applicant’s registration. If the renewal fee is not paid prior to the expiration date of the renewal year, the registration is void.

(e) Continuing pharmacy technician education requirements shall be fixed by the board at not more than 20 clock hours biennially of a program of continuing education approved by the board. Continuing education hours may be prorated for licensure periods that are less than biennial in accordance with rules and regulations of the board.

(f) (1) The board may limit, suspend or revoke a registration or deny an application for issuance or renewal of any registration as a pharmacy technician on any ground, which would authorize the board to take action against the license of a pharmacist under K.S.A. 65-1627, and amendments thereto.

(2) The board may require a physical or mental examination, or both, of a person applying for or registered as a pharmacy technician.

(3) The board may temporarily suspend or temporarily limit the registration of any pharmacy technician in accordance with the emergency adjudicative proceedings under the Kansas administrative procedure act if the board determines that there is cause to believe that grounds exist for disciplinary action under this section against the registrant and that the registrant’s continuation of pharmacy technician functions would constitute an imminent danger to the public health and safety.

(4) Proceedings under this section shall be subject to the Kansas administrative procedure act.

(g) Every registered pharmacy technician, within 30 days of obtaining new employment or ceasing employment as a pharmacy technician, shall notify the secretary of the name and address of the new employer or cessation of employment.

(h) Every pharmacy technician who changes their residential address, email address or legal name shall, within 30 days thereof, notify the secretary of such change on a form prescribed and furnished by the board.
(i) Each pharmacy shall at all times maintain a list of the names of pharmacy technicians employed by the pharmacy. A pharmacy technician shall work under the direct supervision and control of a pharmacist, and while on duty, shall wear a name badge or similar identification with the pharmacy technician’s name and designation as a pharmacy technician. It shall be the responsibility of the supervising pharmacist to determine that the pharmacy technician is in compliance with the applicable rules and regulations of the board, and the supervising pharmacist shall be responsible for the acts and omissions of the pharmacy technician in the performance of the pharmacy technician’s duties. The ratio of pharmacy technicians to pharmacists in the prescription area of a pharmacy shall be prescribed by the board by rule and regulation. Any change in the ratio of pharmacy technicians to pharmacists in the prescription area of the pharmacy must be adopted by a vote of no less than six members of the board.

(j) Every registered pharmacy technician shall display the current registration in that part of the place of business in which such person is engaged in pharmacy technician activities.

(k) Every pharmacy technician registered after July 1, 2017, shall be required to pass a certified pharmacy technician examination approved by the board.

(l) The board shall adopt such rules and regulations as are necessary to ensure that pharmacy technicians are adequately trained as to the nature and scope of their lawful duties.

(m) The board may adopt rules and regulations as may be necessary to carry out the purposes and enforce the provisions of this act.

(n) This section shall be part of and supplemental to the pharmacy act of the state of Kansas.


65-1664.

65-1665.

65-1666.

65-1667

65-1668. Utilization of unused medications act; not applicable to certain medications.
(a) K.S.A. 65-1668 through 65-1675, and amendments thereto, shall be known and may be cited as the "utilization of unused medications act."
(b) The provisions of the utilization of unused medications act shall not apply to any drug, prescription drug or medication purchased or provided with moneys provided under title XIX of the federal social security act, 42 U.S.C. § 1396 et seq., and amendments thereto, or title XXI of the federal social security act, section 4901 of public law 105-33, 42 U.S.C. § 1397aa et seq., and amendments thereto.

History: L. 2008, ch. 9, § 1; Mar. 27.

65-1669. Same; definitions.
As used in the utilization of unused medications act:
(a) "Adult care home" has the same meaning as such term is defined in K.S.A. 39-923, and amendments thereto.
(b) “Community mental health center” has the same meaning as such term is defined in K.S.A. 2016 Supp. 39-2002, and amendments thereto.

(c) "Donating entities" means adult care homes, mail service pharmacies, institutional drug rooms and medical care facilities who elect to participate in the program.

(d) “Drug” has the same meaning as such term is defined in K.S.A.65-1626, and amendments thereto.

(e) “Federally qualified health center” means a center that meets the requirements for federal funding under 42 U.S.C. § 1396d (1) of the public health service act, and amendments thereto, and that has been designated as a “federally qualified health center” by the federal government.

(f) “Indigent health care clinic” has the same meaning as such term is defined in K.S.A. 75-6102, and amendments thereto.

(g) "Institutional drug room" has the meaning as such term is defined in K.S.A. 65-1626, and amendments thereto.

(h) "Mail service pharmacy" means a licensed Kansas pharmacy that ships, mails or delivers by any lawful means a lawfully dispensed medication in tamper-resistant packaging to residents of this state or another state.

(i) "Medical care facility" has the same meaning as such term is defined in K.S.A. 65-425, and amendments thereto.

(j) "Medically indigent" has the same meaning as such term is defined in K.S.A. 75-6102, and amendments thereto.

(k) "Medication" means a prescription drug or drug as defined by this section.

(l) "Mid-level practitioner" has the same meaning as such term is defined in K.S.A. 65-1626, and amendments thereto.

(m) "Practitioner" has the same meaning as such term is defined in K.S.A. 65-1626, and amendments thereto.

(n) "Prescription drug" means a drug that may be dispensed only upon prescription of a practitioner or mid-level practitioner authorized by law and that is approved for safety and effectiveness as a prescription drug under section 505 or 507 of the federal food, drug and cosmetic act, 52 Stat. 1040 (1938), 21 U.S.C.A. § 301.

(o) "Qualifying center or clinic" means an indigent health care clinic, federally qualified health center or community mental health center.

(p) "Samples of medications or injectables" means a unit of drug that is not intended to be sold and is intended to promote the sale of the drug.

**History:** L. 2008, ch. 9, § 2; Mar. 27; L. 2011, ch. 114, § 8, L. 2013, ch. 114, § 8; L. 2017, ch. 34, § 20; April 20.

### 65-1670. Same; duties of the board of pharmacy; duties of qualifying center or clinic.

(a) The board of pharmacy shall establish and implement a program consistent with public health and safety through which unused drugs may be transferred from donating entities that elect to participate in the program for the purpose of distributing the unused medications to Kansas residents who are medically indigent.

(b) A qualifying center or clinic in consultation with a pharmacist shall establish procedures necessary to implement the program established by the utilization of unused medications act.

(c) The state board of pharmacy shall provide technical assistance to entities who may wish to participate in the program.

**History:** L. 2008, ch. 9, § 3; L. 2013, ch. 114, § 9; July 1.
65-1671. Same; criteria for accepting unused medications; dispensing.
The following criteria shall be used in accepting unused medications for use under the utilization of unused medications act:
(a) The medications shall have come from a controlled storage unit of a donating entity;
(b) only medications in their original or pharmacist sealed unit dose packaging or in tamper evident packaging, unit of use or sealed, unused injectables, including samples of medications or injectables, shall be accepted and dispensed pursuant to the utilization of unused medications act;
(c) expired medications shall not be accepted;
(d) a medication shall not be accepted or dispensed if the person accepting or dispensing the medication has reason to believe that the medication is adulterated;
(e) no controlled substances shall be accepted, unless the state board of pharmacy designates certain controlled substances as accepted medications in the adoption of rules and regulations pursuant to K.S.A. 65-1674, and amendments thereto; and
(f) subject to the limitation specified in this section, unused medications dispensed for purposes of a medical assistance program or drug product donation program may be accepted and dispensed under the utilization of unused medications act.

65-1672. Same; participation; adult care homes; powers and duties of qualifying center or clinic.
(a) Participation in the utilization of unused medications act by residents of adult care homes and donating entities shall be voluntary. Nothing in the utilization of unused medications act shall require any resident of an adult care home or any donating entity to participate in the program.
(b) A qualifying center or clinic which meets the eligibility requirements established in the utilization of unused medications act may:
   (1) Dispense medications donated under the utilization of unused medications act to persons who are medically indigent residents of Kansas; and
   (2) charge persons receiving donated medications a handling fee not to exceed 200% of the medicaid dispensing fee.
(c) A qualifying center or clinic which meets the eligibility requirements established and authorized by the utilization of unused medications act which accepts donated medications shall:
   (1) Comply with all applicable federal and state laws related to the storage and distribution of medications;
   (2) inspect all medications prior to dispensing the medications to determine that such medications are not adulterated; and
   (3) dispense prescription drugs only pursuant to a prescription issued by a practitioner or mid-level practitioner.
(d) Medications donated under the utilization of unused medications act shall not be resold but are available for transfer to another qualifying center or clinic.
(e) For purposes of the utilization of unused medications act, medications dispensed by qualifying centers or clinics shall not be considered resale of such medications.
History: L. 2008, ch. 9, § 5; Mar. 27.

65-1673. Same; criminal and civil liability under the act.
(a) For matters related only to the lawful donation, acceptance or dispensing of medications under the utilization of unused medications act, the following persons and entities, in compliance
with the utilization of unused medications act, in the absence of bad faith or gross negligence, shall not be subject to criminal or civil liability for injury other than death, or loss to person or property, or professional disciplinary action:

(1) The state board of pharmacy;
(2) the department of health and environment;
(3) the Kansas department for aging and disability services;
(4) any governmental entity or donating entity donating medications under the utilization of unused medications act;
(5) any qualifying center or clinic that accepts or dispenses medications under the utilization of unused medications act; and
(6) any qualifying center or clinic that employs a practitioner or midlevel practitioner who accepts or can legally dispense prescription drugs under the utilization of unused medications act and the pharmacy act of the state of Kansas.

(b) For matters related to the donation, acceptance or dispensing of a medication manufactured by the prescription drug manufacturer that is donated by any entity under the utilization of unused medications act, a prescription drug manufacturer shall not, in the absence of bad faith or gross negligence, be subject to criminal or civil liability for injury other than for death, or loss to person or property including, but not limited to, liability for failure to transfer or communicate product or consumer information or the expiration date of the donated prescription drug.

(c) Any person who in good faith donates medications without charge under the utilization of unused medications act, which medications are in compliance with such act at the time donated, shall not be subject to criminal or civil liability arising from any injury or death due to the condition of such medications unless such injury or death is a direct result of the willful, wanton, malicious or intentional misconduct of such person.


65-1674. Same; rules and regulations; duties of the board of pharmacy.
(a) The state board of pharmacy shall adopt rules and regulations to implement the utilization of unused medications act. Such rules shall:

(1) Include standards and procedures for transfer, acceptance and safe storage of donated medications;
(2) include standards and procedures for inspecting donated medications to ensure that the medications are in compliance with the utilization of unused medications act and to ensure that, in the professional judgment of a pharmacist, the medications meet all federal and state standards for product integrity;
(3) establish standards and procedures for acceptance of unused medications from donating entities;
(4) establish standards and procedures for designating certain controlled substances as accepted donated medications;
(5) establish standards and procedures for a qualifying center or clinic to prepare any donated medications for dispensing or administering; and
(6) establish, in consultation with the department of health and environment and the Kansas department for aging and disability services, any additional rules and regulations, and standards and procedures it deems appropriate or necessary to implement the provisions of the utilization of unused medications act.
(b) In accordance with the rules and regulations and procedures of the program established pursuant to this section, a resident of an adult care home, or the representative or guardian of a resident may donate unused medications for dispensation to medically indigent persons.


65-1675. Same; duties of the secretary of health and environment; records.
The secretary of health and environment shall maintain records of program participation including the number of donating entities donating medications, recipient locations, the amount of medications received and the number of clients served.

History: L. 2008, ch. 9, § 8; Mar. 27.

65-1676. Registration of pharmacist interns; applications; registration fees; qualifications for registration; expiration and renewal; revocation, suspension, or limitation; responsibilities of pharmacist and pharmacies; rules and regulations.
(a) It shall be unlawful for any person to function as a pharmacist intern in this state unless such person is registered with the board as a pharmacist intern.
(b) All applications for registration shall be made on a form to be prescribed and furnished by the board. Each application for registration shall be accompanied by a registration fee fixed by the board by rule and regulation not to exceed $25.
(c) Each pharmacist intern registration issued by the board shall expire six years from the date of issuance.
(d) (1) The board may limit, suspend or revoke a registration or deny an application for issuance or renewal of any registration as a pharmacist intern on any ground that would authorize the board to take action against the license of a pharmacist under K.S.A. 65-1627, and amendments thereto.
   (2) The board may temporarily suspend or temporarily limit the registration of any pharmacist intern in accordance with the emergency adjudicative proceedings under the Kansas administrative procedure act, if the board determines that there is cause to believe that grounds exist for disciplinary action under this section against the registrant and that the registrant’s continuation of pharmacist intern functions would constitute an imminent danger to the public health and safety.
   (3) Proceedings under this section shall be subject to the Kansas administrative procedure act.
(e) Every registered pharmacist intern, within 30 days of obtaining new employment, shall furnish the secretary notice of the name and address of the new employer.
(f) Every pharmacist intern who changes their residential address, email address or legal name shall, within 30 days thereof, notify the secretary of such change on a form prescribed and furnished by the board.
(g) Each pharmacy shall at all times maintain a list of the names of pharmacist interns employed by the pharmacy. A pharmacist intern shall work under the direct supervision and control of a pharmacist. It shall be the responsibility of the supervising pharmacist to determine that the pharmacist intern is in compliance with the applicable rules and regulations of the board, and the supervising pharmacist shall be responsible for the acts and omissions of the pharmacist intern in the performance of the pharmacist intern’s duties.
(h) A person holding a pharmacist intern registration shall display such registration in that part of the place of business in which such person is engaged in pharmacist intern activities.
(i) The board shall adopt such rules and regulations as are necessary to ensure that pharmacist interns are adequately trained as to the nature and scope of their lawful duties. The board may adopt rules and regulations as may be necessary to carry out the purposes of and enforce the provisions of this section.

(j) This section shall be part of and supplemental to the pharmacy act of the state of Kansas.  

**History:** L. 2014, ch. 49, § 8; L. 2017, ch. 34, § 16; April 20.

65-1677. Collaborative Drug Therapy Management Committee; purpose and membership.

(a) Not later than 90 days after the effective date of this act, the state board of pharmacy and the state board of healing arts shall appoint a seven-member committee to be known as the collaborative drug therapy management advisory committee for the purpose of promoting consistent regulation and to enhance coordination among such boards with jurisdiction over licensees involved in collaborative drug therapy management. Such committee shall advise and make recommendations to the state board of pharmacy and state board of healing arts on matters relating to collaborative drug therapy management.

(b) The collaborative drug therapy management advisory committee shall consist of seven members: (1) One member of the board of pharmacy appointed by the board of pharmacy, who shall serve as the non-voting chairperson; (2) three licensed pharmacists appointed by the state board of pharmacy, at least two of whom shall have experience in collaborative drug therapy management; and (3) three persons licensed to practice medicine and surgery appointed by the state board of healing arts, at least two of whom shall have experience in collaborative drug therapy management. The state board of pharmacy shall give consideration to any names submitted by the Kansas pharmacists association when making appointments to the committee. The state board of healing arts shall give consideration to any names submitted by the Kansas medical society when making appointments to the committee. Members appointed to the committee shall serve terms of two years, except that of the four members of the committee first appointed to the committee by the state board of pharmacy, two shall be appointed for terms of two years and two shall be appointed for terms of one year as specified by the state board of pharmacy and that of the three members of the committee first appointed to the committee by the state board of healing arts, two shall be appointed for terms of two years and one shall be appointed for a term of one year as specified by the state board of healing arts. Members appointed to the committee shall serve without compensation. All expenses of the committee shall be equally divided and paid by the state board of pharmacy and state board of healing arts.

(c) This section shall be part of and supplemental to the pharmacy act of the state of Kansas.  

**History:** L. 2014, ch. 49, L. 2014, ch. 9, July 1.

65-1678 to 65-1679. Reserved.

65-1680. Epinephrine kits in schools; rules and regulations.

The state board of pharmacy may adopt any rules and regulations which the board deems necessary in relation to the maintenance of epinephrine kits under K.S.A. 2013 Supp. 72-8258, and amendments thereto.  

**History:** L. 2009, ch. 102, § 3; July 1.
65-1681. Prescription monitoring program act.
This act shall be known and may be cited as the prescription monitoring program act.
History: L. 2008, ch. 104, § 1; July 1.

65-1682. Same; definitions.

As used in this act, unless the context otherwise requires:
(a) "Audit trail information" means information produced regarding requests for prescription monitoring program data that the board and advisory committee use to monitor compliance with this act.
(b) "Board" means the state board of pharmacy.
(c) "Delegate" means:
   (1) A registered nurse, licensed practical nurse, respiratory therapist, emergency medical responder, paramedic, dental hygienist, pharmacy technician or pharmacy intern who has registered for access to the program database as an agent of a practitioner or pharmacist to request program data on behalf of the practitioner or pharmacist;
   (2) a death investigator who has registered for limited access to the program database as an agent of a medical examiner, coroner or another person authorized under law to investigate or determine causes of death; or
   (3) an individual authorized to access the program database by the board in rules and regulations.
(d) "Dispenser" means a practitioner, pharmacy or pharmacist who delivers a scheduled substance or drug of concern to an ultimate user, but does not include:
   (1) A licensed hospital pharmacy that distributes such substances for the purpose of inpatient hospital care;
   (2) a medical care facility as defined in K.S.A. 65-425, and amendments thereto, practitioner or other authorized person who administers such a substance;
   (3) a registered wholesale distributor of such substances;
   (4) a veterinarian licensed by the Kansas board of veterinary examiners who dispenses or prescribes a scheduled substance or drug of concern;
   (5) a practitioner who has been exempted from the reporting requirements of this act in rules and regulations promulgated by the board.
(e) "Drug of concern" means any drug that demonstrates a potential for abuse and is designated as a drug of concern in rules and regulations promulgated by the board.
(f) "Patient" means the individual who is the ultimate user of a drug for whom a prescription is issued or for whom a drug is dispensed.
(g) "Pharmacist" means an individual currently licensed by the board to practice the profession of pharmacy in this state.
(h) "Pharmacy" means a premises, laboratory, area or other place currently registered with the board where scheduled substances or drugs of concern are offered for sale or dispensed in this state.
(i) "Practitioner" means an individual licensed to practice medicine and surgery, dentist, podiatrist, optometrist or other individual authorized by law to prescribe or dispense scheduled substances and drugs of concern.
(j) "Program" means the prescription monitoring program.
(k) "Scheduled substance" means controlled substances included in schedules II, III or IV of the schedules designated in K.S.A. 65-4107, 65-4109 and 65-4111, and amendments thereto, respectively, or the federal controlled substances act, 21 U.S.C. § 812.

History: L. 2008, ch. 104, § 2; L. 2022, ch. 74, § 3; April 28.
65-1683 Same; required information to be submitted by dispenser; rules and regulations; waiver; acceptance of gifts and grants.

(a) The board shall establish and maintain a prescription monitoring program for the monitoring of scheduled substances and drugs of concern dispensed in this state or dispensed to an address in this state.

(b) Each dispenser shall submit to the board by electronic means information required by the board regarding each prescription dispensed for a substance included under subsection (a). The board shall promulgate rules and regulations specifying the nationally recognized telecommunications format to be used for submission of information that each dispenser shall submit to the board. Such information may include, but not be limited to:

1. The dispenser identification number;
2. the date the prescription is filled;
3. the prescription number;
4. whether the prescription is new or is a refill;
5. the national drug code for the drug dispensed;
6. the quantity dispensed;
7. the number of days' supply of the drug;
8. the patient identification number;
9. the patient's name;
10. the patient's address;
11. the patient's date of birth;
12. the prescriber identification number;
13. the date the prescription was issued by the prescriber;
14. the source of payment for the prescription;
15. the diagnosis code;
16. the patient's species code; and
17. the date the prescription was sold.

(c) The board shall promulgate rules and regulations specifying the transmission methods and frequency of the dispenser submissions required under subsection (b).

(d) The board may, in consultation with the advisory committee, enable features and include additional information to enhance the program database. Such information may include, but not be limited to:

1. The date or fact of death;
2. the dispensation or administration of emergency opioid antagonists, as defined by K.S.A. 65-16,127, and amendments thereto; and
3. the data related to an overdose event.

(e) The board is hereby authorized to apply for and to accept grants and may accept any donation, gift or bequest made to the board for furthering any phase of the prescription monitoring program.

(f) The board shall remit all moneys received by it under subsection (e) to the state treasurer in accordance with the provisions of K.S.A. 75-4215, and amendments thereto. Upon receipt of such remittance, the state treasurer shall deposit the entire amount in the state treasury to the credit of the non-federal gifts and grants fund. All expenditures from such fund shall be made in accordance with appropriation acts upon warrants of the director of accounts and reports issued pursuant to vouchers approved by the president of the board or a person designated by the president.

65-1684. Same; charges and fees prohibited.
The board shall not impose any charge for the establishment or maintenance of the prescription monitoring program database on a registered wholesale distributor, pharmacist, dispenser or other person authorized to prescribe or dispense scheduled substances and drugs of concern. The board shall not charge any fees for the transmission of data to the database or for the receipt of information from the database, except that the board may charge a fee to an individual who requests the individual's own prescription monitoring information in accordance with procedures adopted by the board.


65-1685 Same; database information privileged and confidential; persons authorized to receive data; oversight thereof; advisory committee review of information.

(a) The program database, all information contained therein and any records maintained by the board, or by any entity contracting with the board, submitted to, maintained or stored as a part of the database, including audit trail information, shall be privileged and confidential, shall not be subject to subpoena or discovery in civil proceedings and may only be used for investigatory or evidentiary purposes related to violations of state or federal law and regulatory activities of entities charged with administrative oversight of those individuals engaged in the prescribing or dispensing of scheduled substances and drugs of concern, shall not be a public record and shall not be subject to the Kansas open records act, K.S.A. 45-215 et seq., and amendments thereto, except as provided in subsections (c) and (d).

(b) The board shall maintain procedures to ensure that the privacy and confidentiality of patients and patient information collected, recorded, transmitted and maintained is not disclosed to individuals except as provided in subsections (c) and (d).

(c) The board is hereby authorized to provide data in the program to the following individuals:

1. Individuals authorized to prescribe or dispense scheduled substances and drugs of concern, for the purpose of providing medical or pharmaceutical care for their patients;
2. an individual who requests the individual's own prescription monitoring information in accordance with procedures established by the board;
3. designated representatives from the professional licensing, certification or regulatory agencies charged with administrative oversight of those individuals engaged in the prescribing or dispensing of scheduled substances and drugs of concern;
4. local, state and federal law enforcement or prosecutorial officials engaged in the administration, investigation or enforcement of the laws governing scheduled substances and drugs of concern subject to the requirements in K.S.A. 22-2502, and amendments thereto;
5. designated representatives from the department of health and environment regarding authorized medicaid program recipients or practitioners;
6. individuals authorized by a grand jury subpoena, inquisition subpoena or court order in a criminal action;
7. personnel of the prescription monitoring program advisory committee for the purpose of operation of the program;
8. personnel of the board for purposes of operation of the program and administration and enforcement of this act or the uniform controlled substances act, K.S.A. 65-4101 et seq., and amendments thereto;
9. individuals authorized to prescribe or dispense scheduled substances and drugs of concern, when an individual is obtaining prescriptions in a manner that appears to be misuse, abuse or diversion of scheduled substances or drugs of concern;
(10) medical examiners, coroners or other individuals authorized under law to investigate or determine causes of death;

(11) persons operating a practitioner or pharmacist impaired provider program in accordance with K.S.A. 65-4924, and amendments thereto, for the purpose of reviewing drugs dispensed to a practitioner or pharmacist enrolled in the program;

(12) delegates of individuals authorized by paragraphs (1), (9) and (10);

(13) individuals or organizations notified by the advisory committee as provided in subsection (g);

(14) practitioners or pharmacists conducting research approved by an institutional review board who have obtained patient consent for the release of program data; and

(15) an overdose fatality review board established by the state of Kansas.

(d) An individual registered for access to the program database shall notify the board in writing within 30 calendar days of any action that would disqualify the individual from being authorized to receive program data as provided in subsection (c).

(e) The state board of healing arts, board of nursing, Kansas dental board and board of examiners in optometry shall notify the board in writing within 30 calendar days of any denial, suspension, revocation or other administrative limitation of a practitioner's license or registration that would disqualify the practitioner from being authorized to receive program data as provided in subsection (c).

(f) A practitioner or pharmacist shall notify the board in writing within 30 calendar days of any action that would disqualify a delegate from being authorized to receive program data on behalf of the practitioner or pharmacist.

(g) The prescription monitoring program advisory committee established pursuant to K.S.A. 65-1689, and amendments thereto, is authorized to review and analyze program data for purposes of identifying patterns and activity of concern.

(1) If a review of information appears to indicate an individual may be obtaining prescriptions in a manner that may represent misuse or abuse of scheduled substances and drugs of concern, the advisory committee is authorized to notify the prescribers and dispensers who prescribed or dispensed the prescriptions. If the review does not identify a recent prescriber as a point of contact for potential clinical intervention, the advisory committee is authorized to notify the disability and behavioral health services section of the Kansas department for aging and disability services for the purpose of offering confidential treatment services. Further disclosure of information is prohibited. If the review identifies patterns or other evidence sufficient to create a reasonable suspicion of criminal activity, the advisory committee is authorized to notify the appropriate law enforcement agency.

(2) If a review of information appears to indicate that a violation of state or federal law relating to prescribing scheduled substances and drugs of concern may have occurred, or that a prescriber or dispenser has knowingly prescribed, dispensed or obtained scheduled substances and drugs of concern in a manner that is inconsistent with recognized standards of care for the profession, the advisory committee shall determine whether a report to the professional licensing, certification or regulatory agencies charged with administrative oversight of those individuals engaged in prescribing or dispensing of scheduled substances and drugs of concern or to the appropriate law enforcement agency is warranted.

(A) For purposes of such determination the advisory committee may, in consultation with the appropriate regulatory agencies and professional organizations, establish criteria regarding appropriate standards and utilize volunteer peer review committees of professionals with expertise in the particular practice to create such standards and review individual cases.

(B) The peer review committee or committees appointed herein shall have authority to request and receive information in the program database from the director of the program.
(C) If the determination is made that a referral to a regulatory or law enforcement agency is not warranted but educational or professional advising might be appropriate, the advisory committee may refer the prescribers or dispensers to other such resources.

(3) If a review of information appears to indicate that program data has been accessed or used in violation of state or federal law, the advisory committee shall determine whether a report to the professional licensing, certification or regulatory agencies charged with administrative oversight of those individuals engaged in prescribing or dispensing of scheduled substances and drugs of concern is warranted and may make such report.

(e) The board is hereby authorized to provide program data to public or private entities for statistical, research or educational purposes after removing information that could be used to identify individual practitioners, dispensers, patients or individuals who received prescriptions from dispensers.

(f) The board is hereby authorized to provide a medical care facility with its program data for statistical, research or education purposes after removing information that could be used to identify individual practitioners or individuals who received prescriptions from dispensers.

(g) The board may, in its discretion, block any user's access to the program database if the board has reason to believe that access to the data is or may be used by such user in violation of state or federal law.


65-1685a. Same; another agency as contractor.

65-1686. Same; another agency as contractor.
The board is hereby authorized to contract with another agency of this state or with a private vendor, as necessary, to ensure the effective operation of the prescription monitoring program. Any contractor shall be bound to comply with the provisions regarding confidentiality of prescription information in K.S.A. 2013 Supp. 65-1685, and amendments thereto, and shall be subject to the penalties specified in K.S.A. 2013 Supp. 65-1693, and amendments thereto, for unlawful acts.

65-1687 Same; maintenance of records.
(a) All information collected for the prescription monitoring program database and any records maintained by the board, or by any entity contracting with the board, submitted to, maintained or stored as a part of the database, shall be retained for five years.

(b) Program data shall not be stored outside of the program database, with the following exceptions:

1. Temporary storage necessary to deliver program data to electronic health records or pharmacy management systems approved by the board;

2. retention of specific information or records related to an investigation or proceeding under administrative or criminal law;

3. program data provided under K.S.A. 65-1685(e), and amendments thereto; or

4. board retention of information for purposes of operation of the program and administration and enforcement of this act or the uniform controlled substances act, K.S.A. 65-4101 et seq., and amendments thereto.

History: L. 2008, ch. 104, § 7; L. 2022, ch. 74, § 6; April 28.
65-1688 Same; act does not create civil liability or duty.
No person authorized to prescribe or dispense scheduled substances and drugs of concern shall be liable to any person in a civil action for damages or other relief for injury, death or loss to person or property on the basis that such person authorized to prescribe or dispense scheduled substances and drugs of concern did or did not seek or obtain information from the prescription monitoring program prior to prescribing or dispensing scheduled substances and drugs of concern to a patient. Nothing in this act shall be construed to create a duty or otherwise require a person authorized to prescribe or dispense scheduled substances and drug of concern to obtain information about a patient from the prescription monitoring program prior to prescribing or dispensing scheduled substances and drug of concern to such patient.


65-1689 Same; advisory committee created; members; terms.
(a) There is hereby created the program advisory committee which, subject to the oversight of the board, shall be responsible for the operation of the program. The advisory committee shall consist of at least 10 members appointed by the board as follows:
   (1) Two licensed physicians, one nominated by the Kansas medical society and one nominated by the Kansas association of osteopathic medicine;
   (2) two licensed pharmacists nominated by the Kansas pharmacists association;
   (3) one person representing the Kansas bureau of investigation nominated by the attorney general;
   (4) one person representing the university of Kansas school of medicine nominated by the dean of such school;
   (5) one person representing the university of Kansas school of pharmacy nominated by the dean of such school;
   (6) one licensed dentist nominated by the Kansas dental association;
   (7) one person representing the Kansas hospital association nominated by such association;
   (8) one licensed advanced practice provider nominated by either the board of nursing or the state board of healing arts; and
   (9) the board may also appoint other persons authorized to prescribe or dispense scheduled substances and drugs of concern, recognized experts and representatives from law enforcement.
(b) The appointments to the advisory committee shall be for terms of three years.
(c) The advisory committee shall elect a chairperson from among its members who shall serve a one-year term. The chairperson may serve consecutive terms.
(d) The advisory committee, in accordance with K.S.A. 75-4319, and amendments thereto, may recess for a closed or executive meeting when it is considering matters relating to identifiable patients or providers.
(e) Upon the expiration of the term of office of any member of the advisory committee on or after the effective date of this act, and in any case of a vacancy existing on or after the effective date of this act, a successor shall be appointed by the board pursuant to this section.
(f) All members of the advisory committee shall serve without compensation.

History: L. 2008, ch. 104, § 9; L. 2022, ch. 74, § 7; April 28.

65-1690 Same; advisory committee in cooperation with other entities.
(a) The prescription monitoring program advisory committee shall work with each entity charged with administrative oversight of those persons engaged in the prescribing or dispensing of
scheduled substances and drugs of concern to develop a continuing education program for such persons about the purposes and uses of the prescription monitoring program.
(b) The advisory committee shall work with the Kansas bar association to develop a continuing education program for attorneys about the purposes and uses of the prescription monitoring program.
(c) The advisory committee shall work with the Kansas bureau of investigation to develop a continuing education program for law enforcement officers about the purposes and uses of the prescription monitoring program.

65-1691 Same; board consultation with advisory committee; annual report.
In consultation with and upon recommendation of the prescription monitoring program advisory committee, the board shall review the effectiveness of the prescription monitoring program and submit an annual report to the Senate standing committee on public health and welfare and the House standing committee on health and human services.

65-1692 Same; rules and regulations.
The board is hereby authorized to promulgate rules and regulations necessary to carry out the provisions of this act.

65-1693 Same; penalties.
(a) A dispenser who knowingly fails to submit prescription monitoring information to the board as required by this act or knowingly submits incorrect prescription monitoring information shall be guilty of a severity level 10 non-person felony.
(b) A person authorized to have prescription monitoring information pursuant to this act who knowingly discloses such information in violation of this act shall be guilty of a severity level 10, non-person felony.
(c) A person authorized to have prescription monitoring information pursuant to this act who knowingly uses such information in a manner or for a purpose in violation of this act shall be guilty of a severity level 10 non-person felony.
(d) A person who knowingly, and without authorization, obtains or attempts to obtain prescription monitoring information shall be guilty of a severity level 10, nonperson felony.
(e) It shall not be a violation of this act for a practitioner or dispenser to disclose or use information obtained pursuant to this act when such information is disclosed or used solely in the course of such practitioner's or dispenser's care of the patient who is the subject of the information.

65-1694 Same; veterinary prescription monitoring program task force; study; members; report.
(a) There is hereby established the veterinary prescription monitoring program task force which shall study and determine whether to require veterinarians to report to a prescription monitoring program under this act. Such study shall include appropriate methods and procedures of reporting by the veterinarians with the necessary database field information. The task force shall
utilize nationally available resources afforded by the American Association of Veterinary State boards and the American veterinary medical associations department of state legislative and regulatory affairs and development of the plan in consultation with the advisory committee. (b) The task force shall consist of three members as follows: one member appointed by the prescription monitoring program advisory committee; one member appointed by the Kansas board of veterinary examiners; and one member nominated by the Kansas veterinary medical association and appointed by the Kansas board of veterinary examiners. (c) Appointments shall be made within 120 days after the effective date of this act. The initial meeting of the task force shall be convened within 180 days after the effective date of this act. The task force shall elect a chairperson and may elect any additional officers from among its members. All task force members shall serve without compensation. (d) The task force shall report its findings and progress to the prescription monitoring program advisory committee at least annually or when requested by the advisory committee. The task force shall report its progress to the Senate committee on public health and welfare and the House committee on health and human services, if requested, and report its conclusions and recommendations to such committees within 5 years after the effective date of this act. Based on the recommendation by the task force, this act shall be amended to include the veterinarians as practitioners. 


65-1694a. Same; prescription monitoring program fund created.
(a) There is hereby established in the state treasury the prescription monitoring program fund. Such fund shall be administered by the president of the state board of pharmacy or the president's designee. All expenditures from the prescription monitoring program fund shall be for the purpose of operating the prescription monitoring program that is established in accordance with the prescription monitoring program act. All expenditures from the prescription monitoring program fund shall be made in accordance with appropriation acts upon warrants of the director of accounts and reports issued pursuant to vouchers approved by the president of the state board of pharmacy or the president's designee.

(b) This section shall be a part of and supplemental to the prescription monitoring program act. 

History: L. 2021, ch. 110, § 8; May 27.

65-1695. Continuous quality improvement program; purpose; confidential peer review documents; rules and regulations.
(a) No later than July 1, 2009, each pharmacy shall establish a continuous quality improvement (CQI) program. The purpose of the CQI program shall be to assess errors that occur in the pharmacy in dispensing or furnishing prescription medications so that the pharmacy may take appropriate action to prevent a recurrence. 
(b) Reports, memoranda, proceedings, findings and other records generated as part of a pharmacy's CQI program shall be considered confidential and privileged peer review documents and not subject to discovery, subpoena or other means of legal compulsion for their release to any person or entity and shall not be admissible in any civil or administrative action other than an administrative proceeding initiated by the board of pharmacy. Nothing in this section shall be construed to prohibit a patient from accessing such patient's own prescription records. Nothing in this section shall affect the discoverability of any record not solely generated for or maintained as a part of a pharmacy's CQI program.
(c) No person in attendance at any meeting being conducted as part of a CQI program shall be compelled to testify in any civil, criminal or administrative action, other than an administrative proceeding initiated by the board of pharmacy as to any discussions or decisions which occurred as part of the CQI program.
(d) All reports and records generated as part of a pharmacy's CQI program shall be available for inspection by the board of pharmacy within a time period established by the board in rules and regulations.
(e) In conducting a disciplinary proceeding in which admission of any matters that are confidential and privileged under subsection (b) are proposed, the board of pharmacy shall hold the hearing in closed session when any report, record or testimony is disclosed. Unless otherwise provided by law, the board of pharmacy in conducting a disciplinary proceeding may close only that portion of the hearing in which disclosure of such privileged matters are proposed. In closing a portion of a hearing as provided in this subsection, the presiding officer may exclude any person from the hearing except members of the board, the licensee, the licensee's attorney, the agency's attorney, the witness, the court reporter and appropriate staff support for either counsel. The board of pharmacy shall make the portions of the administrative record in which such privileged matters are disclosed subject to a protective order prohibiting further disclosure. Such privileged matters shall not be subject to discovery, subpoena or other means of legal compulsion for their release to any person or entity. No person in attendance at a closed portion of a disciplinary proceeding shall be required to testify at a subsequent civil, criminal or administrative hearing regarding the privileged matters, nor shall such testimony be admitted into evidence in any subsequent civil, criminal or administrative hearing. The board of pharmacy may review any matters that are confidential and privileged under subsection (b) in conducting a disciplinary proceeding but must prove its findings with independently obtained testimony or records which shall be presented as part of the disciplinary proceeding in an open meeting of the board of pharmacy. Offering such testimony or records in an open public hearing shall not be deemed a waiver of the peer review privilege relating to any peer review committee testimony, record or report.
(f) The board may establish by rules and regulations requirements regarding the functions and record keeping of a pharmacy CQI program.
(g) This section shall be part of and supplemental to the pharmacy act of the state of Kansas.


65-1696. State board of pharmacy; fingerprinting and criminal history.
(a) As part of an original application for or reinstatement of any license, registration, permit or certificate or in connection with any investigation of any holder of a license, registration, permit or certificate, the state board of pharmacy may require a person to be fingerprinted and submit to a state and national criminal history record check. The fingerprints shall be used to identify the person and to determine whether the person has a record of criminal history in this state or other jurisdiction. The state board of pharmacy is authorized to submit the fingerprints to the Kansas bureau of investigation and the federal bureau of investigation for a state and national criminal history record check. The state board of pharmacy may use the information obtained from fingerprinting and the criminal history for purposes of verifying the identification of the person and in the official determination of the qualifications and fitness of the person to be issued or to maintain a license, registration, permit or certificate.
(b) Local and state law enforcement officers and agencies shall assist the state board of pharmacy in taking and processing of fingerprints of applicants for and holders of any license, registration, permit or certificate and shall release all records of adult convictions and nonconvictions and adult convictions or adjudications of another state or country to the state board of pharmacy.

(c) The state board of pharmacy may fix and collect a fee as may be required by the board in an amount equal to the cost of fingerprinting and the criminal history record check. Any moneys collected under this subsection shall be deposited in the state treasury and credited to the pharmacy fee fund. The board of pharmacy shall remit all moneys received by or for it from fees, charges or penalties to the state treasurer in accordance with the provisions of K.S.A. 75-4215, and amendments thereto. Upon receipt of each such remittance, the state treasurer shall deposit the entire amount in the state treasury to the credit of the pharmacy fee fund.

(d) This section shall be part of and supplemental to the pharmacy act of the state of Kansas.

History: L. 2009, ch. 131, § 10; July 1.

65-1697 to 65-16,100. Reserved.


As used in the statewide electronic logging system for sale of methamphetamine precursor act, unless the context otherwise requires:

(a) “Board” means the state board of pharmacy.
(b) “Methamphetamine precursor” means any compound, mixture or preparation containing pseudoephedrine, ephedrine or phenylpropanolamine, or any of their salts or optical isomers, or salts of optical isomers, but does not include products that have been formulated in such a way as to effectively prevent the conversion of the active ingredient into methamphetamine, or its salts for precursors, and does not include animal feed products containing ephedrine or any naturally occurring or herbal ephedra or extract of ephedra.
(c) “Pharmacy” means premises, laboratory, area or other place, including in-state and out-of-state facilities that are required to be registered under K.S.A. 65-1643 or 65-1657, and amendments thereto:

(1) Where drugs are offered for sale where the profession of pharmacy is practiced and where prescriptions are compounded and dispensed; or
(2) which has displayed upon it or within it the words “pharmacist,” “pharmaceutical chemist,” “pharmacy,” “apothecary,” “drugstore,” “druggist,” “drugs,” “drug sundries” or any of these words or combinations of these words or words of similar import either in English or any sign containing any of these words; or
(3) where the characteristic symbols of pharmacy or the characteristic prescription sign “Rx” may be exhibited.

History: L. 2009, ch. 131, § 1; July 1.

65-16, 102. Same; maintenance of program by the board of pharmacy; rules and regulations; waiver and liability.

(a) The board shall establish and maintain a program for a statewide electronic logging system for sale of methamphetamine precursors.
(b) Each pharmacy shall maintain an electronic methamphetamine precursor recording log documenting the sale of methamphetamine precursors. The board shall promulgate rules and
regulations specifying a standardized format for the log and the information that each pharmacy shall submit to the board, which shall include, but not be limited to:

1) The name and address of the person purchasing, receiving or otherwise acquiring the methamphetamine precursor;
2) the name of the product and quantity purchased;
3) the date and time of the purchase; and
4) the name, or initials, of the licensed pharmacist, registered pharmacy technician or pharmacy intern or clerk supervised by a licensed pharmacist who sold the product.

c) Notwithstanding the requirements of this section, each pharmacy shall maintain the purchaser’s signature in accordance with subsection (k) of K.S.A. 65-1643, and amendments thereto.

d) Each pharmacy that is capable shall submit the information from the log in real time in accordance with transmission methods specified in rules and regulations promulgated by the board.

e) The board may grant a waiver exempting a pharmacy from compliance with the requirements of this section upon showing of good cause by the pharmacy that it is otherwise unable to submit log information by electronic means for various reasons, including, but not limited to, mechanical or electronic failure or financial, technological or any other undue burden on the pharmacy, established by rules and regulations. Such waiver may permit the pharmacy to submit log information by paper form or other means, provided that all information required by rules and regulations is submitted in this alternative format.

(f) No pharmacy or pharmacy employee shall be liable to any person in a civil action for damages or other relief arising from a sale of a methamphetamine precursor that occurs at another pharmacy.

(g) The requirements of this section shall not apply where there is a lawful prescription present for the methamphetamine precursor sold.

**History:** L. 2009, ch. 131, § 2; July 1.

### 65-16,103. Same; no cost charged to pharmacies; funding of program.

(a) The cost of establishing and maintaining the statewide electronic logging system shall be borne by the state, other non-state units of government, private entities, or others. Pharmacies shall not be required to bear the costs associated with establishing and maintaining the electronic logging system, through any additional charges, whether statewide, regional, county-wide or otherwise as provided in this section.

(b) In the event that funding for a statewide program is not available, the board may implement the program on a non-statewide basis, whether such program is funded regionally or county-wide or otherwise. The board shall, by rules and regulations, prescribe that such regional or non-statewide program comply with requirements applicable to a statewide program, including that such non-state governmental units or regional programs may not utilize different vendors. Any requirements of this act shall only be applicable to pharmacies within such units of government or regions, if a regional program is established, and all other pharmacies in the state shall be exempt from requirements for the electronic logging system required pursuant to this act.

(c) If the state, other non-state units of government, private entities or others are unable to bear the costs of establishing and maintaining the electronic logging system, pharmacies within the state, or in the case of regional or other non-statewide programs, pharmacies within those program areas shall be relieved of any obligation to comply with the statewide electronic logging
system program pursuant to this act. Such pharmacies shall still be subject to the requirements of maintaining a log as provided in subsection (k) of K.S.A. 65-1643, and amendments thereto.

(d) The board shall not impose any additional charges for the establishment or maintenance of the program for the recording of methamphetamine precursors on a pharmacy. The board shall not charge any fees for the transmission of data to the program database or for the receipt of information from the database.

(e) The state board of pharmacy may receive and expend, or supervise the expenditure of, any donation, gift, grant or bequest made to the board for furthering any phase of the statewide electronic logging system program.

History: L. 2009, ch. 131, § 3; July 1.

65-16,104. Same; confidential information; authorized access to data in the log.

(a) Methamphetamine precursor recording log information submitted to the board shall be confidential and not a public record and not subject to the Kansas open records act, K.S.A. 45-215 et seq., and amendments thereto, except as provided in subsections (c) and (d).

(b) The board shall maintain procedures to ensure that the privacy and confidentiality of information collected, recorded, transmitted and maintained is not disclosed to persons except as provided in subsections (c) and (d).

(c) The board shall be authorized to provide data in the log to the following persons:

(1) Any person authorized to prescribe or dispense products containing pseudoephedrine, ephedrine or phenylpropanolamine, for the purpose of complying with the provisions of this act; and

(2) local, state and federal law enforcement or prosecutorial officials.

(d) The board may provide data to public or private entities for statistical, research or educational purposes after removing information that could be used to identify individual patients or persons who received methamphetamine precursors from pharmacies.


65-16,105. Same; another agency or private vendor as contractor; maintenance and destruction of records; educational program for pharmacies; annual report.

(a) The board is hereby authorized to contract with another agency of this state or with a private vendor, as necessary, to ensure the effective implementation and operation of the methamphetamine precursor recording log. The state agency or private vendor selected shall have the technological capability to receive electronic log data from pharmacies submitted pursuant to K.S.A. 2013 Supp. 65-16,102, and amendments thereto, and to send real time notification to law enforcement officials. Regardless of the entity selected to manage the program, pharmacies are not required to use any one particular vendor's product to comply with the requirements under K.S.A. 2013 Supp. 65-16,102, and amendments thereto. Any electronic system implemented by the state shall be capable of bridging with existing and future operational systems used by pharmacies at no cost to such pharmacies. Any contractor shall be bound to comply with the provisions regarding confidentiality of log information in this section, and amendments thereto, and shall be subject to the penalties specified in K.S.A. 2013 Supp. 65-16,107, and amendments thereto, for unlawful acts.

(b) All information collected for the program database and any records maintained by the board, or by any entity contracting with the board, submitted to, maintained or stored as a part of the database, shall be retained for five years. Such information and records shall then be destroyed...
unless a law enforcement entity has submitted a written request to the board for retention of specific information or records in accordance with procedures adopted by the board.
(c) The board shall develop and implement a program to educate pharmacies and pharmacy employees about the program for the recording of methamphetamine precursors.
(d) The board shall review the effectiveness of the program for the recording of methamphetamine precursors and submit an annual report to the senate standing committee on public health and welfare and the house standing committee on health and human services.

**History:** L. 2009, ch. 131, § 5; July 1.

### 65-16, 106. Same; rules and regulations.

The board shall adopt, within six months after the effective date of this act, such rules and regulations the board deems necessary to carry out the provisions of this act.

**History:** L. 2009, ch. 131, § 6; July 1.

### 65-16, 107. Same; penalties.

(a) A pharmacy that knowingly fails to submit methamphetamine precursor recording log information to the board as required by this act or knowingly submits incorrect log information shall be guilty of a severity level 10, nonperson felony.
(b) A person authorized to have log information pursuant to this act who knowingly discloses such information in violation of this act shall be guilty of a severity level 10, nonperson felony.
(c) A person authorized to have log information pursuant to this act who knowingly uses such information in a manner or for a purpose in violation of this act shall be guilty of a severity level 10, nonperson felony.

**History:** L. 2009, ch. 131, § 7; July 1.

### 65-16, 108. Same; short title.

K.S.A. 2009 Supp. 65-16,101 through 65-16,108, and amendments thereto, shall be known and may be cited as the statewide electronic logging system for sale of methamphetamine precursor act.

**History:** L. 2009, ch. 131, § 8; July 1.

### 65-16,121. Pharmacy audit integrity act.

(a) K.S.A. 2013 Supp. 65-16,121 through 65-16,126, and amendments thereto, shall be known and may be cited as the pharmacy audit integrity act.
(b) This section shall take effect on and after July 1, 2011.

**History:** L. 2011, ch. 114, § 1; June 9.

### 65-16,122. Same; definitions.

(a) As used in this act, "pharmacy benefits manager" or "PBM" means a person, business or other entity that performs pharmacy benefits management. The term includes a person or entity acting for a PBM in contractual or employment relationship in the performance of pharmacy benefits management for a managed care company, not-for-profit hospital or medical service organization, insurance company, third-party payor or health program administered by the state board of pharmacy.
(b) This section shall take effect on and after July 1, 2011.

**History:** L. 2011, ch. 114, § 2; June 9.
65-16,123. Same; procedural requirements.

(a) The entity conducting the audit shall follow the following procedures:

(1) An entity conducting an on-site audit must give the pharmacy at least seven days written notice before conducting an initial audit;

(2) an audit that involves clinical or professional judgment must be conducted by or in consultation with a licensed pharmacist;

(3) the period covered by the audit may not exceed two years from the date that the claim was submitted to or adjudicated by the entity;

(4) the pharmacy may request an extension not to exceed seven days from the date of an originally scheduled on-site audit;

(5) the pharmacy may use the records of a hospital, physician or other authorized practitioner to validate the pharmacy record;

(6) any legal prescription, in compliance with the requirements of the state board of pharmacy, may be used to validate claims in connection with prescriptions, refills or changes in prescriptions;

(7) each pharmacy shall be audited under the same standards and parameters as other similarly situated pharmacies; and

(8) the entity conducting the audit must establish a written appeals process.

(b) The entity conducting the audit shall also comply with the following requirements:

(1) A finding of overpayment or underpayment must be based on the actual overpayment or underpayment and not a projection based on the number of patients served having a similar diagnosis or on the number of similar orders or refills for similar drugs;

(2) the entity conducting the audit shall not use extrapolation in calculating the recoupments or penalties for audits, unless required by state or federal contracts;

(3) the auditing company or agent may not receive payment based on a percentage of the amount recovered, unless required by contracts; and

(4) interest may not accrue during the audit period.

(c) This section shall take effect on and after July 1, 2011.

History: L. 2011, ch. 114, § 3; June 9.

65-16,124. Same; audit reports; recoupment and repayment of funds; access to audit information.

(a) Any preliminary audit report must be delivered to the pharmacy within 60 days after the conclusion of the audit. Any pharmacy shall be allowed at least 30 days following receipt of the preliminary audit to provide documentation to address any discrepancy found in the audit. Any final audit report shall be delivered to the pharmacy within 120 days after receipt of the preliminary audit report or final appeal, whichever is later.

(b) Recoupment of any disputed funds or repayment of funds to the entity by the pharmacy, if permitted pursuant to contracts, shall occur, to the extent demonstrated or documented in the pharmacy audit findings, after final internal disposition of the audit including the appeals process. If the identified discrepancy for an individual audit exceeds $20,000, any future payments to the pharmacy may be withheld pending finalization of the audit. Unless otherwise required by the federal or state law, any audit information may not be shared. Auditors shall only have access to previous audit reports on a particular pharmacy conducted by that same entity.

(c) This section shall take effect on and after July 1, 2011.

65-16,125. Same; final report; availability.
(a) Any auditing entity, upon request of the plan sponsor, shall provide a copy of the final report, including the disclosure of any money recouped in the audit. The pharmacy may provide a copy of the report to the commissioner of insurance, provided such report shall not contain any personally identifiable health information in violation of the provisions of the health insurance portability and accountability act of 1996 (Pub. L. No. 104-191).
(b) This section shall take effect on and after July 1, 2011.

65-16,126. Same; application of the act.
(a) This act shall apply to contracts between an auditing entity and a pharmacy entered into, extended or renewed on or after the effective date of this act. This act shall not apply to any audit, review or investigation that is initiated based upon suspected or alleged fraud, willful misrepresentation or abuse.
(b) This section shall take effect on and after July 1, 2011.

65-16,127. Emergency opioid antagonists; dispensing, storing and administering; duties of the state board of pharmacy and first responder agencies; rules and regulations.
(a) As used in this section:
(1) “Bystander” means a family member, friend, caregiver or other person in a position to assist a person who the family member, friend, caregiver or other person believes, in good faith, to be experiencing an opioid overdose.
(2) “Emergency opioid antagonist” means any drug that inhibits the effects of opioids and that is approved by the United States food and drug administration for the treatment of an opioid overdose.
(3) “First responder” includes any attendant, as defined by K.S.A. 65-6112, and amendments thereto, any law enforcement officer, as defined by K.S.A. 22-2202, and amendments thereto, and any actual member of any organized fire department, whether regular or volunteer.
(4) “First responder agency” includes, but is not limited to, any law enforcement agency, fire department or criminal forensic laboratory of any city, county or the state of Kansas.
(5) “Opioid antagonist protocol” means the protocol established by the state board of pharmacy pursuant to subsection (b).
(6) “Opioid overdose” means an acute condition including, but not limited to, extreme physical illness, decreased level of consciousness, respiratory depression, coma, mania or death, resulting from the consumption or use of an opioid or another substance with which an opioid was combined, or that a layperson would reasonably believe to be resulting from the consumption or use of an opioid or another substance with which an opioid was combined, and for which medical assistance is required.
(7) “Patient” means a person believed to be at risk of experiencing an opioid overdose.
(8) “School nurse” means a professional nurse licensed by the board of nursing and employed by a school district to perform nursing procedures in a school setting.
(9) “Healthcare provider” means a physician licensed to practice medicine and surgery by the state board of healing arts, a licensed dentist, a mid-level practitioner as defined by K.S.A. 65-1626, and amendments thereto, or any person authorized by law to prescribe medication.
(b) The state board of pharmacy shall issue a statewide opioid antagonist protocol that establishes requirements for a licensed pharmacist to dispense emergency opioid antagonists to a person pursuant to this section. The opioid antagonist protocol shall include procedures to ensure accurate recordkeeping and education of the person to whom the emergency opioid antagonist is furnished, including, but not limited to: Opioid overdose prevention, recognition and response; safe administration of an emergency opioid antagonist; potential side effects or adverse events that may occur as a result of administering an emergency opioid antagonist; a requirement that the administering person immediately contact emergency medical services for a patient; and the availability of drug treatment programs.

c) A pharmacist may furnish an emergency opioid antagonist to a patient or bystander subject to the requirements of this section, the pharmacy act of the state of Kansas and any rules and regulations adopted by the state board of pharmacy thereunder.

d) A pharmacist furnishing an emergency opioid antagonist pursuant to this section may not permit the person to whom the emergency opioid antagonist is furnished to waive any consultation required by this section or any rules and regulations adopted thereunder.

e) Any first responder, scientist or technician operating under a first responder agency or school nurse is authorized to possess, store and administer emergency opioid antagonists as clinically indicated, provided that all personnel with access to emergency opioid antagonists are trained, at a minimum, on the following:
   (1) Techniques to recognize signs of an opioid overdose;
   (2) standards and procedures to store and administer an emergency opioid antagonist;
   (3) emergency follow-up procedures, including the requirement to summon emergency ambulance services either immediately before or immediately after administering an emergency opioid antagonist to a patient; and
   (4) inventory requirements and reporting any administration of an emergency opioid antagonist to a healthcare provider.

(f) (1) Any first responder agency electing to provide an emergency opioid antagonist to its employees or volunteers for the purpose of administering the emergency opioid antagonist shall procure the services of a physician to serve as physician medical director for the first responder agency’s emergency opioid antagonist program.
   (2) The first responder agency shall utilize the physician medical director or a licensed pharmacist for the purposes of:
      (A) Obtaining a supply of emergency opioid antagonists;
      (B) receiving assistance developing necessary policies and procedures that comply with this section and any rules and regulations adopted thereunder;
      (C) training personnel; and
      (D) coordinating agency activities with local emergency ambulance services and medical directors to provide quality assurance activities.

(g) (1) Any healthcare provider or pharmacist who, in good faith and with reasonable care, prescribes or dispenses an emergency opioid antagonist pursuant to this section shall not, by an act or omission, be subject to civil liability, criminal prosecution or any disciplinary or other adverse action by a professional licensure entity arising from the healthcare provider or pharmacist prescribing or dispensing the emergency opioid antagonist.
   (2) Any patient, bystander, or school nurse, or a first responder, scientist or technician operating under a first responder agency, who, in good faith and with reasonable care, receives and administers an emergency opioid antagonist pursuant to this section to a person experiencing a
suspected opioid overdose shall not, by an act or omission, be subject to civil liability or criminal prosecution, unless personal injury results from the gross negligence or willful or wanton misconduct in the administration of the emergency opioid antagonist.

(3) Any first responder agency employing or contracting any person that, in good faith and with reasonable care, administers an emergency opioid antagonist pursuant to this section to a person experiencing a suspected opioid overdose shall not, by an act or omission, be subject to civil liability, criminal prosecution, any disciplinary or other adverse action by a professional licensure entity or any professional review.

(h) The state board of pharmacy shall adopt rules and regulations as may be necessary to implement the provisions of this section prior to January 1, 2018.

(i) This section shall be part of and supplemental to the pharmacy act of the state of Kansas.

**History:** L. 2017, ch. 21, § 1; July 1.

**65-16,128.** Electronic transmission of prescription orders required, when; exceptions.

(a) Every prescription order issued for a controlled substance in schedules II-V that contains an opiate, as described in the uniform controlled substances act, shall be transmitted electronically unless:

(1) Electronic prescription orders are not possible due to technological or electronic system failures;

(2) electronic prescribing is not available to the prescriber due to economic hardship or technological limitations that are not reasonably within the control of the prescriber, or other exceptional circumstances exist, as demonstrated by the prescriber;

(3) the prescription order is for a compounded preparation containing two or more components or requires information that makes electronic submission impractical, such as complicated or lengthy instructions for use;

(4) the prescription order is issued by a licensed veterinarian;

(5) the prescriber reasonably determines that it would be impractical for the patient to obtain the substances prescribed by electronic prescription in a timely manner, and such delay would adversely impact the patient's medical condition;

(6) the prescription order is issued pursuant to drug research or drug therapy protocols;

(7) the prescription order is by a prescriber who issues 50 or fewer prescription orders per year for controlled substances that contain opiates; or

(8) the United States food and drug administration requires the prescription order to contain elements that are not compatible or possible with electronic prescriptions.

(b) (1) A prescriber may request a waiver from the provisions of subsection (a) for a period not to exceed six months if such prescriber cannot comply with subsection (a) due to economic hardship, technological limitations that reasonably are not within the prescriber's control or other circumstance demonstrated by the prescriber. If a waiver is granted by the board, the prescriber may request that such waiver be renewed for a period not to exceed six months. Requests for a waiver or renewal shall be submitted to the board in such form and manner as prescribed by the board and shall include the reason for the request and any other information required by the board.

(2) If a prescriber prescribes a controlled substance by non-electronic prescription, such prescriber shall indicate the prescription is made pursuant to a waiver granted pursuant to this section. A pharmacist shall not be required to verify the validity of any waiver, either with the
prescriber or the board, but may do so in accordance with K.S.A. 65-1637, and amendments thereto.

c) The provisions of this section shall be a part of and supplemental to the pharmacy act of the state of Kansas.

d) The provisions of this section shall take effect on and after July 1, 2021.

History: L. 2019, ch. 52, § 1; July 1.

65-16,129. Pharmacists authorized to administer drugs, when; exceptions.

(a) (1) A licensed pharmacist may administer a drug by injection that, in the judgment of the prescriber, may be safely self-administered by a patient, to a patient pursuant to a prescription order, unless the prescription order includes the words "not to be administered by a pharmacist," or words of like effect.

(2) Nothing in this section shall replace, repeal or supersede the requirements prescribed in K.S.A. 65-4a10, and amendments thereto.

(b) This section shall be a part of and supplemental to the pharmacy act of the state of Kansas.

History: L. 2019, ch. 52, § 6; July 1.

65-16,130. Telepharmacy; definitions; requirements for operation; state board of pharmacy rules and regulations.

(a) As used in this section:

(1) "Telepharmacy" means the practice of pharmacy by a pharmacist located in Kansas using telecommunications or other automations and technologies to deliver personalized, electronically documented, real-time pharmaceutical care to patients or their agents, who are located at sites other than where the pharmacist is located, including prescription dispensing and counseling and to oversee and supervise telepharmacy outlet operations.

(2) "Telepharmacy outlet" means a pharmacy site located in Kansas that:

(A) Is registered as a pharmacy under the act;

(B) is owned by the managing pharmacy;

(C) is connected via computer link, video link and audio link or other functionally equivalent telecommunications equipment with a supervising pharmacy located in Kansas; and

(D) has a pharmacy technician on site who performs activities under the electronic supervision of a pharmacist located in Kansas.

(b) A pharmacist shall be in attendance at the telepharmacy outlet by connecting to the telepharmacy outlet via computer link, video link and audio link or other functionally equivalent telecommunications equipment and shall be available to consult with and assist the pharmacy technician in performing activities.

(c) Not later than January 1, 2023, the board shall adopt rules and regulations necessary to specify additional criteria for a managing pharmacy and telepharmacy outlet under this section, including, but not limited to:

(1) Application requirements;

(2) structural, security, technology and equipment requirements;

(3) staffing, training and electronic supervision requirements;

(4) inventory record keeping and storage requirements;

(5) labeling requirements;

(6) establishment of policies and procedures;

(7) the number of telepharmacy outlets that may be operated by a supervising pharmacy;
(8) use of automated dispensing machines; and
(9) criteria for requesting exemptions or waivers from the requirements set forth in rules and regulations adopted under this subsection.
(d) This section shall be a part of and supplemental to the pharmacy act of the state of Kansas.

History: L. 2021, ch. 106, § 3; June 3.

65-16,131. Pharmacist-initiated therapy for certain health conditions; requirements; establishment of protocols by collaborative drug therapy management advisory committee; penalty for violation.

(a) A pharmacist may initiate therapy within the framework of a statewide protocol for the following health conditions:

(1) Influenza;
(2) streptococcal pharyngitis; or
(3) urinary tract infection.

(b) The collaborative drug therapy management advisory committee established pursuant to K.S.A. 65-1677, and amendments thereto, may adopt a statewide protocol for each condition listed in subsection (a). In establishing such statewide protocols, the committee shall specify:

(1) The medications or categories of medications included in the protocol for each health condition;
(2) the training or qualifications required for pharmacists to implement the protocols;
(3) requirements for documentation and maintenance of records, including patient inclusion and exclusion criteria, medical referral criteria, patient assessment tools based on current clinical guidelines, follow-up monitoring or care plans and the pharmacist's adherence to the applicable protocols; and
(4) communication requirements, including, but not limited to, notification to the patient's personal or primary care provider.

(c) The board may deny an application or renewal or revoke or suspend the license of a pharmacist upon a finding that the pharmacist has violated the provisions of this section or failed to practice within the framework of statewide protocols established pursuant to this section by the collaborative drug therapy management advisory committee.

(d) This section shall take effect and be in force on and after July 1, 2022.

History: L. 2022, ch. 74, § 1; April 28.
II. Pharmacy Practice Act - Regulations

KAR Agency 68.—Kansas State Board of Pharmacy
Article 1: Registration and Examination of Pharmacists

68-1-1

68-1-1a Application for registrations or permits; withdrawal of application.
After an application for a registration or permit has been accepted, the failure of the applicant or authorized representative to respond to official correspondence regarding the application, when sent by registered or certified mail, return receipt requested, shall be deemed to be a withdrawal of the application.

68-1-1b Continuing education for pharmacists.
(a)(1) “Continuing education” shall mean an organized and systematic education experience beyond basic preparation that is designed to achieve the following:
(A)(i) Increase knowledge, improve skills, or enhance the practice of pharmacy; or
(ii) improve protection of the public health and welfare; and
(B) ensure continued competence.
(2) “ACPE-NABP CPE monitor service” shall mean the electronic tracking service of the accreditation council for pharmacy education and the national association of boards of pharmacy for monitoring continuing education that pharmacists receive from continuing education providers.
(b)(1) Thirty clock-hours of continuing education shall be required for renewal of a pharmacist license during each licensure period. Continuing education clock-hours may be prorated for licensure periods that are less than biennial at a rate of 1.25 clock-hours per month.
(2) Each licensee shall complete a continuing education course consisting of one clock-hour that is provided by the board for renewal of a pharmacist license, which shall be counted toward the 30 clock-hour requirement. This paragraph shall take effect on July 1, 2023.
(c)(1) Each continuing education program shall be approved by the board. Each provider or licensee shall submit the continuing education program to the board at least 10 days in advance for consideration for approval. Each provider shall advertise the continuing education program as having only pending approval until the provider is notified of approval by the board.
(2) Continuing education programs shall not include in-service programs, on-the-job training, orientation for a job, an education program open to the general public, a cardiopulmonary resuscitation (CPR) course, a basic cardiac life support (BCLS) course, emergency or disaster training or direct experience at a healthcare facility under a code blue, testing out of a course, and medical school courses.
(3) Each provider shall furnish a certificate of completion to the licensee for each continuing education program that the licensee has successfully completed. Each certificate shall be in a format approved by the board and shall include the following:
(A) The licensee’s name;
(B) the title and date of the approved continuing education program;
(C) the name of the provider;
(D) the number of continuing education clock-hours approved by the board;
(E) the number of continuing education clock-hours completed by the licensee;
(F) the approved program number issued by the board; and
(G) the provider’s dated signature, certifying program completion.
(d) Within 30 days of completion, each licensee shall submit to the board proof of completion of any approved continuing education program not reported to the ACPE-NABP CPE monitor service. No credit shall be given for any certificate of completion received by the board after the June 30 expiration date of each licensure period.
(e) A licensee shall not be allowed to carry forward excess clock-hours earned in one licensure period into the next licensure period.

68-1-1c
(Authorized by and implementing K.S.A. 1982 Supp. 65-1631; effective May 1, 1983; revoked May 1, 1987.)

68-1-1d Approved schools.
The following may be recognized and approved by the board:
(a) Any school or college of pharmacy or department of a university accredited by the accreditation council for pharmacy education; and
(b) any other school or college of pharmacy or department of a university that, as determined by the board, has a standard of education not below that of the university of Kansas school of pharmacy.
(Authorized by and implementing K.S.A. 65-1631; effective May 1, 1983; amended May 1, 1987; amended Oct. 20, 2006.)

68-1-1e
(Authorized by and implementing K.S.A. 65-1631; effective May 1, 1983; amended May 1, 1987; revoked March 22, 2002.)

68-1-1f Foreign graduates.
(a) Each applicant who has graduated from a school or college of pharmacy or a pharmacy department of a university located outside of the United States or who is not a citizen of the United States shall provide proof that the applicant has reasonable ability to communicate verbally and in writing with the general public in English as specified in this regulation.
(b) Each foreign applicant shall be required to meet the English language requirements for licensure under the pharmacy act of the state of Kansas by passing the internet-based test of English as a foreign language (TOEFL iBT) with at least the following minimum scores:
(1) 22 in reading;
(2) 21 in listening;
(3) 26 in speaking; and
(4) 24 in writing.

68-1-1g
(Authorized by and implementing K.S.A. 65-1631; effective Oct. 20, 2006; revoked Aug. 19, 2016a.)

68-1-1h. Foreign pharmacy graduate equivalency examination.
In addition to meeting the requirements of K.A.R. 68-1-1f, each foreign applicant shall meet the following requirements for licensure under the pharmacy act of the state of Kansas:
(a) Pass the foreign pharmacy graduate equivalency examination (FPGEE) with a score of at least 75;
(b) obtain foreign pharmacy graduate examination committee (FPGEC) certification from the national association of boards of pharmacy (NABP); and
(c) submit a copy of the FPGEC certificate to the board.
(Authorized by and implementing K.S.A. 65-1631; effective Oct. 23, 2009.)

68-1-2 Grades required.
(a) Each successful applicant for licensure by examination under the pharmacy act of the state of Kansas shall:
   (1) pass an examination approved by the board; and
   (2) obtain a grade of not less than 75% on the law examination administered by the board.
(b) Each successful applicant for licensure by reciprocity from another state shall score not less than 75% on the law examination administered by the board.
(c) This regulation shall be effective on May 1, 1989.
(Authorized by and implementing K.S.A. 1987 Supp. 65-1631(c), as amended by L. 1988, Ch. 243, Sec. 7; effective Jan. 1, 1966; amended, E-76-31, Aug. 11, 1975; amended May 1, 1976; amended May 1, 1978; amended May 1, 1980; amended May 1, 1985; amended May 1, 1986; amended May 1, 1989.)

68-1-2a Pharmacist-in-charge acknowledgment; notice of designation.
(a) Each pharmacy or registrant required to have a pharmacist-in-charge that operates for more than 30 days without a designated pharmacist-in-charge who meets the requirements of this regulation shall be deemed to be in violation of K.S.A. 65-1627, and amendments thereto.
(b) Each prospective pharmacist-in-charge shall, at the time of assuming these duties, sign an acknowledgment that states the pharmacist has reviewed the pharmacy act and the board’s regulations and is aware of the responsibilities of a pharmacist-in-charge. The pharmacist-in-charge shall provide this acknowledgment to the board within 30 days of assuming the duties of a pharmacist-in-charge.
(c) Except as specified in subsection (d), each pharmacy owner shall submit to the board, on a form provided by the board, notice of designation of a new pharmacist-in-charge at the pharmacy
or facility required to have a pharmacist-in-charge no later than 30 days after the previous pharmacist-in-charge has ceased to serve as the pharmacist-in-charge.

(d) Any pharmacy owner that is unable to designate a new pharmacist-in-charge within 30 days may submit to the board, on a form provided by the board, a request for a 30-day extension to designate a new pharmacist-in-charge. The request shall be submitted to the board no more than 30 days after the previous pharmacist-in-charge has ceased to serve as pharmacist-in-charge and shall provide the reason for the request. (Authorized by K.S.A. 2022 Supp. 65-1626 and K.S.A. 65-1630; implementing K.S.A. 2022 Supp. 65-1626, and K.S.A. 65-1637c; effective Aug. 1, 1997; amended May 31, 2002; amended June 2, 2023.)

68-1-3

68-1-3a Qualifying pharmaceutical experience.
(a) Pharmaceutical experience that qualifies as one year of experience shall consist of 1,740 clock-hours as a pharmacy student or registered intern while being supervised by a preceptor. A preceptor may supervise no more than two individuals who are pharmacy students or interns at any time. All hours worked when the pharmacy student or intern is in regular attendance at an approved school of pharmacy and during vacation times and other times when the pharmacy student or intern is enrolled but not in regular attendance at an approved school of pharmacy may be counted as qualified hours. However, not more than 60 hours of work shall be acquired in any one week.
(b) No time may accrue to a pharmacy student before acceptance in an approved school of pharmacy or before being registered as an intern with the board. However, any foreign pharmacy graduate who has passed equivalent examinations as specified in K.A.R. 68-1-1f and K.A.R. 68-1-1h may apply for registration as an intern.
(c) Once registered as an intern, the intern shall complete all required hours within six years.
(d) Reciprocity shall not be denied to any applicant who is otherwise qualified and who meets either of the following conditions:
   (1) Has met the internship requirements of the state from which the applicant is reciprocating; or
   (2) has at least one year of experience as a registered pharmacist.

68-1-4

68-1-5
68-1-6

68-1-7 Reinstatement after lapse.
Upon failure of a pharmacist to renew a registration under the provisions of K.S.A. 65-1632 for three consecutive years or more, the board shall require the applicant to take a written or oral examination prior to reinstatement. Upon satisfactory completion of that examination and compliance with the provisions of K.S.A. 65-1632, the applicant shall be entitled to a renewal of registration if no grounds exist for denying the renewal.

68-1-8 Registered pharmacist to be on duty.
It shall be the duty of the pharmacist in charge of every premise having a pharmacy registration, to ensure that a registered pharmacist is on duty at all times during which the pharmacy is open.

68-1-9 Pharmacist-in-charge; responsibilities.
(a) Each pharmacist-in-charge shall develop, supervise, and coordinate all pharmaceutical services performed within the pharmacy to ensure compliance with the Kansas pharmacy act, the state and federal uniform controlled substances act, the state and federal food, drug, and cosmetic act, and all applicable regulations.
(b) Each pharmacist-in-charge shall be personally available to the extent required to ensure comprehensive pharmaceutical services within the pharmacy and to develop a staff of additional licensed pharmacists and supportive personnel as necessary to serve the needs of the pharmacy. Each pharmacist-in-charge shall maintain records in the pharmacy describing the training and education regarding work functions performed by all pharmacy personnel. Each pharmacist-in-charge shall maintain in the pharmacy written procedures for the following:
   (1) Designating the person or persons functioning as pharmacy technicians and supportive personnel;
   (2) describing the job duties of all personnel;
   (3) documenting the procedural steps taken by the pharmacist-in-charge to limit the functions of all personnel to their respective pharmacy work functions; and
   (4) documenting training and related education for nondiscretionary tasks performed by pharmacy technicians.
(c) Each pharmacist-in-charge shall be responsible for direct supervision of all pharmacy personnel, for the security of the pharmacy, and for the security of all drugs in the pharmacy.
(d) Each pharmacist-in-charge shall ensure that the pharmacy maintains adequate drug information references commensurate with services offered and a current copy of the state laws and regulations listed in subsection (a).
(e) Each pharmacist-in-charge shall be responsible for establishing a drug recall procedure that can be effectively implemented.
(f) Each pharmacist-in-charge shall be responsible for developing written procedures for maintaining records of drug distribution, prepackaging, repackaging, and compounding.
Prepackaging and repackaging of drugs shall be done in accordance with K.A.R. 68-7-15 and labeled in accordance with K.A.R. 68-7-16.

(g) Each pharmacist-in-charge shall be responsible for reviewing each published board newsletter and posting the newsletter in a conspicuous area within the pharmacy until publication of the next board newsletter.

(h)(1) Each pharmacist shall submit to the board, on a form provided by the board, notice of ceasing to serve as the pharmacist-in-charge at a pharmacy or facility required to have a pharmacist-in-charge no later than five days after ceasing to serve as the pharmacist-in-charge.

(2) Each pharmacist ceasing to serve as the pharmacist-in-charge shall inventory all controlled substances and drugs of concern, as defined by K.S.A. 65-1682 and amendments thereto, in the pharmacy or facility in accordance with the inventory requirements of K.A.R. 68-20-16 no more than two days before ceasing to serve as the pharmacist-in-charge and no later than the day ceasing to serve as the pharmacist-in-charge.

(3) Each pharmacist beginning to serve as the pharmacist-in-charge shall inventory all controlled substances and drugs of concern, as defined by K.S.A. 65-1682 and amendments thereto, in the pharmacy or facility in accordance with the requirements of K.A.R. 68-20-16 after beginning to serve as the pharmacist-in-charge but no more than two days after beginning to serve as the pharmacist-in-charge. The inventory may be taken simultaneously with the previous pharmacist-in-charge on the last day of the previous pharmacist-in-charge if both pharmacists are present in the pharmacy, actively participate in the inventory, and sign the inventory.

(4) If a pharmacist ceasing to serve as pharmacist-in-charge is unable to complete the inventory specified in paragraph (2) of this subsection or is terminated for a suspected or known violation of the Kansas pharmacy act, the pharmacy or facility owner shall request approval from the board to designate another pharmacist to conduct the inventory. If the board approves the request, the pharmacy or facility owner may designate another pharmacist to conduct the inventory specified in paragraph (2) of this subsection within the designated time frame.

Article 2: Drugstores

68-2-1 to 68-2-4

68-2-6 to 68-2-8

68-2-9 Change of ownership; duty of registrant to notify board.
Each registrant shall notify the executive secretary of the board in writing of any change in majority ownership of the operation for which the registration was issued within five days after the date the change in ownership becomes effective.

68-2-10 Cessation of operations.
(a) When any pharmacy ceases operations at the location for which the registration was received, the pharmacist-in-charge shall meet the following requirements:
(1) Within five days after ceasing operations at that location, submit to the board, on a form provided by the board, notice of cessation of pharmacy operations, which shall include the following:
(A) The date the pharmacy ceased operations;
(B) a signed statement attesting that an inventory of all controlled substances was conducted;
(C) the location, pharmacy registration number, contact information, and manner of disposition of the remaining stocks of drugs; and
(D) the location, pharmacy registration number, contact information, and manner of disposition of all records required by the Kansas pharmacy practice act to be maintained; and
(2) no more than 10 days after ceasing operations at that location, notify each patient household that has received a prescription from the pharmacy within the previous two-year period, by U.S. mail, phone, text message, or electronic mail, of the cessation of operations of the pharmacy and the contact information and location for obtaining copies of patient records.
(b) The pharmacist-in-charge of any pharmacy that acquires patient records from a pharmacy that ceases operation shall be responsible for the preservation of the acquired records for the remainder of the term that the records are required by the Kansas pharmacy practice act to be preserved.
(c) In the absence of a pharmacist-in-charge, the owner of each pharmacy shall meet the requirements of this regulation.
Each premises for which a pharmacy registration is issued, except medical care facilities, shall be constructed so that the pharmacy can be secured to prevent access to prescription-only drugs when a pharmacist is not on duty.

68-2-12

68-2-5 Pharmacist-in-charge; notice to board.
Each pharmacist shall submit to the board, on a form provided by the board, notice of ceasing to serve as the pharmacist-in-charge at a pharmacy or registrant required to have a pharmacist-in-charge no later than five days after ceasing to serve as the pharmacist-in-charge.

68-2-12a Minimum requirements for library, equipment, and supplies.
(a) Each registered pharmacy, other than a medical care facility pharmacy, shall have a reference library, either immediately accessed by a computer or printed, that is updated at least annually and that includes the following:
   (1) A current copy of the Kansas pharmacy practice act, the Kansas uniform controlled substances act, and the regulations under both acts;
   (2) a drug information reference specifically drafted for patients, which may include the "professional's guide to patient drug facts," published by facts and comparisons, or "United States pharmacopeia dispensing information," volume II;
   (3) one recognized reference in toxicology, pharmacology, and drug interactions;
   (4) one recognized reference in drug equivalencies; and
   (5) a medical dictionary.
(b) Each registered pharmacy shall also have on the premises the equipment and supplies necessary to compound, dispense, label, administer, and distribute drugs. The equipment shall be in good repair and shall be available in sufficient quantities to meet the needs of the practice of pharmacy conducted there.

68-2-13
68-2-14

68-2-15 Nametags.
(a) The following individuals shall wear a visible nametag under the following conditions:
   (1) Each pharmacist, pharmacy student, and intern, while performing pharmacist functions in a pharmacy; and
   (2) each pharmacy technician, while performing technician functions in a pharmacy.
(b) Each nametag shall include the person's name and the designation of whether the person is a pharmacist, a pharmacy student, an intern, or a pharmacy technician.

68-2-16 Branches, agents and pickup stations.
No pharmacy nor pharmacist shall have, participate in, or permit an arrangement, branch, connection or affiliation whereby prescriptions are solicited, accepted, collected, or picked up, or advertised to be such, from or at any location other than a pharmacy for which a registration in good standing has been issued by the board.

68-2-17

68-2-18
(Authorized by K.S.A. 65-1630; effective Jan. 1, 1966; revoked May 1, 1987.)

68-2-19 Prescription copies.
(a) No registered pharmacist shall fill, and no pharmacy shall permit the filling of, a copy of a prescription.
(b) Every reference copy of a prescription shall bear the following legend:"This prescription copy is issued for reference only."

68-2-20 Pharmacist's function in filling a prescription.
(a) As used in this regulation, each of the following terms shall have the meaning specified in this subsection:
(1) “Prescriber” means a “practitioner” as defined by K.S.A. 65-1626 and amendments thereto, a “mid-level practitioner” as defined by K.S.A. 65-1626 and amendments thereto, or a person authorized to issue a prescription by the laws of another state.
(2) “Legitimate medical purpose,” when used regarding the dispensing of a prescription drug, means that the prescription for the drug was issued with a valid preexisting patient-prescriber relationship rather than with a relationship established through an internet-based questionnaire.
(b) Except as provided in subsection (c), judgmental functions that constitute the filling or refilling of a prescription shall be performed only by a pharmacist or by a pharmacist intern under the direct supervision of a licensed pharmacist and shall consist of the following steps:

1. Read and interpret the prescription of the prescriber;
2. Limit any filling or refilling of a prescription to one year from the date of origin, except as provided by K.S.A. 65-1637 and K.S.A. 65-4123, and amendments thereto;
3. Verify the compounding, counting, and measuring of ingredients and document the accuracy of the prescription;
4. Personally offer to counsel each patient or the patient’s agent with each new prescription dispensed, once yearly on maintenance medications and, if the pharmacist deems appropriate, with prescription refills in accordance with subsection (e);
5. Ensure the proper selection of the prescription medications, devices, or suppliers as authorized by law; and
6. Interpret and verify patient medication records and perform drug regimen reviews.

(c) The pharmacist-in-charge shall prohibit all other pharmacy personnel from performing those judgmental functions restricted to the pharmacist. The following judgmental functions shall be performed only by a pharmacist and shall not be delegated:

1. Final verification of the accuracy of a completed compound or prescription;
2. Documentation of the pharmacist’s final verification in the pharmacy record; and
3. Direct supervision of a pharmacist intern or pharmacy technician.

(d) Any pharmacist may delegate nonjudgmental functions to a pharmacist intern or pharmacy technician. Each pharmacist shall conduct in-process and final checks associated with the preparation of medications, except as provided by K.A.R. 68-7-11.

(e) In order to comply with subsection (b), the pharmacist or the pharmacist intern under the pharmacist’s direct supervision shall perform the following:

1. Personally offer to counsel each patient or the patient’s agent with each new prescription dispensed, once yearly on maintenance medications and, if the pharmacist deems appropriate, with prescription refills. Any pharmacist may authorize an exception to the verbal counseling requirement on a case-by-case basis for the continuation of therapy prescriptions issued more frequently than once yearly;
2. Provide the verbal counseling required by this regulation in person or by the utilization of a telephone or other communication service available to the patient or patient’s agent if the prescription is not collected at the pharmacy;
3. When appropriate, provide alternative forms of patient information to supplement verbal patient counseling. These supplemental forms of patient information may include written information, leaflets, pictogram labels, video programs, and auxiliary labels on the prescription vials. However, the supplemental forms of patient information shall not be used as a substitute for the verbal counseling required by this regulation;
4. Encourage proper patient drug utilization and medication administration. The pharmacist shall counsel the patient or patient’s agent on those elements that, in the pharmacist’s professional judgment, are significant for the patient. These elements may include the following:
   (A) The name and a description of the prescribed medication or device;
   (B) The dosage form, dosage, route of administration, and duration of therapy;
   (C) Special directions and precautions for preparation, administration, and use by the patient;
(D) common side effects, adverse effects or interactions, or therapeutic contraindications that could be encountered; the action required if these effects, interactions, or contraindications occur; and any activities or substances to be avoided while using the medication;

(E) techniques for self-monitoring drug therapy;

(F) proper storage requirements and disposal instructions; and

(G) action to be taken in the event of a missed dose; and

(5) expressly notify the patient or the patient’s agent if a brand exchange has been exercised.

(f) Except as required by K.S.A. 65-16,127 and amendments thereto for the dispensing of an emergency opioid antagonist, nothing in this regulation shall be construed to require a pharmacist to provide the required patient counseling if either of the following occurs:

(1) The patient or the patient’s agent refuses counseling.

(2) The pharmacist, based upon professional judgment, determines that the counseling could be detrimental to the patient’s care.

(g) Each pharmacist shall make a reasonable effort to ensure that any prescription, regardless of the means of transmission, has been issued for a legitimate medical purpose by a prescriber.


68-2-21


68-2-22 Electronic transmission of a prescription.

(a) Each prescription drug order transmitted electronically shall be issued for a legitimate medical purpose by a prescriber acting within the course of legitimate professional practice.

(b) Each prescription drug order communicated by way of electronic transmission shall meet these requirements:

(1) Be transmitted to a pharmacist in a licensed pharmacy of the patient’s choice, exactly as transmitted by the prescriber;

(2) identify the transmitter’s phone number for verbal confirmation, the time and date of transmission, and the identity of the pharmacy intended to receive the transmission, as well as any other information required by federal and state laws and regulations;

(3) be transmitted by an authorized prescriber or the prescriber’s designated agent; and

(4) be deemed the original prescription drug order, if the order meets the requirements of this regulation.

(c) Any prescriber may authorize an agent to communicate a prescription drug order orally or electronically to a pharmacist in a licensed pharmacy if the identity of the transmitting agent is included in the order.

(d) Each pharmacist shall exercise professional judgment tregarding the accuracy, validity, and authenticity of the prescription drug order communicated by way of electronic transmission, consistent with existing federal and state laws and regulations.

(e) All electronic equipment for receipt of prescription drug orders communicated by way of electronic transmission shall be maintained so as to ensure against unauthorized access.
(f) Persons other than those bound by a confidentiality agreement shall not have access to pharmacy records containing confidential information or personally identifiable information concerning the pharmacy’s patients.

(g) If communicated by electronic transmission, the prescription drug order shall be maintained in hard copy or as an electronic document for the time required by existing federal or state laws and regulations, whichever is longer.

(h) Any prescription drug order, including that for any controlled substance listed in schedules II, III, IV, and V, may be communicated by way of electronic transmission, if all requirements of K.A.R. 68-20-10a are met.

(i) After the pharmacist views the prescription drug order, this order shall be immediately reduced to a hard copy or an electronic document and shall contain all information required by federal and state laws and regulations.

(j) Each electronic prescription drug order created and transmitted in conformance with 21 C.F.R. part 1311 shall be considered an original, written, signed prescription drug order.


68-2-23 Notification to board; disciplinary action.

Each pharmacy owner shall notify the board in writing within 30 days of any denial, limitation, suspension, revocation, voluntary surrender, or other disciplinary action taken by the state of Kansas or another jurisdiction against the pharmacy or the pharmacy owner or any application, license, registration, or permit held by the pharmacy owner.

Article 3: Retail Dealers Permit

68-3-1

68-3-2

68-3-3 and 68-3-4

68-3-5 Retail dealer permit required.
A retail dealer may engage in the selling in Kansas of nonprescription drugs that are prepackaged, fully prepared by the manufacturer or distributor for use by the consumer, and labeled in accordance with the requirements of the state and federal food, drug, and cosmetic acts only if the retail dealer has obtained a permit to do so from the board.

68-3-6 Minimum required information for permit.
(a) Each retail dealer shall provide the board with the following minimum information as part of the application for the permit required by K.S.A. 65-1643(f), and amendments thereto, and as part of any renewal of this permit:
   (1) The name, full business address, and telephone number of the permit holder;
   (2) each trade or business name used by the permit holder; and
   (3) the address, telephone number, and name of the contact person for each facility used by the permit holder for the storage, handling, and distribution of drugs.
(b) Each permit holder shall submit all revised information required by subsection (a) within 30 days after any change in that information.
Article 4: Manufacturers

68-4-1 to 68-4-4

68-4-5

Article 5: General Rules

68-5-1 Definitions.
The following words and phrases as used throughout these rules and regulations shall have the meanings specified below, unless otherwise indicated by the context of the specific regulation.
(a) Beyond-use date. The term "beyond-use date" means a date placed on a prescription label at the time of dispensing, repackaging, or prepackaging that is intended to indicate to the patient or caregiver a time beyond which the contents of the prescription are not recommended to be used.
(b) Intern. The word "intern" means an individual who is a prospective candidate for examination as a licensed pharmacist and who is qualified to receive and is obtaining pharmaceutical experience as set forth in the pharmacy act of the state of Kansas and its rules and regulations.
(c) Medication order. The term "medication order" means an order by a prescriber for a registered patient of a Kansas licensed medical care facility.
(d) Prescriber. The word "prescriber" means a person who is authorized to issue a prescription order.

68-5-2
(Authorized by K.S.A. 65-1630; effective Jan. 1, 1966; amended, E-76-31, Aug. 11, 1975; amended May 1, 1976; revoked May 1, 1980.)

68-5-3 to 68-5-5

68-5-6

68-5-7 and 68-5-8
68-5-9

68-5-10

68-5-11

68-5-12 and 68-5-13

68-5-14

68-5-15 Training of pharmacy technicians.
(a) The pharmacist-in-charge of any pharmacy in which one or more pharmacy technicians perform any tasks authorized by the pharmacy act shall assure that each pharmacy technician complies with the training requirements in this regulation.
(b) The pharmacist-in-charge of any pharmacy in which one or more pharmacy technicians perform any tasks authorized by the pharmacy act shall assure that there exists for the pharmacy a current pharmacy technician training course, designed for the functioning of that pharmacy and addressing at least the following:
   (1) Knowledge and understanding of the different pharmacy practice settings;
   (2) knowledge and understanding of the duties and responsibilities of a pharmacy technician in relationship to other pharmacy personnel and knowledge of standards, ethics, laws, and regulations governing the practice of pharmacy;
   (3) knowledge and ability to identify and employ pharmaceutical and medical terms, abbreviations, and symbols commonly used in prescribing and dispensing drugs and in record keeping;
   (4) knowledge of and the ability to carry out calculations required for common dosage determinations;
   (5) knowledge and understanding of the identification of drugs, drug dosages, routes of administration, dosage forms, storage requirements, and manufacturer recalls;
   (6) knowledge of and the ability to perform the manipulative and record-keeping functions involved in and related to dispensing prescriptions or other drug distribution systems; and
   (7) knowledge of and the ability to perform procedures and techniques, including aseptic techniques, relating to the compounding, packaging, and labeling of drugs.
(c) The pharmacist-in-charge of any pharmacy shall permit a pharmacy technician to perform tasks authorized by the pharmacy act only if the pharmacy technician has successfully completed, within 180 days of the effective date of this regulation or the effective date of the
(c) The pharmacist-in-charge of any pharmacy in which one or more pharmacy technicians perform any tasks authorized by the pharmacy act shall also insure that the following requirements are met:
    (1) There is an annual review of the pharmacy technician training course developed for the pharmacy.
    (2) Adequate records are maintained documenting the training of each pharmacy technician as required by this regulation. These records shall be maintained at the pharmacy in a manner available for inspection by a board representative.
    (3) The board is notified, within 30 days of the effective date of this regulation or the effective date of the employment of a pharmacy technician, of the following:
        (i) The full name and current residence address of pharmacy technicians working in a pharmacy for which the pharmacist-in-charge has responsibility;
        (ii) the date on which the pharmacy technician began the pharmacy technician training course or courses designed for the pharmacy or pharmacies in which the pharmacy technician is working; and
        (iii) the name and address of the pharmacy or pharmacies in which the pharmacy technician is working.


68-5-16 Ratio of pharmacy technicians to pharmacists.
The ratio of pharmacy technicians to pharmacists in any pharmacy shall not exceed four to one. A pharmacist shall not supervise at any time more than two pharmacy technicians who have not passed a certification examination approved by the board pursuant to K.A.R. 68-5-17.

68-5-17. Pharmacy technicians; certification examination; request for extension.
The following requirements shall apply to each individual who applies for a new pharmacy technician registration on or after July 1, 2017:
(a) Each pharmacy technician shall be required to pass either the pharmacy technician certification board (PTCB) certification examination or the national healthcareer association (NHA) ExCPT certification examination before the first renewal of the pharmacy technician’s registration.
(1) Each pharmacy technician shall be required to attain a scaled score of at least 1400 on the PTCB certification examination in order to pass.
(2) Each pharmacy technician shall be required to attain a score of at least 390 on the NHA ExCPT certification examination in order to pass.
(b) Any pharmacy technician who is unable to take or pass an approved certification examination before the first renewal of the pharmacy technician’s registration may submit to the board, on a form provided by the board, a request for a six-month extension to pass an approved certification examination. The request shall be submitted to the board at least 30 days before the pharmacy
technician’s registration expiration date and shall provide the reason for the request, which may include any of the following:
(1) Previous examination attempts and failures;
(2) the commencement date of training or preparation and the reasons for delay;
(3) an event that directly resulted from the occurrence of natural causes outside the pharmacy technician’s control;
(4) a change in employment and the relevant dates; or
(5) medical necessity.
(c) Within 30 days after passing an approved certification examination or before the first renewal, whichever is earlier, each pharmacy technician shall submit to the board proof of successful completion of the examination.


68-5-18. Pharmacy technicians; continuing education.
(a)(1) “Continuing education” shall mean an organized and systematic education experience beyond basic preparation that is designed to achieve the following:
   (A)(i) Increase knowledge, improve skills, or enhance the practice of pharmacy; or
   (ii) improve protection of the public health and welfare; and
   (B) ensure continued competence.
   (2) “ACPE-NABP CPE monitor service” shall mean the electronic tracking service of the accreditation council for pharmacy education and the national association of boards of pharmacy for monitoring continuing education that pharmacy technicians receive from continuing education providers.
(b) Twenty clock-hours of continuing education shall be required for renewal of a pharmacy technician registration during each registration period. Continuing education clock-hours may be prorated for registration periods that are less than biennial at a rate of 0.8 clock-hours per month.
(c)(1) Each continuing education program shall be approved by the board. Each provider or registrant shall submit the continuing education program to the board at least 10 days in advance for consideration for approval. Each provider shall advertise the continuing education program as having only pending approval until the provider is notified of approval by the board.
   (2) Continuing education programs shall not include in-service programs, on-the-job training, orientation for a job, an education program open to the general public, a cardiopulmonary resuscitation (CPR) course, a basic cardiac life support (BCLS) course, emergency or disaster training or direct experience at a healthcare facility under a code blue, testing out of a course, and medical school courses.
   (3) Each provider shall furnish a certificate of completion to the pharmacy technician for each continuing education program that the registrant has successfully completed. Each certificate shall be in a format approved by the board and shall include the following:
      (A) The registrant’s name;
      (B) the title and date of the approved continuing education program;
      (C) the name of the provider;
      (D) the number of continuing education clock-hours approved by the board;
      (E) the number of continuing education clock-hours completed by the registrant;
      (F) the approved program number issued by the board; and

(G) the provider’s dated signature, certifying program completion.
(d) Within 30 days of completion, each pharmacy technician shall submit to the board proof of completion of any approved continuing education program not reported to the ACPE-NABP CPE monitor service. No credit shall be given for any certificate of completion received by the board after the October 31 expiration date of each registration period.
(e) A licensee shall not be allowed to carry forward excess clock-hours earned in one registration period into the next registration period.
(f) The required continuing education shall be obtained in the two-year registration period ending on the October 31 expiration date of each registration.
Article 6: Poisons, Additions and Deletions to Statutory List

68-6-1

68-6-2
(Authorized by K.S.A. 65-1638; effective Jan. 1, 1966; revoked May 1, 1980.)

Article 7: Miscellaneous Provisions

68-7-1 to 68-7-6

68-7-7

68-7-8 Records.
(a) Each of the following terms, as used in this regulation, shall have the meaning specified in this subsection:
(1) “Digital image” means the electronic record produced when a hard-copy prescription is scanned by a computer and converted from human-readable format to a computer-readable digital format and maintained as part of the prescription record in a pharmacy prescription application.
(2) “Electronic annotation” means a method to mark up a digital image or electronic prescription to allow both notes and clarifications to be added to the prescription record without altering the original digital image.
(b) Each pharmacy owner and pharmacist-in-charge shall keep a book or file that records every prescription order filled at the pharmacy.
(c)(1) A digital image of the prescription may constitute the original prescription order. A hard copy of the prescription order shall not be required to be maintained if all of the following conditions are met:
(A) The prescription is not for a controlled substance.
(B) The pharmacy prescription application can capture and store an exact and legible image of the original prescription.
(C) The digital image includes the front and back of the prescription and retains all colors and graphics on the prescription.
(D) The digital image is unalterable.
(E) The digital image and all electronic annotations are readily retrievable and can be immediately reproduced by the pharmacy prescription application in electronically viewable and paper formats. In lieu of reproducing the digital image in a color paper format, the digital image may be provided in color in an electronic portable document format (PDF).
(F) Policies and procedures for the use of digital images are developed and implemented to include capturing, making, storing, retrieving, and recovering digital images and electronic annotations, and destruction of the original hard-copy prescription.

(G) The pharmacy maintains a back-up copy of the digital image and all electronic annotations stored in the pharmacy prescription application and updates the back-up copy at least once every seven days.

(H) A secure destruction method is used to dispose of the hard-copy prescription to ensure privacy and confidentiality.

(2) If the pharmacy prescription application data is automatically entered by a prescription order received by electronic transmission, the automated record shall constitute the original prescription order and a hard copy shall not be required if all of the following conditions are met:

(A) The electronic prescription and its means of transmission meet all requirements of the pharmacy act of the state of Kansas and the state and federal controlled substance acts, and amendments thereto.

(B) The pharmacy prescription application can capture and store all prescription information received.

(C) The prescription information is readily retrievable, and the pharmacy prescription application can immediately reproduce all prescription information received in both electronically viewable and paper formats.

(D) The pharmacy maintains a back-up copy of the electronic prescription record and all electronic annotations stored in the pharmacy prescription application and updates the back-up copy at least once every seven days.

(3) Nothing in paragraph (c)(1) shall be construed as requiring a pharmacy to maintain a digital image in lieu of hard-copy prescription.

(d) Any digital image may contain electronic annotations if the original image is still available for review and the name of the individual who made the annotations is documented.

(e) The pharmacist shall ensure that each printout of a digital image provided to a patient or the patient’s representative is conspicuously marked “Copy Only” or “Not Valid for Dispensing Purposes.”

(f) Each pharmacy owner shall establish policies and procedures in accordance with this regulation and shall ensure that all policies and procedures comply with the pharmacy act of the state of Kansas, and amendments thereto, and the implementing regulations. Each pharmacist-in-charge shall document an annual review of the policies and procedures for compliance with the pharmacy act, and amendments thereto, and the implementing regulations.

(g) Each of the following individuals shall be responsible for ensuring that each digital image is a complete, accurate, and legible representation of the corresponding hard-copy prescription:

(1) The pharmacist, pharmacist intern, or pharmacy technician who generates the digital image;

(2) the pharmacist, pharmacist intern, or pharmacy technician who enters the prescription information into the pharmacy prescription application; and

68-7-9
(Authorized by K.S.A. 1977 Supp. 74-1606; effective, E-76-31, Aug. 11, 1975; effective May 1, 1976; amended May 1, 1978; revoked May 1, 1987.)

68-7-10. Pharmacy based drug distribution systems in long-term care facilities; emergency medication kits.
(a) Each of the following terms, as used in this regulation, shall have the meaning specified in this subsection:
   (1) “Automated drug delivery system” means an automated dispensing system, as defined by K.S.A. 2017 Supp. 65-1626 and amendments thereto, that is located in a long-term care facility, uses a robotic, mechanical, or computerized device to supply each drug to an individual licensed by the board of healing arts or the board of nursing, who shall administer the drug to a patient, and meets the requirements of K.A.R. 68-9-3.
   (2) “Formulary” means a prescription drug list approved by the pharmacy and therapeutics committee or an equivalent committee governing the security, control, and distribution of drugs within a long-term care facility.
   (4) “Traditional system” means a drug distribution system in which the pharmacist receives a prescription order for an individual patient and fills the prescription in any manner other than packaging individual doses in unit-dose containers.
   (5) “Unit-dose container” means a single-unit or multiple-unit container for articles intended for administration in single doses and directly from the container, by other than parenteral route.
      (A) “Multiple-unit container” means a container that permits the withdrawal of successive portions of the contents without changing the strength, quality, or purity of the remaining portion.
      (B) “Single-unit container” means a container that is designed to hold a quantity of a drug intended for administration as a single dose promptly after the container is opened.
   (6) “Unit-dose system” means a drug distribution system that is pharmacy-based and uses unit-dose containers that enable distribution of packaged doses in a manner that preserves the identity of the drug until the time of administration.
(b) Each pharmacy-based drug distribution system for a long-term care facility shall meet the following requirements:
   (1) Be consistent with the medication needs of each patient;
   (2) conform to all federal and state laws and regulations pertaining to pharmacies; and
   (3) meet the following additional requirements:
      (A) Each prescription shall be dispensed from a pharmacy within a time period that reasonably meets the needs of the patient, considering the following factors:
         (i) The need for the drug as an emergency;
         (ii) the availability of the drug;
         (iii) the pharmacy’s hours of operation; and
         (iv) the stability of the drug;
      (B) the supplying pharmacy shall be responsible for the safe delivery of drugs to a designated person or persons in the long-term care facility;
      (C) the supplying pharmacy shall provide a method of identifying the date and quantity of medication dispensed;
(D) a patient medication profile record system shall be maintained for each long-term care facility patient serviced by the supplying pharmacy and shall contain the information necessary to allow the pharmacist to monitor each patient’s drug therapy; and
(E) each medication distribution system container shall be labeled to permit the identification of the drug therapy.
(c) Each unit-dose system shall meet the following requirements, in addition to the requirements in subsection (b):
1. All medication shall be packaged in unit-dose containers as far as practicable and the packaging shall meet the requirements of K.A.R. 68-7-15 and 68-7-16, unless the manufacturer specifies a different type of packaging to be used to prevent adulteration as defined by K.S.A. 65-668, and amendments thereto.
2. The pharmacist shall be responsible for filling and refilling prescriptions or prescriber’s orders, or both, according to the directions of the prescriber by relying on the original prescription or prescriber’s order or a copy thereof.
3. The pharmacist shall comply with all requirements for prescription orders, including inventory and recordkeeping requirements, under the following:
   (A) The Kansas uniform controlled substances act, K.S.A. 65-4101 et seq. and amendments thereto;
   (B) the Kansas pharmacy act, K.S.A. 65-1625 et seq. and amendments thereto;
   (C) the board’s applicable regulations in articles 1 and 20; and
   (D) all federal laws and regulations applicable to prescriptions or medication orders.
4. Packaging for the unit-dose system shall take place at the address of the pharmacy providing the unit-dose system.
5. Container requirements for unit-dose systems may include trays, bins, carts, and locked cabinets if the requirements of K.A.R. 68-7-14 are met. If these options are used, all patient medication trays or drawers shall be sufficiently labeled to identify each patient.
6. Each unit-dose system shall provide a verification check at the point of patient administration in order to ensure proper drug utilization.
7. The delivery time-cycle or hours of exchange shall not be limited to a specific time, but shall depend upon the pharmacist’s discretion, the needs of the long-term care facility, the stability of the drug, and the type of container used.
8. The pharmacist shall have sole responsibility for dispensing under the unit-dose system.
(d)(1) Each emergency medication kit shall contain only the drugs that are generally regarded by practitioners as essential to the prompt treatment of sudden and unforeseen changes in a patient’s condition that present an imminent threat to the patient’s life or well-being.
2. Each drug to be contained within an emergency medication kit shall be approved by the long-term care facility’s pharmaceutical services committee or its equivalent, either of which shall be composed of at least a practitioner and a pharmacist.
3. The pharmacist providing each emergency medication kit shall ensure that the following requirements are met:
   (A) The kit shall be supplied by a pharmacist, who shall retain possession of the drug until it is administered to the patient upon the valid order of a prescriber.
   (B) If the kit is not in an automated drug delivery system, the kit shall be locked or sealed in a manner that indicates when the kit has been opened or tampered with.
   (C) The kit shall be securely locked in a sufficiently well-constructed cabinet or cart or in an automated drug delivery system, with drugs properly stored according to the manufacturer’s
recommendations. Access to the cabinet or cart shall be available only to each nurse specified by
the pharmaceutical services committee or its equivalent.
(D) The kit shall have an expiration date equivalent to the earliest expiration date of the drugs
within the kit, but in no event more than one year after all of the drugs were placed in the kit.
(E) Unless the kit is in an automated drug delivery system, all drugs contained within the
emergency medication kit shall be returned to the pharmacy as soon as the kit has been opened,
along with the prescriber’s drug order for medications administered.
65-1642, and K.S.A. 65-1648; effective May 1, 1978; amended May 1, 1983; amended Sept. 9,

68-7-11. Medical care facility pharmacy.
The scope of pharmaceutical services within a medical care facility pharmacy shall meet the
following requirements:
(a) The pharmacist-in-charge shall be responsible for developing programs and supervising all
personnel in the distribution and control of drugs and all pharmaceutical services in the medical
care facility.
(b) The pharmacist-in-charge shall develop a policy and procedure manual governing the
storage, control, and distribution of drugs within the medical care facility. The pharmacist-in-
charge shall submit the policy and procedure manual for approval to the pharmacy and
therapeutics committee or an equivalent committee governing the security, control, and
distribution of drugs within the facility.
(c) The pharmacist-in-charge shall be responsible for the maintenance of all emergency
medication kits.
(d) The pharmacist-in-charge shall be responsible for developing procedures for the distribution
and control of drugs within the medical care facility when a pharmacist is not on the premises.
These procedures shall be consistent with the following requirements:
(1) Drugs may be obtained upon a prescriber’s medication order for administration to the
inpatient by a physician’s assistant, designated registered professional nurse, or nurses with
approval and supervision of the pharmacist-in-charge. Adequate records of these withdrawals
shall be maintained.
(2)(A) An interim supply of prepackaged drugs shall be supplied to an outpatient on an
emergency basis only by a designated registered professional nurse or nurses pursuant to a
prescriber’s medication order when a pharmacist is not on the premises and a prescription cannot
be filled. The interim supply shall be labeled in accordance with K.A.R. 68-7-14.
(B) The interim supply shall be limited in quantity to an amount sufficient to supply the
outpatient’s needs until a prescription can be filled. Adequate records of the distribution of the
interim supply shall be maintained and shall include the following information:
(i) The original or a copy of the prescriber’s order or, if an oral order, a written record prepared
by a designated registered professional nurse or nurses that reduces the oral order to writing. The
written record shall be signed by the designated registered professional nurse or nurses and the
prescriber; and
(ii) the name of the patient; the date supplied; the drug or device, strength, and quantity
distributed; directions for use; the prescriber’s name; and, if appropriate, the DEA number.
(3) The designated registered professional nurse or physician’s assistant may enter the medical
care facility pharmacy and remove properly labeled pharmacy stock containers, commercially
labeled packages, or properly labeled prepackaged units of drugs. The registered professional nurse or physician’s assistant shall not transfer a drug from one container to another for future use, but may transfer a single dose from a stock container for immediate administration to the ultimate user.

(e) The pharmacist-in-charge of the medical care facility pharmacy shall maintain documentation of at least quarterly checks of drug records and conditions of drug storage, in all locations within the facility, including nursing stations, emergency rooms, outpatient departments, and operating suites.

(f) The pharmacist-in-charge shall participate with the pharmacy and therapeutics committee or an equivalent committee in formulating broad professional policies regarding the evaluation, appraisal, selection, procurement, storage, distribution, use, and safety procedures for drugs within the medical care facility.

(g) The pharmacist-in-charge shall be responsible for establishing policies and procedures for the mixing or preparation of parenteral admixtures. Whenever drugs are added to intravenous solutions, distinctive supplemental labels shall be affixed that indicate the name and amount of the drug added, the date and the time of addition, the beyond-use date, storage instructions, and the name or initials of the person who prepared the admixture. The pharmacist-in-charge shall comply with all requirements of article 13 of the board’s regulations. Before the parenteral admixture is released from the pharmacy, the pharmacist shall verify the accuracy of all parenteral admixtures prepared by pharmacy technicians.

(h) The pharmacist shall interpret the prescriber’s original order, or a direct copy of it, before the drug is distributed and shall verify that the medication order is filled in strict conformity with the direction of the prescriber. This requirement shall not preclude orders transmitted by the prescriber through electronic transmission. Variations in this procedure with “after-the-fact” review of the prescriber’s original order shall be consistent with medical care facility procedures established by the pharmacist-in-charge. Each medication order shall be reviewed by a pharmacist within three days of the date it was written.

(i)(1) When a pharmacist is on the premises but not in the pharmacy, a pharmacy technician may be in the pharmacy. A pharmacy technician shall not distribute any drug or device out of the pharmacy when a pharmacist is not physically in the pharmacy unless authorized by the pharmacist.

(2) When a pharmacist is not on the premises, no one shall be permitted in the pharmacy except the designated registered professional nurse or nurses or a physician’s assistant.

(j) Except with regard to drugs that have not been checked for accuracy by a pharmacist after having been repackaged, prepackaged, or compounded in a medical care facility pharmacy, a pharmacy technician in a medical care facility may check the work of another pharmacy technician in filled floor stock, a crash cart tray, a unit-dose cart, or an automated dispensing machine if the checking pharmacy technician meets each of the following requirements:

(1) Has passed a certification examination approved by the board;

(2) has either of the following experience levels:

(A) One year of experience working as a pharmacy technician plus at least six months of experience working as a pharmacy technician in the medical care facility at which the checking will be performed; or

(B) one year of experience working as a pharmacy technician in the medical care facility at which the checking will be performed; and
(3) has successfully completed a written training program and related examination designed by
the pharmacist-in-charge of the medical care facility pharmacy to demonstrate competency in
accurately checking whether floor stock, a crash cart tray, and an automated dispensing machine
have been properly filled. (Authorized by K.S.A. 65-1630; implementing K.S.A. 2022 Supp. 65-
1626, K.S.A. 65-1642, and K.S.A. 65-1648; effective, E-77-39, July 22, 1976; effective Feb. 15,
1977; amended May 1, 1978; amended May 1, 1988; amended May 1, 1989; amended Dec. 27,
1999; amended April 28, 2000; amended July 20, 2007; amended July 16, 2010; amended June
2, 2023.)

68-7-12 Responsibility of pharmacist-in-charge in other than a medical care facility
pharmacy.
Each pharmacist-in-charge for premises having a pharmacy registration, other than a medical
care facility pharmacy, shall be responsible for the following functions:
(a) Each pharmacist-in-charge shall develop or approve written policies and procedures for the
pharmacy that meet the following conditions:
(1) Provide adequate accountability and control of drugs in compliance with the Kansas
pharmacy act, the state and federal uniform controlled substances act, and the state and federal
food, drug, and cosmetic act; and
(2) ensure that any incident that occurs as a result of an alleged or real error in filling or
dispensing a prescription or medication order is brought to the attention of the pharmacist-in-
charge and completely documented in accordance with K.A.R. 68-7-12b.
(b) Each pharmacist-in-charge shall develop written procedures for maintaining records of the
pharmacy’s dispensing, prepackaging, and bulk compounding actions and shall ensure that
prepackaged medication is packaged in suitable containers and properly labeled. (Authorized by
amended July 20, 2007; amended June 2, 2023.)

68-7-12a Nonresident pharmacies.
Each nonresident pharmacy shall meet the requirements of this regulation to be and remain
registered in Kansas by the board.
(a)(1) Each pharmacy shall be currently licensed or registered in good standing in the state in
which it is located.
(2) Each practicing pharmacist employed by or under contract with the pharmacy shall be
licensed as a pharmacist in the state where the pharmacist practices.
(3) Each pharmacy shall provide and maintain, in readily retrievable form, the record of a
satisfactory inspection conducted within the previous 18-month period by the licensing entity of
the state where the pharmacy is located. If no such inspection record is readily available, the
record of a satisfactory inspection conducted at the expense of the pharmacy within the previous
18-month period by a third party recognized by the board to inspect may be accepted.
(4) Each pharmacy shall designate a pharmacist-in-charge, as defined by K.S.A. 65-1626 and
amendments thereto, who shall be named in the application and who shall be responsible for
receiving communications from the board.
(A) The pharmacist-in-charge shall timely respond to any lawful request for information from
the board or law enforcement authorities.
(B) The pharmacist-in-charge shall be responsible for receiving and maintaining publications distributed by the board.

(b) The owner or the owner's authorized representative of the nonresident pharmacy shall apply for registration and renewal on forms approved by the board. The information reasonably necessary to carry out the provisions of K.S.A. 65-1657 and amendments thereto, including the name, address, and position of each officer and director of a corporation or of the owners if the pharmacy is not a corporation, shall be required by the board.

(c) An exemption for registration may be granted by the board under K.S.A. 65-1657 and amendments thereto, upon application by any nonresident pharmacy that confines its dispensing activity to isolated transactions. The following shall be considered to determine whether to grant an exemption:

1. The number of prescriptions dispensed or reasonably expected to be dispensed into Kansas;
2. The number of patients served or reasonably expected to be served in Kansas;
3. Any efforts to promote the pharmacy's services in Kansas;
4. Any contract between the pharmacy and either an employer or organization to provide pharmacy services to employees or other beneficiaries in Kansas;
5. Medical necessity;
6. The effect on the health and welfare of persons in Kansas; and
7. Any other relevant matters.

(d) The pharmacy owner shall pay an annual registration fee as specified in K.A.R. 68-11-2.

(e) The pharmacy records of drugs dispensed to Kansas addresses shall be maintained so that the records are readily retrievable upon request. These records shall be made available for inspection by the board or by Kansas law enforcement authorities upon request.

(f) The pharmacy shall maintain an incoming toll-free telephone number for use by Kansas customers to facilitate personal communication with a pharmacist with access to patient records.

1. This service shall be available during normal business hours for at least 40 hours and six days per week.
2. This telephone number and any others available for use shall be printed on each container of drugs dispensed in Kansas.
3. The toll-free number shall have a sufficient number of extensions to provide reasonable access to incoming callers.

(g) Generic drugs shall be dispensed into Kansas only pursuant to K.S.A. 65-1637, and amendments thereto.

(h) The facilities and records of the pharmacy shall be subject to inspection by the board. Satisfactory inspections conducted within the previous 18-month period by the licensing entity of the state where the pharmacy is located or a third party recognized by the board to inspect may be accepted in lieu of inspection by the board.

(i) Each owner or owner's authorized representative of the nonresident pharmacy either doing business in Kansas or providing pharmacy services, dispensing, or either delivering or causing to be delivered prescription drugs to Kansas consumers shall designate a resident agent in Kansas for service of process and file this information with the secretary of state.

68-7-12b Incident reports.
(a) For purposes of this regulation, "reportable incident" and "incident" shall mean a preventable medication error involving a prescription drug and resulting in any of the following:
   (1) The patient receiving the wrong drug;
   (2) the patient receiving an incorrect drug strength
   (3) the patient receiving an incorrect dosage form;
   (4) the drug being received by the wrong patient;
   (5) inadequate or incorrect packaging, labeling, or directions; or
   (6) the dispensing of a drug to a patient in a situation that results in or has the potential to result in serious harm to the patient.
(b) For each pharmacy other than a medical care pharmacy, the pharmacist-in-charge shall ensure that procedures exist requiring each pharmacist who becomes aware of a reportable incident to report the incident to the pharmacist-in-charge as soon as practical.
(c) As soon as possible after discovery of the incident, the pharmacist shall prepare a report containing the following information:
   (1) The name, address, age, and phone number of any complainant, if available;
   (2) the name of each pharmacy employee and the license number of each licensee involved;
   (3) the date of the incident and the date of the report;
   (4) a pharmacist's description of the incident;
   (5) the prescriber's name and whether or not the prescriber was contacted; and
   (6) the signatures of all pharmacy employees involved in the incident.
For each pharmacy, the pharmacist-in-charge shall ensure that procedures exist requiring that the incident report be maintained in the pharmacy for at least five years in a manner so that the report can be provided to the board or its representative within three business days, upon request.
(d) The preparation of an incident report that meets the requirements of this regulation shall be the responsibility of each pharmacist involved in the incident and the pharmacist-in-charge. The maintenance of incident reports as required by this regulation shall be the responsibility of the pharmacist-in-charge.

68-7-13 Pharmacist in charge of more than one location.
No pharmacist shall be a pharmacist in charge of more than one full-time pharmacy operation, which is defined as being one where the on-premises pharmacist services total 30 hours or more weekly.

68-7-14 Prescription labels.
(a) The label of each drug or device shall be typed or machine-printed and shall include the following information:
   (1) The name, address, and telephone number of the pharmacy dispensing the prescription;
   (2) the name of the prescriber;
   (3) the full name of the patient;
   (4) the identification number assigned to the prescription by the dispensing pharmacy;
   (5) the date the prescription was filled or refilled;
(6) adequate directions for use of the drug or device;
(7) the beyond-use date of the drug or device dispensed;
(8) the brand name or corresponding generic name of the drug or device;
(9) the name of the manufacturer or distributor of the drug or device, or an easily identified
abbreviation of the manufacturer's or distributor's name;
(10) the strength of the drug;
(11) the contents in terms of weight, measure, or numerical count; and
(12) necessary auxiliary labels and storage instructions, if needed.

(b) A pharmacy shall be permitted to label or relabel only those drugs or devices originally
dispensed from the providing pharmacy.

(Authorized by K.S.A. 65-1630; implementing K.S.A. 65-1626a; effective, E-77-39, July 22,
1976; effective Feb. 15, 1977; amended May 1, 1978; amended May 1, 1980; amended May 1,
23, 2009.)

68-7-15 Prepackaging of drugs or devices in advance of immediate need.
All drugs or devices, whether in a unit-dose container or multiple-dose container, packaged in
advance of immediate need shall meet the requirements of this regulation.
(a) Packaging shall be done by a pharmacist or under the pharmacist’s direct supervision. The
pharmacist shall verify and document verification of the packaged drugs or devices before the
packaged drugs or devices are released from a facility registered with the board.
(b) Packaging shall be limited to the drugs or devices dispensed from or supplied by the facility
registered with the board or in accordance with a shared services agreement.
(c) All containers used for packaging shall preserve the stability and integrity of the drug or
device. The storage conditions of each packaged drug or device shall be maintained according to
the manufacturer’s recommendations to preserve the stability and integrity of the drug. The
beyond-use date assigned to each packaged drug or device shall be the manufacturer’s expiration
date, the maximum allowable beyond-use date for the type of packaging material used, or not
more than 12 months from the date of packaging, whichever is earlier.
(d) An electronic or a written record shall be established for lot numbers for recall purposes and
shall be kept readily retrievable in the facility registered with the board.
(e) If an area apart or separated from the prescription drug area is used for packaging, the area
shall be enclosed and locked when a pharmacist is not in attendance in that area.
(f) In lieu of separately dispensing a drug and an ingestible event marker approved by the food
and drug administration to monitor whether a patient is taking the drug as prescribed, any
pharmacist may use an ingestible event medication adherence package pursuant to a valid
prescription order or after obtaining the consent of the practitioner, caregiver, or patient.
(g) For purposes of this regulation, “ingestible event medication adherence package” shall mean
an ingestible unit-dose package designed to ensure medication adherence that contains drugs
from a manufacturer’s original container and an ingestible event marker, as defined by 21 C.F.R.
880.6305, effective February 1, 2022 and hereby adopted by reference.
(h) In addition to meeting the requirements of this regulation, all packaging of sterile
preparations shall meet the requirements of K.A.R. 68-13-4. (Authorized by K.S.A. 65-1630;
amended Dec. 15, 2017; amended Nov. 29, 2019; amended June 2, 2023.)
Labels of drugs or devices packaged in advance of immediate need.
(a) Except as specified in subsection (b), each label for a drug or device packaged in advance of immediate need shall contain the following:
(1) The generic name of the drug or device and the manufacturer’s name. If the packaged drug or device bears a brand name, the brand name may be substituted for the generic name of the drug or device;
(2) the strength and quantity of the drug or device;
(3) the lot number, date of packaging, and the name of the individual responsible for packaging;
(4) the beyond-use date; and
(5) necessary auxiliary labels.
(b) If the owner of a facility registered with the board maintains a record system that includes the manufacturer’s name, lot numbers, date of packaging, and the name of the individual responsible for packaging the drug or device, this information may be deleted from the label. (Authorized by K.S.A. 65-1630; implementing K.S.A. 2022 Supp. 65-1626a and K.S.A. 65-1634; effective May 1, 1978; amended June 2, 2023.)

Health departments and private not-for-profit family planning clinics.
The distribution and control of drugs provided by health departments and private not-for-profit family planning clinics authorized under K.S.A. 65-1648(d)(1), and amendments thereto, shall conform to the following requirements:
(a) The approved drugs that may be stored and distributed by health departments and not-for-profit family planning clinics shall be only noncontrolled drugs that are approved by the food and drug administration. In determining the formulary for each health department or not-for-profit family planning clinic, the pharmacist-in-charge shall consult with the medical supervisor and director of nursing for that facility. No state or federal controlled drugs shall be allowed.
(b)(1) The pharmacist-in-charge shall review the procedures outlined below for the distribution and control of all drugs within health department facilities and family planning clinics and shall be responsible for the following:
   (A) Ensuring the development of programs for supervision of all personnel in the distribution and control of drugs;
   (B) ensuring the development of a policy and procedure manual governing the storage, control, and distribution of drugs;
   (C) maintaining documentation of at least quarterly checks of drug records, drug storage conditions, and drugs stored in all locations within the facility;
   (D) establishing a drug recall procedure that can be effectively implemented; and
   (E) ensuring the development of written procedures for maintaining records of distribution and prepackaging of drugs.
(2) Labels for prepackaged drugs shall contain the following:
   (A) The brand name or corresponding generic name of the drug;
   (B) the name of the manufacturer or distributor of the drug, or an easily identified abbreviation of the manufacturer's or distributor's name;
   (C) the strength of the drug;
   (D) the contents in terms of weight, measure, or numerical count;
(E) the lot number of the drug, if the lot number is not recorded on a suitable log; and
(F) the beyond-use date of the drug.

(3) Prepackaged drugs shall be packaged in suitable containers and shall be subject to all
other provisions of the Kansas state board of pharmacy regulations under the uniform
controlled substances act of the state of Kansas and under the pharmacy act of the state of
Kansas.

(c) The procedures for the control and distribution of drugs within health department facilities
and family planning clinics shall be consistent with the following requirements:

(1) Adequate records of the distribution of drugs by the designated registered professional
nurse or nurses shall be maintained and shall include the physician's order or written
protocol.

(A) If the physician's order was given orally, electronically, or by telephone, the
designated registered professional nurse or nurses shall reduce that order to writing. The
written copy of the order shall be signed by the designated registered professional nurse
and maintained in a permanent patient file.

(B) The records shall include the following:
   (i) The full name of the patient;
   (ii) the date supplied;
   (iii) the name of the drug, the quantity supplied, and strength of the drug distributed;
   (iv) the directions for use;
   (v) the prescriber's name. The record shall include the name of the practitioner and, if
   involved, the name of either the physician's assistant (PA) or the advanced registered
   nurse practitioner (ARNP);
   (vi) the expiration date of the drug; and
   (vii) the lot number of the drug.

(2) A supply of drugs shall be provided to a patient by a designated registered professional
nurse or nurses pursuant to a prescriber's order. Only a designated registered professional
nurse or nurses may access the pharmacy area and remove the supply of the drugs. The
supply shall conform with the following labeling requirements:

(A) The name, address, and telephone number of the health department or family
planning clinic from which the drug is supplied;
(B) the full name of the patient;
(C) adequate directions for use of the drug;
(D) the name of the prescriber. The label shall include the name of the practitioner and, if
involved, the name of either the physician's assistant (PA) or the advanced registered
nurse practitioner (ARNP);
(E) the date the supply was distributed;
(F) the identification number assigned to the supply of the drug distributed by the health
department or family planning clinic;
(G) the brand name or corresponding generic name of the drug;
(H) necessary auxiliary labels and storage instructions, if needed; and
(I) the beyond-use date of the drug issued.

(3) Repackaged drugs shall be packaged in suitable containers and shall be subject to all
other provisions of the Kansas state board of pharmacy rules and regulations under the
pharmacy act of the state of Kansas.
(d) The appointment of any Kansas licensed pharmacist as pharmacist-in-charge of a health department or family planning clinic shall be subject to the provisions of K.A.R. 68-1-2a and 68-7-13.


68-7-19 Transfer of a refillable prescription between pharmacies.

(a) As used in K.S.A. 65-1656 and amendments thereto, the requested or transferring pharmacy shall mean the pharmacy that has on file the original refillable prescription that the patient wants to transfer to a second pharmacy. The dispensing or requesting pharmacy shall mean the pharmacy that is wanting the information transferred from the original refillable prescription so that the patient may obtain the medication at this second pharmacy or the pharmacy receiving the transferred prescription.

(b) Before any prescription is transferred, the prescription information at the transferring pharmacy shall meet all of the following conditions:

1. The prescription information indicates authorization for refilling by the prescriber.
2. The drug on the prescription information is not a schedule II controlled substance.
3. The number of lawfully allowable refills directed by the prescriber has not been exceeded.
4. The maximum allowable time limit from the original dating of the prescription has not been exceeded.

(c) When a prescription on record is transferred, the following recordkeeping shall be required:

1. The transferring pharmacy shall cancel the transferred prescription by writing the word “void” on its face and shall record the following on the prescription:
   (i) The name, address, and phone number of the receiving pharmacy;
   (ii) the DEA registration number of the receiving pharmacy, if the drug is a schedule III, IV, or V controlled substance;
   (iii) the date of the transfer request and the date of the prescription transfer;
   (iv) the first name and last name of the person providing the requested prescription transfer information at the transferring pharmacy and, if applicable, the first name and last name of the pharmacist supervising the transfer; and
   (v) the first name and last name of the person receiving the prescription transfer information at the requesting pharmacy and, if applicable, the first name and last name of the pharmacist supervising the transfer.

2. If the pharmacy from which the prescription is transferred utilizes a computerized prescription recordkeeping system adequate to do so, the information required by this regulation shall be documented in the computer record of the prescription and shall not be required to be manually recorded on the prescription.

(b) The prescription record at the pharmacy receiving the transferred prescription shall show the following, in addition to all other lawfully required information for an original prescription:

1. The word “transfer” written on the face of the prescription record;
2. the date issued, the date of original filling, and the date of the last fill;
3. the original number of refills authorized and the number of remaining authorized refills;
4. the original prescription number;
5. the name, address, and telephone number of the transferring pharmacy;
(vi) the first name and last name of the person providing the requested prescription transfer information at the transferring pharmacy and, if applicable, the first name and last name of the pharmacist supervising the transfer; and
(vii) the first name and last name of the person receiving the prescription transfer information at the requesting pharmacy and, if applicable, the first name and last name of the pharmacist supervising the transfer;
(viii) the name, address, and telephone number of the prescriber; and
(ix) if the transfer involves a schedule III, IV, or V controlled substance, the DEA registration number of the prescriber and of the transferring pharmacy.

(B) If the pharmacy receiving the prescription transfer utilizes a computerized prescription recordkeeping system adequate to do so, the information required by this regulation shall be documented in the computer record of the prescription and shall not be required to be manually recorded on the prescription.

d) Pharmacies sharing a common computerized recordkeeping system that permits the electronic transfer of prescriptions and prescription information from the transferring pharmacy to the requesting pharmacy shall be required to do the following:
(1) Establish procedures to permit these transfers only in instances of valid and legal requests;
(2) ensure that at the time of the transfer there is a sufficient electronic record left at the transferring pharmacy so that a pharmacist at the transferring pharmacy can comply with the recordkeeping requirements of K.S.A. 65-1656, and amendments thereto, and this regulation; and
(3) ensure that the common files contain the following information in a manner readily available to any person accessing the files:
   (A) Any authorization for refilling by the prescriber;
   (B) an indication of whether or not the number of lawfully allowable refills authorized by the prescriber has been exceeded;
   (C) an indication of whether the maximum allowable time limit from the original date of the prescription has been exceeded;
   (D) any other information provided by the original prescription or prescription order; and
   (E) the name and address of the pharmacy last dispensing the drug pursuant to the prescription.

e) The dispensing pharmacy shall advise the patient and notify the transferring pharmacy that the original prescription shall be canceled in the transferring pharmacy.
f) Any pharmacist may transfer a valid, refillable prescription from or to another pharmacy in or outside Kansas. Noncontrolled substance prescriptions may be transferred more than once, but schedule III, IV, and V controlled substance prescriptions shall not be transferred more than one time.

g) Drugs shall not be dispensed more frequently or in larger amounts, except as allowed by K.S.A. 65-1637 and amendments thereto, than the prescriber ordered without direct prescriber authorization by way of a new prescription order.
h) Valid refillable prescription transfers for prescription drugs not listed in schedule II of the uniform controlled substances act may be received or transferred by a pharmacist, or a pharmacist intern under the direct supervision of a pharmacist, utilizing any of the following methods of communication:
(1) Direct verbal communication;
(2) facsimile; or
(3) automated computer software.
(i) Valid refillable prescription transfers for noncontrolled substances may be received or transferred by a pharmacy technician that has passed a national certification exam approved by the board and has been authorized by the supervising pharmacist to perform this function by means of automated computer pharmacy software or by facsimile of a transfer document created by the transferring pharmacy’s prescription processing software.

(j) A pharmacy technician shall not forward or transfer an original, unfilled prescription.

(k) Any pharmacist or pharmacist intern may forward or transfer an original, unfilled prescription to a receiving pharmacy.

(l) A pharmacy shall not initiate the transfer of a prescription without authorization from the patient or the patient’s caregiver.

(m) All records required by this regulation shall be kept readily retrievable for five years.

68-7-20 Shared services.

(a)(1) "Order" shall mean either of the following:
(A) A prescription order as defined in K.S.A. 65-1626, and amendments thereto; or
(B) a medication order as defined in K.A.R. 68-5-1.

(2) "Shared order filling" shall mean the following:
(A) Preparing, packaging, compounding, or labeling an order, or any combination of these functions, by a person authorized by the pharmacy act to do so and located at a pharmacy on behalf of and at the request of another pharmacy; and
(B) returning the filled order to the requesting pharmacy for delivery to the patient or patient's agent or, at the request of the requesting pharmacy, directly delivering the filled order to the patient.

(3) "Shared order processing" shall mean the following order-processing functions that are performed by a person authorized by the pharmacy act and located at a pharmacy, on behalf of and at the request of another pharmacy:
(A) Interpreting and entering the order; and
(B) performing drug utilization reviews, claims adjudication, refill authorizations, or therapeutic interventions, or any combination of these functions.

(4) "Shared services" shall mean shared order filling or shared order processing, or both.
(b) Each pharmacy participating in shared services shall be registered by the board as either a resident or a nonresident pharmacy.
(c) Pharmacies may provide or utilize shared services functions only if the pharmacies involved meet the following requirements:
(1) Share a common electronic file or appropriate technology to allow access to sufficient information necessary to fill, refill, or perform shared services in conformance with the pharmacy act and the board's regulations; and
(2) (A) Have the same owner; or
(B) have a written contract outlining the services provided and the shared responsibilities of each party in complying with the pharmacy act and the board's regulations.
(d) Each pharmacy engaged in shared services shall meet the following requirements:
(1) Maintain records identifying, individually for each order processed, the name of each pharmacist, technician, pharmacy student, and intern who took part in the drug utilization review, refill authorization, or therapeutic intervention functions performed at that pharmacy;
(2) maintain records identifying, individually for each order filled or dispensed, the name of each pharmacist, technician, pharmacy student, and intern who took part in the filling, dispensing, and counseling functions performed at that pharmacy;
(3) report to the board within 30 days the results of any disciplinary action taken by another state's pharmacy board;
(4) maintain a mechanism for tracking the order during each step of the processing and filling procedures performed at the pharmacy;
(5) maintain a mechanism to identify on the prescription label all pharmacies involved in filling the order;
(6) provide for adequate security to protect the confidentiality and integrity of patient information; and
(7) be able to obtain for inspection any required record or information within 72 hours of any request by a board representative.
(e) Each pharmacy providing or utilizing shared services shall adopt and maintain a joint policies and procedures manual that meets both of the following conditions:
(1) The manual describes how compliance with the pharmacy act and the board's regulations will be accomplished while engaging in shared services.
(2) A copy of the manual is maintained in each pharmacy.
(f) Nothing in this regulation shall prohibit an individual pharmacist licensed in Kansas who is an employee of or under contract with the pharmacy from accessing the pharmacy's electronic database from inside or outside the pharmacy and performing the order-processing functions permitted by the pharmacy act and the board’s regulations, if both of the following conditions are met:
(1) The pharmacy establishes controls to protect the privacy and security of confidential records.
(2) None of the database is duplicated, downloaded, or removed from the pharmacy's electronic database.
(g) Nothing in this regulation shall permit a pharmacy, physician, physician assistant, or mid-level practitioner to utilize shared services to operate a requesting pharmacy that is not actively engaged in the practice of pharmacy.


68-7-21 Institutional Drug Rooms.
(a) All prescription-only drugs dispensed or administered from an institutional drug room shall be in prepackaged units, the original manufacturer's bulk packaging, or patient-specific pharmacy labeled packaging. All prepackaging shall meet the requirements of K.A.R. 68-7-15.
(b) Each pharmacist of practitioner, as that term is defined in K.S.A. 65-1637a and amendments thereto; who is responsible for supervising an institutional drug room shall perform the following:
(1) Develop or approve programs for the training and supervision of all personnel in the providing and control of drugs;
(2) develop or approve a written manual of policies and procedures governing the storage, control, and provision of drugs when a pharmacist or practitioner is not on duty;
(3) maintain documentation of at least quarterly reviews of drug records, drug storage conditions, and the drugs stored in all locations within the institutional drug room;
(4) develop or approve written procedures for documenting all reportable incidents, as defined in K.A. R. 68-7-12b, and documenting the steps taken to avoid a repeat of each reportable incident.
(c) The policies and procedures governing the storage, control, and provision of drugs in an institutional drug room when a pharmacist or practitioner is not on duty shall include the following requirements:

1. A record of all drugs provided to each patient from the institutional drug room shall be maintained in the patient's file and shall include the practitioner's order or written protocol.
2. If the practitioner's order was given orally, electronically, or by telephone, the order shall be recorded, either manually or electronically. The recorded copy of the order shall include the name of the person who created the recorded copy and shall be maintained as part of the permanent patient file.
3. The records maintained in each patient's file shall include the following information:
   - The full name of the patient;
   - The date on which the drug was provided;
   - The name of the drug, the quantity provided, and the strength of the drug provided;
   - The directions for use of the drug; and
   - The prescriber's name and, if the prescriber is a physician's assistant or advanced registered nurse practitioner, the name of that person's supervising practitioner.

(d) All drugs dispensed from an institutional drug room for use outside the institution shall be in a container or package that contains a label bearing the following information:
1. The patient's name
2. The identification number assigned to the drug provided;
3. The brand name or corresponding generic name of the drug, the strength of the drug, and either the name of the manufacturer or an easily identified abbreviation of the manufacturer's name;
4. Any necessary auxiliary labels and storage instructions;
5. The beyond-use date of the drug provided;
6. The instructions for use; and
7. The name of the institutional drug room.
(c) Each label for any prepackaged or repackaged drug shall meet the requirements of K.A.R. 68-7-16.

68-7-22. Collaborative Practice.
(a) Each of the following terms, as used in this regulation, shall have the meaning specified in this subsection:

1. “Collaborative drug therapy management” and “CDTM” mean a practice of pharmacy in which a pharmacist performs certain pharmaceutical-related patient care functions for a specific patient, and the functions have been delegated to the pharmacist by a physician through a collaborative practice agreement.
(2) “Collaborative practice agreement” and “CPA” mean a signed agreement or protocol voluntarily entered into between one or more pharmacists and one or more physicians that provides for collaborative drug therapy management.

(3) “Pharmacist” means a person licensed, without limitation or restriction, to practice pharmacy in Kansas.

(4) “Physician” means a person who is licensed to practice medicine and surgery in Kansas and who is a signing party to the pharmacist’s CPA or update.

(b) Any pharmacist may practice collaborative drug therapy management only pursuant to a collaborative practice agreement or update established and maintained in accordance with this regulation. Although a physician shall remain ultimately responsible for the care of the patient, each pharmacist who engages in CDTM shall be responsible for all aspects of the CDTM performed by the pharmacist.

A pharmacist shall not become a party to a CPA or update that authorizes the pharmacist to engage in any CDTM function that is not appropriate to the training and experience of the pharmacist or physician, or both. A pharmacist shall not provide CDTM to a patient if the pharmacist knows that the patient is not being treated by a physician who has signed the pharmacist’s current CPA.

(c)(1) Each CPA and update shall be dated and signed by each physician and each pharmacist. Each CPA and update shall include the following:

(A) A statement of the general methods, procedures, and decision criteria that the pharmacist is to follow in performing CDTM;

(B) a statement of the procedures that the pharmacist is to follow to document the CDTM decisions made by the pharmacist;

(C) a statement of the procedures that the pharmacist is to follow to communicate to the physician either of the following:
   (i) Each change in a patient’s condition identified by the pharmacist; or
   (ii) each CDTM decision made by the pharmacist;

(D) a statement identifying the situations in which the pharmacist is required to initiate contact with the physician; and

(E) a statement of the procedures to be followed by the pharmacist if an urgent situation involving a patient’s health occurs, including identification of an alternative health care provider that the pharmacist should contact if the pharmacist cannot reach a physician.

(2) A CPA shall not authorize a pharmacist to administer influenza vaccine except pursuant to K.S.A. 65-1635a, and amendments thereto.

(d) Each CPA and update shall be reviewed and updated at least every two years. A signing pharmacist shall deliver a digital or paper copy of each CPA and update to the board within five business days after the CPA or update has been signed by all parties.

(e) Within 48 hours of making any drug or drug therapy change to a patient’s treatment, the pharmacist shall initiate contact with a physician, identifying the change.

(f) This regulation shall not be interpreted to impede, restrict, inhibit, or impair either of the following:

(1) Current hospital or medical care facility procedures established by the hospital or medical care facility pharmacy and either the therapeutics committee or the medical staff executive committee; or

(2) the provision of medication therapy management as defined by the centers for medicare and medicaid services under the medicare part D prescription drug benefit.
(g) As part of each pharmacist’s application to renew that individual’s license, the pharmacist shall advise the board if the pharmacist has entered into a CPA. (Authorized by K.S.A. 65-1630; implementing K.S.A. 2015 Supp. 65-1626a; effective May 27, 2016.)

68-7-23. Dispensing and administration of emergency opioid antagonist without a prescription.

(a) Any pharmacist may dispense an emergency opioid antagonist and the necessary medical supplies needed to administer an emergency opioid antagonist to a patient, bystander, first responder agency, or school nurse without a prescription, in accordance with the opioid antagonist protocol and this regulation.

(b) Each pharmacist dispensing an emergency opioid antagonist pursuant to this regulation shall submit to the board a form provided by the board, within five days of signing the opioid antagonist protocol, and shall maintain a signed and dated copy of the opioid antagonist protocol, which shall be made available to the pharmacist-in-charge, the board, and the board’s designee. Each pharmacist that no longer dispenses emergency opioid antagonists pursuant to the opioid antagonist protocol shall notify the board, in writing, within 30 days of discontinuation.

(c) Each emergency opioid antagonist dispensed by a pharmacist shall be labeled in accordance with the pharmacy practice act and any implementing regulations.

(d) Each pharmacist who dispenses an emergency opioid antagonist pursuant to this regulation shall perform the following:

1. For each patient, bystander, first responder agency, or school nurse to whom the emergency opioid antagonist is dispensed, instruct that person or entity to summon emergency medical services as soon as practicable either before or after administering the emergency opioid antagonist;

2. For each patient or bystander to whom the emergency opioid antagonist is dispensed, provide in-person counseling, training, and written educational materials appropriate to the dosage form dispensed, including the following:
   (A) Risk factors of opioid overdose;
   (B) strategies to prevent opioid overdose;
   (C) signs of opioid overdose;
   (D) steps in responding to an overdose;
   (E) information on emergency opioid antagonists;
   (F) procedures for administering an emergency opioid antagonist;
   (G) proper storage, disposal, and expiration date of the emergency opioid antagonist dispensed; and
   (H) information on where to obtain a referral for substance use disorder treatment; and

3. For each first responder agency or school nurse to whom the emergency opioid antagonist is dispensed, provide that person or entity with written education and training materials that meet the requirements of paragraphs (d)(1) and (2) and include the requirements to keep inventory records and report any administration of the emergency opioid antagonist to the appropriate healthcare provider pursuant to this regulation.

(e) Each pharmacist shall document the dispensing of any emergency opioid antagonist pursuant to this regulation in a written or electronic prescription record for the patient, bystander, first responder agency, or school nurse to whom the emergency opioid antagonist is dispensed. The pharmacist shall record as the prescriber either that pharmacist or the physician who has signed
the opioid antagonist protocol. The prescription record shall be maintained so that the required information is readily retrievable during the pharmacy’s normal operating hours and shall be securely stored within the pharmacy for at least five years.

(f) Any of the following individuals or facilities licensed or registered with the board of pharmacy or the board of healing arts may sell emergency opioid antagonists at wholesale to a first responder agency or school nurse:
(1) A pharmacist;
(2) a physician medical director; or
(3) a pharmacy.

(g) Each first responder, scientist, and technician operating under a first responder agency administering an emergency opioid antagonist shall perform the following:
(1) Summon emergency medical services as soon as practicable either before or after administering the emergency opioid antagonist;
(2) immediately provide information related to the administration to any responding emergency medical services personnel, any emergency room personnel, or any treating physician; and
(3) notify the physician medical director for the first responder agency within 24 hours of administration.

(h) Each first responder agency that is dispensed an emergency opioid antagonist shall ensure that any first responder, scientist, or technician operating under the first responder agency is appropriately trained on the use of emergency opioid antagonists and meets the training requirements in subsection (d) and the opioid antagonist protocol.

This regulation shall become effective on July 1, 2017.

(Authorized by and implementing 2017 HB 2217, sec. 1; effective, T-68-6-19-17, July 1, 2017; effective September 15, 2017.)

68-7-25 Notification to board; pharmacist, pharmacy technician, or pharmacy intern.
Each pharmacist, pharmacy technician, and pharmacy intern shall notify the board in writing of any of the following circumstances within 30 days of the date of occurrence:
(a) Any conduct resulting in a charge of, arrest or indictment for, plea of guilty or no contest to, diversion agreement, or suspended imposition of sentence against the registrant or licensee that would constitute any of the following:
(1) Unprofessional conduct as defined by K.S.A. 65-1626, and amendments thereto;
(2) a violation of the federal or state food, drug, and cosmetic act; or
(3) a violation of the Kansas uniform controlled substances act;
(b) any conviction of any felony against the registrant or licensee; or
(c) any denial, limitation, suspension, revocation, voluntary surrender, or other disciplinary action taken by another jurisdiction against any pharmacy, pharmacist, pharmacy intern, or pharmacy technician application, license, registration, or permit held by the registrant or licensee.

Article 8: Advertising

68-8-1 Advertising.
Licensees, registrants, and permit holders shall not use or allow to be used for their benefit any advertising that is false or misleading.

Article 9: Automated Prescription Systems

68-9-1 Electronic data storage systems.
All electronic data storage systems operating within this state shall comply with the following requirements:
(a) The pharmacist in charge of such a system shall perform the following:
   (1) Adopt a written policy and procedures manual for control, use, and operation of the system;
   (2) assure that only licensed pharmacists make decisions concerning judgmental functions as stated in K.A.R. 68-2-20;
   (3) be responsible for all drug information within the system;
   (4) assure that complete control over the dispensing of medication is vested in licensed pharmacists;
   (5) have an auxiliary procedure that shall be used for documentation of refills of all prescription orders if the system becomes inoperable. This auxiliary procedure shall insure that the following criteria are met:
      (A) Refills are authorized by the original prescription order;
      (B) the maximum number of refills has not been exceeded; and
      (C) a daily backup is performed for use in restoring required information in case of a system failure;
   (6) maintain a written prescription on file that preserves all information contained in the original prescription. A machine-printed supplement that provides all information necessary to comply with the law may be filed with or attached to the written prescription, if the supplement does not obscure the required information on the original prescription;
   (7) provide a method of numerically identifying each patient's written prescription;
   (8) maintain the confidentiality of prescriptions and assure that the system has adequate security and systems safeguards to prevent unauthorized access, modification, or manipulation of patient medication profile data; and
   (9) maintain a written or electronic prescription daily log. The daily log shall include the following information:
      (A) The original prescription number;
      (B) the date of the issuance of the original prescription order by the practitioner;
      (C) the full name and address of the patient;
      (D) the name and address of the practitioner;
      (E) the practitioner's DEA registration number if required;
      (F) the name, strength, dosage form, and quantity of the medication prescribed;
      (G) the quantity dispensed, if different from the quantity prescribed; and
(H) the total number of refills authorized by the prescribing practitioner.

(b) Each electronic data storage system shall have a method for each of the following:
   (1) Storing each active patient's medication profile record so that this record is immediately available upon request at the practice site. Sufficient historical patient medication profile data shall be stored and made available for the pharmacist to exercise appropriate clinical judgment when dispensing the prescription;
   (2) documenting that an individual pharmacist has taken responsibility for the accuracy of the following:
      (A) The information entered; and
      (B) Each authorized refilling of the prescription;
   (3) drug use control, which shall include the following:
      (A) The ability to ascertain quantities;
      (B) the exact refill data;
      (C) the dates of previous refillings; and
      (D) the number of refills remaining;
   (4) identifying on a daily basis the pharmacist filling each prescription;
   (5) handling partial fillings and refillings of prescriptions;
   (6) handling compounded prescriptions;
   (7) reproducing all information within the system, in written form and upon authorized request, within 72 hours; and
   (8) providing a label containing the information required under K.A.R. 68-7-14 and the date of the original filling of any scheduled drugs.


68-9-2 Automated drug delivery systems in pharmacies.

(a) For purposes of this regulation, “automated drug delivery system” shall mean an automated dispensing system, as defined by K.S.A. 65-1626 and amendments thereto, that is located in a Kansas pharmacy and uses a robotic, mechanical, or computerized device to perform operations or activities other than compounding or administration, involving the storage, packaging, or labeling of, or any other step before dispensing, drugs. Each prescription medication prepared by an automated drug delivery system shall be verified and documented by a Kansas-licensed pharmacist as part of the dispensing process.

(b) A pharmacist-in-charge of any licensed pharmacy, licensed health care facility, or other location that is required to be supervised by a pharmacist-in-charge and that uses an automated drug delivery system shall perform the following before allowing the automated drug delivery system to be used:
   (1) Ensure that the automated drug delivery system is in good working order and accurately selects the correct strength, dosage form, and quantity of the drug prescribed while maintaining appropriate recordkeeping and security safeguards;
   (2) ensure that the automated drug delivery system has a mechanism for securing and accounting for all drugs removed from and subsequently returned to the system;
   (3) ensure that the automated drug delivery system has a mechanism for securing and accounting for all wasted or discarded drugs, including a manual override for the pharmacist, pharmacy
intern, or pharmacy technician to clear a jammed, blocked, or malfunctioning automated drug delivery system;
(4) ensure compliance with an ongoing continuous quality improvement program pursuant to K.S.A. 65-1695, and amendments thereto, or a risk management program that monitors total system performance and includes the requirement for accuracy in the drug and strength delivered;
(5) ensure that the automated drug delivery system is loaded accurately and according to the original manufacturer’s storage requirements;
(6) approve and implement an operational policy that limits the personnel responsible for the loading and unloading of drugs to or from the automated drug delivery system to any of the following:
(A) A Kansas-licensed pharmacist;
(B) a Kansas-registered pharmacy intern;
(C) a Kansas-registered pharmacy technician; or
(D) a nurse with a license issued pursuant to K.S.A. 65-1115, and amendments thereto;
(7) at the location of the automated drug delivery system, maintain a current list of those approved individuals who are authorized to unload any drug from the automated drug delivery system;
(8) approve and implement security measures that meet the requirements of all applicable state and federal laws and regulations in order to prevent unauthorized individuals from accessing or obtaining drugs;
(9) preapprove all individuals who are authorized to unload any drug from the automated drug delivery system;
(10) ensure that all drugs loaded in the automated drug delivery system are packaged in the manufacturer’s original packaging or in repackaged containers, in compliance with K.A.R. 68-7-15 and K.A.R. 68-7-16, or in containers with the lot number and expiration date tracked by the automated drug delivery system;
(11) provide the board with prior written notice of the installation or removal of the automated drug delivery system; and
(12) ensure that a system of preventive maintenance and sanitation for the automated drug delivery system is established and followed.

68-9-3 Automated drug delivery system to supply drugs for administration in certain facilities.
(a) Each of the following terms, as used in this regulation, shall have the meaning specified in this subsection:
(1) “Automated drug delivery system” means an automated dispensing system, as defined by K.S.A. 2017 Supp. 65-1626 and amendments thereto, that is located in a facility outside of a managing pharmacy and uses a robotic, mechanical, or computerized device to supply each drug to an individual licensed by the board of healing arts or the board of nursing, who shall administer the drug to a patient.
(2) “Facility” means any of the following:
(A) A medical care facility, as defined in K.S.A. 65-1626 and amendments thereto;
(B) an institutional drug room, as defined in K.S.A. 65-1626 and amendments thereto; or
(C) a long-term care facility, which shall mean any of the following:
(i) A nursing facility, as defined in K.S.A. 39-923 and amendments thereto;
(ii) a nursing facility for mental health, as defined in K.S.A. 39-923 and amendments thereto; or
(iii) any other type of adult care home, as defined in K.S.A. 39-923 and amendments thereto, that is not specified in paragraphs (a)(2)(C)(i) and (ii) and, after submitting an application, is approved by the board for an automated drug delivery system.
(3) “Managing pharmacy” means a pharmacy located in Kansas.
(4) “Pharmacist-in-charge” means the pharmacist-in-charge of the managing pharmacy.
(b) Before the initial stocking and use of an automated drug delivery system to supply drugs for administration, the pharmacist-in-charge shall meet the following requirements:
(1) Provide the board with at least 14-day prior written notice, on a form provided by the board; and
(2) ensure that all necessary licenses, registrations, and authorizations, including a drug enforcement administration registration if supplying controlled substances, have been obtained.
(c) The pharmacist-in-charge shall consult with the pharmacy and therapeutics committee or an equivalent committee in establishing the criteria and process for determining a formulary of approved drugs that may be stored in the automated drug delivery system.
(d) A bar code verification, electronic verification, or similar verification process shall be utilized to ensure the correct selection of drugs placed or to be placed into each automated drug delivery system. The utilization of a bar code, electronic verification, or similar verification process shall require an initial quality assurance validation, followed by a quarterly assurance review by a pharmacist.
(e) The pharmacist-in-charge shall ensure that a policy exists requiring that if, at the time of loading any controlled substance, a discrepancy in the count of that drug in the automated drug delivery system exists, the discrepancy is immediately reported to the pharmacist-in-charge. Whenever the pharmacist-in-charge becomes aware of a discrepancy regarding the count of a controlled substance in the automated drug delivery system, the pharmacist-in-charge shall be responsible for reconciliation of the discrepancy or proper reporting of the loss.
(f) The pharmacist-in-charge shall be responsible for the following:
(1) Controlling access to the automated drug delivery system;
(2) maintaining policies and procedures for the following:
(A) Operating the automated drug delivery system;
(B) providing prior training and authorization of personnel who are authorized to remove any drug from the automated drug delivery system;
(C) maintaining, at the location of the automated drug delivery system, a list of those individuals who are authorized to remove any drug from the automated drug delivery system;
(D) maintaining patient services whenever the automated drug delivery system is not operating; and
(E) defining a procedure for a pharmacist to grant access to the drugs in the automated drug delivery system;
(3) securing the automated drug delivery system;
(4) ensuring that each patient receives the pharmacy services necessary for appropriate pharmaceutical care;
(5) ensuring that the automated drug delivery system maintains the integrity of the information in the system and protects patient confidentiality;
(6) ensuring compliance with all requirements for packaging and labeling each medication pursuant to K.A.R. 68-7-15 and K.A.R. 68-7-16, unless the medication is already packaged in the manufacturer's original container or in repackaged containers;
(7) ensuring that a system of preventive maintenance and sanitation exists and is implemented for the automated drug delivery system;
(8) ensuring that a policy exists for securing and accounting for all drugs that are wasted or discarded from the automated drug delivery system;
(9) ensuring that inspections are conducted and documented at least monthly to ensure the accuracy of the contents of the automated drug delivery system; and
(10) ensuring the accurate loading and unloading of the automated drug delivery system by approving and implementing an operational policy that limits the personnel responsible for the loading and unloading of the automated drug delivery system to a Kansas-licensed pharmacist or any of the following, each of whom shall be under the supervision of a Kansas-licensed pharmacist:
   (A) A Kansas-registered pharmacy intern;
   (B) a Kansas-registered pharmacy technician; or
   (C) a nurse with a license issued pursuant to K.S.A. 65-1115, and amendments thereto.

(g) A pharmacist shall comply with the medication order review and verification requirements specified in K.A.R. 68-7-11.
(h) Except in the event of a sudden and unforeseen change in a patient’s condition that presents an imminent threat to the patient’s life or well-being, any authorized individual at a facility may distribute patient-specific drugs utilizing an automated drug delivery system without verifying each individual drug selected or packaged by the automated drug delivery system only if both of the following conditions are met:
   (1) The initial medication order has been reviewed and approved by a pharmacist.
   (2) The drug is distributed for subsequent administration by a health care professional permitted by Kansas law to administer drugs.
(i) The pharmacist-in-charge shall be responsible for establishing a continuous quality improvement program for the automated drug delivery system. This program shall include written procedures for the following:
   (1) Investigation of any medication error related to drugs supplied or packaged by the automated drug delivery system;
   (2) review of any discrepancy or transaction reports and identification of patterns of inappropriate use of or access to the automated drug delivery system; and
   (3) review of the operation of the automated drug delivery system.
(j) The pharmacist-in-charge shall ensure that the managing pharmacy maintains, in a readily retrievable manner and for at least five years, the following records related to the automated drug delivery system:
   (1) Transaction records for all drugs or devices supplied by the automated drug delivery system; and
   (2) any report or analysis generated as part of the continuous quality improvement program.
(k) A Kansas-registered pharmacy technician, a Kansas-registered pharmacy intern, or a nurse with a license issued pursuant to K.S.A. 65-1115, and amendments thereto, who the pharmacist-in-charge has determined is properly trained may be authorized by that pharmacist-in-charge to perform the functions of loading and unloading an automated drug delivery system utilizing a bar
code verification, electronic verification, or similar verification process as specified in subsection (d).

(l) If any drug has been removed from the automated drug delivery system, that drug shall not be replaced into the automated drug delivery system unless either of the following conditions is met:

(1) The drug's purity, packaging, and labeling have been examined according to policies and procedures established by the pharmacist-in-charge to determine that the reuse of the drug is appropriate.

(2) The drug is one of the specific drugs, including multidose vials, that have been exempted by the pharmacy and therapeutics committee or an equivalent committee.

(m) Upon the removal of any automated drug delivery system, the pharmacist-in-charge shall provide the board with notification, on a form provided by the board.


**Article 10: Nuclear Pharmacies**

**68-10-1 to 68-10-3 Not in active use.**
Article 11: Fees

68-11-1 Fees for examination and licensure as a pharmacist.
The following fees shall be paid to the board by each applicant for examination and licensure as a pharmacist:
(a) Each applicant for examination shall pay a fee of $100.00.
(b) Each applicant for reciprocal licensure shall pay a fee of $125.00.
(c) An additional fee of $250.00 to evaluate the education and training shall be paid by each applicant for reciprocal licensure or examination who graduated from a school or college of pharmacy or department of a university not approved by the board.
(d) Each licensed pharmacist shall pay a renewal fee of $150.00.
(e) The penalty fee for a late renewal of a pharmacist license shall be $200.00.

68-11-2 Fees for premises registrations and permits.
(a) Pharmacy registration fees shall be as follows:
(1) Each new pharmacy registration shall be $150.00.
(2) Each renewal pharmacy registration shall be $125.00.
(b) Manufacturer registration fees shall be as follows:
(1) Each new registration shall be $350.00.
(2) Each renewal registration shall be $350.00.
(c) Wholesaler distributor registration fees shall be as follows:
(1) Each new registration shall be $350.00.
(2) Each renewal registration shall be $350.00.
(3) For each wholesale distributor who deals exclusively in nonprescription drugs, the registration fee shall be $50.00.
(4) For each wholesale distributor who deals exclusively in nonprescription drugs, the renewal fee shall be $50.00.
(d) For each institutional drug room or veterinary medical teaching hospital pharmacy, registration fees shall be as follows:
(1) Each new registration shall be $25.00.
(2) Each renewal registration shall be $20.00.
(e) Retail dealer permit fees shall be as follows:
(1) Each new permit shall be $10.00.
(2) Each renewal permit shall be $10.00.
(f) Each special auction permit shall be $28.00.
(g) Sample distribution fees shall be as follows:
(1) Each new permit shall be $30.00.
(2) Each renewal permit shall be $30.00.
(h) For each place of business that sells durable medical equipment, registration fees shall be as follows:
(1) Each new registration shall be $300.00.
(2) Each renewal registration shall be $350.00.
(i) Third-party logistics provider registration fees shall be as follows:
(1) Each new registration shall be $350.00.
(2) Each renewal registration shall be $350.00.
(3) For each third-party logistics provider who deals exclusively in nonprescription drugs, the registration fee shall be $50.00.
(4) For each third-party logistics provider who deals exclusively in nonprescription drugs, the renewal fee shall be $50.00.
(j) For each outsourcing facility or virtual outsourcing facility, registration fees shall be as follows:
(1) Each new registration shall be $350.00.
(2) Each renewal registration shall be $350.00.
(k) Repackager registration fees shall be as follows:
(1) Each new registration shall be $350.00.
(2) Each renewal registration shall be $350.00.
(l) For each place of business that operates an automated dispensing system for patient medication administration, registration fees shall be as follows:
(1) Each new registration shall be $20.00.
(2) Each renewal registration shall be $20.00.

68-11-3. Fees for registration as a pharmacy technician or pharmacy intern.
The following fees shall be paid to the board:
(a) Each applicant for initial registration as a pharmacy technician shall pay a fee of $20.00.
(b) Each registered pharmacy technician shall pay a renewal fee of $20.00.
(c) Each applicant for a pharmacy intern registration shall pay a fee of $20.00.

Article 12: Resale of Medication

68-12-1 Not in active use.
EDITOR'S NOTE: Proposed regulation 68-12-1, rejected by legislature, see L. 1983, ch. 356.

68-12-2 Resale of dispensed prescription drugs.
Except for prescription drugs in unit-dose systems that contain only one medication and in which the drug has not reached the patient and is still intact, prescription drugs that have been dispensed to the final consumer shall not be resold, redispensed, or distributed by a licensed pharmacist.

Article 13: Compounding Sterile and Nonsterile Preparations

68-13-1 REVOKED.

68-13-2 Definitions.
As used in this article of the board’s regulations, each of the following terms shall have the meaning specified in this regulation:
(a) “Active ingredients” means chemicals, substances, or other components intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases in humans or for use as nutritional supplements.
(b) “Added substances” and “inactive ingredients” mean the ingredients necessary to compound a sterile preparation or nonsterile preparation and not intended or expected to cause a human pharmacologic response if administered alone in the amount or concentration contained in a single dose of the drug product.
(c) “Antearea” means an area, separate from the buffer area, that meets the requirements of an ISO class eight environment and in which personal hygiene and garbing procedures, staging of components, order entry, and labeling are performed.
(d) “Batch” means multiple sterile dosage units in a quantity greater than 25 that are compounded in a discrete process by the same individual or individuals during one limited period.
(e) “Beyond-use date” means a date placed on a prescription label at the time of dispensing, repackaging, or prepackaging that is intended to indicate to the patient or caregiver a time beyond which the contents of the prescription are not recommended to be used.
(f) “Biological safety cabinet” and “BSC” mean a ventilated cabinet for sterile preparations and hazardous drugs to protect personnel, products, and the environment that has an open front with inward airflow for protection of personnel, downward-airflow LAFS for product protection, and HEPA-filtered exhausted air for environmental protection.
(g) “Buffer area” means an area that meets the requirements for an ISO class seven environment and in which the primary engineering control is located.
(h) “Clean room” means a room that meets the requirements for an ISO class five environment.
(i) “Complex nonsterile compounding” means making a nonsterile preparation that requires special training, environment, facilities, equipment, and procedures to ensure appropriate therapeutic outcomes. Nonsterile preparations made using complex nonsterile compounding shall include transdermal dosage forms, modified-release forms, and suppositories for systemic effects.
(j) “Component” means any active ingredient or added substance intended for use in the compounding of a drug product, including any ingredient that does not appear in the drug product.
(k) “Compounding” has the meaning specified in K.S.A. 2017 Supp. 65-1626, and amendments thereto.
(l) “Compounding area” means any area in a pharmacy or outsourcing facility where compounding is performed.
(m) “Compounding aseptic containment isolator” and “CACI” mean a compounding aseptic isolator designed to provide worker protection from exposure to undesirable levels of airborne drugs throughout the compounding and material transfer process and to provide an aseptic environment for compounding sterile preparations. Air exchange with the surrounding environment shall not occur unless the air is first passed through a HEPA filter capable of containing airborne concentrations of the physical size and state of the drug being compounded. Whenever volatile hazardous drugs are compounded, the exhaust air from the CACI shall be removed by the building’s ventilation system.
(n) “Compounding aseptic isolator” and “CAI” mean a type of isolator specifically designed for compounding sterile preparations or nonsterile preparations and designed to maintain an aseptic compounding environment within the isolator throughout the compounding and material transfer process. Air exchange into the CAI from the surrounding environment shall not occur unless the air has first passed through a HEPA filter and an ISO class five environment is maintained.
(o) “Cytotoxic,” when used to describe a pharmaceutical, means that the pharmaceutical is capable of killing living cells. This term is also used to describe components classified as cancer chemotherapeutic, carcinogenic, mutagenic, or antineoplastic.
(p) “Dosage unit” means the amount of a sterile preparation that would be administered to or taken by one patient at a time.
(q) “Endotoxin” means a potentially toxic, natural compound that is a structural component of bacterial cell walls and that is released mainly when bacteria undergo destruction or decomposition.
(r) “Essentially a copy” means any sterile preparation or nonsterile preparation that is comparable in active ingredients to a commercially available drug product, unless either of the following conditions is met:
(1) There is a change made for an identified individual patient that produces a clinically significant difference for the patient, as determined by the prescribing practitioner, between the comparable commercially available drug product and either the sterile preparation or the nonsterile preparation.
(2) The drug appears on the drug shortage list in section 506E of the federal food, drug, and cosmetic act, 21 U.S.C. 356e, at the time of compounding, distribution, and dispensing.
(s) “Excursion” means a deviation from the range of temperatures specified by the manufacturer for storage or transport of a pharmaceutical based on stability data.
(t) “Glove fingertip test” means a test in which a gloved fingertip is pressed to and cultured on a microbiological growth media plate. Each successful glove fingertip test shall yield no more than three colony-forming units per contact plate for the annual competency evaluation and shall yield zero colony-forming units at least three times for the initial competency evaluation.

(u) “Hazardous drug” means any drug or compounded drug identified by at least one of the following criteria:

1. Carcinogenicity;
2. Teratogenicity or developmental toxicity;
3. Reproductive toxicity;
4. Organ toxicity at low doses;
5. Genotoxicity; or
6. Drug product structure or toxicity that mimics that of existing hazardous drugs.

(v) “HEPA” means high-efficiency particulate air.

(w) “ISO class eight environment” means an atmospheric environment containing less than 3,520,000 airborne particles measuring at least 0.5 micron in diameter per cubic meter of air.

(x) “ISO class five environment” means an atmospheric environment containing less than 3,520 airborne particles measuring at least 0.5 micron in diameter per cubic meter of air.

(y) “ISO class seven environment” means an atmospheric environment containing less than 352,000 airborne particles measuring at least 0.5 micron in diameter per cubic meter of air.

(z) “Laminar airflow system” and “LAFS” mean an apparatus designed to provide an ISO class five environment for the compounding of sterile preparations using air circulation in a defined direction that passes through a HEPA filter.

(aa) “Manufacturing” means manufacture as defined in K.S.A. 65-1626, and amendments thereto.

(bb) “Media fill test” means a test in which a microbiological growth medium, which may consist of a soybean-casein digest medium, is substituted for an actual drug product to simulate admixture compounding. The media fill test shall be successful if it produces a sterile preparation without microbial contamination.

(cc) “Moderate nonsterile compounding” means making a nonsterile preparation that requires special calculations or procedures to determine quantities of components per nonsterile preparation or per dosage unit or making a nonsterile preparation for which stability data is not available. Nonsterile preparations made using moderate nonsterile compounding shall include morphine sulfate suppositories, diphenhydramine troches, and a mixture of two or more manufactured creams if stability of the mixture is not known.

(dd) “Multiple-dose container” means a multiple-unit container for any sterile preparation intended only for parenteral administration, usually containing antimicrobial preservatives.

(ee) “Nonsterile preparation” means a pharmaceutical made using simple nonsterile compounding, moderate nonsterile compounding, or complex nonsterile compounding.

(ff) “Official compendium” has the meaning specified in K.S.A. 65-656, and amendments thereto.

(gg) “Order” means either a prescription order as defined in K.S.A. 65-1626, and amendments thereto, or a medication order as defined in K.A.R. 68-5-1.

(hh) “Parenteral,” when used to refer to a solution, means that the solution is administered by injection through one or more layers of skin or by other routes of administration that bypass the gastrointestinal tract.
(ii) “Parenteral product” means a sterile preparation administered by injection through one or more layers of skin or by other routes of administration that bypass the gastrointestinal tract.

(jj) “Practitioner-patient-pharmacist relationship” means a relationship that meets all of the following conditions:

(1) The practitioner has assumed the responsibility for making medical judgments regarding the health of the patient and the need for medical treatment.
(2) The practitioner has sufficient knowledge of the patient to initiate at least a general or preliminary diagnosis of the medical condition, and the practitioner has examined the patient and is available for follow-up.
(3) The practitioner has communicated the necessary prescriptions to the pharmacist, who is able to provide pharmaceutical care to the patient and, if needed, communicate with the practitioner.

(kk) “Primary engineering control” means a clean room or an apparatus for compounding sterile preparations, including an LAFS, a BSC, a CAI, or a CACI, designed to provide an ISO class five environment for compounding sterile preparations.

(ll) “Purified water” means water that meets the requirements for ionic and organic chemistry purity and protection from microbial contamination specified in section 1231 of the official compendium.

(mm) “Refrigeration” and “controlled cold temperature” mean a temperature maintained thermostatically between 2° and 8°C (36° to 46°F) that allows for excursions between 0° and 15°C (32° to 59°F) that are experienced during storage, shipping, and distribution, such that the allowable calculated mean kinetic temperature is not more than 8°C (46°F).

(nn) “Room temperature” means a temperature maintained thermostatically that meets the following criteria:

(1) Encompasses the usual and customary working environment of 20° to 25°C (68° to 77°F);
(2) results in a mean kinetic temperature calculated to be not more than 25°C (77°F); and
(3) allows for excursions between 15° and 30°C (59° to 86°F) experienced in pharmacies, hospitals, and storage facilities, such that the allowable calculated mean kinetic temperature remains in the allowed range.

(oo) “Segregated compounding area” means a designated, demarcated area or room that is restricted to compounding low-risk sterile preparations, which shall contain a primary engineering control providing unidirectional airflow that maintains an ISO class five environment and shall be void of all activities and materials extraneous to the sterile compounding process.

(pp) “Simple nonsterile compounding” means either of the following:

(1) Making a nonsterile preparation that has a compounding monograph listed in the official compendium or that appears in a peer-reviewed journal containing specifics on component quantities, compounding procedure, equipment, and stability data for the formulation and appropriate beyond-use dates; or
(2) reconstituting or manipulating commercially available products that require the addition of one or more ingredients as directed by the manufacturer.

Nonsterile preparations made using simple nonsterile compounding shall include captopril oral solution, indomethacin topical gel, and potassium bromide oral solution.

(qq) “Single-dose container” means a single-unit container for any sterile preparation intended for parenteral administration that is accessed once for one patient.

(rr) “Specific medical need” means a medical reason why a commercially available drug product cannot be used, excluding cost and convenience.
“Sterile preparation” means any dosage form of a drug, including parenteral products free of viable microorganisms, made using currently accepted aseptic compounding techniques under acceptable compounding conditions. This term shall include any commercially compounded sterile drug dosage form that has been altered in the compounding process.

“Sufficient documentation” means either of the following:
(1) A prescription documenting a specific medical need; or
(2) a notation in a pharmacy’s or an outsourcing facility’s records that verbal or other documentation of the specific medical need was received for each prescription, including the name of the person verifying the specific medical need, the date, and the specific medical need.


68-13-3 Nonsterile Preparations.
(a) This regulation shall apply to the following:
(1) Nonsterile preparations that are compounded in Kansas; and
(2) nonsterile preparations that are shipped or delivered into Kansas by a pharmacy and are to be administered to a patient in Kansas.
(b) “Pharmacy,” as used in this regulation, shall mean a pharmacy, nonresident pharmacy, or outsourcing facility as defined by K.S.A. 2017 Supp. 65-1626, and amendments thereto.
(c) Any pharmacist may compound a nonsterile preparation that is commercially available only if it is different from a product approved by the FDA and there is sufficient documentation of a specific medical need for an individual patient.
(d) A pharmacist shall not compound a nonsterile preparation by any of the following methods:
(1) Using any component withdrawn from the market by the FDA for safety reasons;
(2) receiving, storing, or using any drug component that is not guaranteed or otherwise determined to meet the requirements of an official compendium;
(3) compounding finished drugs from bulk active ingredients that do not meet the requirements of a monograph listed in the official compendium; or
(4) compounding finished drugs from bulk active ingredients that are not components of FDA-approved drugs.
(e) For the convenience of any patient, any pharmacist may compound a nonsterile preparation before receiving an order based on routine, regularly observed prescribing patterns.
(f) Compounding for non-human animals shall meet the same requirements as those for human prescriptions, except that a pharmacist shall not compound bulk chemicals for food-producing animals.
(g) Each nonsterile preparation sold by a pharmacy to a practitioner for administration to a patient shall be packaged with a label that includes the following text: “For Office Use Only -- Not for Resale.”
(h) Any pharmacy may distribute nonsterile preparations without a prescription, including providing limited quantities to a practitioner in the course of professional practice to administer limited quantities to an individual patient, if the nonsterile preparations are not intended for resale.
(i) Each pharmacy selling any prescription nonsterile preparation to a practitioner for office use shall maintain an invoice documenting the following:
(1) The name and address of the practitioner;
(2) the drug compounded, including the lot number and expiration date of each component;
(3) the quantity sold; and
(4) the date of the transaction.
The invoice shall be maintained in the pharmacy and shall be made readily available to the pharmacist-in-charge, the board, and the board’s designee.

(j) Within each pharmacy in which compounding occurs, one area shall be designated as the principal compounding area, where all nonsterile compounding shall take place.
(1) Each compounding area shall be well-lighted and well-ventilated, with clean and sanitary surroundings, and shall be free of food and beverages.
(2) Each compounding area shall provide the drugs, chemicals, and devices with necessary protection from deterioration due to light, heat, and evaporation and shall be arranged to protect all prescription drugs and devices from theft and any other unauthorized removal.
(3) All components used in compounding nonsterile preparations shall be stored in labeled containers in a clean, dry area and, if required, under proper refrigeration.
(4) Each compounding area shall include a sink that is equipped with hot and cold running water for hand and equipment washing.
(k) Each pharmacist compounding nonsterile preparations shall use purified water if the formulations indicate the inclusion of water.
(l) Each pharmacist-in-charge shall maintain a uniform formulation record for each nonsterile preparation, documenting the following:
(1) The ingredients, quantities, strength, and dosage form of the nonsterile preparation;
(2) the equipment used to compound the nonsterile preparation and the mixing instructions;
(3) the container used in dispensing;
(4) the storage requirements;
(5) the beyond-use date to be assigned;
(6) quality control procedures, which shall include identification of each person performing or either directly supervising or checking each step in the compounding process and which may include monitoring the following:
   (A) Capsule weight variation;
   (B) adequacy of mixing to ensure uniformity and homogeneity; and
   (C) the clarity, completeness, or pH of solutions;
(7) the source of the formulation, including the name of the person, entity, or publication; and
(8) the name or initials of the person creating the formulation record and the date on which the formulation record was established at the pharmacy.
(m) Each pharmacist-in-charge shall maintain on the original order or on a separate, uniform record a compounding record for each nonsterile preparation, documenting the following:
(1) The name and strength of the nonsterile preparation;
(2) the identifier used to distinguish the nonsterile preparation's formulation record from other formulation records;
(3) the name of the manufacturer or repackager and, if applicable, the lot number and expiration date of each component;
(4) the total number of dosage units or total quantity compounded;
(5) the name of each person who compounded the nonsterile preparation;
(6) the name of the pharmacist, or the pharmacy student or intern working under the direct supervision and control of the pharmacist, who verified the accuracy of the nonsterile preparation;
(7) the date of compounding;
(8) the assigned internal identification number, if used;
(9) the prescription number, if assigned;
(10) the results of quality control procedures; and
(11) the assigned beyond-use date. In the absence of valid scientific stability information that is
applicable to a specific drug or nonsterile preparation, the beyond-use date shall not be later than
the expiration date of any component of the formulation and shall be established in accordance
with the following criteria:
(A) For nonaqueous and solid formulations, either of the following:
(i) If a manufactured drug product is the source of the active ingredient, six months from the date
of compounding or the time remaining until the manufactured drug product's expiration date,
whichever is earlier; or
(ii) if a substance listed in an official compendium is the source of an active ingredient, six
months from the date of compounding or the time remaining until the expiration date of any
component of the formulation, whichever is earlier;
(B) for water-containing oral formulations, not more than 14 days when stored under
refrigeration; and
(C) for water-containing non-oral formulations, not longer than the intended duration of therapy
or 30 days, whichever is earlier.
(n) The compounding record and the corresponding formulation record specified in subsections
(m) and (l), respectively, shall be retained at the pharmacy for at least five years and shall be
made readily available to the pharmacist-in-charge, the board, and the board’s designee.
(o) If a patient requests a transfer of the patient’s prescription, a copy of the original prescription
shall be transmitted upon the request of the receiving pharmacist. The transferring pharmacist
shall also transfer the following written information with the prescription:
(1) Active ingredients;
(2) concentration;
(3) dosage form;
(4) route of delivery;
(5) delivery mechanism;
(6) dosing duration; and
(7) details about the compounding procedure.
(p) The pharmacist-in-charge shall ensure that all support personnel are trained and successfully
demonstrate the following before performing delegated compounding:
(1) Comprehensive knowledge of the pharmacy's standard operating procedures with regard to
compounding as specified in the policy and procedure manual; and
(2) familiarity with the compounding techniques used at the pharmacy.
May 11, 2018.)

68-13-4 Sterile Preparations.
(a) This regulation shall apply to the following:
(1) Sterile preparations that are compounded in Kansas; and
(2) sterile preparations that are shipped or delivered into Kansas by a pharmacy to be
administered to a patient in Kansas.
(b) As used in this regulation, each of the following terms shall have the meaning specified in this subsection:

(1)(A) “High-risk,” when used to describe a sterile preparation, means that the sterile preparation meets at least one of the following conditions:

(i) The sterile preparation is compounded from nonsterile ingredients or with nonsterile containers or equipment before terminal sterilization.

(ii) The sterile ingredients or components of the sterile preparation are exposed to air quality inferior to that of an ISO class five environment for more than one hour.

(iii) The sterile preparation contains nonsterile water and is stored for more than six hours before being sterilized.

(iv) The compounding pharmacist cannot verify from documentation received from the supplier or by direct examination that the chemical purity and content strength of the ingredients meet the specifications of an official compendium.

(v) The sterile preparation has been stored at room temperature and administered more than 24 hours after compounding, stored under refrigeration more than three days, or stored frozen from 0° to -20°C (32° to -4°F) or colder for 45 or fewer days, and sterility has not been confirmed by testing.

(B) This term shall apply to sterile preparations including the following:

(i) Alum bladder irrigation solution;

(ii) any morphine preparation made for parenteral administration from nonsterile powder or tablets;

(iii) any total parenteral nutrition solution made from dried amino acids;

(iv) any total parenteral nutrition solution sterilized by final filtration; and

(v) any autoclaved intravenous solution.

(2) “Immediate use” means a situation in which a sterile preparation is compounded pursuant to an order in a medical care facility for administration to the patient within one hour of the start of compounding the sterile preparation.

(3) “Low-risk,” when used to describe a sterile preparation, means that the sterile preparation meets the following conditions:

(A) In the absence of sterility testing, is stored at room temperature and administration to the patient has begun not more than 48 hours after compounding, is stored under refrigeration for 14 or fewer days before administration to the patient over a period not to exceed 24 hours, or is stored frozen at -20°C (-4°F) or colder for 45 or fewer days before administration to the patient over a period not to exceed 24 hours;

(B) is prepared for administration to one patient or is batch-prepared and contains suitable preservatives for administration to more than one patient; and

(C) is prepared by a simple or closed-system aseptic transfer of no more than three sterile, nonpyrogenic, finished pharmaceuticals obtained from licensed manufacturers into sterile final containers obtained from licensed manufacturers with no more than two instances in which a transfer device passes through the designated access point into any one sterile container or package.

(4)(A) “Medium-risk,” when used to describe a sterile preparation, means that the sterile preparation meets at least one of the following conditions:

(i) In the absence of sterility testing, is stored at room temperature and administered to the patient not more than 30 hours after compounding, is stored under refrigeration for nine or fewer days, or is stored frozen at -20°C (-4°F) or colder for 45 or fewer days;
(ii) is batch-prepared and intended for use by more than one patient or by one patient on multiple occasions;
(iii) is created by a compounding process that includes complex aseptic manipulations other than a single-volume transfer; or
(iv) is compounded by at least four manipulations of sterile ingredients obtained from licensed manufacturers in a sterile container obtained from a licensed manufacturer by using a simple or closed-system aseptic transfer.

(B) This term shall apply to the following:
(i) Sterile preparations for use in a portable pump or reservoir over multiple days;
(ii) batch-reconstituted sterile preparations;
(iii) batch-prefilled syringes; and
(iv) total parenteral nutrient solutions that are compounded by the gravity transfer of carbohydrates and amino acids into an empty container with the addition of sterile additives using a syringe and needle or that are mixed with an automatic compounding device.

(5) “Pharmacy” means a pharmacy, nonresident pharmacy, or outsourcing facility as defined by K.S.A. 2017 Supp. 65-1626, and amendments thereto.

(c) Any sterile preparation for immediate use may be compounded outside a primary engineering control if both of the following conditions are met:
(1) Administration to the patient begins within one hour of the start of compounding the sterile preparation.
(2) The sterile preparation is compounded by a simple or closed-system aseptic transfer of sterile, nonpyrogenic, finished pharmaceuticals obtained from licensed manufacturers into sterile final containers obtained from licensed manufacturers.

(d) When a multiple-dose container with antimicrobial preservatives has been opened or entered, the container shall be labeled with a beyond-use date not to exceed 28 days, unless otherwise specified by the manufacturer.

(e) Each compounding area shall contain a primary engineering control providing unidirectional airflow that will maintain an ISO class five environment for compounding sterile preparations and shall be void of all activities and materials that are extraneous to compounding.

(f) Each sterile preparation compounded in a segregated compounding area shall be labeled with a beyond-use date of no more than 12 hours.

(g) Each single-dose container shall be labeled as such.

(h) The contents of each single-dose container shall be used within one hour if the container is opened or entered in an area with air quality that does not meet the requirements of an ISO class five environment.

(i) The contents of each single-dose container shall be used within six hours if the container is opened or entered in an area that meets the requirements of an ISO class five environment.

(j) For the convenience of any patient, any pharmacist may compound a sterile preparation before receiving an order if the pharmacist has previously filled orders for the sterile preparation and the sterile preparation is based on routine, regularly observed prescribing patterns.

(k) Compounding for non-human animals shall meet the same requirements as those for human prescriptions, except that a pharmacist shall not compound bulk chemicals for food-producing animals.

(l) Each sterile preparation sold by a pharmacy to a practitioner for administration to a patient shall be packaged with a label that includes the following text: “For Office Use Only -- Not For Resale.”
(m) Any pharmacy may distribute sterile preparations without a prescription, including providing limited quantities to a practitioner in the course of professional practice to administer limited quantities to an individual patient, if the sterile preparations are not intended for resale.
(n) A pharmacist shall not compound a sterile preparation that is essentially a copy.
(o) Any pharmacist may compound a sterile preparation that is commercially available only if there is sufficient documentation of a specific medical need for the prescription or the product is temporarily unavailable due to problems other than safety or effectiveness. Each pharmacist shall document any unavailability in the patient’s prescription record, including the date the product was unavailable, and shall maintain documentation from the manufacturer or distributor demonstrating the product’s unavailability. The pharmacist shall cease compounding the sterile preparation as soon as the product becomes commercially available.
(p) A pharmacist shall not compound a sterile preparation by any of the following methods:
(1) Using any component withdrawn from the market by the FDA for safety reasons;
(2) receiving, storing, or using any drug component that is not guaranteed or otherwise determined to meet the requirements of an official compendium; or
(3) compounding finished drugs through manufacturing, as defined in K.S.A. 65-1626 and amendments thereto, without first receiving an FDA-sanctioned investigational new drug application in accordance with 21 U.S.C. 355(i) and 21 C.F.R. Part 312.
(q) Each pharmacist or pharmacy compounding sterile preparations shall have the following resources:
(1) A primary engineering control that is currently certified by an inspector certified by the controlled environmental testing association to ensure aseptic conditions within the working area and that has the required documentation. The certification shall be deemed current if the certification occurred within the previous six months or on the date the device was last moved to another location, whichever is more recent. The required documentation shall include the following:
(A) Inspection certificates for the past five years or since the date of installation, whichever is more recent;
(B) records of all filter maintenance for the past five years or since the date of installation, whichever is more recent;
(C) records of all HEPA filter maintenance for the past five years or since the date of installation, whichever is more recent; and
(D) records of all disinfecting and cleaning for the past year or since the date of installation, whichever is more recent;
(2) a sink with hot and cold running water;
(3) a refrigerator capable of maintaining a temperature of 2° to 8°C (36° to 46°F) and, if needed, a freezer capable of maintaining a temperature of -25° to -10°C (-13° to 14°F). The temperature shall be monitored and recorded each business day. Each pharmacy with an electronic system that alerts the pharmacist to noncompliant temperatures shall be exempt from daily recording;
(4) the reference materials required by K.A.R. 68-2-12a and a current copy of a reference text on intravenous incompatibilities and stabilities. If an electronic library is provided, a workstation shall be readily available for use by pharmacy personnel, students, interns, and board personnel;
(5) a policy and procedure manual, with a documented review at least every two years by the pharmacist-in-charge or designee, which shall include the following subjects:
(A) Sanitation;
(B) storage;
(C) dispensing;
(D) labeling;
(E) destruction and return of controlled substances;
(F) recordkeeping;
(G) recall procedures;
(H) responsibilities and duties of supportive personnel;
(I) aseptic compounding techniques; and
(J) ongoing evaluation of all staff compounding sterile preparations; and
(6) supplies necessary for compounding sterile preparations.

(r) Each pharmacist-in-charge shall maintain a uniform formulation record for each sterile preparation, documenting the following:
(1) The quantities, strength, and dosage form of all components of the sterile preparation;
(2) the equipment used to compound the sterile preparation and the mixing instructions;
(3) the container used in dispensing;
(4) the storage requirements;
(5) the beyond-use date to be assigned;
(6) quality control procedures, which may include monitoring the following, if applicable:
   (A) Adequacy of mixing to ensure uniformity and homogeneity; and
   (B) the clarity, completeness, or pH of solutions;
(7) the sterilization methods;
(8) the source of the formulation; and
(9) the name of the pharmacist who verified the accuracy of the formulation record and the date of verification.

(s) Each pharmacist-in-charge shall maintain on the original order or on a separate, uniform record a compounding record for each sterile preparation, documenting the following:
(1) The name and strength of the sterile preparation;
(2) the formulation record reference for the sterile preparation;
(3) the name of the manufacturer or repackager and, if applicable, the lot number and the expiration date of each component;
(4) the total number of dosage units or total quantity compounded;
(5) the name of the person or persons who compounded the sterile preparation;
(6) the name of the pharmacist, or the pharmacy student or intern working under the direct supervision and control of the pharmacist, who verified the accuracy of the sterile preparation;
(7) the date of compounding;
(8) the assigned internal identification number, if applicable;
(9) the prescription number, if assigned;
(10) the results of quality control procedures;
(11) the results of the sterility testing and, if applicable, pyrogen testing for the batch; and
(12) the assigned beyond-use-date. In the absence of valid scientific stability information that is applicable to a component or the sterile preparation, the beyond-use date shall be established in accordance with the following criteria:
   (A) For nonaqueous and solid formulations, one of the following:
      (i) If the manufactured drug product is the source of the active ingredient, six months from the date of compounding or the time remaining until the manufactured drug product's expiration date, whichever is earlier; or
(ii) if the substance listed in an official compendium is the source of an active ingredient, six months from the date of compounding or the time remaining until the expiration date of any component of the formulation, whichever is earlier;
(B) for formulations containing water and made from ingredients in solid form, not more than 14 days when stored under refrigeration; and
(C) for all other formulations, not longer than the intended duration of therapy or 30 days, whichever is earlier.

(t) The compounding record and corresponding formulation record specified in subsections (s) and (r), respectively, shall be retained at the pharmacy for at least five years and shall be made readily available to the pharmacist-in-charge, the board, and the board’s designee.
(u) Medical care facility pharmacies shall generate a compounding record and a corresponding formulation record only for batch compounding or for any sterile preparation with a beyond-use date of more than seven days.
(v) Except when compounding in any CAI, each person involved in compounding a sterile preparation shall follow personal garbing and washing procedures that include the following minimum requirements:
(1) Preparing for garbing by removing any outer garments, cosmetics, jewelry, and artificial nails;
(2) performing the following procedures, in the order listed:
(A) Donning dedicated shoes or shoe covers;
(B) donning head and facial hair covers;
(C) either washing the hands with soap for at least 20 seconds or using an antiseptic hand scrub in accordance with the manufacturer's instructions; and
(D) donning a nonsheding gown; and
(3) entering the work area and immediately performing an antiseptic hand-cleaning procedure using an alcohol-based surgical hand scrub and successively donning sterile, powder-free gloves. Sterile gloves shall be disinfected after touching any nonsterile area.
(w) All sterile preparations shall be stored and delivered in a manner that is designed to maintain parenteral product stability and sterility.
(x) All sterile preparations, except for sterile preparations for immediate use, shall be compounded under aseptic conditions as follows:
(1) Each low-risk sterile preparation labeled with a beyond-use date of 12 hours or longer shall be compounded in an ISO class five environment using techniques that ensure sterility. Each low-risk sterile preparation labeled with a beyond-use date of less than 12 hours shall, at a minimum, be made in a segregated compounding area.
(2) Each medium-risk sterile preparation shall be compounded in an ISO class five environment using techniques that ensure sterility.
(3) Each high-risk sterile preparation made with nonsterile components shall be sterilized before being administered to a patient and shall have a certificate of analysis indicating that all nonsterile components meet the standards of the “United States pharmacopeia” and the FDA for identity, purity, and endotoxin levels as verified by a pharmacist.
(y) Each pharmacist engaged in the dispensing of sterile preparations shall meet all labeling requirements under state and federal law. In addition, the label of each sterile preparation shall contain the following information:
(1) The name and quantity of each component;
(2) the beyond-use date;
(3) the prescribed flow rate;
(4) the name or initials of each person who compounded the sterile preparation; and
(5) any special storage instructions.

(2) The pharmacist-in-charge and all personnel involved in compounding sterile preparations shall have practical or academic training in sterile compounding, clean room technology, laminar flow technology, and quality assurance techniques. The training shall include the following:
(A) At least one successful media fill test; and
(B) a successful glove fingertip test.

(2) The pharmacist-in-charge shall ensure that all supportive personnel are trained and successfully demonstrate the following before performing any delegated sterile admixture services:
(A) Comprehensive knowledge of the pharmacy's standard operating procedures with regard to sterile admixture services, as specified in the policy and procedure manual;
(B) familiarity with the compounding techniques; and
(C) aseptic technique, which shall be proven by means of a media fill test and a glove fingertip test.

(3) The pharmacist-in-charge shall be responsible for testing the aseptic technique of all personnel involved in compounding sterile preparations annually by means of a media fill test. All personnel involved in compounding high-risk sterile preparations shall undergo this testing twice each year. Each individual who fails to demonstrate acceptable aseptic technique shall be prohibited from compounding sterile preparations until the individual demonstrates acceptable technique by means of a media fill test.

(aa) The pharmacist-in-charge shall document all training and test results for each person before that person begins compounding sterile preparations. This documentation shall be maintained by the pharmacy for at least five years and shall be made available to the board upon request.

(bb) The pharmacist-in-charge shall be responsible maintaining records documenting the frequency of cleaning and disinfection of all compounding areas, according to the following minimum requirements:
(1) Each ISO class five environment shall be cleaned and disinfected as follows:
(A) At the beginning of each shift;
(B) every 30 minutes during continuous periods of compounding individual sterile preparations;
(C) before each batch; and
(D) after a spill or known contamination.

(2) All counters, work surfaces, and floors shall be cleaned and disinfected daily.

(3) All walls, ceilings, and storage shelves shall be cleaned and disinfected monthly.

(cc) The pharmacist-in-charge shall be responsible for maintaining records documenting the monitoring of the air pressure and air flow and shall initiate immediate corrective action if indicated. The air pressure of the antearea shall be maintained at five pascals, and the air flow shall be maintained at 0.2 meters per second. The air pressure and air flow values shall be checked and recorded at least once daily.

(dd) The pharmacist-in-charge shall be responsible for maintaining records documenting the monitoring of the cleanliness and sterility of the sterile compounding environment. Environmental sampling shall be performed in each new facility before any sterile preparation in that facility is provided to a patient and, at a minimum, every six months thereafter. The environmental sampling shall include the primary engineering control, antearea and buffer area,
and equipment and shall be performed following any repair or service performed at the facility and in response to any identified problem or concern.

Environmental sampling shall consist of the following, at a minimum:

(1) Environmental nonviable particle counts;
(2) environmental viable airborne particle testing by volumetric collection;
(3) environmental viable surface sampling; and
(4) certification of operational efficiency of the primary engineering control by an independent contractor according to the international organization of standardization classification of particulate matter in room air, at least once every six months.

(ee) The environmental sampling records specified in subsection (dd) shall be retained at the pharmacy for at least five years and shall be made readily available to the pharmacist-in-charge, the board, and the board’s designee.

(ff) If a microbial growth above acceptable levels is detected in an ISO class five environment, ISO class seven environment, or ISO class eight environment, an immediate reevaluation of the adequacy of compounding practice, cleaning procedures, operational procedures, and air filtration efficiency with the aseptic compounding location shall be conducted and documented. Each investigation into the source of the contamination shall include air sources, personnel garbing, and all filters, at a minimum. The ISO class five environment, ISO class seven environment, or ISO class eight environment shall be cleaned three times and environmental sampling shall be performed and reevaluated. Sterile preparations may be compounded and labeled with a beyond-use date according to subsection (gg) until microbial growth has decreased to acceptable levels.

(1) An ISO class five environment shall have acceptable levels of microbial growth if both of the following conditions are met:
   (A) An airborne sample demonstrates no more than one colony-forming unit per cubic meter of air.
   (B) A surface sample demonstrates no more than three colony-forming units per contact plate.

(2) An ISO class seven environment shall have acceptable levels of microbial growth if both of the following conditions are met:
   (A) An airborne sample demonstrates no more than 10 colony-forming units per cubic meter of air.
   (B) A surface sample demonstrates no more than five colony-forming units per contact plate.

(3) An ISO class eight environment shall have acceptable levels of microbial growth if both of the following conditions are met:
   (A) An airborne sample demonstrates no more than 100 colony-forming units per cubic meter of air.
   (B) A surface sample demonstrates no more than 100 colony-forming units per contact plate.

(gg) Unless sterility has been confirmed by testing, each high-risk sterile preparation shall be administered according to the following:

(1) Within 24 hours of compounding if stored at room temperature;
(2) within three days of compounding if stored under refrigeration; or
(3) within 45 days of compounding if stored frozen at -20°C (-4°F) or colder.

Article 14: Wholesale Distributors

68-14-1 REVOKED.

68-14-2 Definitions.
As used in this article of the board’s regulations and the pharmacy practice act, each of the following terms shall have the meaning specified in this regulation:
(a) “Blood” means whole blood collected from a single donor and processed either for transfusion or for further manufacturing.
(b) “Blood component” means that part of blood separated by physical or mechanical means.
(c) “Common ownership and control” means the power to direct or cause the direction of the management and policies of a person or an organization, whether by ownership of stock, by voting rights, by contract, or by other means.
(d) “Drug sample” means a unit of a prescription-only drug that is not intended to be sold, is intended to promote the sale of the drug, and is distributed on a gratuitous basis.
(e) “Device” has the meaning specified in K.S.A. 65-656, and amendments thereto.
(f) “Emergency medical reasons” shall include transfers of prescription-only drugs by a retail pharmacy to another retail pharmacy to alleviate a temporary shortage, except that the gross dollar value of these transfers shall not exceed five percent of the total prescription-only drug sales revenue of either the transferor or transferee pharmacy during any period of 12 consecutive months.
(g) “Excursion” means a deviation from the range of temperatures specified by the manufacturer for storage or transport of a prescription-only drug or device based on stability data.
(h) “Intracompany sales” and “intracompany distribution” mean any transaction or transfer between any division, subsidiary, parent, affiliated, or related company under the common ownership and control of a corporate entity.
(i) “Primary owner” means any person owning or controlling more than 50 percent of the wholesaler's business.
(j) “Room temperature” means a temperature that is maintained thermostatically and meets the following requirements:
   (1) Encompasses the usual and customary working environment of 20°C to 25°C (68°F to 77°F);
   (2) results in a mean kinetic temperature calculated to be not more than 25°C (77°F); and
   (3) allows for excursions between 15°C and 30°C (59°F to 86°F) experienced in facilities, such that the allowable calculated mean kinetic temperature remains in the allowed range.
(k) “Virtual wholesale distribution” means arranging for the distribution of a drug or device, which may include taking actual possession of the drug or device and shall include contracting with another entity for the distribution, purchase, and sale of the drug or device.
(l) “Virtual wholesale distributor” means a business entity that arranges for the distribution of a drug or device, with or without taking actual possession of the drug or device, and contracts with others for the distribution, purchase, and sale.
(m) “Wholesale distribution” means distribution of prescription-only drugs or devices to persons other than a consumer or patient and shall include virtual wholesale distribution and virtual wholesale distributors, but this term shall not include either of the following:
(1) The distribution of drug samples by manufacturers' representatives or representatives of the authorized distributor of record, in accordance with 21 U.S.C. 353; or
(2) the sale, purchase, or trade of blood and blood components intended for transfusion.


68-14-3 REVOKED.


68-14-4 Minimum required information for registration.

(a) Each wholesale distributor, virtual wholesale distributor, third-party logistics provider, or outsourcing facility shall provide the board with the following minimum information as part of the registration requirements described in K.S.A. 65-1645, and amendments thereto, and as part of any renewal of any registration:

1. The name, commercial business address, and telephone number of the registrant;
2. each trade or business name used by the registrant;
3. the address, telephone number, and name of the contact person for each facility used by the registrant for the storage, handling, and distribution of prescription-only drugs or devices;
4. the type of ownership or operation, including partnership, corporation, or sole proprietorship;
5. the name of each owner, operator, facility manager, and designated representative of the registrant, including the following:
   A. If a person, the name, address, and date of birth of the person;
   B. if a partnership, the name, address, and date of birth of each partner and the name of the partnership;
   C. if a corporation, the name, title, address, and date of birth of each corporate officer and director, the corporate name, and the name of the state of incorporation; and
   D. if a sole proprietorship, the name, address, and date of birth of the sole proprietor and the name of the business entity;
6. a list of all states where the registrant is registered as a wholesale distributor, virtual wholesale distributor, third-party logistics provider, or outsourcing facility;
7. a copy of any current DEA registration;
8. all disciplinary actions or sanctions by any state or federal agency against the registrant or any principal, owner, director, officer, facility manager, or designated representative thereof;
9. if the facility is located outside of Kansas, a record of the following:
   A. A current registration in the state where the registrant is located;
   B. a satisfactory inspection conducted within the previous 36-month period by the registering entity of the state where the registrant is located. If no such inspection record is readily available, the record of a satisfactory inspection conducted at the expense of the registrant within the previous 36-month period by a third party recognized by the board to inspect may be accepted; and
   C. a designated resident agent in Kansas for service of process, the record of whom shall also be on file with the secretary of state; and
10. if the registrant is an outsourcing facility, a record of the following:
   A. A current outsourcing facility registration from the food and drug administration (FDA); and
(B) a current inspection report from an FDA inspection conducted within the previous 24-month period that indicates compliance with the requirements of the federal food, drug and cosmetic act, including guidance documents and current good manufacturing practices established by the FDA. If no such inspection record is readily available, the record of a satisfactory inspection conducted at the expense of the registrant within the previous 36-month period by a third party recognized by the board to inspect may be accepted.
(b) Each registrant shall provide the board with a surety bond that meets the requirements of 21 U.S.C. 360eee-2.
(c) Each registrant shall provide and maintain, in readily retrievable form, a list of all manufacturers, wholesale distributors, third-party logistics providers, outsourcing facilities, and dispensers with which the registrant is transacting business.
(d) Each registrant shall submit revised information requested by subsection (a) within 30 days after any change in that information.

68-14-5 Personnel.
(a) Each wholesale distributor registrant, virtual wholesale distributor registrant, third-party logistics registrant, or outsourcing facility registrant shall require each person employed in any wholesale distribution, virtual wholesale distribution, third-party logistics, or outsourcing activity, or any combination of these activities, to receive education, training, and experience sufficient for that person to perform the assigned functions in a manner providing assurance that the drug product quality, safety, and security will at all times be maintained as required by law. Each registrant shall maintain records of the training, education, and experience for five years.
(b) Each wholesale distributor registrant, virtual wholesale distributor registrant, or third-party logistics provider registrant shall designate an individual as the facility manager, who shall be responsible for all aspects of the registrant’s operation.
(c) Each outsourcing facility registrant shall designate a pharmacist-in-charge, as defined by K.S.A. 65-1626 and amendments thereto, who shall be responsible for all aspects of the registrant’s operation.

68-14-6 Violations and penalties.
Any license or registration granted under this article may be suspended or revoked by the board for willful and serious violation of these regulations.

68-14-7 Wholesale distributors; minimum requirements for the storage and handling of prescription-only drugs and devices and for the establishment and maintenance of prescription-only drug and device distribution records.
Each wholesale distributor registrant shall meet the following minimum requirements for the storage and handling of prescription-only drugs and devices and for the establishment and maintenance of prescription-only drug and device distribution records by the registrant and its officers, agents, representatives, and employees:
(a) Facilities. Each facility at which prescription-only drugs and devices are stored, warehoused, handled, held, offered, marketed, transported from, or displayed shall meet the following requirements:

1. Be of suitable size and construction to facilitate cleaning, maintenance, and proper operations;
2. have storage areas designed to provide adequate lighting, ventilation, temperature, sanitation, humidity, space, equipment, and security conditions;
3. have a quarantine area for storage of prescription-only drugs and devices that are outdated, damaged, deteriorated, misbranded, adulterated, counterfeit, or suspected of being counterfeit, or that are in immediate or sealed, secondary containers that have been opened or deemed unfit for distribution;
4. be maintained in a clean and orderly condition;
5. be free from infestation by insects, rodents, birds, or vermin of any kind;
6. be a commercial location and not a personal dwelling or residence;
7. have sufficient storage space to maintain records of all transactions for at least five years; and
8. be in a location separate from any other wholesale distributor or pharmacy registered by the board or another state.

(b) Security.

1. Each facility used for wholesale distribution shall be secure from unauthorized entry.
   (A) Access from outside the premises shall be kept to a minimum and be well controlled.
   (B) The outside perimeter of the premises shall be well lighted.
   (C) Entry into areas where prescription-only drugs or devices are held shall be limited to authorized personnel.
2. Each facility shall be equipped with an alarm system to detect entry after hours.
3. Each facility shall be equipped with a security system that will provide suitable protection against theft and diversion. When appropriate, the security system shall provide protection against theft or diversion that is facilitated or hidden by tampering with computers or electronic records.
4. Each registrant shall ensure adequate accountability and control of all controlled substances in compliance with the Kansas uniform controlled substances act, federal drug laws, and all applicable regulations.
5. Each registrant shall verify that all persons or entities who undertake, either directly or by any other arrangement, to transport prescription-only drugs or devices on behalf of the registrant ensure security.

(c) Storage. All prescription-only drugs and devices shall be stored at appropriate temperatures and under appropriate conditions in accordance with manufacturer’s recommendations to preserve the stability of these drugs and devices.

1. If no storage requirements are established for a prescription-only drug or device, the drug or device may be held at room temperature, as defined in an official compendium, to help ensure that its identity, strength, quality, and purity are not adversely affected.
2. Appropriate manual, electromechanical, or electronic temperature and humidity-recording equipment, devices, logs, or a combination of these means shall be utilized to document proper storage of prescription-only drugs and devices at least once during each 24-hour period.
3. The recordkeeping requirements in subsection (f) shall be followed for all stored prescription-only drugs and devices.

(d) Examination of materials.
(1) Upon receipt, each outside shipping container shall be visually examined to identify and to prevent the acceptance of prescription-only drugs or devices that are contaminated or otherwise unfit for distribution. This examination shall be adequate to reveal container damage that would suggest possible contamination or other damage to the contents.

(2) Each outgoing shipment shall be carefully inspected to identify the prescription-only drugs or devices and to ensure that there is no delivery of prescription-only drugs or devices that have been damaged in storage or held under improper conditions.

(3)(A) No registrant shall engage in the wholesale distribution of prescription-only drugs or devices that are purchased or received from pharmacies or practitioners or from wholesale distributors that obtained the drugs or devices from pharmacies or practitioners.

(B) Any registrant may receive for redistribution prescription-only drugs or devices returned from pharmacies or practitioners that were distributed by the registrant. Before redistribution, the registrant shall examine the prescription-only drug or device to ensure that it has not been opened or used. If the prescription-only drug or device has been opened, it shall be quarantined and physically separated from other prescription-only drugs or devices until the prescription-only drug or device is destroyed.

(C) Any registrant that also operates as a reverse logistics provider or returns processor may receive prescription-only drugs or devices for destruction from pharmacies and practitioners regardless of where the drugs or devices are obtained. Each registrant shall maintain documentation for the disposition of prescription-only drugs or devices sent for destruction with proof of destruction, including a certificate of destruction, for inventory accountability and shall maintain records documenting any return to the supplier.

(4) The recordkeeping requirements in subsection (f) shall be followed for all incoming and outgoing prescription-only drugs or devices.

(e) Returned, damaged, and outdated prescription-only drugs or devices.

(1) Prescription-only drugs or devices that are outdated, damaged, deteriorated, misbranded, or adulterated shall be quarantined and physically separated from other prescription-only drugs and devices until they are destroyed or returned to their supplier.

(2) Each prescription-only drug or device whose immediate or sealed outer or sealed secondary container has been opened or used shall be identified as such and shall be quarantined and physically separated from other prescription-only drugs or devices until the drug or device is either destroyed or returned to the supplier.

(3) If the conditions under which a prescription-only drug or device has been returned cast doubt on the drug's or device’s safety, identity, strength, quality, or purity, then the drug or device shall be destroyed or returned to the supplier, unless examination, testing, or other investigations prove that the drug or device meets appropriate standards of safety, identity, strength, quality, and purity. In determining whether or not the conditions under which a drug or device has been returned cast doubt on the drug's or device’s safety, identity, strength, quality, or purity, the registrant shall consider, among other factors, the conditions under which the drug or device has been held, stored, or shipped before or during its return and the condition of the drug or device and its container, carton, or labeling, as a result of storage or shipping.

(4) The recordkeeping requirements in subsection (f) shall be followed for all outdated, damaged, deteriorated, misbranded, or adulterated prescription-only drugs or devices.

(f) Recordkeeping.
Each registrant shall establish and maintain inventories and records of all transactions regarding the receipt and distribution or other disposition of prescription-only drugs and devices. These records shall include the following information:

(A) The source of the drugs and devices, including the name and principal address of the seller or transferor, and the address of the location from which the drugs or devices were shipped;

(B) the identity and quantity of the drugs and devices received and either distributed or disposed of; and

(C) the dates of receipt and either distribution or other disposition of the drugs and devices.

Each record related to the wholesale distribution of prescription-only drugs or devices, including invoices of purchase or sale, packing slips, and shipment records, shall accurately reflect the name of the registrant as that name appears on the registration issued by the board.

Inventories and records shall be made available for inspection and photocopying by an authorized representative of the board for five years following disposition of the prescription-only drugs or devices.

Records described in this regulation that are kept at the inspection site or that can be immediately retrieved by computer or other electronic means shall be readily available for authorized inspection during the retention period. Records kept at a central location apart from the inspection site and not electronically retrievable shall be made available for inspection within two working days of a request by an authorized representative of the board.

Each registrant shall post all current federal and state registrations in a conspicuous place.

Written policies and procedures. Each registrant shall establish, maintain, and adhere to written policies and procedures concerning the receipt, security, storage, inventory, and distribution of prescription-only drugs and devices, including policies and procedures for identifying, recording, and reporting losses or thefts, and for correcting all errors and inaccuracies in inventories. In addition, each registrant shall establish, maintain, and adhere to the following written policies and procedures:

(1) A procedure by which the oldest approved stock of a prescription-only drug or device is distributed first. The procedure may permit deviation from this requirement, if the deviation is temporary and appropriate to meet the needs of the receiving facility;

(2) a procedure to be followed for handling recalls and withdrawals of prescription-only drugs and devices. This procedure shall be adequate to deal with recalls and withdrawals due to any of the following:

(A) Any action initiated at the request of the food and drug administration or other federal, state, or local law enforcement or other government agency, including the board;

(B) any voluntary action by the manufacturer to remove defective or potentially defective drugs or devices from the market; or

(C) any action undertaken to promote public health and safety by replacing existing merchandise with an improved product or new package design;

(3) a procedure to ensure that wholesale distributors prepare for, protect against, and handle any crisis that affects security or operation of any facility in the event of strike, fire, flood, or other natural disaster, or other situations of local, state, or national emergency;

(4) a procedure to ensure that all outdated prescription-only drugs or devices are segregated from other drugs or devices and either returned to the manufacturer or destroyed. This procedure shall provide for written documentation of the disposition of outdated prescription-only drugs and devices. This documentation shall be maintained for five years after disposition of the outdated prescription-only drugs or devices; and
(5) a procedure to ensure that prescription-only drugs and devices are distributed only to registered entities with the authority to possess prescription-only drugs or devices in Kansas and to maintain documentation of this authority as part of the distribution record.

(h) Responsible persons. Each registrant shall establish and maintain a list of officers, directors, managers, and other persons in charge of wholesale prescription-only drug and device distribution, storage, and handling, including a description of their duties and a summary of their qualifications. This list shall be made available for inspection by the board.

(i) Compliance with federal, state, and local law.

(1) Each registrant that deals in controlled substances shall register with the DEA.

(2) Each registrant shall permit the board's authorized personnel to enter and inspect the registrant’s premises and delivery vehicles and to audit the records and written operating procedures, at reasonable times and in a reasonable manner, to the extent authorized by law.


(j) Salvaging and reprocessing. Each registrant shall be subject to the provisions of any applicable federal, state, or local laws or regulations that relate to prescription-only drug or device salvaging or reprocessing.


68-14-7a. Third-party logistics providers; minimum requirements for operation and maintenance of records.

Each third-party logistics provider registrant shall meet the following minimum requirements for operation and the maintenance of records:

(a) Facilities. Each facility at which a third-party logistics provider is located shall meet the following requirements:

(1) Be of suitable size and construction to facilitate cleaning, maintenance, and proper operations;

(2) have storage areas designed to provide adequate lighting, ventilation, temperature, sanitation, humidity, space, equipment, and security conditions;

(3) have a quarantine area for storage of prescription-only drugs and devices that are outdated, damaged, deteriorated, misbranded, adulterated, counterfeit, or suspected of being counterfeit or that are in immediate or sealed, secondary containers that have been opened or deemed unfit for distribution;

(4) be maintained in a clean and orderly condition;

(5) be free from infestation by insects, rodents, birds, or vermin of any kind;

(6) be in a location separate from any pharmacy registered by the board or another state;

(7) be a commercial location and not a personal dwelling or residence; and

(8) have sufficient storage space to maintain records of all shipments pertaining to third-party logistics for at least five years.

(b) Security.

(1) Each facility used for third-party logistics shall be secure from unauthorized entry.

(A) Access from outside the premises shall be kept to a minimum and be well controlled.

(B) The outside perimeter of the premises shall be well lighted.

(C) Entry into areas where prescription-only drugs or devices are held shall be limited to authorized personnel.
(2) Each facility shall be equipped with an alarm system to detect entry after hours.
(3) Each facility shall be equipped with a security system that will provide suitable protection against theft and diversion. When appropriate, the security system shall provide protection against theft or diversion that is facilitated or hidden by tampering with computers or electronic records.

c) Storage. All prescription-only drugs and devices shall be stored at appropriate temperatures and under appropriate conditions in accordance with manufacturer’s recommendations to preserve the stability of these drugs and devices.

1) If no storage requirements are established for a prescription-only drug or device, the drug or device may be held at room temperature, as defined in an official compendium, to help ensure that its identity, strength, quality, and purity are not adversely affected.

2) Appropriate manual, electromechanical, or electronic temperature and humidity-recording equipment, devices, logs, or a combination of these means shall be utilized to document proper storage of prescription-only drugs and devices at least once during each 24-hour period.

3) The recordkeeping requirements in subsection (f) shall be followed for all stored prescription-only drugs and devices.

d) Examination of materials.

1) Upon receipt, each outside shipping container shall be visually examined to identify and to prevent the acceptance of prescription-only drugs or devices that are contaminated or otherwise unfit for distribution. This examination shall be adequate to reveal container damage that would suggest possible contamination or other damage to the contents.

2) Each outgoing shipment shall be carefully inspected to identify the prescription-only drugs or devices and to ensure that there is no delivery of prescription-only drugs or devices that have been damaged in storage or held under improper conditions.

3) The recordkeeping requirements in subsection (f) shall be followed for all incoming and outgoing prescription-only drugs or devices.

e) Returned, damaged, and outdated prescription-only drugs or devices.

1) Prescription-only drugs or devices that are outdated, damaged, deteriorated, misbranded, or adulterated shall be quarantined and physically separated from other prescription-only drugs and devices until they are destroyed or returned to their supplier.

2) Each prescription-only drug or device whose immediate or sealed outer or sealed secondary container has been opened or used shall be identified as such and shall be quarantined and physically separated from other prescription-only drugs and devices until the drug or device is either destroyed or returned to the supplier.

3) If the conditions under which a prescription-only drug or device has been returned cast doubt on the drug's or device’s safety, identity, strength, quality, or purity, then the drug or device shall be destroyed or returned to the supplier, unless examination, testing, or other investigations prove that the drug or device meets appropriate standards of safety, identity, strength, quality, and purity. In determining whether or not the conditions under which a drug or device has been returned cast doubt on the drug's or device’s safety, identity, strength, quality, or purity, the registrant shall consider, among other factors, the conditions under which the drug or device has been held, stored, or shipped before or during its return and the condition of the drug or device and its container, carton, or labeling, as a result of storage or shipping.

4) The recordkeeping requirements in subsection (f) shall be followed for all outdated, damaged, deteriorated, misbranded, or adulterated prescription-only drugs or devices.

(f) Recordkeeping.
(1) Each registrant shall establish and maintain inventories and records of all transactions regarding the receipt and distribution or other disposition of prescription-only drugs and devices. These records shall include the following information:

(A) The source of the drugs and devices, including the name and principal address of the seller or transferor, and the address of the location from which the drugs or devices were shipped;

(B) the identity and quantity of the drugs and devices received and either distributed or disposed of; and

(C) the dates of receipt and either distribution or other disposition of the drugs and devices.

(2) Inventories and records shall be made available for inspection and photocopying by an authorized representative of the board for five years following disposition of the prescription-only drugs or devices.

(3) The records described in this regulation that are kept at the inspection site or that can be immediately retrieved by computer or other electronic means shall be readily available for authorized inspection during the retention period. Records kept at a central location apart from the inspection site and not electronically retrievable shall be made available for inspection within two working days of a request by an authorized representative of the board.

(4) Each registrant shall post all current federal and state registrations in a conspicuous place.

(g) Written policies and procedures. Each registrant shall establish, maintain, and adhere to written policies and procedures concerning the receipt, security, storage, inventory, and distribution of prescription-only drugs and devices, including policies and procedures for identifying, recording, and reporting losses or thefts, and for correcting all errors and inaccuracies in inventories. In addition, each registrant shall establish, maintain, and adhere to the following written policies and procedures:

(1) A procedure by which the oldest approved stock of a prescription-only drug or device is distributed first. The procedure may permit deviation from this requirement, if the deviation is temporary and appropriate to meet the needs of the receiving facility;

(2) a procedure to be followed for handling recalls and withdrawals of prescription-only drugs and devices. This procedure shall be adequate to deal with recalls and withdrawals due to any of the following:

(A) Any action initiated at the request of the food and drug administration or other federal, state, or local law enforcement or other government agency, including the board;

(B) any voluntary action by the manufacturer to remove defective or potentially defective drugs or devices from the market; or

(C) any action undertaken to promote public health and safety by replacing existing merchandise with an improved product or new package design;

(3) a procedure to ensure that the registrant prepares for, protects against, and handles any crisis that affects security or operation of any facility in the event of strike, fire, flood, or other natural disaster, or other situations of local, state, or national emergency; and

(4) a procedure to ensure that all outdated prescription-only drugs or devices are segregated from other drugs and devices and either returned to the manufacturer or destroyed. This procedure shall provide for written documentation of the disposition of outdated prescription-only drugs or devices. Each registrant shall maintain this documentation for five years after disposition of each outdated prescription-only drug or device.

(h) Responsible persons. Each registrant shall establish and maintain a list of officers, directors, managers, and other persons in charge of prescription-only drug and device distribution, storage,
and handling, including a description of their duties and a summary of their qualifications. This list shall be made available for inspection by the board.

(i) Compliance with federal, state, and local law.
(1) Each registrant that deals in controlled substances shall register with the DEA.
(2) Each registrant shall permit the board's authorized personnel to enter and inspect the registrant’s premises and delivery vehicles and to audit the records and written operating procedures, at reasonable times and in a reasonable manner, to the extent authorized by law.
(3) Each registrant shall operate in accordance with the requirements of 21 U.S.C. 360eee, or any implementing regulation.


68-14-7b. Outsourcing facilities; minimum requirements for operation and maintenance of records.
Each registrant who is the owner of an outsourcing facility shall meet the following minimum requirements for operation and the maintenance of records:
(a) Facilities. Each outsourcing facility shall meet the following requirements:
(1) Be of suitable size and construction to facilitate cleaning, maintenance, and proper operations;
(2) have storage areas designed to provide adequate lighting, ventilation, temperature, sanitation, humidity, space, equipment, and security conditions;
(3) have a quarantine area for storage of prescription-only drugs and devices that are outdated, damaged, deteriorated, misbranded, adulterated, or deemed unfit for distribution;
(4) have a quarantine area designated for holding products waiting for testing data before being released for distribution;
(5) be maintained in a clean and orderly condition;
(6) be free from infestation by insects, rodents, birds, or vermin of any kind;
(7) be a commercial location and not a personal dwelling or residence; and
(8) have sufficient storage space to maintain records of all shipments pertaining to outsourcing for at least five years.
(b) Security.
(1) Each facility used for outsourcing shall be secure from unauthorized entry.
(A) Access from outside the premises shall be kept to a minimum and be well controlled.
(B) The outside perimeter of the premises shall be well lighted.
(C) Entry into areas where prescription-only drugs and devices are held shall be limited to authorized personnel.
(2) Each facility shall be equipped with an alarm system to detect entry after hours.
(3) Each facility shall be equipped with a security system that will provide suitable protection against theft and diversion. When appropriate, the security system shall provide protection against theft or diversion that is facilitated or hidden by tampering with computers or electronic records.
(c) Storage. All prescription-only drugs and devices shall be stored at appropriate temperatures and under appropriate conditions in accordance with manufacturer’s recommendations to preserve the stability of these drugs and devices.
(1) If no storage requirements are established for a prescription-only drug or device, the drug or device may be held at room temperature, as defined in an official compendium, to help ensure that its identity, strength, quality, and purity are not adversely affected.

(2) Appropriate manual, electromechanical, or electronic temperature and humidity-recording equipment, devices, logs, or a combination of these means shall be utilized to document proper storage of prescription-only drugs and devices at least once during each 24-hour period.

(3) The recordkeeping requirements in subsection (f) shall be followed for all stored prescription-only drugs and devices.

(d) Examination of materials.

(1) Upon receipt, each outside shipping container shall be visually examined to identify and to prevent the acceptance of prescription-only drugs or devices that are contaminated or otherwise unfit for distribution. This examination shall be adequate to reveal container damage that would suggest possible contamination or other damage to the contents.

(2) Each outgoing shipment shall be carefully inspected to identify the prescription-only drugs or devices and to ensure that there is no delivery of prescription-only drugs or devices that have been damaged in storage or held under improper conditions.

(3) The recordkeeping requirements in subsection (f) shall be followed for all incoming and outgoing prescription-only drugs and devices.

(e) Returned, damaged, and outdated prescription-only drugs and devices.

(1) Prescription-only drugs or devices that are outdated, damaged, deteriorated, misbranded, or adulterated shall be quarantined and physically separated from other prescription-only drugs and devices until they are destroyed.

(2) Each prescription-only drug or device whose immediate or sealed outer or sealed secondary container has been opened or used shall be identified as such and shall be quarantined and physically separated from other prescription-only drugs until the drug or device is either destroyed or returned to the supplier.

(3) If the conditions under which a prescription-only drug or device has been returned cast doubt on the drug’s or device’s safety, identity, strength, quality, or purity, then the drug or device shall be destroyed, unless examination, testing, or other investigations prove that the drug or device meets appropriate standards of safety, identity, strength, quality, and purity. In determining whether or not the conditions under which a drug or device has been returned cast doubt on the drug’s or device’s safety, identity, strength, quality, or purity, the registrant shall consider, among other factors, the conditions under which the drug or device has been held, stored, or shipped before or during its return and the condition of the drug or device and its container, carton, or labeling, as a result of storage or shipping.

(4) The recordkeeping requirements in subsection (f) shall be followed for all outdated, damaged, deteriorated, misbranded, or adulterated prescription-only drugs and devices.

(f) Recordkeeping.

(1) Each registrant shall establish and maintain records of all transactions regarding the receipt and distribution or other disposition of prescription-only drugs and devices and any bulk active pharmaceutical ingredients used in compounding or manufacturing. These records shall include the following information:

(A) The source of the drugs and devices or the active pharmaceutical ingredients, including the name and principal address of the seller or transferor, the address of the location from which the drugs or devices were shipped, and the certificate of analysis if an active pharmaceutical ingredient was received;
(B) the identity and quantity of the drugs and devices or the active pharmaceutical ingredients received and either distributed or disposed of; and
(C) the date of receipt of the drugs and devices and the date of distribution or any other disposition of the drugs and devices.
(2) Records shall be made available for inspection and photocopying by an authorized representative of the board for five years following disposition of the prescription-only drugs or devices.
(3) The records described in this regulation that are kept at the inspection site or that can be immediately retrieved by computer or other electronic means shall be readily available for authorized inspection during the retention period. Records kept at a central location apart from the inspection site and not electronically retrievable shall be made available for inspection within two working days of a request by an authorized representative of the board.
(4) Each registrant shall post all current federal and state registrations in a conspicuous place.
(g) Written policies and procedures. Each registrant shall establish, maintain, and adhere to written policies and procedures concerning the receipt, security, storage, inventory, and distribution of prescription-only drugs and devices, including policies and procedures for identifying, recording, and reporting losses or thefts, and for correcting all errors and inaccuracies in inventories. In addition, each registrant shall establish, maintain, and adhere to the following written policies and procedures:
(1) A procedure by which the oldest approved stock of a prescription-only drug or device is distributed first. The procedure may permit deviation from this requirement, if the deviation is temporary and appropriate to meet the needs of the receiving facility;
(2) a procedure to be followed for handling recalls and withdrawals of prescription-only drugs and devices including written notification to the board within 24 hours. This procedure shall be adequate to deal with recalls and withdrawals due to any of the following:
(A) Any action initiated at the request of the food and drug administration or other federal, state, or local law enforcement or other government agency, including the board;
(B) any voluntary action by the registrant to remove defective or potentially defective drugs or devices from the market; or
(C) any action undertaken to promote public health and safety by replacing existing merchandise with an improved product or new package design;
(3) a procedure to ensure that the registrant prepares for, protects against, and handles any crisis that affects security or operation of any facility in the event of strike, fire, flood, or other natural disaster, or other situations of local, state, or national emergency;
(4) a procedure to ensure that all outdated prescription-only drugs or devices are segregated from other drugs or devices and destroyed. This procedure shall provide for written documentation of the disposition of outdated prescription-only drug or device. This documentation shall be maintained for five years after disposition of the outdated prescription-only drug or device; and
(5) a procedure to ensure that prescription-only drugs and devices are sold only to registered entities with the authority to possess prescription-only drugs and devices in Kansas and to maintain documentation of this authority as part of the distribution record.
(h) Responsible persons. Each registrant shall establish and maintain a list of officers, directors, managers, pharmacists, pharmacy technicians, and other persons in charge of drug compounding, distribution, storage, and handling, including a description of their duties and a summary of their qualifications. This list shall be made available for inspection by the board.
(i) Compliance with federal, state, and local law.
(1) Each registrant that deals in controlled substances shall register with the DEA.
(2) Each registrant shall permit the board’s authorized personnel to enter and inspect the registrant’s premises and delivery vehicles and to audit the records and written operating procedures, at reasonable times and in a reasonable manner, to the extent authorized by law.
(3) Each registrant shall operate in accordance with section 503B of the federal food, drug, and cosmetic act, 21 U.S.C. 353b.
(4) Each drug manufactured, prepared, propagated, compounded, or processed by an outsourcing facility without a registration issued by the board shall be deemed misbranded.

68-14-8 Wholesale distributors transaction.
(a) Notwithstanding any other provision of these regulations under article 14, a wholesale distributor, duly registered with the board, may sell or deliver to a layperson responsible for the control of an animal, a prescription-only drug to be administered to the animal only if a licensed veterinarian practitioner has issued, before the sale or delivery, a lawful written prescription or order for the prescription-only drug in the course of an existing, valid veterinarian-client-patient relationship as defined in K.S.A. 47-816 and amendments thereto. As used in these regulations under article 14, "wholesale distribution" shall include this transaction.
   (1) Except as otherwise provided in this regulation, at the time the prescription-only drug leaves the registered location of the wholesale distributor, the wholesale distributor shall possess, at the registered location, a copy of the written prescription or order for the drug.
   (2) Except as otherwise provided in this regulation, at the time the prescription-only drug is delivered to the layperson, the person making the delivery shall possess a copy of the written prescription or order for the drug.
   (3) The wholesale distributor shall retain, for a period of five years, a copy of the written prescription or order in a manner that makes it readily available for review by a board representative.
(b) In lieu of receiving a written prescription or order from a licensed veterinarian practitioner before a prescription-only drug leaves the registered location, the wholesale distributor may accept a verbal order from a licensed veterinarian practitioner if all of the following conditions are met:
   (1) The licensed veterinarian practitioner has created a written prescription or order, but advised the wholesale distributor that, under the circumstances, it is not reasonably possible for the licensed veterinarian practitioner to provide the written prescription or order to the wholesale distributor before the prescription-only drug leaves the registered location.
   (2) The licensed veterinarian practitioner provides to the wholesale distributor all of the information required by K.A.R. 70-7-1(n) to be included in a written order for a prescription of legend drugs.
   (3) The verbal order is received in a communication directly with the licensed veterinarian practitioner.
   (4) The wholesale distributor makes, at the time the verbal order is received, a written confirmation of the information provided by the licensed veterinarian practitioner and records the following information:
      (A) The name of the licensed veterinarian practitioner;
      (B) the date and time the verbal order was received; and
(C) the name of the person making the written confirmation.

(5) At the time of receiving the verbal order, the wholesale distributor requests that the licensed veterinarian practitioner send a written prescription for the prescription-only drugs so that it is received by the wholesale distributor within 72 hours of receipt of the verbal order and, if it is not received, advises the Kansas board of veterinary examiners of this in writing.

(6) At the time the prescription-only drug leaves the registered location of the wholesale distributor, the wholesale distributor possesses, at the registered location, the original written confirmation.

(7) At the time the prescription-only drug is delivered to the layperson responsible for the control of the animal, the person making the delivery possesses a copy of the written confirmation.

(8) The original written confirmation is maintained by the wholesale distributor for five years in a manner that makes it readily available for review by a board representative.

(Authorized by K.S.A. 65-1630; implementing K.S.A. 1999 Supp. 65-1635(d); effective July 23, 1999; amended Nov. 27, 2000.)
Article 15: Nonprescription Wholesale Distributors

68-15-1 Nonprescription wholesale distributors.
"Nonprescription wholesale distributor" shall mean any person, partnership, corporation, or business firm registered in this state and engaging in the distribution of drugs that are not prescription-only drugs to persons or entities other than a consumer or patient.
(Authorized by K.S.A. 65-1630; implementing K.S.A. 1998 Supp. 65-1643(c); effective July 23, 1999.)

68-15-2 Nonprescription wholesale distributor registration required.
A nonprescription wholesale distributor may engage in the distribution of nonprescription drugs to persons or entities, other than a consumer or patient in Kansas, if both of the following conditions are met:
(a) The drugs are prepackaged, fully prepared by the manufacturer or distributor for use by a consumer, and appropriately labeled.
(b) The distributor has first obtained a registration to do so from the board.
(Authorized by K.S.A. 65-1630; implementing K.S.A. 1998 Supp. 65-1643(c) and K.S.A. 65-1634; effective Sept. 24, 1999.)

68-15-4 Minimum requirements for storage.
All drugs shall be stored at appropriate temperatures and under appropriate conditions in accordance with any requirements in the labeling or packaging of the drugs, or with any requirements in the United States pharmacopeia: the national formulary (USP/NF), as in effect on March 15, 1999 and published January 1, 1995.
(Authorized by K.S.A. 65-1630; implementing K.S.A. 1998 Supp. 65-1643(c) and K.S.A. 65-1634; effective Sept. 24, 1999.)
Article 18.—Utilization of Unused Medications

68-18-1. Transferring unused medications
(a) Each administrator or operator of an adult care home, pharmacist-in-charge of a mail service pharmacy, and administrator of a medical care facility who wants to become a donating entity, as defined in L. 2008, ch. 9, sec. 2 and amendments thereto, shall submit to the board written notification of intent to participate in the unused medications program. The notification shall be submitted on a form approved by the board.
(b) Before the transfer of each unused medication to a qualifying center or clinic, each mail service pharmacy and medical care facility that has become a donating entity as specified in subsection (a) shall perform the following:
   (1) Determine the quality and suitability of each unused medication by a pharmacist’s verification that the unused medication meets the following requirements:
      (A) Can be identified;
      (B) is in the manufacturer’s sealed container, a pharmacy unit-dose package, or a hermetically sealed tamper evident package from the pharmacy;
      (C) has not passed its beyond-use date;
      (D) is not a controlled substance;
      (E) has not been adulterated; and
      (F) is not a medication that can be dispensed only to a patient or resident registered with the drug manufacturer;
   (2) remove the name of the patient or resident and all of the patient’s or resident’s personal identifiers in order to protect confidentiality;
   (3) consult with the qualifying center or clinic to determine whether the qualifying center or clinic is willing to accept each unused medication; and
   (4) ensure that the qualifying center or clinic has a consulting pharmacist and is registered with the board to accept unused medications.
(c) Before the transfer of each unused medication to a qualifying center or clinic, each adult care home that has become a donating entity as specified in subsection (a) shall meet the requirements specified in paragraphs (b)(2), (3), and (4).
(d) When a donating entity transfers an unused medication to a qualifying center or clinic, the donating entity shall meet the following requirements:
   (1) Complete a manifest on a form approved by the board; and
   (2) include a copy of the manifest with the unused medications.
(e) Each donating entity shall maintain a copy of the manifest that the donating entity provided to the qualifying center or clinic for at least five years. The donating entity shall also maintain a copy of the manifest that was signed and returned by the qualifying center or clinic for at least five years.
(f) A donating entity shall not transfer an unused medication that can be dispensed only to a patient or resident registered with the drug manufacturer.
(Authorized by and implementing L. 2008, ch. 9, §7; effective Jan. 2, 2009.)

(a) Each qualifying center or clinic that elects to participate in the unused medications program shall submit to the board written notification of intent to participate on a form approved by the board.
(b) Each qualifying center or clinic shall maintain all unused medications in a storage unit with controlled access.

(c) After the acceptance of each unused medication from an adult care home that has become a donating entity as specified in K.A.R. 68-18-1(a), each qualifying center or clinic shall perform the following:

(1) Determine the quality and suitability of each unused medication by verification of a pharmacist that the unused medication meets the following requirements, in addition to the requirements of L. 2008, ch. 9, sec. 4 and amendments thereto:
   (A) Can be identified; and
   (B) is not a medication that can be dispensed only to a patient or resident registered with the drug manufacturer;

(2) ensure that the name of the patient or resident and all of the patient’s or resident’s personal identifiers have been removed in order to protect confidentiality;

(3) check each unused medication against the manifest to resolve any discrepancies with the donating entity; and

(4) complete the manifest and return a copy of the manifest to the donating entity.

(d) After the acceptance of each unused medication from a mail service pharmacy or a medical care facility that has become a donating entity as specified in K.A.R. 68-18-1(a), each qualifying center or clinic shall perform the following:

(1) Determine the quality and suitability of each unused medication by the verification of a pharmacist or practitioner that the unused medication meets the following requirements, in addition to the requirements of L. 2008, ch. 9, sec. 4 and amendments thereto:
   (A) Can be identified; and
   (B) is not a medication that can be dispensed only to a patient or resident registered with the drug manufacturer; and

(2) meet all of the requirements specified in paragraphs (c)(2), (3), and (4).

(e) Each qualifying center or clinic shall maintain a copy of the manifest that was provided by the donating entity for at least five years. The qualifying center or clinic shall also maintain a copy of the manifest signed and returned to the donating agency for at least five years.

(f) A qualifying center or clinic shall not accept or dispense an unused medication that can be dispensed only to a patient or resident registered with the drug manufacturer.

(Authorized by and implementing L. 2008, ch. 9, §7; effective Jan. 2, 2009.)


(a) If an unused medication is recalled and the qualifying center or clinic does not have the lot number on the label to differentiate between the recalled medications and the nonrecalled medications, all of the unused medications shall be destroyed.

(b) If a donating entity has transferred an unused medication to a qualifying center or clinic, the medication is subsequently recalled, and the donating entity has been notified of the recall, the donating entity shall be responsible for notifying the qualifying center or clinic of the recall.

(c) Each qualifying center or clinic in possession of any unused medication that is expired, adulterated, or recalled shall make a manifest for and destroy that medication.

(d) Following the destruction of any unused medications, the manifest shall be signed by the consulting pharmacist and a witness to verify the destruction. Each drug destruction manifest shall be maintained for at least five years.

(Authorized by and implementing L. 2008, ch. 9, §7; effective Jan. 2, 2009.)
Article 19-Continuous Quality Assurance Programs

68-19-1. Minimum program requirements.
Each pharmacy's continuous quality improvement program shall meet the following minimum requirements:
(a) Meet at least once each quarter of each calendar year;
(b) have the pharmacy's pharmacist-in-charge in attendance at each meeting; and
(c) perform the following during each meeting:
(1) Review all incident reports generated for each reportable event associated with that pharmacy since the last quarterly meeting;
(2) for each incident report reviewed, establish the steps taken or to be taken to prevent a recurrence of the incident;
(3) review each board newsletter published since the last quarterly meeting; and
(4) create a report of the meeting, including at least the following information:
(A) A list of the persons in attendance;
(B) a list of the incident reports and newsletters reviewed; and
(C) a description of the steps taken or to be taken to prevent recurrence of each incident reviewed.
(Authorized by and implementing K.S.A. 65-1695; effective April 10, 2009; amended November 29, 2019.)
Article 22. — Electronic Supervision of Medical Care Facility’s Pharmacy Personnel

68-22-1. Definitions.
(a) “Medical care facility” shall have the meaning provided in K.S.A. 65-1626(w), and amendments thereto.
(b) “Pharmacy student” shall have the meaning provided in K.S.A. 65-1626(ee), and amendments thereto, and shall include a pharmacy intern registered with the board.
(c) “Pharmacy technician” shall have the meaning provided in K.S.A. 65-1626(ff), and amendments thereto.
(d) “Real-time,” when used to describe the transmission of information through data, video, and audio links, shall mean that the transmission is sufficiently rapid that the information is available simultaneously to the electronically supervising pharmacist and the pharmacy student or pharmacy technician being electronically supervised in the medical care facility’s pharmacy.
(e) “Electronic supervision” shall mean the oversight provided by a pharmacist licensed in Kansas and supervising, by means of real-time communication equipment that meets the operating requirements listed in K.A.R. 68-22-5, a registered pharmacy student or pharmacy technician who is working in a Kansas medical care facility’s pharmacy.


The pharmacist in charge of any medical care facility’s pharmacy located in Kansas and registered by the board who wants to seek approval for electronic supervision of a pharmacy student or pharmacy technician in that medical care facility pharmacy shall submit an application to the board. Each application shall be submitted on a form provided by the board and shall include the following:
(a) Identifying information concerning the applying medical care facility’s pharmacy;
(b) the type and operational capabilities of the computer, video, and communication systems to be used for the electronic supervision; and
(c) a copy of the electronic supervision procedures manual and training manual approved by the pharmacist in charge of the medical care facility’s pharmacy.


68-22-3. Prior approval and training required.
(a) The pharmacist in charge of a medical care facility’s pharmacy shall not permit a pharmacy student or pharmacy technician to be in the pharmacy working under electronic supervision unless the pharmacy has a current approval for electronic supervision from the board.
(b) The pharmacist in charge of a medical care facility’s pharmacy shall not permit a pharmacy student or pharmacy technician to be in the pharmacy working under electronic supervision before completing the pharmacy’s electronic supervision training course.

68-22-4. Electronic supervision.
(a) Only a pharmacist licensed by the board may electronically supervise a pharmacy student or pharmacy technician working in a medical care facility’s pharmacy.
(b) A pharmacist licensed by the board may be electronically connected to multiple medical care facility pharmacies at one time for the purpose of electronically supervising.
(c) A pharmacist licensed by the board may electronically supervise no more than one pharmacy technician working in any medical care facility’s pharmacy at one time.
(d) No more than one pharmacy student or pharmacy technician that is being electronically supervised may work in a medical care facility’s pharmacy at one time.
(e) Electronic supervision conducted in conformance with these regulations shall constitute direct supervision.


68-22-5. Minimum operating requirements.
(a) A pharmacy student or pharmacy technician may enter the pharmacy without a pharmacist present for purposes of turning on the data, video, or audio links and determining if a pharmacist is available for electronic supervision.
(b) Electronic supervision shall not be permitted if an interruption occurs in any of the data, video, or audio links. Whenever an interruption in any of the data, video, or audio links occurs, no medication order shall be filled or dispensed using electronic supervision.
(c) Data entry may be performed by the electronically supervising pharmacist or the pharmacy student or pharmacy technician being electronically supervised. Each entry performed by an electronically supervised pharmacy student or pharmacy technician shall be verified by the electronically supervising pharmacist before the drug leaves the pharmacy.
(d) All medication orders processed by a pharmacy student or a pharmacy technician being electronically supervised shall be capable of being displayed on a computer terminal at both the location of the electronically supervising pharmacist and the medical care facility’s pharmacy. The quality of the image viewed by the pharmacist shall be sufficient for the pharmacist to be able to determine the accuracy of the work of the pharmacy student or pharmacy technician.
(e) All patient demographic information shall be viewable in real time at both the location of the electronically supervising pharmacist and the medical care facility’s pharmacy.
(f) Before a drug leaves the medical care facility’s pharmacy, all of the following requirements shall be met:
   (1) The electronically supervising pharmacist shall utilize the data, audio, and video links and review the patient profile, the original scanned medication order, and the drug to be dispensed to ensure accuracy.
   (2) The supervising pharmacist, pharmacy student, or pharmacy technician shall cause an electronic or paper image of the medication order and the drug, as seen by the electronically supervising pharmacist, to be captured and retained in the electronic or paper records of the medical care facility’s pharmacy for the same time period as that required for the written medication order.
   (3) The supervising pharmacist, pharmacy student, or pharmacy technician shall cause a paper or electronic record that includes the patient’s name, the medication order number, the name of the pharmacy student or pharmacy technician, and the name of the electronically supervising pharmacist to be made.
(4) The pharmacist in charge of the medical care facility’s pharmacy shall ensure that controls exist to protect the privacy and security of confidential records.

(5) The supervising pharmacist, pharmacy student, or pharmacy technician shall cause a permanent digital record of all duties electronically supervised and all data transmissions associated with the electronic supervision to be made. Each record shall be maintained for at least five years.

III. Controlled Substances Act - Statutes

Chapter 65.—Public Health
Article 41.- Controlled Substances
Uniform Controlled Substances Act

65-4101. Definitions.
As used in this act:
(a) "Administer" means the direct application of a controlled substance, whether by injection, inhalation, ingestion or any other means, to the body of a patient or research subject by:
(1) A practitioner or pursuant to the lawful direction of a practitioner; or
(2) the patient or research subject at the direction and in the presence of the practitioner.
(b) "Agent" means an authorized person who acts on behalf of or at the direction of a manufacturer, distributor or dispenser. “Agent” does not include a common carrier, public warehouseman or employee of the carrier or warehouseman.
(c) "Application service provider" means an entity that sells electronic prescription or pharmacy prescription applications as a hosted service where the entity controls access to the application and maintains the software and records on its server.
(d) "Board" means the state board of pharmacy.
(e) "Bureau" means the bureau of narcotics and dangerous drugs, United States department of justice, or its successor agency.
(f) "Controlled substance" means any drug, substance or immediate precursor included in any of the schedules designated in K.S.A. 65-4105, 65-4107, 65-4109, 65-4111 and 65-4113, and amendments thereto.
(g) (1) "Controlled substance analog" means a substance that is intended for human consumption, and at least one of the following:
(A) The chemical structure of the substance is substantially similar to the chemical structure of a controlled substance listed in or added to the schedules designated in K.S.A. 65-4105 or 65-4107, and amendments thereto;
(B) the substance has a stimulant, depressant or hallucinogenic effect on the central nervous system substantially similar to the stimulant, depressant or hallucinogenic effect on the central nervous system of a controlled substance included in the schedules designated in K.S.A. 65-4105 or 65-4107, and amendments thereto; or
(C) with respect to a particular individual, such individual represents or intends the substance to have a stimulant, depressant or hallucinogenic effect on the central nervous system substantially similar to the stimulant, depressant or hallucinogenic effect on the central nervous system of a controlled substance included in the schedules designated in K.S.A. 65-4105 or 65-4107, and amendments thereto.
(2) "Controlled substance analog" does not include:
(A) A controlled substance;
(B) a substance for which there is an approved new drug application; or
(C) a substance with respect to which an exemption is in effect for investigational use by a particular person under section 505 of the federal food, drug and cosmetic act, 21 U.S.C. § 355, to the extent conduct with respect to the substance is permitted by the exemption.
(h) "Counterfeit substance" means a controlled substance that, or the container or labeling of which, without authorization bears the trademark, trade name or other identifying mark, imprint,
number or device or any likeness thereof of a manufacturer, distributor or dispenser other than the
person who in fact manufactured, distributed or dispensed the substance.

(i) "Cultivate" means the planting or promotion of growth of five or more plants that contain or
can produce controlled substances.

(j) "DEA" means the U.S. department of justice, drug enforcement administration.

(k) "Deliver" or "delivery" means the actual, constructive or attempted transfer from one person
to another of a controlled substance, whether or not there is an agency relationship.

(l) "Dispense" means to deliver a controlled substance to an ultimate user or research subject by
or pursuant to the lawful order of a practitioner, including the packaging, labeling or compounding
necessary to prepare the substance for that delivery, or pursuant to the prescription of a mid-level
practitioner.

(m) "Dispenser" means a practitioner or pharmacist who dispenses, or a physician assistant who
has authority to dispense prescription-only drugs in accordance with K.S.A. 65-28a08(b), and
amendments thereto.

(n) "Distribute" means to deliver other than by administering or dispensing a controlled substance.

(o) "Distributor" means a person who distributes.

(p) (1) "Drug" means substances:

(A) Recognized as drugs in the official United States pharmacopeia, official homeopathic
pharmacopoeia of the United States or official national formulary or any supplement to any of them;

(B) intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease in human
or animals;

(C) other than food intended to affect the structure or any function of the body of human or
animals; and

(D) intended for use as a component of any article specified in subparagraph (A), (B) or (C).

(2) "Drug" does not include devices or their components, parts or accessories.

(q) "Immediate precursor" means a substance that the board has found to be and by rule and
regulation designates as being the principal compound commonly used or produced primarily for use
and that is an immediate chemical intermediary used or likely to be used in the manufacture of a
controlled substance, the control of which is necessary to prevent, curtail or limit manufacture.

(r) "Electronic prescription" means an electronically prepared prescription that is authorized and
transmitted from the prescriber to the pharmacy by means of electronic transmission.

(s) "Electronic prescription application" means software that is used to create electronic
prescriptions and that is intended to be installed on the prescriber's computers and servers where access
and records are controlled by the prescriber.

(t) "Electronic signature" means a confidential personalized digital key, code, number or other
method for secure electronic data transmissions that identifies a particular person as the source of the
message, authenticates the signatory of the message and indicates the person's approval of the
information contained in the transmission.

(u) "Electronic transmission" means the transmission of an electronic prescription, formatted as an
electronic data file, from a prescriber's electronic prescription application to a pharmacy's computer,
where the data file is imported into the pharmacy prescription application.

(v) "Electronically prepared prescription" means a prescription that is generated using an
electronic prescription application.

(w) "Facsimile transmission" or "fax transmission" means the transmission of a digital image of a
prescription from the prescriber or the prescriber's agent to the pharmacy. "Facsimile transmission"
includes, but is not limited to, transmission of a written prescription between the prescriber's fax
machine and the pharmacy's fax machine; transmission of an electronically prepared prescription from
the prescriber's electronic prescription application to the pharmacy's fax machine, computer or printer; 
or transmission of an electronically prepared prescription from the prescriber's fax machine to the 
pharmacy's fax machine, computer or printer.

(x) "Intermediary" means any technology system that receives and transmits an electronic 
prescription between the prescriber and the pharmacy.

(y) "Isomer" means all enantiomers and diastereomers.

(z) "Manufacture" means the production, preparation, propagation, compounding, conversion or 
processing of a controlled substance either directly or indirectly or by extraction from substances of 
natural origin or independently by means of chemical synthesis or by a combination of extraction and 
chemical synthesis and includes any packaging or repackaging of the substance or labeling or 
relabeling of its container, except that this term does not include the preparation or compounding of a 
controlled substance by an individual for the individual's own lawful use or the preparation, 
compounding, packaging or labeling of a controlled substance:

(1) By a practitioner or the practitioner's agent pursuant to a lawful order of a practitioner as an 
incident to the practitioner's administering or dispensing of a controlled substance in the course of the 
practitioner's professional practice; or

(2) by a practitioner or by the practitioner's authorized agent under such practitioner's supervision 
for the purpose of or as an incident to research, teaching or chemical analysis or by a pharmacist or 
medical care facility as an incident to dispensing of a controlled substance.

(aa) "Marijuana" means all parts of all varieties of the plant Cannabis whether growing or not, the 
seeds thereof, the resin extracted from any part of the plant and every compound, manufacture, salt, 
derivative, mixture or preparation of the plant, its seeds or resin. It does not include:

(1) The mature stalks of the plant, fiber produced from the stalks, oil or cake made from the seeds 
of the plant, any other compound, manufacture, salt, derivative, mixture or preparation of the mature 
stalks, except the resin extracted therefrom, fiber, oil or cake or the sterilized seed of the plant that is 
incapable of germination;

(2) any substance listed in schedules II through V of the uniform controlled substances act;

(3) drug products approved by the United States food and drug administration as of the effective 
date of this act;

(4) cannabidiol (other trade name: 2-[(3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-
pentyl-1,3-benzenediol); or

(5) industrial hemp as defined in K.S.A. 2-3901, and amendments thereto, when cultivated, 
produced, possessed or used for activities authorized by the commercial industrial hemp act.

(bb) "Medical care facility" shall have the meaning ascribed to that term in K.S.A. 65-425, and 
amendments thereto.

(cc) "Mid-level practitioner" means a certified nurse-midwife engaging in the independent practice 
of midwifery under the independent practice of midwifery act, an advanced practice registered nurse 
issued a license pursuant to K.S.A. 65-1131, and amendments thereto, who has authority to prescribe 
drugs under K.S.A. 65-1130, and amendments thereto, or a physician assistant licensed under the 
physician assistant licensure act who has authority to prescribe drugs pursuant to a written agreement 
with a supervising physician under K.S.A. 65-28a08, and amendments thereto.

(dd) "Narcotic drug" means any of the following whether produced directly or indirectly by 
extraction from substances of vegetable origin or independently by means of chemical synthesis or by 
a combination of extraction and chemical synthesis:

(1) Opium and opiate and any salt, compound, derivative or preparation of opium or opiate;
(2) any salt, compound, isomer, derivative or preparation thereof that is chemically equivalent or identical with any of the substances referred to in paragraph (1) but not including the isoquinoline alkaloids of opium;

(3) opium poppy and poppy straw;

(4) coca leaves and any salt, compound, derivative or preparation of coca leaves, and any salt, compound, isomer, derivative or preparation thereof that is chemically equivalent or identical with any of these substances, but not including decocainized coca leaves or extractions of coca leaves that do not contain cocaine or ecgonine.

(ee) "Opiate" means any substance having an addiction-forming or addiction-sustaining liability similar to morphine or being capable of conversion into a drug having addiction-forming or addiction-sustaining liability. It does not include, unless specifically designated as controlled under K.S.A. 65-4102, and amendments thereto, the dextrorotatory isomer of 3-methoxy-n-methylmorphinan and its salts (dextromethorphan). It does include its racemic and levorotatory forms.

(ff) "Opium poppy" means the plant of the species Papaver somniferum l. except its seeds.

(gg) "Person" means an individual, corporation, government, or governmental subdivision or agency, business trust, estate, trust, partnership or association or any other legal entity.

(hh) "Pharmacist" means any natural person licensed under K.S.A. 65-1625 et seq., and amendments thereto, to practice pharmacy.

(ii) "Pharmacist intern" means: (1) A student currently enrolled in an accredited pharmacy program; (2) a graduate of an accredited pharmacy program serving such person's internship; or (3) a graduate of a pharmacy program located outside of the United States that is not accredited and who had successfully passed equivalency examinations approved by the board.

(jj) "Pharmacy prescription application" means software that is used to process prescription information, is installed on a pharmacy's computers and servers, and is controlled by the pharmacy.

(kk) "Poppy straw" means all parts, except the seeds, of the opium poppy, after mowing.

(ll) "Practitioner" means a person licensed to practice medicine and surgery, dentist, podiatrist, veterinarian, optometrist, or scientific investigator or other person authorized by law to use a controlled substance in teaching or chemical analysis or to conduct research with respect to a controlled substance.

(mm) "Prescriber" means a practitioner or a mid-level practitioner.

(nn) "Production" includes the manufacture, planting, cultivation, growing or harvesting of a controlled substance.

(oo) "Readily retrievable" means that records kept by automatic data processing applications or other electronic or mechanized recordkeeping systems can be separated out from all other records within a reasonable time not to exceed 48 hours of a request from the board or other authorized agent or that hard-copy records are kept on which certain items are asterisked, redlined or in some other manner visually identifiable apart from other items appearing on the records.

(pp) "Ultimate user" means a person who lawfully possesses a controlled substance for such person's own use or for the use of a member of such person's household or for administering to an animal owned by such person or by a member of such person's household.

65-4101a.  

65-4101b.  

65-4101c.  

65-4101d.  

65-4102.  
**Board of pharmacy to administer act; authority to control; report to speaker of house and president of senate on substances proposed for scheduling, rescheduling or deletion; scheduling of the controlled substance analog.**

(a) The board shall administer this act and may adopt rules and regulations relating to the registration and control of the manufacture, distribution and dispensing of controlled substances within this state. All rules and regulations of the board shall be adopted in conformance with article 4 of chapter 77 of the Kansas Statutes Annotated, and amendments thereto, and the procedures prescribed by this act.

(b) Annually, the board shall submit to the speaker of the house of representatives and the president of the senate a report on substances proposed by the board for scheduling, rescheduling or deletion by the legislature with respect to any one of the schedules as set forth in this act and a report of the substances scheduled during the preceding calendar year under subsection (e), if any, along with the reasons for the proposal and the scheduling. In making a determination regarding the proposal to schedule, reschedule or delete a substance, the board shall consider the following:

1. The actual or relative potential for abuse;
2. the scientific evidence of its pharmacological effect, if known;
3. the state of current scientific knowledge regarding the substance;
4. the history and current pattern of abuse;
(5) the scope, duration and significance of abuse;
(6) the risk to the public health;
(7) the potential of the substance to produce psychological or physiological dependence liability; and
(8) whether the substance is an immediate precursor of a substance already controlled under this article.

c) The board shall not include any nonnarcotic substance within a schedule if such substance may be lawfully sold over the counter without a prescription under the federal food, drug and cosmetic act.

d) Authority to control under this section does not extend to distilled spirits, wine, malt beverages or tobacco.

e) (1) Upon receipt of notice under K.S.A. 2017 Supp. 21-5715, and amendments thereto, or upon the board's finding of an imminent hazard to the public safety, the board shall initiate scheduling of the controlled substance analog or a new drug, as defined in this subsection, on an emergency basis pursuant to this subsection. The scheduling of a substance under this subsection expires on July 1 of the following calendar year after the adoption of the scheduling rule and regulation.

(2) With respect to the finding of an imminent hazard to the public safety, the board shall consider whether the substance has been scheduled on a temporary basis under federal law or factors set forth in subsections (b)(4), (5) and (6), and may also consider clandestine importation, manufacture or distribution, and if available, information concerning the other factors set forth in subsection (b).

(3) A rule and regulation may not be adopted under this subsection until the board initiates a rulemaking proceeding under subsection (a) with respect to the substance. A rule and regulation adopted under this subsection shall expire on July 1 of the calendar year following the year of its adoption.

(4) As used in this subsection, "new drug" means: (A) Any drug the composition of which is such that such drug is not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, as safe and effective for use under the conditions prescribed, recommended or suggested in the labeling thereof; or (B) any drug the composition of which is such that such drug, as a result of investigations to determine its safety and effectiveness for use under such conditions, has become so recognized, but that has not, other than in such investigations, been used to a material extent or for a material time under such conditions. The term "new drug" shall not include amygdalin (laetrile).


The controlled substances listed or to be listed in the schedules in K.S.A. 65-4105, 65-4107, 65-4109, 65-4111 and 65-4113 are included by whatever official, common, usual, chemical, or trade name designated.

History: L. 1972, ch. 234, § 3; July 1.

65-4104.

65-4105. Substances included in schedule I.

(a) The controlled substances listed in this section are included in schedule I and the number set forth opposite each drug or substance is the DEA controlled substances code that has been assigned to it.

(b) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation:

(1) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide) 9821
(2) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide) 9815
(3) Acetylmethadol 9601
(4) Acrylfentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide; acryloylfentanyl) 9811
(5) AH-7921 (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide) 9551
(6) Allylprodine 9602
(7) Alphacetylmethadol 9603
(8) Alphameprodine 9604
(9) Alphamethadol 9605
(10) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl] propionanilide; 1-(1-methyl-2-phenethyl)-4-(N-propanilido) piperidine) 9814
(11) Alpha-methylthiofentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N-phenylpropanamide) 9832
(12) Benzethidine 9606
(13) Betacetylmethadol (except levo-alphacetylmethadol, levomethadyl acetate or LAAM) 9607
(14) Betameprodine 9608
(15) Betamethadol 9609
(16) Betaprodine 9611
(17) Butyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide) 9822
(21) Clonitazene 9612
(22) Crotonyl fentanyl ((E)-N-(1-phenethylpiperidin-4-yl)-N-phenylbut-2-enamide) 9844
(23) Cyclopentyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide) 9847
(24) Cyclopropyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide) 9845
(25) Dextromoramide 9613
(26) Diampromide 9615
(27) Diethylthiambutene 9616
(28) Difenoxin 9617
(29) Dimenoxadol 9618
(30) Dimepheptanol 9619
(31) Dimethylthiambutene 9621
(32) Dioxaphethyl butyrate 9622
(33) Dipipanone 9623
(34) Ethylmethylthiambutene 9624
(35) Etonitazene 9625
(36) Etoxeridine 9626
(37) Furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide)
(38) Furethidine
(39) Hydroxypethidine
(40) Isotominazene (N,N-diethyl-2-(2-(4-isopropoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine; N,N-diethyl-2-[4-(1-methylethoxy)phenyl][methy])-5-nitro-1H-benzimidazole-1-ethanamine)
(41) Isobutyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide)
(42) Ketoheptazine
(43) Levomoramide
(45) Methoxyacetyl fentanyl (2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide)
(46) 3-Methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-phenylpropanamide)
(47) 3-Methylthiofentanyl (N-[3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide)
(48) Morpheridine
(49) Ocfentanil (N-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpiperidin-4-yl)acetamide)
(50) O-desmethyltramadol
Some trade or other names: 2-((dimethylamino)methyl-1-(3-hydroxyphenyl)cyclohexanol; 3-(2-((dimethylamino)methyl)-1-hydroxycyclohexyl)phenol
(51) MPPP (1-methyl-4-phenyl-4-propionoxyxypiperidine)
(52) MT-45 (1-cyclohexyl-4-(1,2-diphenylethyl)piperazine)
(53) Noracymethadol
(54) Norlevorphanol
(55) Normethadone
(56) Norpipanone
(57) Ortho-fluorofentanyl (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide; 2-fluorofentanyl)
(58) Para-chloroisobutryl fentanyl (N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide)
(59) Para-fluorobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide)
(60) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenyl)-4-piperidinyl]propanamide)
(61) Para-fluoroisobutryl fentanyl (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide, 4-fluoroisobutryl fentanyl)
(62) Para-methoxybutyryl fentanyl (N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide)
(63) PEPAP (1-[(2-phenethyl)-4-phenyl-4-acetoxyxypiperidine)
(64) Phenadoxone
(65) Phenampromide
(66) Phenomorphinan
(67) Phenoperidine
(68) Piritramide
(69) Proheptazine
(70) Properidine
(71) Propiram
(72) Racemoramide
(73) Tetrahydrofuranyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofur-an-2-carboxamide)
(74) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]propanamide
(75) Tilidine
(76) Trimeperidine
(77) U-47700 (3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide)
(78) Valeryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylpentanamide)
(c) Any of the following opium derivatives, their salts, isomers and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers and salts of isomers is possible within the specific chemical designation:

1. Acetorphine (9319)
2. Acetyldihydrocodeine (9051)
3. Benzylmorphine (9052)
4. Brorphine (9098)
5. Codeine methylbromide (9070)
6. Codeine-N-Oxide (9053)
7. Cyprenorphine (9054)
8. Desomorphine (9055)
9. Dihydromorphine (9145)
10. Drotebanol (9335)
11. Etorphine (except hydrochloride salt) (9056)
12. Heroin (9200)
13. Hydromorphinol (9301)
14. Methyldesorphine (9302)
15. Methyldihydromorphine (9304)
16. Morphine methylbromide (9305)
17. Morphine methylsulfonate (9306)
18. Morphine-N-Oxide (9307)
19. Myrophine (9308)
20. Nicocodeine (9309)
21. Nicomorphine (9312)
22. Normorphine (9313)
23. Pholcodine (9314)
24. Thebacon (9315)

(d) Any material, compound, mixture or preparation that contains any quantity of the following hallucinogenic substances, their salts, isomers and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers and salts of isomers is possible within the specific chemical designation:

1. Alpha-ethyltryptamine (7249)
   Some trade or other names: etryptamine; Monase; α-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole; α-ET; and AET.
2. 4-bromo-2,5-dimethoxy-amphetamine (7391)
   Some trade or other names: 4-bromo-2,5-dimethoxy-alpha-methylphenethylamine; 4-bromo-2,5-DMA.
3. 2,5-dimethoxyamphetamine (7396)
   Some trade or other names: 2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA.
4. 4-methoxyamphetamine (7411)
   Some trade or other names: 4-methoxy-alpha-methylphenethylamine; paramethoxyamphetamine; PMA.
5. 5-methoxy-3,4-methylenedioxy-amphetamine (7401)
6. 4-methyl-2,5-dimethoxy-amphetamine (7395)
   Some trade or other names: 4-methyl-2,5-dimethoxy-alpha-methylphenethylamine; "DOM"; and "STP".
7. 3,4-methylenedioxy amphetamine (7400)
8. 3,4-methylenedioxyamphetamine (MDMA) (7405)
9. 3,4-methylenedioxy-N-ethylamphetamine (also known as N-ethyl-alpha-methyl-3,4 (methylenedioxy) phenethylamine, N-ethyl MDA, MDE, and MDEA) (7404)
(10) N-hydroxy-3,4-methylenedioxyamphetamine (also known as N-hydroxy-alpha-methyl-3,4-(methylenedioxy)phenethylamine, and N-hydroxy MDA)  
(11) 3,4,5-trimethoxyamphetamine  
(12) Bufotenine  
Some trade or other names: 3-(Beta-Dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminoethyl)-5-indolol; N,N-dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine; mappine.  
(13) Diethyltryptamine  
Some trade or other names: N,N-Diethyltryptamine; DET.  
(14) Dimethyltryptamine  
Some trade or other names: DMT.  
(15) Ibogaine  
Some trade or other names: 7-Ethyl-6,6 Beta,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyrido[1',2':1,2]azepino[5,4-b]indole; Tabernanthe iboga  
(16) Lysergic acid diethylamide  
(17) Marijuana  
(18) Mescaline  
(19) Parahexyl  
Some trade or other names: 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran; Synhexyl.  
(20) Peyote  
Meaning all parts of the plant presently classified botanically as Lophophora williamsii Lemaire, whether growing or not, the seeds thereof, any extract from any part of such plant, and every compound, manufacture, salts, derivative, mixture or preparation of such plant, its seeds or extracts.  
(21) N-ethyl-3-piperidyl benzilate  
(22) N-methyl-3-piperidyl benzilate  
(23) Psilocybin  
(24) Psilocyn  
Some trade or other names: Psilocin.  
(25) Ethylamine analog of phencyclidine  
Some trade or other names: N-ethyl-1-phenyl-cyclo-hexylamine; (1-phenylcyclohexyl)ethylamine; N-(1-phenylcyclohexyl)ethylamine; cyclohexamine; PCE.  
(26) Pyrrolidine analog of phencyclidine  
Some trade or other names: 1-(1-phenylcyclohexyl)-pyrrolidine; PCPy; PHP  
(27) Thiophene analog of phencyclidine  
Some trade or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine; 2-thienyl analog of phencyclidine; TPCP; TCP  
(28) 1-[1-(2-thienyl)-cyclohexyl] pyrrolidine  
Some other names: TCPy.  
(29) 2,5-dimethoxy-4-ethylamphetamine  
Some trade or other names: DOET.  
(30) Salvia divinorum or salvinorum A; all parts of the plant presently classified botanically as salvia divinorum, whether growing or not, the seeds thereof, any extract from any part of such plant, and every compound, manufacture, salts, derivative, mixture or preparation of such plant, its seeds or extracts.  
(31) Datura stramonium, commonly known as gypsum weed or jimson weed; all parts of the plant presently classified botanically as datura stramonium, whether growing or not, the seeds thereof, any extract from any part of such plant, and every compound, manufacture, salts, derivative, mixture or preparation of such plant, its seeds or extracts.  
(32) N-benzylpiperazine  
Some trade or other names: BZP  
(33) 1-(3-[trifluoromethylphenyl]piperazine  
Some trade or other names: TFMPP.  
(34) 4-Bromo-2,5-dimethoxyphenethylamine
the specific chemical designation:

salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within
substances having a depressant effect on the central nervous system, including its salts, isomers, and
mixture or preparation that contains any quantity of the following substances having a stimulant effect

(f) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation that contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers:  

(1) 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7), its optical isomers, salts and salts of optical isomers

(36) Alpha-methyltryptamine (other name: AMT)

(37) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT), its isomers, salts and salts of isomers

(38) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E)

(39) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D)

(40) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C)

(41) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I)

(42) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2)

(43) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4)

(44) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H)

(45) 2-(2,5-Dimethoxy-4-nitrophenyl)ethanamine (2C-N)

(46) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P)

(47) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT)

Some trade or other names: 5-methoxy-3-[2-(dimethylamino)ethyl]indole.

(48) 2-(4-ido-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine

Some trade or other names: 25I-NBOMe; 2C-I–NBOMe; 25I; Cimbi–5.

(49) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine

Some trade or other names: 25C–NBOMe; 2C–C–NBOMe; 25C; Cimbi–82.

(50) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine

Some trade or other names: 25B–NBOMe; 2C–B–NBOMe; 25B; Cimbi–36.

(51) 2-(2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine

Some trade or other names: 25H-NBOMe.

(52) 2-(2,5-dimethoxy-4-methylphenyl)-N-(2-methoxybenzyl)ethanamine

Some trade or other names: 25D-NBOMe; 2C-D-NBOMe.

(53) 2-(2,5-dimethoxy-4-nitrophenyl)-N-(2-methoxybenzyl)ethanamine

Some trade or other names: 25N-NBOMe; 2C-N-NBOMe.

(54) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3-carboxamide (5F-CUMYL-P7AICA)

(e) Any material, compound, mixture or preparation that contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:  

(1) Etizolam

Some trade or other names: (4-(2-chlorophenyl)-2-ethyl-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine)

(2) Mecloqualone

2572

(3) Methaqualone

2565

(4) Gamma hydroxybutyric acid

(f) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation that contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers and salts of isomers:

(1) Aminorex

Some other names: Aminoxaphen 2-amino-5-phenyl-2-oxazoline or 4,5-dihydro-5-phenyl-2-oxazolamine

1585

(2) Fenethylline

1503

(3) N-ethylamphetamine

1475

(4) (+)cis-4-methylaminorex ((+)(+)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine)

1590

(5) N,N-dimethylamphetamine (also known as N,N-alpha-trimethyl-benzeneethanamine; N,N-alpha-trimethylphenethylamine)

1480
(6) Cathinone (some other names: 2-amino-1-phenol-1-propanone, alpha-amino propiophenone, 2-amino propiophenone and norphedrone)

(7) Substituted cathinones
Any compound, except bupropion or compounds listed under a different schedule, structurally derived from 2–aminopropan–1–one by substitution at the 1-position with either phenyl, naphthyl, or thiophene ring systems, whether or not the compound is further modified in any of the following ways:

(A) By substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring system by one or more other univalent substituents;

(B) by substitution at the 3-position with an acyclic alkyl substituent;

(C) by substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or methoxybenzyl groups; or

(D) by inclusion of the 2-amino nitrogen atom in a cyclic structure.

(g) Any material, compound, mixture or preparation that contains any quantity of the following substances:

(1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl), its optical isomers, salts and salts of isomers

(2) N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl), its optical isomers, salts and salts of isomers

(h) Any of the following cannabinoids, their salts, isomers and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers and salts of isomers is possible within the specific chemical designation:

(1) Tetrahydrocannabinols
Meaning tetrahydrocannabinols naturally contained in a plant of the genus Cannabis (cannabis plant), as well as synthetic equivalents of the substances contained in the plant, or in the resinous extracts of Cannabis, sp. and/or synthetic substances, derivatives, and their isomers with similar chemical structure and pharmacological activity such as the following: Delta 1 cis or trans tetrahydrocannabinol, and their optical isomers Delta 6 cis or trans tetrahydrocannabinol, and their optical isomers Delta 3,4 cis or trans tetrahydrocannabinol, and its optical isomers (Since nomenclature of these substances is not internationally standardized, compounds of these structures, regardless of numerical designation of atomic positions covered.), except tetrahydrocannabinols in any of the following:

(A) Industrial hemp, as defined in K.S.A. 2-3901, and amendments thereto;

(B) solid waste, as defined in K.S.A. 65-3402, and amendments thereto, and hazardous waste, as defined in K.S.A. 65-3430, and amendments thereto, if such waste is the result of the cultivation, production or processing of industrial hemp, as defined in K.S.A. 2-3901, and amendments thereto, and such waste contains a delta-9 tetrahydrocannabinol concentration of not more than 0.3%; or

(C) hemp products, as defined in K.S.A. 2-3901, and amendments thereto, unless otherwise deemed unlawful pursuant to K.S.A. 2-3908, and amendments thereto.

(2) Naphthylpyrroloindoles
Any compound containing a 1H-indol-3-yl-(1-naphthyl) methanone structure with substitution at the nitrogen atom of the indole group by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted on the indole group to any extent and whether or not substituted on the benzyl or naphthyl ring to any extent.

(3) Naphthylindoles
Any compound containing a 3-(1-naphthyl)pyrrole structure with substitution at the nitrogen atom of the pyrrole group by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted on the pyrrole group to any extent, whether or not substituted on the benzyl or naphthyl ring to any extent.

(4) Naphthylmethylindenes
Any compound containing a naphthylmethylindene structure with substitution at the 3-position of the indene group by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted on the indene group to any extent, whether or not substituted on the benzyl or naphthyl ring to any extent.

(5) Cyclohexylphenols
Any compound containing a 2-(3-hydroxy cyclohexyl)phenol structure with substitution at the 5-position of the phenolic ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not substituted on the cyclohexyl ring to any extent.
(6) 2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethylone. Some trade or other names: WIN 55,212-2.

(7) 9-(hydroxymethyl)-6, 6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol Some trade or other names: HU-210, HU-211.

(8) Indole-3-carboxylate esters
Any compound containing a 1H-indole-3-carboxylate ester structure with the ester oxygen bearing a naphthyl, quinolinyl, isoquinolinyl or adamantlyl group and substitution at the 1 position of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)methyl group, whether or not further substituted on the indole ring to any extent and whether or not substituted on the naphthyl, quinolinyl, isoquinolinyl, adamantlyl or benzyl groups to any extent.

(9) Indazole-3-carboxamides
Any compound containing a 1H-indazole-3-carboxamide structure with substitution at the nitrogen of the carboxamide by a naphthyl, quinolinyl, isoquinolinyl, adamantlyl, benzyl, 1-amino-1-oxoalkan-2-yl or 1-alkoxy-1-oxoalkan-2-yl group and substitution at the 1 position of the indazole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)methyl group, whether or not further substituted on the indole ring to any extent and whether or not substituted on the naphthyl, quinolinyl, isoquinolinyl, adamantlyl, 1-amino-1-oxoalkan-2-yl, 1-alkoxy-1-oxoalkan-2-yl or benzyl groups to any extent.

(10) Indole-3-carboxamides
Any compound containing a 1H-indole-3-carboxamide structure with substitution at the nitrogen of the carboxamide by a naphthyl, quinolinyl, isoquinolinyl, adamantlyl, benzyl, 1-amino-1-oxoalkan-2-yl or 1-alkoxy-1-oxoalkan-2-yl group and substitution at the 1 position of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)methyl group, whether or not further substituted on the indole ring to any extent and whether or not further substituted on the naphthyl, quinolinyl, isoquinolinyl, adamantlyl, 1-amino-1-oxoalkan-2-yl, 1-alkoxy-1-oxoalkan-2-yl or benzyl groups to any extent.

(11) (1H-indazol-3-yl)methanones
Any compound containing a (1H-indazol-3-yl)methaneone structure with the carbonyl carbon bearing a naphthyl group and substitution at the 1 position of the indazole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)methyl group, whether or not further substituted on the indole ring to any extent and whether or not substituted on the naphthyl or benzyl groups to any extent.

(12) (1H-indol-3-yl)methanones
Any compound containing a (1H-indol-3-yl)methaneone structure with the carbonyl carbon bearing a naphthyl, quinolinyl, isoquinolinyl, adamantlyl, phenyl, benzyl or tetramethyleclolopropyl group and substitution at the 1 position of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted on the indole ring to any extent and whether or not substituted on the naphthyl, quinolinyl, isoquinolinyl, adamantlyl, phenyl, benzyl or tetramethyleclolopropyl groups to any extent.


65-4105b.
65-4106.  

65-4107. Substances included in schedule II.

(a) The controlled substances listed in this section are included in schedule II and the number set forth opposite each drug or substance is the DEA controlled substances code which has been assigned to it.

(b) Any of the following substances, except those narcotic drugs listed in other schedules, whether produced directly or indirectly by extraction from substances of vegetable origin or independently by means of chemical synthesis or by combination of extraction and chemical synthesis:

(1) Opium and opiate and any salt, compound, derivative or preparation of opium or opiate, excluding apomorphine, dextrophan, nalbuphine, nalmefene, naloxone, 6β-naltrexol and naltrexone and their respective salts, but including the following:

<table>
<thead>
<tr>
<th>Code</th>
<th>Substance</th>
</tr>
</thead>
<tbody>
<tr>
<td>9600</td>
<td>Raw opium</td>
</tr>
<tr>
<td>9610</td>
<td>Opium extracts</td>
</tr>
<tr>
<td>9620</td>
<td>Opium fluid</td>
</tr>
<tr>
<td>9639</td>
<td>Powdered opium</td>
</tr>
<tr>
<td>9640</td>
<td>Granulated opium</td>
</tr>
<tr>
<td>9630</td>
<td>Tincture of opium</td>
</tr>
<tr>
<td>9050</td>
<td>Codeine</td>
</tr>
<tr>
<td>9190</td>
<td>Ethylmorphine</td>
</tr>
<tr>
<td>9059</td>
<td>Etorphine hydrochloride</td>
</tr>
<tr>
<td>9193</td>
<td>Hydrocodone</td>
</tr>
<tr>
<td>9260</td>
<td>Metopon</td>
</tr>
<tr>
<td>9300</td>
<td>Morphine</td>
</tr>
<tr>
<td>9668</td>
<td>Noroxymorphone</td>
</tr>
<tr>
<td>9143</td>
<td>Oxycodone</td>
</tr>
<tr>
<td>9652</td>
<td>Oxymorphone</td>
</tr>
<tr>
<td>9333</td>
<td>Thebaine</td>
</tr>
<tr>
<td>9334</td>
<td>Dihydroetorphine</td>
</tr>
<tr>
<td>9330</td>
<td>Oripavine</td>
</tr>
</tbody>
</table>

(2) Any salt, compound, isomer, derivative or preparation thereof which is chemically equivalent or identical with any of the substances referred to in paragraph (1), but not including the isoquinoline alkaloids of opium.

(3) Opium poppy and poppy straw.

(4) Coca leaves (9040) and any salt, compound, derivative or preparation of coca leaves, but not including decocainized coca leaves or extractions which do not contain cocaine (9041) or ecgonine (9180).

(5) Cocaine, its salts, isomers and salts of isomers (9041).

(6) Ecgonine, its salts, isomers and salts of isomers (9180).

(7) Concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid or powder form which contains the phenanthrene alkaloids of the opium poppy) (9670).

(c) Any of the following opiates, including their isomers, esters, ethers, salts and salts of isomers, esters and ethers, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation dextrophan and levopropoxyphene excepted:
<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>(1)</td>
<td>Alfentanil</td>
</tr>
<tr>
<td>(2)</td>
<td>Alphaprodine</td>
</tr>
<tr>
<td>(3)</td>
<td>Anileridine</td>
</tr>
<tr>
<td>(4)</td>
<td>Bezitramide</td>
</tr>
<tr>
<td>(5)</td>
<td>Bulk dextropropoxyphene (nondosage forms)</td>
</tr>
<tr>
<td>(6)</td>
<td>Carfentanil</td>
</tr>
<tr>
<td>(7)</td>
<td>Dihydrocodeine</td>
</tr>
<tr>
<td>(8)</td>
<td>Diphenoxylate</td>
</tr>
<tr>
<td>(9)</td>
<td>Fentanyl</td>
</tr>
<tr>
<td>(10)</td>
<td>Isomethadone</td>
</tr>
<tr>
<td>(11)</td>
<td>Levomethorphan</td>
</tr>
<tr>
<td>(12)</td>
<td>Levorphanol</td>
</tr>
<tr>
<td>(13)</td>
<td>Metazocine</td>
</tr>
<tr>
<td>(14)</td>
<td>Methadone</td>
</tr>
<tr>
<td>(15)</td>
<td>Methadone-intermediate, 4-cyano-2-dimethyl amino-4,4-diphenyl butane</td>
</tr>
<tr>
<td>(16)</td>
<td>Moramide-intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane-carboxylic acid</td>
</tr>
<tr>
<td>(17)</td>
<td>Oliceridine (N-(3-methoxythiophen-2-yl)methyl) ((2)-(9 R)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl)ethyl)amine fumarate)</td>
</tr>
<tr>
<td>(18)</td>
<td>Pethidine (meperidine)</td>
</tr>
<tr>
<td>(19)</td>
<td>Pethidine-intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine</td>
</tr>
<tr>
<td>(20)</td>
<td>Pethidine-intermediate-B, ethyl-4-phenyl-piperidine-4-carboxylate</td>
</tr>
<tr>
<td>(21)</td>
<td>Pethidine-intermediate-C, 1-methyl-4-phenyl-piperidine-4-carboxylic acid</td>
</tr>
<tr>
<td>(22)</td>
<td>Phenazocine</td>
</tr>
<tr>
<td>(23)</td>
<td>Piminodine</td>
</tr>
<tr>
<td>(24)</td>
<td>Racemethorphan</td>
</tr>
<tr>
<td>(25)</td>
<td>Racemorphan</td>
</tr>
<tr>
<td>(26)</td>
<td>Sufentanil</td>
</tr>
<tr>
<td>(27)</td>
<td>Levo-alphacetyl methadol</td>
</tr>
<tr>
<td></td>
<td>Some other names: levo-alpha-acetyl methadol, levomethadyl acetate or LAAM</td>
</tr>
<tr>
<td>(28)</td>
<td>Remifentanil</td>
</tr>
<tr>
<td>(29)</td>
<td>Tapentadol</td>
</tr>
<tr>
<td>(30)</td>
<td>Thiafentanil</td>
</tr>
</tbody>
</table>

(d) Any material, compound, mixture, or preparation which contains any quantity of the following substances having a potential for abuse associated with a stimulant effect on the central nervous system:

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>(1)</td>
<td>Amphetamine, its salts, optical isomers and salts of its optical isomers</td>
</tr>
<tr>
<td>(2)</td>
<td>Phenmetrazine and its salts</td>
</tr>
<tr>
<td>(3)</td>
<td>Methamphetamine, including its salts, isomers and salts of isomers</td>
</tr>
<tr>
<td>(4)</td>
<td>Methylphenidate</td>
</tr>
<tr>
<td>(5)</td>
<td>Lisdexamfetamine, its salts, isomers, and salts of its isomers</td>
</tr>
</tbody>
</table>

(e) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers and salts of isomers whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation:

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>(1)</td>
<td>Amobarbital</td>
</tr>
<tr>
<td>(2)</td>
<td>Glutethimide</td>
</tr>
</tbody>
</table>
(f) Any material, compound, mixture, or preparation which contains any quantity of the following substances:

1. Immediate precursor to amphetamine and methamphetamine:
   (A) Phenylacetone
   Some trade or other names: phenyl-2-propanone; P2P; benzyl methyl ketone; methyl benzyl ketone.

2. Immediate precursors to phencyclidine (PCP):
   (A) 1-phenylcyclohexylamine
   (B) 1-piperidinocyclohexanecarbonitrile (PCC)

3. Immediate precursor to fentanyl:
   (A) 4-anilino-N-phenethylpiperidine (ANPP)
   (B) N-phenyl-N-(piperidin-4-yl)propionamide (norfentanyl)

(g) Any material, compound, mixture or preparation which contains any quantity of the following hallucinogenic substance, its salts, isomers and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers and salts of isomers is possible within the specific chemical designation:

1. Dronabinol [(+)-delta-9-trans-tetrahydrocannabinol] in an oral solution in a drug product approved for marketing by the United States food and drug administration

2. Nabilone
   [Another name for nabilone: (+)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-9H-dibenzo[b,d]pyran-9-one]

(h) Any material, compound, mixture or preparation containing any of the following narcotic drugs or any salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below:

1. Not more than 300 milligrams of dihydrocodeinone (hydrocodone) or any of its salts per 100 milliliters or not more than 15 milligrams per dosage unit with a fourfold or greater quantity of an isoquinoline alkaloid of opium

2. Not more than 300 milligrams of dihydrocodeinone (hydrocodone) or any of its salts per 100 milliliters or not more than 15 milligrams per dosage unit with one or more active, nonnarcotic ingredients in recognized therapeutic amounts


**65-4108.**

**History:** L. 1972, ch. 234, § 8; Repealed, L. 1982, ch. 269, § 9; July 1.

**65-4109. Substances included in schedule III.**

(a) The controlled substances listed in this section are included in schedule III and the number set forth opposite each drug or substance is the DEA controlled substances code which has been assigned to it.

(b) Unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a potential for abuse associated with a depressant effect on the central nervous system:

1. Any compound, mixture or preparation containing:
(A) Amobarbital
(B) Secobarbital
(C) Pentobarbital
or any salt thereof and one or more other active medicinal ingredients which are not listed in any schedule

(2) Any suppository dosage form containing:
(A) Amobarbital
(B) Secobarbital
(C) Pentobarbital
or any salt of any of these drugs and approved by the Food and Drug Administration for marketing only as a suppository.

(3) Any substance which contains any quantity of a derivative of barbituric acid, or any salt of a derivative of barbituric acid, except those substances which are specifically listed in other schedules

(4) Chlorhexadol

(5) Lysergic acid

(6) Lysergic acid amide

(7) Methyprylon

(8) Sulfondiethylmethane

(9) Sulfonethylmethane

(10) Sulfonmethane

(11) Tiletamine and zolazepam or any salt thereof
Some trade or other names for a tiletamine-zolazepam combination product: Telazol
Some trade or other names for tiletamine: 2-(ethylamino)-2-(2-thienyl)-cyclohexanone
Some trade or other names for zolazepam: 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-e][1,4]-diazepin-7(1H)-one, flupyrazapon

(12) Ketamine, its salts, isomers, and salts of isomers
Some other names for ketamine: (±)-2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone

(13) Gamma hydroxybutyric acid, any salt, hydroxybutyric compound, derivative or preparation of gamma hydroxybutyric acid contained in a drug product for which an application has been approved under section 505 of the federal food, drug and cosmetic act

(14) Embutramide

(15) Perampanel, its salts, isomers, and salts of isomers
Some other names for perampanel: 2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2 dihydropyridin-3-yl) benzonitrile

(c) Nalorphine

(d) Any material, compound, mixture or preparation containing any of the following narcotic drugs or any salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below:

(1) Not more than 1.8 grams of codeine or any of its salts per 100 milliliters or not more than 90 milligrams per dosage unit with an equal or greater quantity of an isouquinoline alkaloid of opium

(2) not more than 1.8 grams of codeine or any of its salts per 100 milliliters or not more than 90 milligrams per dosage unit with one or more active, nonnarcotic ingredients in recognized therapeutic amounts

(3) not more than 1.8 grams of dihydrocodeine or any of its salts per 100 milliliters or not more than 90 milligrams per dosage unit with one or more active, nonnarcotic ingredients in recognized therapeutic amounts

(4) not more than 300 milligrams of ethylmorphine or any of its salts per 100 milliliters or not more than 15 milligrams per dosage unit with one or more active, nonnarcotic ingredients in recognized therapeutic amounts

(5) not more than 300 milligrams of opium per 100 milliliters or per 100 grams or not more than 25 milligrams per dosage unit with one or more active, nonnarcotic ingredients in recognized therapeutic amounts

(6) not more than 50 milligrams of morphine or any of its salts per 100 milliliters or per 100 grams with one or more active, nonnarcotic ingredients in recognized therapeutic amounts

(7) any material, compound, mixture or preparation containing any of the following narcotic drugs or their salts, as set forth below:

(A) Buprenorphine
(e) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position or geometric) and salts of such isomers whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation:

(1) Those compounds, mixtures or preparations in dosage unit form containing any stimulant substance listed in schedule II, which compounds, mixtures or preparations were listed on August 25, 1971, as excepted compounds under section 308.32 of title 21 of the code of federal regulations, and any other drug of the quantitative composition shown in that list for those drugs or which is the same, except that it contains a lesser quantity of controlled substances

(2) Benzphetamine

(3) Chlorphentermine

(4) Chlorotermine

(5) Phendimetrazine

(f) Anabolic steroids

"Anabolic steroid" means any drug or hormonal substance, chemically and pharmacologically related to testosterone (other than estrogens, progestins, and corticosteroids) that promotes muscle growth, and includes:

(1) 3β,17-dihydroxy-5α-androstane

(2) 3α,17β-dihydroxy-5α-androstane

(3) 5α-androstan-3,17-dione

(4) 1-androstenediol (3β,17β-dihydroxy-5α-androst-1-ene)

(5) 1-androstenediol (3α,17β-dihydroxy-5α-androst-1-ene)

(6) 4-androstenediol (3β,17β-dihydroxy-androst-4-ene)

(7) 5-androstenediol (3β,17β-dihydroxy-androst-5-ene)

(8) 1-androstenedione ([5α]-androst-1-en-3,17-dione)

(9) 4-androstenedione (androst-4-en-3,17-dione)

(10) 5-androstenedione (androst-5-en-3,17-dione)

(11) bolasterone (7α,17α-dimethyl-17β-hydroxyandrost-4-en-3-one)

(12) boldenone (17β-hydroxyandrost-1,4-diene-3-one)

(13) boldione (androsta-1,4-diene-3,17-dione)

(14) calusterone (7β,17α-dimethyl-17β-hydroxyandrost-4-en-3-one)

(15) clostebol (4-chloro-17β-hydroxyandrost-4-en-3-one)

(16) dehydrochloromethyltestosterone (4-chloro-17β-hydroxy-17α-methyl-androst-1,4-dien-3-one)

(17) desoxymethyltestosterone (17α-methyl-5α-androst-2-en-17β-ol) (also known as "madol")

(18) Δ1-dihydrotestosterone (17β-hydroxy-5α-androst-1-en-3-one) (also known as "1-testosterone")

(19) 4-dihydrotestosterone (17β-hydroxy-androst-3-one)

(20) drostanolone (17β-hydroxy-2α-methyl-5α-androstan-3-one)

(21) ethylestrenol (17α-ethyl-17β-hydroxyestr-4-ene)

(22) fluoxymesterone (9-fluoro-17α-methyl-11β,17β-dihydroxyandrost-4-en-3-one)

(23) formebolone (2-formyl-17α-methyl-11α,17β-dihydroxyandrost-1,4-dien-3-one)

(24) furazabol (17α-methyl-17β-hydroxyandrostano[2,3-c]-furaza

(25) 13β-ethyl-17β-hydroxygon-4-en-3-one

(26) 4-hydroxytestosterone (4,17β-dihydroxy-androst-4-en-3-one)

(27) 4-hydroxy-19-nortestosterone (4,17β-dihydroxy-estr-4-en-3-one)

(28) mestanolone (17α-methyl-17β-hydroxy-5-androstan-3-one)
mesterolone (1α-methyl-17β-hydroxy-[5α]-androstan-3-one)
methandienone (17α-methyl-17β-hydroxyandrost-1,4-dien-3-one)
methandriol (17α-methyl-3β,17β-dihydroxyandrost-5-ene)
methasterone (2α,17α-dimethyl-5α-androstan-17β-ol-3-one)
methenolone (1-methyl-17β-hydroxy-5α-androstan-1-en-3-one)
17α-methyl-3β,17β-dihydroxy-5α-androstan-4-ene
methyltestosterone (17α-methyl-17β-hydroxyandrostan-4-one)
mibolerone (7α,17α-dimethyl-17β-hydroxyestr-4-en-3-one)
17α-methyl-Δ1-dihydrotestosterone (17β-hydroxy-17α-methyl-5α-androst-1-en-3-one) (also known as "17α-methyl-1-testosterone")
nandrolone (17β-hydroxyestr-4-en-3-one)
19-nor-4-androstenediol (3β, 17β-dihydroxyestr-4-one)
19-nor-4-androstenediol (3α, 17β-dihydroxyestr-4-one)
19-nor-5-androstenediol (3β, 17β-dihydroxyestr-5-one)
19-nor-5-androstenediol (3α, 17β-dihydroxyestr-5-one)
19-nor,4,9(10)-androstadienedione (estr-4,9(10)-diene-3,17-dione)
19-nor-4-androstenedione (estr-4-en-3,17-dione)
19-nor-5-androstenedione (estr-5-en-3,17-dione)
norbolethone (13β, 17α-dietethyl-17β-hydroxygon-4-en-3-one)
norclostebo (4-chloro-17β-hydroxyestr-4-en-3-one)
norethandrolone (17α-ethyl-17β-hydroxyestr-4-en-3-one)
normethandrolone (17α-methyl-17β-hydroxyestr-4-en-3-one)
oxandrolone (17α-methyl-17β-hydroxy-2-oxa-[5α]-androstan-3-one)
oxymesterone (17α-methyl-4,17β-dihydroxyandrost-4-en-3-one)
oxymetholone (17α-methyl-2-hydroxymethylene-17β-hydroxy-[5α]-androstan-3-one)
prostanozol (17β-hydroxy-5α-androstano[3,2-c]pyrazole)
stanozolol (17α-methyl-17β-hydroxy-[5α]-androst-2-eno[3,2-c]-pyrazole)
stenbolone (17β-hydroxy-2-methyl-[5α]-androst-1-en-3-one)
testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid lactone)
testosterone (17β-hydroxyandrost-4-en-3-one)
tetrahydrogestrinone (13β, 17α-dietethyl-17β-hydroxygon-4,9,11-trien-3-one)
trenbolone (17β-hydroxyestr-4,9,11-trien-3-one)
any salt, ester, or isomer of a drug or substance described or listed in this paragraph, if that salt, ester, or isomer promotes muscle growth.

(A) Except as provided in (B), such term does not include an anabolic steroid which is expressly intended for administration through implants to cattle or other nonhuman species and which has been approved by the United States' secretary of health and human services for such administration.

(B) If any person prescribes, dispenses or distributes such steroid for human use, such person shall be considered to have prescribed, dispensed or distributed an anabolic steroid within the meaning of this subsection (f).

(g) Any material, compound, mixture or preparation which contains any quantity of the following hallucinogenic substance, its salts, isomers and salts of isomers, unless specifically excepted, whenever
the existence of these salts, isomers and salts of isomers is possible within the specific chemical designation:

(1) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a United States food and drug administration approved product.

Some other names for dronabinol: (6aR-trans)-6a,7,8,10a-tetrahydro -6-6-9-trimethyl-3-pentyl-6H-dibenz(b,d)pyran-1-0l, or (-)-delta-9-(trans)-tetrahydrocannabinol.

(h) The board may except by rule any compound, mixture or preparation containing any stimulant or depressant substance listed in subsection (b) from the application of all or any part of this act if the compound, mixture or preparation contains one or more active medicinal ingredients not having a stimulant or depressant effect on the central nervous system and if the admixtures are included therein in combinations, quantity, proportion or concentration that vitiate the potential for abuse of the substances which have a stimulant or depressant effect on the central nervous system.


65-4110.
History: L. 1972, ch. 234, § 10; Repealed, L. 1982, ch. 269, § 9; July 1.

65-4111. Substances included in schedule IV.

(a) The controlled substances listed in this section are included in schedule IV and the number set forth opposite each drug or substance is the DEA controlled substances code that has been assigned to it.

(b) Any material, compound, mixture or preparation that contains any quantity of the following substances including its salts, isomers and salts of isomers whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation and having a potential for abuse associated with a depressant effect on the central nervous system:

(1) Alprazolam 2882
(2) Barbital 2145
(3) Brexanolone 2400
(4) Bromazepam 2748
(5) Camazepam 2749
(6) Carisoprodol 8192
(7) Chioral hydrate 2460
(8) Chloral hydrate 2465
(9) Chlor Diazepoxide 2744
(10) Clofazam 2751
(11) Clonazepam 2737
(12) Clorazepate 2768
(13) Clofazepam 2752
(14) Cloxazolam 2753
(15) Delorazepam 2754
(16) Diazepam 2765
(17) Dichloralphenazone 2467
(18) Estazolam 2756
(19) Ethchlorvynol 2540
<table>
<thead>
<tr>
<th></th>
<th>Chemical Name</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>(20)</td>
<td>Ethinamate</td>
<td>2545</td>
</tr>
<tr>
<td>(21)</td>
<td>Ethyl loflazepate</td>
<td>2758</td>
</tr>
<tr>
<td>(22)</td>
<td>Fludiazepam</td>
<td>2759</td>
</tr>
<tr>
<td>(23)</td>
<td>Flunitrazepam</td>
<td>2763</td>
</tr>
<tr>
<td>(24)</td>
<td>Flurazepam</td>
<td>2767</td>
</tr>
<tr>
<td>(25)</td>
<td>Fospropofol</td>
<td>2138</td>
</tr>
<tr>
<td>(26)</td>
<td>Halazepam</td>
<td>2762</td>
</tr>
<tr>
<td>(27)</td>
<td>Haloxazolam</td>
<td>2771</td>
</tr>
<tr>
<td>(28)</td>
<td>Ketazolam</td>
<td>2772</td>
</tr>
<tr>
<td>(29)</td>
<td>Lemborexant</td>
<td>2245</td>
</tr>
<tr>
<td>(30)</td>
<td>Lorazepam</td>
<td>2773</td>
</tr>
<tr>
<td>(31)</td>
<td>Loprazolam</td>
<td>2885</td>
</tr>
<tr>
<td>(32)</td>
<td>Lormetazepam</td>
<td>2774</td>
</tr>
<tr>
<td>(33)</td>
<td>Mebutamate</td>
<td>2800</td>
</tr>
<tr>
<td>(34)</td>
<td>Medazepam</td>
<td>2836</td>
</tr>
<tr>
<td>(35)</td>
<td>Meprobamate</td>
<td>2820</td>
</tr>
<tr>
<td>(36)</td>
<td>Methohexital</td>
<td>2264</td>
</tr>
<tr>
<td>(37)</td>
<td>Methylphenobarbital (methylphenobarbital)</td>
<td>2250</td>
</tr>
<tr>
<td>(38)</td>
<td>Midazolam</td>
<td>2884</td>
</tr>
<tr>
<td>(39)</td>
<td>Nimetazepam</td>
<td>2837</td>
</tr>
<tr>
<td>(40)</td>
<td>Nitrazepam</td>
<td>2834</td>
</tr>
<tr>
<td>(41)</td>
<td>Nordiazepam</td>
<td>2838</td>
</tr>
<tr>
<td>(42)</td>
<td>Oxazepam</td>
<td>2835</td>
</tr>
<tr>
<td>(43)</td>
<td>Oxazolam</td>
<td>2839</td>
</tr>
<tr>
<td>(44)</td>
<td>Paraldehyde</td>
<td>2585</td>
</tr>
<tr>
<td>(45)</td>
<td>Petrichloral</td>
<td>2591</td>
</tr>
<tr>
<td>(46)</td>
<td>Phenobarbital</td>
<td>2285</td>
</tr>
<tr>
<td>(47)</td>
<td>Pinazepam</td>
<td>2883</td>
</tr>
<tr>
<td>(48)</td>
<td>Prazepam</td>
<td>2764</td>
</tr>
<tr>
<td>(49)</td>
<td>Quazepam</td>
<td>2881</td>
</tr>
<tr>
<td>(50)</td>
<td>Remimazolam</td>
<td>2846</td>
</tr>
<tr>
<td>(51)</td>
<td>Temazepam</td>
<td>2925</td>
</tr>
<tr>
<td>(52)</td>
<td>Tetrazepam</td>
<td>2886</td>
</tr>
<tr>
<td>(53)</td>
<td>Triazolam</td>
<td>2887</td>
</tr>
<tr>
<td>(54)</td>
<td>Zolpidem</td>
<td>2783</td>
</tr>
<tr>
<td>(55)</td>
<td>Zaleplon</td>
<td>2781</td>
</tr>
<tr>
<td>(56)</td>
<td>Zopiclone</td>
<td>2784</td>
</tr>
<tr>
<td>(57)</td>
<td>2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical and geometric isomers and salts of these isomers (including tramadol)</td>
<td>9752</td>
</tr>
<tr>
<td>(58)</td>
<td>Alfaxalone</td>
<td>2731</td>
</tr>
<tr>
<td>(59)</td>
<td>Suvorexant</td>
<td>2223</td>
</tr>
</tbody>
</table>

(c) Any material, compound, mixture, or preparation that contains any quantity of fenfluramine (1670), including its salts, isomers (whether optical, position or geometric) and salts of such isomers, whenever the existence of such salts, isomers and salts of isomers is possible. The provisions of this subsection (c) shall expire on the date fenfluramine and its salts and isomers are removed from schedule IV of the federal controlled substances act (21 U.S.C. § 812; 21 code of federal regulations 1308.14).
(d) Any material, compound, mixture or preparation that contains any quantity of lorcaserin (1625), including its salts, isomers and salts of such isomers, whenever the existence of such salts, isomers and salts of isomers is possible (21 U.S.C. § 812; 21 code of federal regulations 1308.14).

(e) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation that contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position or geometric) and salts of such isomers whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation:

(1) Cathine ((+)-norpseudoephedrine) 1230
(2) Diethylpropion 1610
(3) Fencamfamin 1760
(4) Fenproporex 1575
(5) Mazindol 1605
(6) Mefenorex 1580
(7) Pemoline (including organometallic complexes and chelates thereof) 1530
(8) Phentermine 1640
(9) Pipradrol 1750
(10) SPA(((-)-1-dimethylamino-1, 2-diphenylethane) 1635
(11) Sibutramine 1675
(12) Solriamfetol (2-aminomethyl-2-propion-oxbutane) 1650
(13) Modafinil 1680

The provisions of this subsection (e)(8) shall expire on the date phentermine and its salts and isomers are removed from schedule IV of the federal controlled substances act (21 U.S.C. § 812; 21 code of federal regulations 1308.14).

(f) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation that contains any quantity of the following, including salts thereof:

(1) Pentazocine 9709
(2) Butorphanol (including its optical isomers) 9720
(3) Eluxadoline (5-[[2S]-2-amino-3-[4-aminocarboxyl]2,6-dimethylphenyl]1-oxopropyl][1S]-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino[methyl]-2-methoxybenzoic acid)(including its optical isomers) and its salts, isomers, and salts of isomers 9725

(g) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below:

(1) Not more than 1 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit 9167
(2) Dextropropoxyphene (alpha(+)-4-dimethylamino-1, 2-diphenyl-3-methyl-2-propion-oxybutane) 9278

(h) Butyl nitrite and its salts, isomers, esters, ethers or their salts.

(i) The board may except by rule and regulation any compound, mixture or preparation containing any depressant substance listed in subsection (b) from the application of all or any part of this act if the compound, mixture or preparation contains one or more active medicinal ingredients not having a depressant effect on the central nervous system, and if the admixtures are included therein in combinations, quantity, proportion or concentration that vitiate the potential for abuse of the substances that have a depressant effect on the central nervous system.

65-4111a.  
**History:**  

65-4112.  
**History:**  

65-4113.  **Substances included in schedule V.**

(a) The controlled substances or drugs, by whatever official name, common or usual name, chemical name or brand name designated, listed in this section are included in schedule V.

(b) Any compound, mixture or preparation containing limited quantities of any of the following narcotic drugs which also contains one or more nonnarcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture or preparation valuable medicinal qualities other than those possessed by the narcotic drug alone:

1. Not more than 200 milligrams of codeine or any of its salts per 100 milliliters or per 100 grams.
2. Not more than 100 milligrams of dihydrocodeine or any of its salts per 100 milliliters or per 100 grams.
3. Not more than 100 milligrams of ethylmorphine or any of its salts per 100 milliliters or per 100 grams.
4. Not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit.
5. Not more than 100 milligrams of opium per 100 milliliters or per 100 grams.
6. Not more than .5 milligram of difenoxin (9168) and not less than 25 micrograms of atropine sulfate per dosage unit.

(c) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position or geometric) and salts of such isomers whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation:

1. Propylhexedrine (except when part of a compound used for nasal decongestion which is authorized to be sold lawfully over the counter without a prescription under the federal food, drug and cosmetic act, so long as it is used only for such purpose)
2. Pyrovalerone

(d) Any compound, mixture or preparation containing any detectable quantity of ephedrine, its salts or optical isomers, or salts of optical isomers.

(e) Any compound, mixture or preparation containing any detectable quantity of pseudoephedrine, its salts or optical isomers, or salts of optical isomers.

(f) Unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts:

1. Brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide) (some trade or other names BRV; UCB-34714; Briviact)
(2) Cenobamate [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate 2720
(3) Ezogabine N-[2-amino-4-(4-fluorobenzylamino)-phenyl]-carbamic acid ethyl ester 2779
(4) Lacosamide [(R)-2-acetoamido-N-benzyl-3-methoxy-propionamide] 2746
(5) Lasmiditan [2,4,6-trifluoro-N-(6-(1-methylpiperidine-4-carbonyl)pyridine-2-yl)-benzamide] 2790
(6) Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic acid] 2782


65-4116. Registration requirements, exceptions; termination of registration.
(a) Every person who manufactures distributes or dispenses any controlled substance within this state or who proposes to engage in the manufacture, distribution or dispensing of any controlled substance within this state shall obtain annually a registration issued by the board in accordance with the uniform controlled substances act and with rules and regulations adopted by the board.
(b) Persons registered by the board under this act to manufacture, distribute, dispense or conduct research with controlled substances may possess, manufacture, distribute, dispense or conduct research with those substances to the extent authorized by their registration and in conformity with the other provisions of this act.
(c) The following persons need not register and may lawfully possess controlled substances under this act, as specified in this subsection:
   (1) An agent or employee of any registered manufacturer, distributor or dispenser of any controlled substance if the agent or employee is acting in the usual course of such agent or employee's business or employment;
   (2) a common carrier or warehouseman or an employee thereof whose possession of any controlled substance is in the usual course of business or employment;
   (3) an ultimate user or a person in possession of any controlled substance pursuant to a lawful order of a practitioner or a mid-level practitioner or in lawful possession of a schedule V substance;
   (4) persons licensed and registered by the board under the provisions of the acts contained in article 16 of chapter 65 of the Kansas Statutes Annotated, and amendments thereto, to manufacture, dispense or distribute drugs are considered to be in compliance with the registration provision of the uniform controlled substances act without additional proceedings before the board or the payment of additional fees, except that manufacturers and distributors shall complete and file the application form required under the uniform controlled substances act;
   (5) any person licensed by the state board of healing arts under the Kansas healing arts act;
   (6) any person licensed by the state board of veterinary examiners;
   (7) any person licensed by the Kansas dental board;
(8) a mid-level practitioner; and
(9) any person who is a member of the Native American Church, with respect to use or possession of peyote, whose use or possession of peyote is in, or for use in, bona fide religious ceremonies of the Native American Church, but nothing in this paragraph shall authorize the use or possession of peyote in any place used for the confinement or housing of persons arrested, charged or convicted of criminal offenses or in the state security hospital.

(d) The board may waive by rules and regulations the requirement for registration of certain manufacturers, distributors or dispensers if the board finds it consistent with the public health and safety, except that licensure of any person by the state board of healing arts to practice any branch of the healing arts, Kansas dental board or the state board of veterinary examiners shall constitute compliance with the registration requirements of the uniform controlled substances act by such person for such person's place of professional practice. Evidence of abuse as determined by the board relating to a person licensed by the state board of healing arts shall be submitted to the state board of healing arts and the attorney general within 60 days. The state board of healing arts shall, within 60 days, make findings of fact and take such action against such person as it deems necessary. All findings of fact and any action taken shall be reported by the state board of healing arts to the board of pharmacy and the attorney general. Evidence of abuse as determined by the board relating to a person licensed by the state board of veterinary examiners shall be submitted to the state board of veterinary examiners and the attorney general within 60 days. The state board of veterinary examiners shall, within 60 days, make findings of fact and take such action against such person as it deems necessary. All findings of fact and any action taken shall be reported by the state board of veterinary examiners to the board of pharmacy and the attorney general. Evidence of abuse as determined by the board relating to a dentist licensed by the Kansas dental board shall be submitted to the Kansas dental board and the attorney general within 60 days. The Kansas dental board shall, within 60 days, make findings of fact and take such action against such dentist as it deems necessary. All findings of fact and any action taken shall be reported by the Kansas dental board to the board of pharmacy and the attorney general.

(e) A separate annual registration is required at each place of business or professional practice where the applicant manufactures, distributes or dispenses controlled substances.

(f) The board may inspect the establishment of a registrant or applicant for registration in accordance with the board's rules and regulations.

(g) (1) The registration of any person or location shall terminate when such person or authorized representative of a location dies, ceases legal existence, discontinues business or professional practice or changes the location as shown on the certificate of registration. Any registrant who ceases legal existence, discontinues business or professional practice, or changes location as shown on the certificate of registration, shall notify the board promptly of such fact and forthwith deliver the certificate of registration directly to the secretary or executive secretary of the board. In the event of a change in name or mailing address the person or authorized representative of the location shall notify the board promptly in advance of the effective date of this change by filing the change of name or mailing address with the board. This change shall be noted on the original application on file with the board.

(2) No registration or any authority conferred thereby shall be assigned or otherwise transferred except upon such conditions as the board may specifically designate and then only pursuant to the written consent of the board.

65-4117. Registration.
(a) The board shall register an applicant to manufacture, dispense or distribute controlled substances included in K.S.A. 65-4105, 65-4107, 65-4109, 65-4111 and 65-4113, and amendments to these sections, unless it determines that the issuance of that registration would be inconsistent with the public interest. In determining the public interest, the board shall consider the following factors:
1. Maintenance of effective controls against diversion of controlled substances into other than legitimate medical, scientific or industrial channels;
2. Compliance with applicable state and local law;
3. Any conviction of the applicant under any federal and state laws relating to any controlled substance;
4. Past experience in the manufacture, dispensing or distribution of controlled substances and the existence in the applicant's establishment of effective controls against diversion;
5. Furnishing by the applicant of false or fraudulent material in any application filed under this act;
6. Suspension or revocation of the applicant's federal registration to manufacture, distribute or dispense controlled substances as authorized by federal law; and
7. Any other factors relevant to and consistent with the public health and safety.
(b) Registration under subsection (a) does not entitle a registrant to manufacture and distribute controlled substances in schedule I or II other than those specified in the registration.
(c) Practitioners shall be registered to dispense any controlled substances or to conduct research with controlled substances in schedules II through V if they are authorized to prescribe or to conduct research under the laws of this state.
(d) Pharmacists shall be registered to dispense schedule I designated prescription substances and controlled substances in schedules II through V if none of the grounds for revocation, suspension or refusal to renew a registration exist at the time of application.
(e) The board need not require separate registration under this act for practitioners or pharmacists engaging in research with nonnarcotic controlled substances in schedules II through V where the registrant is already registered under this act in another capacity. Practitioners or pharmacists registered under federal law to conduct research with schedule I substances may conduct research with schedule I substances within this state upon furnishing the board evidence of that federal registration.
(f) Compliance by manufacturers and distributors with the provisions of the federal law respecting registration (excluding fees) entitles them to be registered under this act.

History: L. 1972, ch. 234, § 17; L. 1986, ch. 242, § 1; May 1.

65-4118. Revocation and suspension of registration.
(a) A registration under K.S.A. 65-4117 to manufacture, distribute or dispense a controlled substance may be suspended or revoked by the board upon a finding that the registrant:
1. Has furnished false or fraudulent material information in any application filed under this act;
2. Has been convicted of a felony under any state or federal law relating to any controlled substance;
3. Has violated any rule or regulation of the board controlling the manufacture, distribution or dispensing of the controlled substances contained in the schedules promulgated in the rules and regulations of the board; or
(4) has had his federal registration suspended or revoked to manufacture, distribute or dispense controlled substances.

(b) The board may limit revocation or suspension of a registration to the particular controlled substance with respect to which grounds for revocation or suspension exist.

(c) If the board suspends or revokes a registration, all controlled substances owned or possessed by the registrant at the time of suspension or the effective date of the revocation order may be placed under seal. No disposition shall be made of substances under seal until the time for taking an appeal has elapsed or until all appeals have been concluded unless a court upon application therefor orders the sale of perishable substances and the deposit of the proceeds of the sale with the court. Upon a revocation order becoming final, all controlled substances shall be forfeited to the state.

(d) The board shall promptly notify the bureau of all orders suspending or revoking registration and all forfeitures of controlled substances.

History: L. 1972, ch. 234; § 18; L. 1974, ch. 258, § 8; July 1.

65-4119. Denial, suspension, revocation or refusal to renew registration; order to show cause.

(a) Before denying, suspending or revoking a registration or refusing a renewal of registration, the board shall serve upon the applicant or registrant an order to show cause why registration should not be denied, revoked or suspended or why the renewal should not be refused. In the case of a denial or renewal of registration the show cause order shall be served not later than 15 days before the expiration of the registration. Proceedings on a show cause order shall be conducted in accordance with the provisions of the Kansas administrative procedure act without regard to any criminal prosecution or other proceeding.

(b) In accordance with the provisions of K.S.A. 77-536 and amendments thereto, the board may suspend, without an order to show cause, any registration simultaneously with the institution of proceedings under K.S.A. 65-4118 and amendments thereto, or where renewal of registration is refused, if it finds that there is an imminent danger to the public health or safety which warrants this action. The suspension shall continue in effect until the conclusion of the proceedings, including judicial review thereof, unless sooner withdrawn by the board or dissolved by a court of competent jurisdiction.


Any action of the board pursuant to the uniform controlled substances act is subject to review in accordance with the Kansas judicial review act.


65-4121. Registrants to keep records and inventories.

Persons registered to manufacture, distribute or dispense controlled substances under this act shall keep records and maintain inventories in conformance with the record-keeping and inventory requirements of federal law and with any additional rules and regulations the board issues.

65-4122.  Order forms for distribution of substances in schedules I and II.
Controlled substances in schedules I and II shall be distributed by a registrant to another registrant only pursuant to an order form. Compliance with the provisions of federal law respecting order forms shall be deemed compliance with this section.
History:  L. 1972, ch. 234, § 22; July 1.

65-4123.  Dispensing of controlled substances; oral, written or electronic prescriptions; limitations on refilling; prescription recordkeeping requirements.
(a) Except as otherwise provided in K.S.A. 65-4117 and amendments thereto or in this subsection (a), no schedule I controlled substance may be dispensed. The board by rules and regulations may designate in accordance with the provisions of this subsection (a) a schedule I controlled substance as a schedule I designated prescription substance.
(b) Except when dispensed by a practitioner, other than a pharmacy, to an ultimate user, no controlled substance in schedule II may be dispensed without the written or electronic prescription of a prescriber. In emergency situations, as defined by rules and regulations of the board, schedule II drugs may be dispensed upon oral prescription of a prescriber reduced promptly to writing or transmitted electronically and filed by the pharmacy. No prescription for a schedule II substance may be refilled.
(c) Except when dispensed by a practitioner, other than a pharmacy, to an ultimate user, a controlled substance included in schedule III, IV, or V which is a prescription drug shall not be dispensed without either a paper prescription manually signed by a prescriber, a facsimile of a manually signed paper prescription transmitted by the prescriber or the prescriber’s agent to the pharmacy, an electronic prescription that has been digitally signed by a prescriber with a digital certificate, or an oral prescription made by an individual prescriber and promptly reduced to writing. The prescription shall not be filled or refilled more than six months after the date thereof or be refilled more than five times.
(d) A controlled substance shall not be distributed or dispensed except by a valid prescription order as defined in K.S.A 65-1626, and amendments thereto. Electronic prescriptions shall be retained electronically for five years from the date of their creation or receipt. The records must be readily retrievable from all other records and easily rendered into a format a person can read. Paper, oral, and facsimile prescriptions shall be maintained as a hard copy for five years at the registered location.

65-4123a.  Gratuitous distribution of certain controlled substances prohibited.
A controlled substance listed in schedules II through V, excluding schedule V nonnarcotic depressants that have an effect on the central nervous system, shall not be distributed on a gratuitous basis by a manufacturer or distributor to a practitioner, mid-level practitioner, pharmacist or any other person.

65-4124 to 65-4126.
65-4127.  

65-4127a.  

65-4127b.  

65-4127c.  General penalties; criminal penalties not applicable to violations of regulations.  Any person violating any of the provisions of the uniform controlled substances act shall be guilty of a class A nonperson misdemeanor. The criminal penalties prescribed for violations of the uniform controlled substances act shall not be applicable to violations of the rules and regulations adopted by the board pursuant thereto.  

65-4127d.  

65-4127e.  Sentencing under 65-4127a and 65-4127b; substances and quantities; crimes committed prior to July 1, 1993.  
(a) For purposes of sentencing pursuant to this act, substances and quantities shall be as follows:

<table>
<thead>
<tr>
<th>SUBSTANCE</th>
<th>gm</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alpha-Methylfentanyl</td>
<td>1</td>
</tr>
<tr>
<td>Amphetamine</td>
<td>25</td>
</tr>
<tr>
<td>Any substance which contains any quantity of a derivative of barbituric acid, or any salt of a derivative of barbituric acid</td>
<td>50</td>
</tr>
<tr>
<td>Cannabis Resin or Hashish</td>
<td>25</td>
</tr>
<tr>
<td>Cocaine</td>
<td>25</td>
</tr>
<tr>
<td>D-Lysergic Acid</td>
<td>.02 pure or 200 dosage units</td>
</tr>
<tr>
<td>Diethylamide/Lysergide/LSD</td>
<td>100</td>
</tr>
<tr>
<td>Dextropropoxyphene/Propoxyphene</td>
<td>100</td>
</tr>
<tr>
<td>Diazepam</td>
<td>50</td>
</tr>
<tr>
<td>Diethyltryptamine/DET</td>
<td>50</td>
</tr>
<tr>
<td>Dimethyltryptamine/DMT</td>
<td>50</td>
</tr>
<tr>
<td>Fentanyl</td>
<td>2</td>
</tr>
<tr>
<td>Hashish Oil</td>
<td>10</td>
</tr>
<tr>
<td>Heroin</td>
<td>5</td>
</tr>
</tbody>
</table>
Hydrocodone/Dihydrocodeinone.................................................................50
Hydromorphone/Dihydromorphinone......................................................25
Marijuana/Cannabis..............................................................................1500
Marijuana/Cannabis Plant ...................................................................50 plants
Meperidine/Pethidine............................................................................100
Mescaline.................................................................................................10
Methamphetamine................................................................................25
Methaqualone.........................................................................................50
Morphine.................................................................................................25
Mushrooms containing Psilocin and/or Psilocybin.................................100
Opium.................................................................................................100
Oxycodone.........................................................................................25
Pentazocine..........................................................................................50
Peyote.................................................................................................100
Phencyclidine/PCP.............................................................................10
Phentermine........................................................................................50
Phenylacetone PP...............................................................................25
Psilocin.................................................................................................2
Psilocybin..............................................................................................2
Tetrahydrocannabinol.......................................................................5
3-Methylfentanyl...............................................................................1
3,4-Methylene-dioxyamphetamine/MDA...........................................10
3,4-Methylene-dioxymethamphetamine/MDMA..............................10

(b) Any reference to a particular controlled substance in this section includes all salts, isomers and all salts of isomers. Any reference to cocaine includes ecgonine and coca leaves, except extracts of coca leaves from which cocaine and ecgonine have been removed.

(c) The scale amounts for all controlled substances in this section refer to the total weight of the controlled substance. If any mixture of a compound contains any detectable amount of a controlled substance, the entire amount of the mixture or compound shall be considered in measuring the quantity. If a mixture or compound contains a detectable amount of more than one controlled substance, the most serious controlled substance shall determine the categorization of the entire quantity.

(d) The provisions of this section shall not be applicable to crimes committed on or after July 1, 1993.

65-4128. Penalties in addition to remedies under other laws.
Any penalty imposed for violation of this act is in addition to, and not in lieu of, any civil or
administrative penalty or sanction otherwise authorized by law.
History: L. 1972, ch. 234, § 28; July 1.

65-4129.

65-4130. Enforcement.
It is hereby made the duty of the state board of pharmacy and its duly authorized officers, agents,
inspectors and representatives, and all law enforcement officers within the state, all county
attorneys, the attorney general and the secretary of health and environment to enforce all
provisions of this act, except those specifically delegated, and to cooperate with all agencies
charged with the enforcement of the laws of the United States, of this state, and of all other
states, relating to narcotic, hypnotic, somnifacient or stimulating drugs.

65-4131. Inspection.
The board and its duly authorized agents and employees may inspect controlled premises and
practitioners' offices during business hours and in a lawful manner upon presenting appropriate
credentials for the purpose of examining:
(a) Any books, inventories, records or other documents required to be kept by a registrant under
the provisions of this act or regulations issued pursuant thereto;
(b) all pertinent equipment, finished and unfinished material, containers and labeling found
therein and, all other things therein, including but not limited to processes, controls and facilities;
and
(c) inventory any stock of any controlled substance therein and obtain samples thereof upon
payment therefor.
History: L. 1972, ch. 234, § 31; July 1.

65-4132. Injunctions.
The district courts of the state shall have jurisdiction in proceedings in accordance with the rules
of civil procedure to enjoin violations of this act.
History: L. 1972, ch. 234, § 32; July 1.

65-4133. Search warrant procedure.
A search warrant relating to offenses involving controlled substances shall be issued in
accordance with the provisions of the Kansas code of criminal procedure.
History: L. 1972, ch. 234, § 33; July 1.

65-4134. Identity of patient or research subject of practitioner confidential.
A practitioner engaged in medical practice or research or a mid-level practitioner acting in the
usual course of such mid-level practitioner's practice is not required or compelled to furnish the
name or identity of a patient or research subject to the board, nor may such practitioner or mid-
level practitioner be compelled in any state or local civil, criminal, administrative, legislative or
other proceedings to furnish the name or identity of an individual that the practitioner or mid-level practitioner is obligated to keep confidential.


**65-4135.**


**65-4136.**


**65-4137. Pending proceedings.**

(a) Prosecution for any violation of law similar to one set out in K.S.A. 65-4124 to 65-4126, inclusive, occurring prior to the effective date of this act is not affected or abated by this act. A violation of law is committed prior to the effective date of this act if any of the essential elements of the violation occurred before that date. Prosecutions for prior violations of law shall be governed, prosecuted and punished under the laws existing at the time such violations of law were committed;

(b) civil seizures or forfeitures and injunctive proceedings commenced prior to the effective date of this act shall not be affected by this act;

(c) the board shall initially permit persons to register who own or operate any establishment engaged in the manufacture, distribution or dispensing of any controlled substance prior to the effective date of this act and who are registered or licensed by the state; and

(d) this act applies to violations of law, seizures and forfeiture, injunctive proceedings, administrative proceedings and investigations which occur following its effective date.

**History:** L. 1972, ch. 234, § 37; L. 1972, ch. 235, § 3; July 1.

**65-4138. Medical care facility exemption.**

Nothing in this act shall be construed to prohibit a medical care facility licensed by the secretary of health and environment from keeping controlled items in a drug room of the medical care facility or supplying such controlled items in a drug room of the medical care facility or supplying such controlled items to its patients as provided under the provisions of K.S.A. 65-1648 and amendments thereto.

**History:** L. 1972, ch. 234, § 38; L. 1975, ch. 462, § 106; L. 1985, ch. 214, § 3; April 18.

**65-4139. Citation of act.**

Article 41 of chapter 65 of the Kansas Statutes Annotated, and amendments thereto, shall be known and may be cited as the uniform controlled substances act.

**History:** L. 1972, ch. 234, § 39; L. 2009, ch. 32, § 56; July 1.

**65-4140. Severability.**

If any provision of this act or the application thereof to any person or circumstance is held invalid, the invalidity does not affect other provisions or applications of the act which can be given effect without the invalid provision or application, and to this end the provisions of this act are severable.
History: L. 1972, ch. 234, § 40; July 1.

65-4141.

65-4142.

65-4143 to 65-4149. Reserved.

65-4150.

65-4151.

65-4152.

65-4153.

65-4154.

65-4155.

65-4156.

If any provisions of this act or the application thereof to any person or circumstances is held invalid, the invalidity shall not affect other provisions or applications of the act which can be given effect without the invalid provisions or application and, to this end, the provisions of this act are severable.

65-4158.
History: L. 1990, ch. 100, § 11; Repealed L. 2009, ch. 32, § 64; July 1.
65-4159.  

65-4159a.  
History:  L. 2004, ch. 125, § 3; Repealed L. 2009, ch. 32, § 64; July 1.

65-4160.  

65-4161.  

65-4162.  

65-4163.  

65-4164.  
History:  L. 2002, ch. 166, § 1; Repealed L. 2009, ch. 32, § 64; July 1.

65-4165.  

65-4166.  

65-4167.  Trafficking in counterfeit drugs.  
(a) Trafficking in counterfeit drugs is intentionally manufacturing, distributing, dispensing, selling or delivering for consumption purposes, or holding or offering for sale, any counterfeit drug.  
(b) Trafficking in counterfeit drugs which have a retail value of less than $500 is a class A nonperson misdemeanor, trafficking in counterfeit drugs which have a retail value of at least $500 but less than $25,000 is a severity level 9, nonperson felony and trafficking in counterfeit drugs which have a retail value of $25,000 or more is a severity level 7, nonperson felony.  
(c) A pharmacy which is inadvertently in possession of counterfeit drugs may return those drugs to the supplier who provided the drugs to the pharmacy.  
History:  L. 2006, ch. 177, § 1; July 1.

65-4168.  
History:  L. 2007, ch. 91, § 1; Repealed L. 2009, ch. 32, § 64; July 1.
65-4168a.  
**History:**  L. 2007, ch. 169, § 10; Repealed L. 2009, ch. 32, § 64; July 1.

65-4169.  **Severability clause.**  
The provisions of this act are declared to be severable and if any provision, word, phrase or clause of the act or the application thereof to any person shall be held invalid, such invalidity shall not affect the validity of the remaining portions of this act.  
**History:**  L. 2007, ch. 169, § 14; May 17.

65-4170.  **Reserved.**

65-4171.  

65-4172.  
**History:**  L. 1988, ch. 258, § 5; Repealed, L. 1994, ch. 339, § 28; July 1.

65-4173.  

65-4174, 65-4175.  
**History:**  L. 1988, ch. 258, §§ 7, 8; Repealed, L. 1994, ch. 339, § 28; July 1.
IV. Controlled Substances Act - Regulations

Article 20: Controlled Substances

68-20-1 Definitions.
As used in this article of the board’s regulations, each of the following terms shall have the meaning specified in this regulation:
(a) “Act” means the uniform controlled substances act of Kansas, K.S.A. 65-4101 et seq., and amendments thereto.
(b) “Basic class,” when referring to controlled substances listed in K.S.A. 65-4105 and K.S.A. 65-4107 and amendments thereto, means any of the following:
(1) Each of the opiates, including its isomers, esters, ethers, and salts, and salts of isomers, esters, and ethers, whenever the existence of the isomers, esters, ethers and salts is possible within the specific chemical designation listed in K.S.A. 65-4105(b) and amendments thereto;
(2) each of the opium derivatives, including its salts and isomers, and salts of isomers, whenever the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation listed in K.S.A. 65-4105(c) and amendments thereto;
(3) each of the hallucinogenic substances, including its salts and isomers, and salts of isomers, whenever the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation listed in K.S.A. 65-4105(d) and amendments thereto;
(4) each of the following substances, whether produced directly or indirectly by extraction from substances of vegetable origin, independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis:
(A) Opium, including raw opium, opium extracts, opium fluid extracts, powdered opium, granulated opium, deodorized opium, and tincture of opium;
(B) apomorphine;
(C) codeine;
(D) ethylmorphine;
(E) hydrocodone;
(F) hydromorphone;
(G) metopon;
(H) morphine;
(I) oxycodone;
(J) oxymorphone;
(K) thebaine;
(L) mixed alkaloid of opium listed in K.S.A. 65-4107(b)(1) and amendments thereto;
(M) cocaine; and
(N) ecgonine;
(5) each of the opiates, including its isomers, esters, ethers, and salts, whenever the existence of the isomers, esters, ethers, and salts of isomers is possible within the specific chemical designation listed in K.S.A. 65-4105(c) and amendments thereto;
(6) methamphetamine, including its salts, isomers, and salts of isomers, when contained in any injectable liquid;
(7) amphetamine, its salts, optical isomers and salts of its optical isomers;
(8) phenterzamine and its salts; or
(9) methylphenidate.
(c) “Controlled premises” means a facility registered with the board and any conveyance operated by the facility where controlled substances or original or copies of records or documents required under the act are kept or required to be kept and where registrants or persons who are exempted from registration under the act may lawfully hold, manufacture, distribute, dispense, administer, or otherwise dispose of controlled substances.

(d) “Drug of concern” has the meaning specified in K.S.A. 65-1682, and amendments thereto.

(e) “Prescription” means an order for medication that is dispensed to or for an ultimate user. This term shall not include an order for medication that is dispensed for immediate administration to the ultimate user. An order for a single dose of a drug for immediate administration to a bed patient in a medical care facility shall not be construed to be a prescription.

(f) “Readily retrievable” has the meaning specified in K.S.A. 65-1626 and K.S.A. 65-4101, and amendments thereto.

(g) “Registrant” means any person who is registered pursuant to K.S.A. 65-4117, and amendments thereto.

(h) “Secretary” means executive secretary of the Kansas state board of pharmacy.

(i) Each term used in this article of the board’s regulations that is not defined in this regulation shall have the meaning specified in the act, the Kansas pharmacy act, or the Kansas prescription monitoring program act, and amendments thereto. (Authorized by and implementing K.S.A. 65-4102; effective, E-72-24, Aug. 25, 1972; effective Jan. 1, 1973; amended May 1, 1985; amended May 1, 1989; amended June 2, 2023.)
68-20-8b and 68-20-8c Revoked.

68-20-9 Fees for registration and reregistration.
(a) Fee amounts.
   (1) For each registration or reregistration of a manufacturer for each additional location in this state where controlled substances are manufactured, the registrant shall pay a fee of $50.00.
   (2) For each registration or reregistration of each additional location from which controlled substances are distributed, the registrant shall pay a fee of $50.00.
   (3) For each registration or reregistration of each location within this state where research or instructional activities are conducted with controlled substances listed in schedules I through V, the registrant shall pay a fee of $50.00.
   (4) For each registration or reregistration to conduct chemical analysis with controlled substances listed in schedules I through V, as set out in K.S.A. 65-4105, K.S.A. 65-4107, K.S.A. 65-4109, K.S.A. 65-4111, K.S.A. 65-4113 and amendments thereto, within this state, the registrant shall pay a fee of $50.00.
(b) Time and method of payment; refund.
   (1) Registration and reregistration fees shall be paid at the time the application for registration or reregistration is submitted for filing.
   (2) Payment shall be made in the form of a personal, certified, cashier's check or a money order payable to the state board of pharmacy.
   (3) Payments made in the form of stamps, foreign currency or third party endorsement checks shall not be accepted.
   (4) If the application is not accepted for filing or is denied, all payments made under paragraphs (1) through (4) of subsection (a) shall be refunded to the applicant.
(c) Exemptions from fees in paragraphs (1) through (4) of subsection (a).
   (1) Any official or agency of the U.S. army, navy, marine corps, air force, coast guard, veteran's administration, or public health service authorized to procure or purchase controlled substances for official use shall be exempted by the board from the fees set forth in subsection (a), paragraphs (1) through (4).
   (2) Any official, employee, or other civil service or agency of the United States, or any state, or any political subdivision or agency thereof, authorized to dispense or administer such substances, to conduct research, instructional activities, or chemical analysis with such substances, or any combination thereof, in the course of the official duties of employment, may be exempted by the board from the fees in subsection (a), paragraphs (1) through (4).
(d) In order to claim exemption from payment of a registration or reregistration fee, the registrant shall have completed the certification on the appropriate application forms. The registrant's superior shall certify the status and address of the registrant and shall certify to the authority of the registrant to acquire, possess, or handle controlled substances.
(e) Exemption from the payment of a registration or reregistration fee shall not relieve the registrant of any other requirements or duties prescribed by law.
68-20-10 Requirements of registration.

(a) Persons required to register. Every person who manufactures, distributes, or dispenses any controlled substances within this state, or who proposes to engage in the manufacture, distribution, or dispensing of any controlled substance in this state shall obtain annually a registration unless exempted by law or pursuant to subsections (d) through (g) of this regulation. Only persons actually engaged in these activities in this state shall be required to obtain a registration.

(b) Separate registration for independent activities.

(1) The following six groups of activities shall be deemed to be independent of each other:
   (A) Manufacturing controlled substances;
   (B) Distributing controlled substances;
   (C) Dispensing, conducting research, other than research described in paragraph (b)(1)(D), with, and conducting instructional activities with, controlled substances listed in schedules II through V;
   (D) Conducting research with narcotic drugs listed in schedules II through V for the purpose of continuing the dependence on these drugs of a narcotic drug-dependent person in the course of conducting an authorized clinical investigation in the development of a narcotic addict rehabilitation program pursuant to a notice of claimed investigational exemption for a new drug approved by the food and drug administration;
   (E) Conducting research and instructional activities with controlled substances listed in schedule I; and
   (F) Conducting chemical analysis with controlled substances listed in any schedule.

(2) Every person who engages in more than one group of independent activities shall obtain a separate registration for each group of activities, except as provided in this subsection (b). Any person, when registered to engage in the group of activities described in each paragraph in this subsection, shall be authorized to engage in the coincident activities described in that paragraph without obtaining a registration to engage in such coincident activities if, unless specifically exempted, the person complies with all requirements and duties prescribed by law for the following persons registered to engage in the coincident activities:
   (A) A person registered to manufacture any controlled substance or basic class of controlled substance shall be authorized to distribute that substance or class, but no other substance or class that the person is not registered to manufacture.
   (B) A person registered to manufacture any controlled substance listed in schedules II through V shall be authorized to conduct chemical analysis and preclinical research, including quality control analysis, with narcotic and nonnarcotic controlled substances listed in those schedules in which the person is authorized to manufacture.
   (C) A person registered to conduct research with a basic class of controlled substances listed in schedule I shall be authorized to manufacture this class if and to the extent that the manufacture is set forth in the research protocol filed with the application for registration and to distribute this class to other persons registered to conduct research with this class or to conduct chemical analysis.
   (D) A person registered to conduct chemical analysis with controlled substances shall be authorized to perform the following:
      (i) Manufacture and import these substances for analytical or instructional purposes;
(ii) distribute these substances to other persons registered to conduct chemical analysis or instructional activities, to persons registered or authorized to conduct research with these substances, and to persons exempted from registration pursuant to subsection (c);

(iii) export these substances to persons in other countries performing chemical analysis or enforcing laws relating to controlled substances or drugs in those countries; and

(iv) conduct instructional activities with controlled substances.

(E) A person registered or authorized to conduct research, other than the research described in paragraph (b)(2)(C), with controlled substances listed in schedules II through V shall be authorized to perform the following:

(i) Conduct chemical analysis with controlled substances listed in those schedules in which the person is authorized to conduct research to manufacture is set forth in a statement filed with the application for registration;

(ii) distribute these substances to other persons registered or authorized to conduct chemical analysis, instructional activities, or research with these substances and to persons exempted from registration pursuant to subsection (c); and

(iii) conduct instructional activities with controlled substances.

(F) A person registered to dispense under the pharmacy act, or to conduct research, other than research described in paragraph (b)(2)(D), with controlled substances listed in schedules II through V shall be authorized to dispense and to conduct research and to conduct instructional research with those substances.

(3) A single registration to engage in any group of independent activities may include one or more controlled substances listed in the schedules authorized in that group of independent activities. A person registered to conduct research with controlled substances listed in schedule I may conduct research with any substance listed in schedule I for which the person has filed and had approved a research protocol.

(c) Separate registrations for separate locations.

(1) A separate registration shall be required for each principal place of business or professional practice at one general physical location where controlled substances are manufactured, distributed, or dispensed by a person.

(2) The following locations shall be deemed not to be places where controlled substances are manufactured, distributed, or dispensed:

(A) A warehouse where controlled substances are stored by or on behalf of a registered person, unless these substances are distributed directly from the warehouse to registered locations other than the registered location from which the substances were delivered or to persons not required to register by virtue of the pharmacy act, K.S.A. 65-4116 and amendments thereto;

(B) an office used by agents of a registrant where sales of controlled substances are solicited, made, or supervised but which neither contains these substances, other than substances for display purposes only, nor serves as a distribution point for filling sales orders; and

(C) an office used by a practitioner or mid-level practitioner who is registered at another location where controlled substances are prescribed but neither administered nor otherwise dispensed as a regular part of the professional practice of the practitioner or mid-level practitioner at this office, and where no supplies of controlled substances are maintained.

(d) Exemption of agents and employees; affiliated practitioners.

(1) Practitioners, mid-level practitioners, pharmacists, and other persons required to register under this act shall not be exempt from registration because of their status as an agent or
employee of a person who is already registered to engage in any group of independent activities. The requirements of registration, however, shall be waived for any agent or employee of a person who is registered to engage in any group of independent activities, if the agent or employee is acting in the usual course of his business or employment.

(2) A practitioner who is an intern, resident, or foreign physician or medical graduate may dispense and prescribe controlled substances under the registration of the hospital or other institution that is registered and by whom the person is employed if all of the following conditions are met:

   (A) The practitioner is authorized or permitted to do so by the laws of the state of Kansas.
   (B) The dispensing or prescribing is done in the usual course of the practitioner’s professional practice.
   (C) The hospital or other institution by whom the person is employed has determined that the practitioner is permitted to dispense or prescribe drugs by the state of Kansas.
   (D) The practitioner is acting only within the scope of employment in the hospital or institution.
   (E) The hospital or other institution authorizes the intern, resident, or foreign physician or medical graduate to dispense or prescribe under the hospital registration and designates a specific internal registration code number for each intern, resident, or foreign physician or medical graduate so authorized. The code number shall consist of numbers, letters, or a combination of both and shall be a suffix to the institution's drug enforcement administration registration number, preceded by a hyphen.
   (F) A current list of internal codes and the corresponding practitioners is kept by the hospital or other institution, and an updated copy is on file with the state board of pharmacy of the state of Kansas for the purposes of verifying the authority of the prescribing practitioner.

(e) Exemption of certain military and other personnel.

(1) The requirement of registration shall be waived for any official of the U.S. army, navy, marine corps, air force, coast guard, or public health service who is authorized to prescribe, dispense, or administer, but not to procure or purchase, controlled substances in the course of official duties. These officials shall follow the procedures set forth in K.A.R. 68-20-18, 68-20-19, 68-20-20, and 68-20-21, but shall state the branch of service or agency and the service identification number of the issuing official in lieu of the registration number required on prescription forms. The service identification number for a public health service employee is the person's social security identification number.

(2) If any official exempted by this subsection also engages as a private individual in any activity or group of activities for which registration is required, the official shall obtain a registration for these private activities.

(f) Exemption of law enforcement officials.

(1) The requirement of registration shall be waived for the following persons in the circumstances described in this subsection:

   (A) Any officer or employee of the bureau, any officer of the U.S. bureau of customs, any officer or employee of the United States food and drug administration, and any other federal officer who is lawfully engaged in the enforcement of any federal law relating to controlled substances, drugs, or customs, and is duly authorized to possess controlled substances in the course of official duties; and
(B) any officer or employee of the state of Kansas, or any political subdivision or agency thereof, who is engaged in the enforcement of Kansas law or local law relating to controlled substances and is duly authorized to possess controlled substances in the course of official duties.

(2) Any official exempted by this subsection may, when acting in the course of official duties, possess any controlled substance and distribute any such substance to any other official who is also exempted by this subsection and acting in the course of official duties.

(3) Any official exempted by this subsection may procure any controlled substance in the course of an inspection, in accordance with the controlled substances act, K.S.A. 65-4131(c) and amendments thereto, or in the course of any criminal investigation involving the person from whom the substance was procured.

(4) In order to enable law enforcement agency laboratories to obtain and transfer controlled substances for use as standards in chemical analysis, these laboratories shall obtain annually a registration to conduct chemical analysis. These laboratories shall be exempted from payment of a fee for registration. Laboratory personnel, when acting in the scope of their official duties, shall be deemed to be officials exempted by this subsection and within the activities described in the controlled substances act, K.S.A. 65-4115 and amendments thereto. For purposes of this subsection, laboratory activities shall not include field or other preliminary chemical tests by officials exempted by this subsection.

(g) Exemption of civil defense officials.

(1) The requirement of registration shall be waived for any official of a civil defense or disaster relief organization who, in the course of official duties, is authorized to perform either of the following:

   (A) Maintain, and distribute for maintenance, controlled substances held for emergency use; or

   (B) procure controlled substances for the purposes of maintaining supplies for emergency use, if all procurement is from the U.S. general services administration and in accordance with the rules of the U.S. office of emergency preparedness.

(2) The requirement of registration shall be waived for any official of a civil defense or disaster relief organization during a state of emergency or disaster within the official's jurisdiction proclaimed by the president or by a concurrent resolution of the congress, which official, in the course of official duties during this emergency or disaster, is authorized to perform either of the following:

   (A) Dispense controlled substances; or

   (B) procure or distribute controlled substances, if all procurement is on a special "civil defense emergency order form," as described in this subsection.

(3) Civil defense emergency order forms shall be furnished by the U.S. office of emergency preparedness and shall contain the name of the civil defense or disaster relief organization. These forms may be used and shall be valid only during a state of emergency disaster proclaimed by the president or by a concurrent resolution of the congress for the area in which the organization using the forms has civil defense or disaster relief jurisdiction, who shall state the position and the nature and legal designation of the emergency or disaster. These forms may be filled by any person registered under the controlled substances act. The organization shall, upon the execution of a civil defense emergency order form, be deemed to be registered under the controlled substances act for purposes of record keeping pursuant to K.A.R. 68-20-16.
68-20-10a Electronic transmission of a controlled substance prescription.
(a) Each prescription drug order transmitted electronically shall be issued for a legitimate
medical purpose by a prescriber acting within the course of legitimate professional practice.
(b) Each prescription drug order communicated by way of electronic transmission shall fulfill all
the requirements of K.A.R. 68-2-22.
(c) A prescription drug order, including that for any controlled substance listed in schedules II,
III, IV, and V, may be communicated by electronic transmission in accordance with 21 C.F.R.
part 1311.
(d) Each electronic prescription drug order created and transmitted in conformance with 21
C.F.R. part 1311 shall be considered an original, written, signed prescription drug order.

68-20-11 Applications for registration.
(a) The expiration date of all registrations shall be the last day of June in each year.
(b) Each application for the following types of registration shall include the controlled
substances code number for each basic class or substance to be covered by the registration:
   (1) Registration to handle any basic class of controlled substances listed in schedule I, except
       registration to conduct chemical analysis with such classes;
   (2) registration to manufacture a basic class of controlled substances listed in schedules II
       through V; and
   (3) registration to conduct research with any narcotic controlled substance in schedules II
       through V.
(c) Each application, attachment, or other document filed as part of an application, shall be
    signed by:
       (1) the applicant, if an individual;
       (2) the authorized representative, if the registration is for a location;
       (3) a partner of the applicant, if a partnership; or
       (4) by an officer of the applicant, if a corporation, corporate division, association, trust or
           other entity.
(d) Any applicant may authorize one or more individuals to sign applications for the applicant or
    location by filing, with the executive secretary of the board, a power of attorney for each such
    individual. The power of attorney shall contain the signature of the individual who shall be
    authorized to sign applications pursuant to that power of attorney. The power of attorney shall be
    valid until revoked by the applicant.
(e) Any person required to obtain more than one registration may submit all applications in one
    package. Each application shall be completed and should not refer to any accompanying
    application for required information.
(f) Applications submitted for filing shall be dated upon receipt. Completed applications shall be
    accepted for filing. If completed with only minor defects, the board may accept the application
for filing and send a request to the applicant for additional information. A defective application shall be returned to the applicant within 10 days following its receipt with a statement of the reason for refusal to accept the application for filing. A defective application may be corrected and resubmitted for filing at any time.

(g) Additional information. The board may require any applicant or the applicant's authorized representative to submit such documents or written statements of fact relevant to the application as it deems necessary to determine whether the application should be granted. The failure of the applicant or authorized representative to provide the documents or statements within a reasonable time after being requested to do so shall be deemed to be a waiver of an opportunity to present the documents or facts for consideration by the board in granting or denying the application.

(h) Amendments to and withdrawal of applications.

(1) Any application may be amended or withdrawn without permission of the board at any time before the date on which the applicant or the applicant's authorized representative receives an order to show cause pursuant to K.S.A. 65-4119. Any application may be amended or withdrawn with permission of the board at any time good cause is shown by the applicant or the applicant's authorized representative, or when the amendment or withdrawal is in the public interest.

(2) After an application has been accepted for filing, a request by the applicant or the applicant's authorized representative for return of the application or failure of the applicant or authorized representative to respond to official correspondence regarding the application, when sent by registered or certified mail, return receipt requested, shall be deemed to be a withdrawal of the application.

(Authorized by and implementing K.S.A. 65-4116 as amended by L. 1987, Ch. 244, Sec. 3; effective, E-72-24, Aug. 25, 1972; effective Jan. 1, 1973; amended May 1, 1985; amended May 1, 1988.)

68-20-12 Revoked.


68-20-13 Hearings generally.

In any case where the board shall hold a hearing on any registration or application therefor, the procedures for such hearing shall be conducted in accordance with the procedural provisions of the act and paragraph 68-20-13 of these regulations. Any hearing under this part shall be independent of and not in lieu of, criminal proceedings or other proceedings under the act or any other law of this state.

(a) Purpose of hearing-The board shall hold a hearing for the purpose of receiving factual evidence regarding the issues involved in the denial, revocation, or suspension of any registration. Extensive argument should not be offered into evidence but rather presented in opening or closing statements of counsel or in memoranda or proposed findings of fact and conclusions of law.

(b) Waiver or modification of rules-The board or its presiding officer (with respect to matters pending before him), may modify or waive any rule or regulation in paragraph 68-20-13 of these regulations by notice in advance of the hearing, if the board determines that no party in the
hearing will be unduly prejudiced and the ends of justice will thereby be served. Such notice of modification or waiver shall be made a part of the records of the hearing.

(c) Hearing; waiver.

(1) Any person entitled to a hearing may file with the board a waiver of an opportunity for a hearing or to participate in a hearing, together with a written statement regarding his position on the matters of fact and law involved in such hearing. Such statement, if admissible, shall be made a part of the record and shall be considered in light of the lack of opportunity for cross-examination in determining the weight to be attached to matters of fact asserted therein.

(2) If any person entitled to a hearing or to participate in a hearing waives his opportunity to participate in the hearing, the board may proceed without the presence of such person.

(d) Burden of proof.

(1) At any hearing for the denial of a registration, the board shall have the burden of proving that the requirements of such registration pursuant to the act (K.S.A. 65-4117, K.S.A. 65-4118) are not satisfied.

(2) At any hearing for the revocation or suspension of a registration, the board shall have the burden of proving that the requirements for such revocation or suspension in accordance with the provisions of the act (K.S.A. 65-4119).

(e) Time and place of hearing-The hearing will commence at the place and time designated in the order to show cause (unless expedited pursuant to paragraph 68-20-12D of these regulations) but thereafter, it may be moved to a different place and may be continued from day to day or recessed to a later day without notice other than announcement thereof by the presiding officer at the hearing.

(f) Final order-As soon as practicable after the presiding officer has certified the record to the board, the board shall issue its order on the granting, denial, revocation or suspension of the registration. In the event that any application for registration is denied, or any registration is revoked or suspended, the order shall include the findings of fact and conclusions of law upon which the order is based. The order shall specify the date on which it shall take effect. The board shall serve one copy of its order upon each party in the hearing by registered, return receipt requested mail.


68-20-14 Modification, transfer and termination of registration.

(a) Modification in registration-Any registrant may apply to modify his registration to authorize the handling of additional controlled substances by submitting a letter of request to the state board of pharmacy. The letter shall contain the registrant's name, address, registration number and the substance and/or schedules to be added to his registration and shall be signed by the same person who signed the most recent application for registration or reregistration. If the registrant is seeking to handle additional controlled substances listed in schedule I for the purpose of research or instructional activities, he shall attach one copy of the federally approved research protocol describing each research project involving the additional substances, or two copies of a statement describing the nature, extent and duration of such instructional activities, as appropriate. One-half of the original fees shall be required to be paid for said modification. The request for modification shall be handled in the same manner as an application for registration.

(b) Termination of registration-The registration of any person or location shall terminate if and when such person or authorized representative of a location dies, ceases legal existence,
discontinues business or professional practice or changes the location as shown on the certificate of registration. Any registrant who ceases legal existence, discontinues business or professional practice, or changes location as shown on the certificate of registration, shall notify the board promptly of such fact and forthwith deliver the certificate of registration directly to the secretary or executive secretary of the board. In the event of a change in name or mailing address the person or authorized representative of the location shall notify the board promptly in advance of the effective date of this change by filing the change of name or mailing address with the board. This change shall be noted on the original application on file with the board.

(c) Transfer of registration-No registration or any authority conferred thereby shall be assigned or otherwise transferred except upon such conditions as the board may specifically designate and then only pursuant to its written consent.


68-20-15 Revoked.

68-20-15a Security requirements.
(a) General security requirements. Each applicant and registrant shall provide effective controls and procedures to guard against theft and diversion of controlled substances in conformance with the security requirements of federal law, including the requirements of 21 CFR 1301.71 as in effect on April 1, 1999, which are hereby adopted by reference.

(b) Physical security controls for nonpractitioners shall comply with the requirements of 21 CFR 1301.72 and 1301.73 as in effect on April 1, 1999, which are hereby adopted by reference.

(c) Other security controls for nonpractitioners.

(1) Good faith inquiry. Before distributing a controlled substance to any person whom the registrant does not know to be registered to possess a controlled substance, each registrant shall make a good faith inquiry with the board to determine that the person is registered to possess a controlled substance.

(2) Suspicious orders. Each registrant shall design an operative system to disclose to the registrant any suspicious orders of controlled substances. Each registrant shall inform the board of suspicious orders when discovered. Suspicious orders shall include orders of unusual size, orders deviating from a normal pattern, and orders of unusual frequency.

(3) A controlled substance listed in schedules II through V shall not be distributed on a gratuitous basis by a manufacturer or distributor to a practitioner, mid-level practitioner, pharmacist, or any other person.

(d) Physical security controls for prescribers. Each prescriber shall provide effective controls and procedures to guard against theft and diversion of controlled substances in conformance with the security requirements of federal law, including the requirements of 21 CFR 1301.75 and 1301.76 as in effect on April 1, 1999, which are hereby adopted by reference.

(e) Other security controls for prescribers.

(1) In order to minimize the opportunities for diversion of controlled substances, each prescriber shall provide effective physical security, shall initiate additional procedures to reduce access by unauthorized personnel, and shall provide an alarm system if necessary.
(2) Minimum security standards for prescribers as set forth in this article shall be considered as guidelines to be used in evaluating security. Additional security controls and operating procedures may be required by the board to prevent diversion of controlled substances.


68-20-15b Notification to board; suspected diversion, theft, or loss of controlled substances.
Either the pharmacist-in-charge or the pharmacy owner shall notify the board in writing within one day of any suspected diversion, theft, or loss of any controlled substance and, upon completion, shall provide the board with a copy of the completed DEA 106 form issued by the U.S. department of justice.


68-20-16 Records and inventories of registrants.
(a) Except as provided in this regulation, each registrant shall keep records and maintain inventories in conformance with the recordkeeping and inventory requirements of 21 C.F.R. 1304.04(a)(2), (a)(3), (f), (g), (h)(1), (h)(2), (h)(3), and (h)(4), as in effect on February 1, 2022, which are hereby adopted by reference. Except as otherwise provided in this regulation, the registrant shall maintain executed order forms and controlled substance inventories at the registered facility and keep the records on file for at least five years.

(b) After the initial inventory is taken, the registrant shall take a subsequent inventory of all controlled substances and drugs of concern on hand at least every year but no later than 375 days after the date of the previous inventory. All controlled substances and drugs of concern shall be inventoried on the same calendar date.

(c) Each required inventory of schedule II controlled substances and nonliquid dosage forms of other controlled substances and drugs of concern shall be taken by exact count.

(d) Each registrant handling schedule V controlled substances and drugs of concern shall be subjected to the same inventory and recordkeeping requirements specified in subsections (a) and (b).

(e) Each inventory of controlled substances shall be maintained in legible, hard-copy format and shall include the following:

(1) The date the inventory was conducted;
(2) the name, license or registration number, and signature of each individual participating in the inventory; and
(3) documentation of whether the inventory was taken before the opening of business or after the close of business. If the pharmacy is open 24 hours per day and does not close, the time that the count was taken shall be documented. (Authorized by K.S.A. 65-4102 and K.S.A. 65-4121; implementing K.S.A. 65-4121; effective, E-72-24, Aug. 25, 1972; effective Jan. 1, 1973; amended May 1, 1989; amended July 31, 1998; amended Dec. 27, 1999; amended Nov. 13, 2009; amended June 2, 2023.)
68-20-17 Order forms.
Each transfer of any schedule I or II controlled substance shall require the use of a drug enforcement agency (DEA) 222 form issued by the United States attorney general in accordance with 21 CFR part 1305 or an electronic order placed in accordance with 21 CFR part 1311.

68-20-18 Information concerning prescriptions.
(a) Any prescription for a controlled substance may be filled by a pharmacist if the prescription has been issued by a prescriber who meets the following requirements:
(1) Is legally authorized to prescribe controlled substances in Kansas or is authorized by the laws of another state; and
(2) is either registered or exempted from registration under K.S.A. 65-4116 or K.S.A. 65-4117 and amendments thereto.
(b)(1) To be valid, a prescription for a controlled substance shall be issued for a legitimate medical purpose by a prescriber acting in the usual course of professional practice. The responsibility for the proper prescribing and dispensing of controlled substances shall rest with the prescriber, but a corresponding responsibility shall rest with the pharmacist who fills the prescription. The individual filling an unlawful prescription, as well as the individual issuing it, shall be subject to the penalties provided for violations of the provisions of the act.
(2) A pharmacist shall not fill a prescription for a controlled substance or drug of concern for office use. However, any pharmacist may document on an invoice any distribution of controlled substances or drugs of concern made to a registrant.
(3) A prescription shall not be issued for the dispensing of narcotic drugs listed in any schedule to a narcotic drug-dependent individual for the purpose of continuing dependence upon these drugs, except as allowed by 21 C.F.R. 1306.07(d), as in effect on November 2, 2020, or in the course of conducting an authorized clinical investigation in the development of a narcotic addict rehabilitation program.
(c)(1) To be valid, a prescription for a controlled substance shall not be issued on a prescription blank that is preprinted or rubber-stamped with the name of a propriety preparation or with the strength, quantity, or directions.
(2) Each prescription for a controlled substance shall meet the following requirements:
(A) Be dated and signed on the date issued;
(B) bear the following information:
(i) The full name, address, and DEA registration number of the prescriber;
(ii) the name and address of the patient;
(iii) the drug name, strength, dosage form, quantity prescribed, and directions for use; and
(iv) if applicable, the identification number issued by the DEA or a written notice of action under the good faith exception pursuant to 21 C.F.R. 1301.28(e), as in effect on November 2, 2020, for a prescription for a schedule III, IV, or V narcotic drug approved by the FDA specifically for detoxification or maintenance treatment; and
(C) be written with ink, indelible pencil, or typewriter or be printed on a computer printer.
(3) A prescriber shall manually sign a paper prescription in the same manner as that individual would sign a check or legal document. Each electronic prescription shall be issued and signed in accordance with 21 C.F.R. 1311.120(b)(9) and (b)(11), 21 C.F.R. 1311.135(a) and (c), 21 C.F.R.
1311.140, and 21 C.F.R. 1311.145, as in effect on February 1, 2022, which are hereby adopted by reference.

(4) Any prescription may be prepared by an agent for the signature of a prescriber, but the prescriber shall be responsible if the prescription does not conform in all essential respects to the state and federal law and regulations. A corresponding liability shall rest upon the pharmacist who fills a prescription that is not prepared in the form prescribed by this regulation.

(5) Each intern, resident, foreign physician, or foreign medical graduate exempted from registration under K.S.A. 65-4116, and amendments thereto, shall include on all prescriptions issued the registration number of the hospital or other institution and the special internal code number assigned to the intern, resident, foreign physician, or foreign medical graduate by the hospital or other institution as provided in K.A.R. 68-20-10. This requirement shall be in lieu of the registration number of the prescriber required by this subsection. Each prescription shall have the name of the intern, resident, foreign physician, or foreign medical graduate stamped or printed on it, as well as the signature of the prescriber.

(6) Each official exempted from registration under K.A.R. 68-20-10 shall include on all prescriptions issued the official’s branch of service or agency and the service identification number. This requirement shall be in lieu of the registration number of the prescriber otherwise required by this subsection. The service identification number for a public health service employee shall be that individual’s social security identification number. Each prescription shall have the name of the officer stamped or printed on it, as well as the signature of the officer.

(7) Any controlled substance prescription in schedules III through V may be issued as a paper or electronic prescription or transmitted by a prescriber or the prescriber’s designated agent to a pharmacy by oral or facsimile transmission. Except as authorized by K.A.R. 68-2-22, each nonpaper prescription order shall be reduced to hard copy as soon as the order is reviewed by the pharmacist. The hard copy reduction shall include all information required by this regulation, except for the signature of the prescriber in the case of an oral transmission, and, if transmitted by other than the prescriber, shall bear the first name and last name of the person so transmitting the prescription. Each prescription sent by facsimile transmission shall be transmitted directly from the prescriber or the prescriber’s designated agent to the pharmacy and shall contain a header identifying the sender of the prescription.

(8) Any controlled substance prescription in schedule II may be issued as a paper or electronic prescription. Each prescription for a schedule II controlled substance transmitted to a pharmacy by oral or facsimile transmission shall be dispensed in accordance with 21 C.F.R. 1306.11 and K.A.R. 68-20-19. Each prescription sent by facsimile transmission shall be transmitted directly from the prescriber or the prescriber’s designated agent to the pharmacy and shall contain a header identifying the sender of the prescription.

(9) Any pharmacist may fill multiple prescriptions issued by a prescriber authorizing the patient to receive up to a 90-day supply of a schedule II controlled substance if all of the following conditions are met:

(A) Each separate prescription is issued for a legitimate medical purpose by a prescriber acting in the usual course of professional practice.

(B) The prescriber provides written instructions on each prescription other than the first prescription, if the prescriber intends for the first prescription to be filled immediately, indicating the earliest date on which the prescription may be filled.

(C) The prescriber concludes that providing the patient with multiple prescriptions does not create an undue risk of diversion or abuse.
(D) Each separate prescription meets all requirements for a schedule II controlled substances prescription, including being dated and signed on the date issued.
(d) A prescription for controlled substances shall be filled only by the following individuals:
(1) A pharmacist acting in the usual course of professional practice in a registered pharmacy, hospital drug room, or other registered place of employment; or

68-20-18a Information concerning prescriptions; recordkeeping; pharmacy prescription application.
(a) Each controlled substance shall be supplied or dispensed directly to a patient only pursuant to a prescription issued in accordance with K.A.R. 68-20-18. Each controlled substance shall be supplied at a registered facility for immediate facility administration to the ultimate user only pursuant to a medication order.
(b) Each dispensing, partial filling, or refilling of a prescription for a controlled substance shall be entered on the back of the prescription with the date, quantity, and name or initials of the pharmacist providing the final verification.
(c) As an alternative to the procedures provided by subsection (b), a pharmacy prescription application may be used for the storage and retrieval of dispensing, refill, and partial filling information for prescription orders for controlled substances if all of the following requirements are met:
(1) Each computerized system shall provide on-line retrieval, by computer monitor display or hard-copy printout, of original prescription order, refill, and partial fill information for those prescription orders that are authorized for filling. Each display or printout of information shall include the following:
(A) The original prescription number;
(B) the date of issuance of the original prescription order by the prescriber;
(C) the dates of dispensing or partial filling;
(D) the full name and address of the patient;
(E) the name, address, and DEA registration number of the prescriber;
(F) the name, strength, dosage form, quantity of the controlled substance prescribed, and the quantity dispensed, if different from the quantity prescribed;
(G) the identification code, or name or initials of the dispensing pharmacist;
(H) the total number of refills authorized by the prescriber, if applicable and allowable; and
(I) the total number of doses dispensed to date for that prescription order.
(2) Each pharmacist who makes use of a pharmacy prescription application shall document that the information in the pharmacy prescription application is correct each time the pharmacist fills, refills, or partially fills a controlled substance.
(A) If the pharmacy prescription application produces a hard-copy printout of each day’s controlled substance prescription order data, the printout shall meet the following requirements:
(i) The printout shall be verified, dated, and signed by the pharmacist who filled or partially filled the prescription order. The pharmacist shall verify that the date indicated is correct and then sign this document in the same manner as the pharmacist would sign a check or legal document.
(ii) The printout shall be provided to each pharmacy using the computerized system within 72 hours of the date on which the controlled substance was dispensed.

(iii) The printout shall be verified and signed by each pharmacist who is involved in the dispensing.

(B) In lieu of signing a hard-copy printout of each day’s controlled substance prescription order data, the pharmacy owner shall maintain a bound logbook or separate file in which each pharmacist involved in the dispensing shall sign a statement, in the manner described in paragraph (c)(2)(A), each day, attesting to the fact that the information entered into the pharmacy prescription application that day has been reviewed by the pharmacist and is correct as shown.

(3) Each pharmacy prescription application shall have the capability of producing a printout of any fill data that the facility is responsible for maintaining. Each printout shall include an audit trail for any specified strength and dosage form of any controlled substance, by brand, generic name, or both, in addition to the following:

(A) The name of the prescriber;
(B) the name and address of the patient;
(C) the quantity dispensed on each fill;
(D) the date of dispensing of each fill;
(E) the name or identification code of the dispensing pharmacist; and
(F) the number of the original prescription order.

(4) If a pharmacy experiences a computer system outage of the pharmacy prescription application, the pharmacy shall have an auxiliary procedure that will be used for documentation of partial fills and refills of controlled substance prescriptions. This auxiliary procedure shall ensure that partial fills or refills are authorized by the original prescription, the maximum number of dosage units or refills has not been exceeded, the prescription is still valid for partial filling or refilling, and all appropriate data is retained for on-line data entry as soon as the computer system is available for use again.

(d) All prescriptions, records, and documents required by this article of the board’s regulations shall be kept readily retrievable at the registered location for five years from the date of the last filling, refilling, partial filling, or entry into the record, except that financial and shipping records may be kept at other than the registered location with approval of the DEA. (Authorized by and implementing K.S.A. 65-4102, K.S.A. 65-4121, and K.S.A. 65-4123; effective June 2, 2023.)

68-20-19 Controlled substances listed in schedule II.

(a)(1) A pharmacist shall dispense a controlled substance listed in schedule II that is a prescription-only drug only pursuant to a signed prescription issued in accordance with K.A.R. 68-20-18, except as provided in paragraph (a)(4).

(2) A prescription under the provisions of paragraph (a)(1) shall not be filled in either of the following circumstances:

(A) More than 90 days after the original date of issue appearing on the prescription; or
(B) before or after any date specified on the prescription by the prescriber.

(3)(A) For an emergency, as defined by paragraph (a)(4), a pharmacist may dispense a controlled substance listed in schedule II upon receiving the oral authorization of a prescriber, if all of the following requirements are met:

(i) The quantity prescribed and dispensed shall be limited to the amount adequate to treat the patient during the emergency period. Dispensing beyond the emergency period shall be pursuant to a signed prescription issued in accordance with K.A.R. 68-20-18.
(ii) The prescription shall be immediately reduced to a hard copy by the pharmacist and shall contain all information required under K.A.R. 68-20-18 except for the signature of the prescriber.

(iii) If the prescriber is not known to the pharmacist, the pharmacist shall make a reasonable effort to determine that the authorization came from the prescriber, which may include a call back to the prescriber, using the prescriber’s phone number as listed in the telephone directory or other good faith efforts to ensure the prescriber’s identity, or both.

(iv) Within seven days after authorizing an emergency prescription drug order, the prescriber shall cause a written or electronic prescription drug order for the emergency quantity prescribed to be delivered to the dispensing pharmacist.

(B) In addition to meeting the requirements of K.A.R. 68-20-18, the prescription drug order shall have written on its face “Authorization for Emergency Dispensing” and the date of the prescription drug order.

(C) The written or electronic prescription drug order shall be delivered to the pharmacist in person within seven days of authorization or, if the written prescription is delivered by mail, it shall be postmarked within the seven-day period.

(D) Upon receipt, the dispensing pharmacist shall attach this written prescription drug order to the pharmacist’s record of the emergency prescription drug order. For each electronic prescription, the dispensing pharmacist shall annotate the record of the electronic prescription with the original authorization and date of the oral order.

(E) The pharmacist shall notify the nearest office of the U.S. drug enforcement administration (DEA) if the prescribing practitioner fails to deliver a written or electronic prescription drug order to the pharmacist. Failure of the pharmacist to notify the DEA shall void the authority conferred by this regulation to dispense without a written or electronic prescription of a prescriber.

(4) For the purposes of authorizing a prescription of any controlled substance listed in schedule II of the federal or state uniform controlled substances act, the term “emergency situation” shall mean any situation in which the prescriber determines the following:

(A) That immediate administration of the controlled substance is necessary for proper treatment of the intended ultimate user;

(B) that no appropriate alternative treatment is available, including administration of a drug that is not a controlled substance under schedule II of the act; and

(C) that it is not reasonably possible for the prescriber to provide a written prescription to be presented, before dispensing, to the pharmacist dispensing the substance.

(b) The partial filling of a prescription for any controlled substance listed in schedule II shall be permissible, only as provided in this subsection.

(1) Whenever the pharmacist is unable to supply the full quantity called for in a written, electronic, or emergency prescription and the pharmacist makes a notation of the quantity supplied on the face of the written prescription, written record of the emergency prescription, or electronic prescription record, the pharmacist shall perform the following:

(A) Fill the remaining portion of the prescription within 72 hours of the first partial filling or, if the remaining portion cannot be filled within the 72-hour period, the pharmacist shall notify the prescriber of the situation; and

(B) supply no further quantity beyond 72 hours without a new prescription.

(2) Prescriptions for schedule II controlled substances for patients in a long-term care facility (LTCF) or for a patient with a medical diagnosis documenting a terminal illness may be filled in
partial quantities, including individual dosage units, as provided in this subsection. The pharmacist shall record on the prescription whether the patient is “terminally ill” or an “LTCF patient.”

(A) The total quantity of schedule II controlled substances dispensed in all partial fillings shall not exceed the total quantity prescribed.

(B) These schedule II prescriptions shall be valid for partial filling for a period not to exceed 60 days from the issue date of the prescription unless terminated sooner by the discontinuance of medication.

(3) Any prescription for a schedule II controlled substance may be partially filled at the request of the patient or the prescriber who wrote the prescription. The pharmacist shall not fill or partially fill any remaining portions of the prescription more than 30 days after the date the prescription was written, except as provided by paragraphs (b)(1) and (2). The total quantity of schedule II controlled substances dispensed in all partial fillings shall not exceed the total quantity prescribed.

(c) Each pharmacist filling a written or emergency prescription for a controlled substance listed in schedule II shall ensure that a label that meets the requirements of K.A.R. 68-7-14 and 21 C.F.R. 290.5 is affixed to the package.


68-20-20 Controlled substances listed in schedules III, IV, and V.

(a) A pharmacist may dispense any controlled substance listed in schedule III, IV, or V that is a prescription-only drug pursuant only to a prescription issued in accordance with K.A.R. 68-20-18.

(b) Additional quantities of controlled substances listed in schedule III, IV, or V may be authorized by a prescriber through an oral refill authorization transmitted to the pharmacist if all of the following conditions are met:

(1) The total quantity authorized, including the amount of the original prescription, does not exceed five refills or extend beyond six months from the date of issue of the original prescription.

(2) The pharmacist obtaining the oral authorization records on the reverse of the original prescription the following:

(A) The date;

(B) the quantity of refill;

(C) the number of additional refills authorized; and

(D) the initials of the pharmacist who received the authorization from the prescriber.

(3) The quantity of each additional refill authorized is equal to or less than the quantity authorized for the initial filling of the original prescription.

(4) The prescriber executes a new prescription as provided in K.A.R. 68-20-18 for any additional quantities beyond the five-refill, six-month limitation.

(5) The authorization of additional quantities is documented by either of the methods specified in K.A.R. 68-20-18a.
(c) A prescription for a controlled substance listed in schedule III, IV, or V may be partially filled if all of the following conditions are met:
(1) Each partial filling is recorded in the same manner as that for a refilling.
(2) The total quantity dispensed in all partial fillings does not exceed the total quantity prescribed.
(3) No dispensing occurs after six months after the date on which the prescription was issued.
(d) Each pharmacist filling a prescription for a controlled substance listed in schedule III, IV, or V shall ensure that a label meeting the requirements of K.A.R. 68-7-14 is affixed to the package.

68-20-21 Revoked.

68-20-22 Selling without a prescription.
Any controlled substance listed in schedule II, III, IV, or V that is not a prescription-only drug may be sold by a pharmacist without a prescription to a purchaser at retail if all of the following conditions are met:
(a) The sale of any substance that is a methamphetamine precursor is made in accordance with K.S.A. 65-16,102, and amendments thereto, and with 21 C.F.R. 1314.20, 21 C.F.R. 1314.25, 21 C.F.R. 1314.30, 21 C.F.R. 1314.100, and 21 C.F.R. 1314.105 as in effect on August 31, 2022.
(b) The sale of any substance that is not a methamphetamine precursor meets all of the following conditions:
(1) Approval of the sale is made only by a pharmacist and not by a nonpharmacist employee, even if under the supervision of a pharmacist.
(2) The pharmacist does not sell at retail more than 240 cc (8 ounces) of any controlled substance containing opium or more than 120 cc (4 ounces) of any other controlled substance to the same purchaser in any 48-hour period.
(3) The pharmacist does not sell at retail more than 48 dosage units of any controlled substance containing opium or more than 24 dosage units of any other controlled substance to the same purchaser in any 48-hour period.
(4) The purchaser is at least 18 years of age.
(5) The pharmacist requires every purchaser of a controlled substance to furnish suitable identification that includes proof of age.
(6) The pharmacist maintains a bound record book for the dispensing of controlled substances. The record book shall contain the name and address of the purchaser, the name and quantity of controlled substance purchased, the date of each purchase, and the name or initials of the pharmacist who approved the sale of the substance to the purchaser. The record book shall be kept readily retrievable at the registered location for five years.
(c) A prescription is not required for dispensing the substance pursuant to any other federal, state, or local law. (Authorized by K.S.A. 65-16,106; implementing K.S.A. 65-16,102 and 65-16,104; effective May 1, 1978; amended June 2, 2023.)
68-20-23. N-Benzylpiperazine included in schedule I.
N-Benzylpiperazine, including its salts, isomers, and salts of isomers, shall be classified as a
schedule I controlled substance.
(Authorized and implementing K.S.A. 65-4102; effective, T-68-11-6-08, Nov. 6, 2008, effective
March 6, 2009.)

(Authorized by and implementing K.S.A. 2010 Supp. 65-4102; effective, T-68-3-23-11, March
23, 2011.)

(Authorized by and implementing K.S.A. 2010 Supp. 65-4102; effective, T-68-3-23-11, March
23, 2011.)

(Authorized by and implementing K.S.A. 2010 Supp. 65-4102; effective, T-68-3-23-11, March
23, 2011.)

(Authorized by and implementing K.S.A. 2010 Supp. 65-4102; effective, T-68-3-23-11, March
23, 2011.)

68-20-30. Revoked.
2012.)

68-20-31. 2,5-dimethoxy-4-methyl-n-(2-methoxybenzyl)phenethylamine included in
schedule I.
2,5-dimethoxy-4-methyl-n-(2-methoxybenzyl)phenethylamine, including its salts, isomers, and
salts of isomers, shall be classified as a schedule I controlled substance.
(Authorized by and implementing K.S.A. 2014 Supp. 65-4102; effective, T-68-1-23-15, Jan. 23,
2015; effective June 5, 2015.)
Article 21: Prescription Monitoring Program

68-21-1. Definitions.
As used in this article of the board’s regulations, each of the following terms shall have the meaning specified in this regulation:
(a) “Authentication” means the provision of information, an electronic device, or a certificate by the board or its designee to a requester that allows the requester to electronically access prescription monitoring information. The authentication may include the provision of a user name, a password, or an electronic identification device or certificate.
(b) “DEA” means the drug enforcement administration of the United States department of justice.
(c) “Dispenser identification number” means the DEA number. If a DEA number is not issued to the dispenser, the dispenser identification number means the NPI number or the Kansas license number.
(d) “Drug enforcement administration number” means a unique registration number issued to a practitioner authorized by the DEA to prescribe controlled substances.
(e) “National provider identifier” and “NPI” mean a unique 10-digit number issued by the national provider identifier registry and used to identify each practitioner whose services are authorized by medicaid or medicare.
(f) “Patient identification number” means that patient’s unexpired temporary or permanent driver’s license number, state-issued identification card number, or pharmacy system-generated identification number. If the patient does not have one of those numbers, the dispenser shall use the patient’s first, middle, and last initials, followed by the patient’s eight-digit birth date. The patient identification number shall not include a social security number.
(g) “Report” means a compilation of data concerning a dispenser, patient, drug of concern, or scheduled substance as defined in K.S.A. 65-1682, and amendments thereto.
(h) “Valid photographic identification” means any of the following:
(1) An unexpired driver’s license, state identification card, or instruction permit;
(2) an unexpired official passport issued by any nation;
(3) a United States military identification card; or
(4) an unexpired identification card issued by a United States Indian tribe.

68-21-2. Electronic reports.
(a) Except as specified in subsections (d) and (e), each dispenser shall file a report with the board for each scheduled substance and drug of concern sold in Kansas or to an address in Kansas. This report shall be submitted by the end of the next business day from the day that the drug is sold.
(b) Except as specified in subsections (c), (d), and (e), each dispenser that does not dispense scheduled substances or drugs of concern in Kansas or to an address in Kansas during the reporting period specified in subsection (a) shall file a zero report with the board. Each zero report shall be filed by the end of the next business day.
(c) Any dispenser that meets the following conditions may submit a written request to the board for an exemption from subsection (b):
(1) The dispenser does not monthly dispense more than 10 prescriptions for scheduled substances and drugs of concern in Kansas or to an address in Kansas.

(2) The dispenser is unable to automate submission of a zero report.

(d) Any medical care facility, as defined by K.S.A. 65-1626 and amendments thereto, may submit a written request to the board for an exemption from subsections (a) and (b) if the medical care facility provides an interim supply of a scheduled substance or drug of concern to an outpatient on an emergency basis and the interim quantity does not exceed a 48-hour supply and, as described in K.A.R. 68-7-11(d)(2)(B), is limited to an amount sufficient to supply the outpatient’s needs until a prescription can be filled in accordance with K.A.R. 68-7-11. This exemption shall apply only to the outpatient emergency interim supply of drugs and not to other outpatient dispensing or supply activities of the medical care facility.

(e) Any dispenser that does not dispense scheduled substances or drugs of concern in Kansas or to an address in Kansas may submit a written request to the board for an exemption from subsections (a) and (b) if both of the following conditions are met:

(1) The dispenser has submitted the required reports for at least three months or has provided three months of dispensing records to the board.

(2) The request is accompanied by the following:

(A) If the dispenser is a nonresident pharmacy, a list of states in which the pharmacy is registered;

(B) the current prescription monitoring program reporting status in each state in which the dispenser is registered; and

(C) a copy of any written reprimand, censure, or other disciplinary action related to prescription monitoring program reporting that the dispenser has had in any state, district, or territory.

(f) Each dispenser or pharmacy that no longer meets the criteria for exemption specified in subsection (c), (d), or (e) shall notify the board and begin submitting reports within seven days.

(g) Each exemption issued by the board shall expire annually on August 31.

(h) Except as specified in K.A.R. 68-21-3, each report required to be submitted pursuant to subsection (a) shall be submitted by secure file transfer protocol in the electronic format established by the American society for automation in pharmacy, dated no earlier than 2020, version 4, release 2b.

(i) Each dispenser shall correct any reporting error within seven days of discovering the error or being notified of the error by the board or the board’s designee. (Authorized by K.S.A. 65-1692; implementing K.S.A. 2022 Supp. 65-1683; effective Oct. 15, 2010; amended April 15, 2011; amended Aug. 13, 2014; amended June 2, 2023.)


Each dispenser who may access information maintained by the board on each drug of concern and scheduled substance dispensed to one of the dispenser’s patients for the purpose of providing medical or pharmaceutical care shall notify the patient of this access to program information by performing either of the following:

(a) Posting an easily viewable sign at the place where prescription orders are issued or accepted for dispensing; or
68-21-5. Access to program information.

(a) Any patient or patient’s designee may obtain a report listing all program information that pertains to the patient by submitting a written request to the board on a form provided by the board, which shall include the following:

1. The patient’s name and, if applicable, the name of the patient’s designee;
2. the patient’s residential address and, if applicable, the residential address of the patient’s designee;
3. the patient’s telephone number and, if applicable, the telephone number of the patient’s designee;
4. the time period for which information is being requested;
5. a copy of a valid photographic identification of the patient or the patient’s designee; and
6. if the requester is not the patient, a copy of official documents establishing either legal guardianship or power of attorney.

(b) Any practitioner, dispenser, or delegate may obtain program information relating to a patient in accordance with K.S.A. 65-1685, and amendments thereto, by submitting an electronic request to the board in a manner established by the board, using authentication. Information regarding more than one patient may be submitted in a single request. Each request shall be submitted in a format established by the board and shall include the following elements for each patient:

1. The patient’s first name and last name;
2. the patient’s date of birth; and
3. the time period for which information is being requested.

(2) The authentication and identity of the practitioner, dispenser, or delegate shall be verified by the board before allowing access to any program information. If the authentication is lost or missing or if the security of the authentication is compromised, the practitioner, dispenser, or delegate shall notify the board in writing as soon as possible.

(c) In conjunction with an active investigation, any designated representative of a professional licensing, certification, or regulatory agency charged with administrative oversight of practitioners or dispensers may obtain program information for a practitioner licensed or regulated by the agency or for a patient by submitting a written request to the board on a form provided by the board.

1. If the request is for program information related to a practitioner, the request shall include the following:
   (A) The requestor’s name and agency;
   (B) the practitioner’s name;
   (C) the practitioner’s DEA number, if issued to the practitioner;
   (D) the practitioner’s NPI number, if issued to the practitioner; and
   (E) the time period for which information is being requested.

2. If the request is for program information related to a patient, the request shall include the following:
   (A) The requestor’s name and agency;
   (B) the patient’s first name and last name;
(C) the patient’s date of birth; and
(D) the time period for which information is being requested.

(d) Any designated representative from the department of health and environment, an overdose fatality review board established by the state, or an impaired provider program for practitioners may obtain program information related to a patient in accordance with K.S.A. 65-1685, and amendments thereto, by submitting an electronic written request to the board in a manner established by the board, using authentication. The request shall include the following:
(1) The patient’s first name and last name;
(2) the patient’s date of birth; and
(3) the time period for which information is being requested. (Authorized by K.S.A. 65-1692; implementing K.S.A. 65-1685, as amended by L. 2022, ch. 74, sec. 5; effective Oct. 15, 2010; amended June 2, 2023.)

68-21-6. Reciprocal agreements with other states or government entities to share information.
(a) Reciprocal agreements with one or more of the following entities within the United States may be entered into by the board to share program data if the entity’s prescription monitoring program is compatible with the program:
(1) A state, commonwealth, district, or territory;
(2) a military or veteran health system;
(3) an Indian health system or service; or
(4) a city, county, municipality, or township.
(b) In determining the compatibility of the entity’s prescription monitoring program, the following may be considered by the board:
(1) The safeguards for privacy of patient records and the entity’s success in protecting patient privacy;
(2) the persons authorized by the entity to view the data collected by the program;
(3) the schedules of controlled substances monitored by the entity;
(4) the data required by the entity to be submitted on each prescription; and
(5) the costs and benefits to the board of mutually sharing data with the entity.
(c) Any reciprocal agreement may be reviewed annually by the board to determine its continued compatibility with the program.
(Authorized by K.S.A. 65-1692; implementing K.S.A. 65-1685; effective October 15, 2010; amended November 29, 2019.)

68-21-7. Drugs of concern.
(a) Each of the following shall be classified as a drug of concern:
(1) Any product containing all three of these drugs: butalbital, acetaminophen, and caffeine;
(2) any compound, mixture, or preparation that contains any detectable quantity of ephedrine, its salts or optical isomers, or salts of optical isomers and is exempt from being reported to the statewide electronic logging system for the sale of methamphetamine precursors;
(3) any compound, mixture, or preparation that contains any detectable quantity of pseudoephedrine, its salts or optical isomers, or salts of optical isomers and is exempt from being reported to the statewide electronic logging system for the sale of methamphetamine precursors;
(4) promethazine with codeine; and
(5) any product, compound, mixture, or preparation that contains gabapentin.

(b) Each request to have a drug added to the program for monitoring shall be submitted in writing to the board.

This regulation shall take effect 90 days after publication in the Kansas register.

65-636. Exhibition of title "drugstore," "pharmacy" or "apothecary."

It shall be unlawful for any individual who is not legally licensed as a pharmacist by the state board of pharmacy or any individual, firm or corporation who does not have in continuous employ, at each place of business, a pharmacist licensed by the state board of pharmacy, to take, use or exhibit the title "drugstore," "pharmacy" or "apothecary" or any combination of such titles, or any title or description of like import, or any other term designed to take the place of such title, if such title is being used in the context of health, medical or pharmaceutical care and the individual, firm or corporation has not provided a disclaimer sufficient to notify consumers that a pharmacist is not employed.

History: L. 1925, ch. 205, § 1; L. 1986, ch. 231, § 8; L. 2021, ch. 106, § 5; June 3.

65-643. Caustic or corrosive substances; definition of terms.

When used in this act, unless the context or subject matter otherwise requires, the following shall be held and construed to mean as follows:

(a) The terms "dangerous caustic or corrosive substance" means each and all of the acids, alkalis, and substances named below: (a) Hydrochloric acid and any preparation containing free or chemically unneutralized hydrochloric acid (HCl) in a concentration of ten percentum or more; (b) sulphuric acid and any preparation containing free or chemically unneutralized sulphuric acid (H2SO4) in a concentration of ten percentum or more; (c) nitric acid or any preparation containing free or chemically unneutralized nitric acid (HNO3) in a concentration of five percentum or more; (d) carbolic acid (C6H5CH), otherwise known as phenol, and any preparation containing carbolic acid in a concentration of five percentum or more; (e) oxalic acid and any preparation containing free or chemically unneutralized oxalic acid (H2C2O4) in a concentration of ten percentum or more; (f) any salt of oxalic acid and any preparation containing any such salt in a concentration of ten percentum or more; (g) acetic acid or any preparation containing free or chemically unneutralized acetic acid (HC2H3O2) in a concentration of twenty percentum or more; (h) hypochlorous acid, either free or combined, and any preparation containing the same in a concentration so as to yield ten percentum or more by weight of available chlorine, excluding calx chlorinata, bleaching powder, and chloride of lime; (i) potassium hydroxide and any preparation containing free or chemically unneutralized potassium hydroxide (KOH), including caustic potash and Vienna paste, in a concentration of ten percentum or more; (j) sodium hydroxide and any preparation containing free or chemically unneutralized sodium hydroxide (NaOH), including caustic soda and lye, in a concentration of ten percentum or more; (k) silver nitrate sometimes known as lunar caustic, and any preparation containing silver nitrate (AgNO3) in a concentration of five percentum or more; and (l) ammonia water and any preparation yielding free or chemically uncombined ammonia (NH3), including ammonium hydroxide and "Hartshorn" in a concentration of five percentum or more.

(b) The term "misbranded parcel, package or container" means a retail parcel, package or container or any dangerous caustic or corrosive substance for household use, not bearing a conspicuous easily legible label or sticker, containing (a) the name of the article; (b) the name and place of business of the manufacturer, packer, seller or distributor; (c) the word "poison" running parallel with the main body of reading matter on said label or sticker on a clear, plain
background or a distinctly contrasting color, in uncondensed gothic capital letters, the letters to be not less than 24-point size, unless there is on said label or sticker no other type so large, in which event the type shall be not smaller than the largest type on the label or sticker, and (d) directions for treatment in case of accidental personal injury by the dangerous caustic or corrosive substance.

(c). The words "person" or "persons" shall be held, understood and construed to mean every person, natural or artificial, and all firms, copartnerships, trust estates, corporations and the principal officers and agents thereof.

History:   L. 1927, ch. 247, § 1; June 1.

65-644. Same; misbranding.
No person shall sell, barter or exchange, or receive, hold, display or offer for sale, barter or exchange, in the state of Kansas, any dangerous caustic or corrosive substance in a misbranded parcel, package or container, said parcel, package or container being designed for household use.

History:   L. 1927, ch. 247, § 2; June 1.

65-645. Same; condemnation and disposition.
Any dangerous caustic or corrosive substance in a misbranded parcel, package or container suitable for household use, that is being sold, bartered or exchanged, or held, displayed or offered for sale, barter or exchange, shall be liable to be proceeded against in any court of competent jurisdiction. If such substance is condemned as misbranded by said court, it shall be disposed of by destruction or sale, as the court may direct; and if sold, the proceeds, less the actual costs and charges, shall be paid over to the clerk of the district court of the county in which such sale is had, but such substance shall not be sold contrary to the laws of the state: Provided, however, That upon the payment of the costs of such proceedings and the execution and delivery of a good and sufficient bond to the effect that such substance will not be unlawfully sold or otherwise disposed of, the court may order [or] direct that such substance be delivered to the owner thereof. Such condemnation proceedings shall conform as near as may be to proceedings in confiscation of intoxicating liquors.

History:   L. 1927, ch. 247, § 3; June 1.

65-646. Same; enforcement of act.
The attorney general and the county attorneys of the respective counties of this state shall enforce the provisions of this act, and they are hereby authorized and empowered to approve and register such brands and labels intended for use under the provisions of this act as may be submitted to him for that purpose and as may, in his judgment, conform to the requirements of this statute.

History:   L. 1927, ch. 247, § 4; June 1.

65-647. Same; penalty.
Any person violating the provisions of this act shall, upon conviction thereof, be punished by a fine of not more than two hundred dollars, or by imprisonment in the county jail for not more than ninety days, or by both such fine and imprisonment in the discretion of the court.

History:   L. 1927, ch. 247, § 5; June 1.
65-648. **Same; prosecutions.**
The attorney general and the county attorneys of the respective counties of the state to whom there is presented, or who in any way procures satisfactory evidence of any violation of the provisions of this act, shall cause appropriate proceedings to be commenced and prosecuted in the proper courts, without delay, for the enforcement of the penalties as in such cases herein provided.

**History:** L. 1927, ch. 247, § 6; June 1.

65-649. **Same; sale of household products.**
Household products for cleaning and washing purposes subject to this act and labeled in accordance therewith may be sold, offered for sale, held for sale and distributed in this state by any dealer, wholesaler or retailer.

**History:** L. 1927, ch. 247, § 7; June 1.

65-650. **Medicines, drugs and poisons sold through vending machines, requirements; penalties for violations.**
(a) Any person, firm or corporation who offers for sale, sells or distributes any prescription medicine, prescription-only drug, drug which contains ephedrine alkaloids, drug intended for human use by hypodermic injection or poison through or by means of any vending machine or other mechanical device, or who uses any vending machine in or for the sale or distribution of any prescription medicine, prescription-only drug, drug which contains ephedrine alkaloids, drug intended for human use by hypodermic injection or poison, shall be guilty of a class C nonperson misdemeanor and upon conviction shall be fined not less than $25 nor more than $500.

(b) No nonprescription drugs shall be offered for sale or sold through a vending machine in anything other than the manufacturer's original tamper-evident and expiration-dated packet. No more than 12 different nonprescription drugs products shall be offered for sale or sold through any one vending machine. Any vending machine in which nonprescription drugs are offered for sale or sold shall be located so that the drugs stored in such vending machine are stored in accordance with drug manufacturer's requirements. Drugs offered for sale or sold in such vending machine shall not be older than the manufacturer's expiration date. Each vending machine through which nonprescription drugs are offered for sale or sold shall have an obvious and legible statement on the machine that identifies the owner of the machine, a toll-free telephone number at which the consumer may contact the owner of the machine, a statement advising the consumer to check the expiration date of the product before using the product and the telephone number of the state board of pharmacy. As used in this subsection, "nonprescription drug" does not include any prescription medicine, prescription-only drug, drug which contains ephedrine alkaloids, drug intended for human use by hypodermic injection or poison. A violation of this subsection is a class C nonperson misdemeanor and upon conviction the violator shall be fined not less than $25 nor more than $500.

**History:** L. 1933, ch. 177, § 1; L. 2001, ch. 40, § 1; L. 2012, ch. 145, § 15; July 1.

65-655. **Food, drug and cosmetic act; title.**

**History:** L. 1953, ch. 286, § 1; L. 2010, ch. 72, § 5; L. 2012, ch. 145, § 15; July 1.
65-656. Same; definitions.

For the purpose of this act:

(a) "Secretary" means the secretary of agriculture or the secretary's authorized representatives.

(b) "Person" means an individual, partnership, governmental entity, corporation, or association of persons.

(c) "Food" means: (1) Articles used for food or drink for humans or other animals; (2) chewing gum; and (3) articles used for components of any such article.

(d) "Drug" means: (1) Articles recognized in the official United States pharmacopoeia, official homeopathic pharmacopoeia of the United States, or official national formulary, or any supplement to any of them; (2) articles intended for use in diagnosis, cure, mitigation, treatment or prevention of disease in humans or other animals; (3) articles, other than food, intended to affect the structure or any function of the body of humans or other animals; and (4) articles intended for use as a component of any article specified in paragraph (1), (2) or (3); but does not include devices or their components, parts or accessories. The term "drug" does not include amygdalin (laetrile).

(e) "Device," except as used in K.S.A. 65-657(j), 65-665(f), 65-669(c) and (o) and 65-671(c), and amendments thereto, means instruments, apparatus and contrivances, including their components, parts and accessories, intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease in humans or other animals or to affect the structure or any function of the body of humans or other animals.

(f) "Cosmetic" means: (1) Articles intended to be rubbed, poured, sprinkled, or sprayed on, introduced into, or otherwise applied to the human body or any part thereof for cleaning, beautifying, promoting attractiveness or altering appearance; and (2) articles intended for use as a component of any such articles, except that such term does not include soap.

(g) "Official compendium" means the official United States pharmacopoeia, official homeopathic pharmacopoeia of the United States, official national formulary or any supplement to any of them.

(h) "Label" means a display of written, printed or graphic matter upon the immediate container of any article; and a requirement made by or under authority of this act that any word, statement, or other information appearing on the label shall not be considered to be complied with unless such word, statement, or other information also appears on the outside container or wrapper, if any, of the retail package of such article, or is easily legible through the outside container or wrapper.

(i) "Immediate container" does not include package liners.

(j) "Labeling" means all labels and other written, printed or graphic matter upon an article or any of its containers or wrappers or accompanying such article.

(k) "Advertisement" means all representations disseminated in any manner or by any means other than by labeling, for the purpose of inducing, or that are likely to induce, directly or indirectly, the purchase of food, drugs, devices or cosmetics.

(l) "New drug" means: (1) Any drug the composition of which is such that such drug is not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, as safe and effective for use under the conditions prescribed, recommended or suggested in the labeling thereof; or (2) any drug the composition of which is such that such drug, as a result of investigations to determine its safety and effectiveness for use under such conditions, has become so recognized, but that has not, otherwise than in such investigations, been used to a material extent or for a material time under such conditions. The term "new drug" does not include amygdalin (laetrile).

(m) "Contaminated with filth" applies to any food, drug, device or cosmetic not securely protected from dust, dirt, and as far as may be necessary by all reasonable means, from all foreign or injurious contaminations.
(n) "Pesticide chemical" means any substance that, alone, in chemical combination, or in formulation with one or more other substances is a "pesticide" within the meaning of the agricultural chemicals act, K.S.A. 2-2202, and amendments thereto, and that is used in the production, storage or transportation of raw agricultural commodities.

(o) "Raw agricultural commodity" means any food in its raw or natural state, including all fruits that are washed, colored or otherwise treated in their unpeeled natural form prior to marketing.

(p) "Food additive" means any substance, the intended use of which results or may be reasonably expected to result, directly or indirectly, in its becoming a component or otherwise affecting the characteristics of any food, including any substance intended for use in producing, manufacturing, packing, processing, preparing, treating, packaging, transporting or holding food. "Food additive" includes any source of radiation intended for any such use, if such substance is not generally recognized, among experts qualified by scientific training and experience to evaluate its safety, as having been adequately shown through scientific procedures, or, in the case of a substance used in a food prior to January 1, 1958, through either scientific procedures or experience based on common use in food, to be safe under the conditions of its intended use. "Food additive" does not include: (1) A pesticide chemical in or on a raw agricultural commodity; (2) a pesticide chemical to the extent that it is intended for use or is used in the production, storage or transportation of any raw agricultural commodity; (3) a color additive; or (4) any substance used in accordance with a sanction or approval granted prior to the enactment of the food additive amendment of 1958, pursuant to the federal act.

(q) (1) "Color additive" means a material that: (A) Is a dye, pigment or other substance made by a process of synthesis or similar artifice, or extracted, isolated or otherwise derived, with or without intermediate or final change of identity from a vegetable, animal, mineral or other source; or (B) when added or applied to a food, drug or cosmetic, or to the human body or any part thereof, is capable, alone or through reaction with another substance, of imparting color thereto; except that such term does not include any material which has been or hereafter is exempted under the federal act.

(2) The term "color" includes black, white and intermediate grays.

(3) Nothing in this subsection shall be construed to apply to any pesticide chemical, soil or plant nutrient, or other agricultural chemical solely because of its effect in aiding, retarding or otherwise affecting, directly or indirectly, the growth or other natural physiological process of produce of the soil and thereby affecting its color, whether before or after harvest.

(r) "Imitation" means, except for imitation food as provided in K.S.A. 65-665, and amendments thereto, any article made in the semblance of another, consisting of similar or dissimilar ingredients and being capable of being substituted for the imitated article without the knowledge of the consumer.

(s) "Federal act" means the federal food, drug and cosmetic act, 21 U.S.C. § 301 et seq.

(t) "Department" means the Kansas department of agriculture.

(u) "Distribution" means the provision of food, drug, cosmetic or device to another person and includes selling, offering for sale, giving, supplying, transporting, applying and dispensing.

(v) "Food establishment" means any place in which food is prepared, served or offered for sale or service on the premises or elsewhere. "Food establishment" does not include roadside markets that offer only whole fresh fruits, nuts and vegetables for sale. "Food establishment" includes, but is not limited to:

(1) Eating or drinking establishments, fixed or mobile restaurants, coffee shops, cafeterias, short-order cafes, luncheonettes, tea rooms, grills, sandwich shops, soda fountains, taverns, private clubs, roadside stands, industrial-feeding establishments, catering kitchens, commissaries and any other private, public or nonprofit organizations routinely serving food; and

(2) grocery stores, convenience stores, bakeries and locations where food is provided for the public with or without charge.
(w) "Food processing plant" means a commercial operation that processes or stores food for human consumption and provides food for distribution to other business entities at other locations, including other food processing plants and food establishments. "Food processing plant" does not include any operation or individual beekeeper that produces and distributes honey to other business entities if the producer does not process the honey beyond extraction from the comb.

(x) "Food vending machine" means any self-service device that, upon payment, dispenses unit servings of food, either in bulk or in packages. Such device shall not necessitate replenishing between each vending operation. "Food vending machine" does not include any vending machine dispensing only canned or bottled soft drinks or prepackaged food that does not require temperature control for safety.

(y) "Food vending machine company" means any person in the business of operating and servicing food vending machines.

(z) "Location" means a physical address, or absent an address, the geographical area within 300 feet of a food establishment or food processing plant. In the case of a mobile food establishment housed in a trailer, such trailer shall be considered a food establishment with its own location. In the case of a mobile food establishment that is not housed in a trailer, the equipment used for storage, preparation or offering of food shall be considered a food establishment with its own location.

(aa) "Municipality" means any city or county of this state.

(bb) "Processing" means the handling of a food, drug, cosmetic or device, including the production, manufacturing, packaging, packing and labeling of such item.

(cc) "Sample" means a small quantity of food and does not include a meal or entree.

(dd) "Storage" means holding for distribution or processing.

(ee) "Meat analog" means any food that approximates the aesthetic qualities, primarily texture, flavor and appearance, or the chemical characteristics of any specific type of meat, meat food product, poultry product or poultry food product, but does not contain any meat, meat food product, poultry product or poultry food product.

(ff) "Identifiable meat term" includes, but is not limited to, terms such as meat, beef, pork, poultry, chicken, turkey, lamb, goat, jerky, steak, hamburger, burger, ribs, roast, bacon, bratwurst, hot dog, ham, sausage, tenderloin, wings, breast and other terms for food that contain any meat, meat food product, poultry product or poultry food product.

(gg) "Meat" means the same as provided in 9 C.F.R. § 301.2, as in effect on January 1, 2022.

(hh) "Meat food product" means the same as provided in 9 C.F.R. § 301.2, as in effect on January 1, 2022.

(ii) "Poultry product" means the same as provided in 9 C.F.R. § 381.1, as in effect on January 1, 2022.

(jj) "Poultry food product" means the same as provided in 9 C.F.R. § 381.1, as in effect on January 1, 2022.


65-657. Same; unlawful acts.
The following acts and the causing thereof within the state of Kansas are hereby prohibited:

(a) The processing, storage or distribution of any food, drug, device or cosmetic that is adulterated or misbranded.

(b) The adulteration or misbranding of any food, drug, device or cosmetic.

(c) The receipt in commerce of any food, drug, device or cosmetic knowing it to be adulterated or misbranded, and the delivery or proffered delivery thereof for pay or otherwise.
(d) The dissemination of any false advertisement.
(e) The refusal to permit entry, inspection or taking of a sample, as authorized by K.S.A. 65-674, and amendments thereto.
(f) The giving of a guaranty or undertaking which guaranty or undertaking is false, except by a person who relied on a guaranty or undertaking to the same effect signed by, and containing the name and address of the person residing in the United States from whom such person received in good faith the food, drug, device or cosmetic.
(g) The removal or disposal of a detained or embargoed article in violation of K.S.A. 65-660, and amendments thereto.
(h) The alteration, mutilation, destruction, obliteration or removal of the whole or any part of the labeling of, or the doing of any other act with respect to a food, drug, device or cosmetic, if such act is done while such article is held for sale and results in such article being misbranded.
(i) Forging, counterfeiting, simulating or falsely representing, or without proper authority using any mark, stamp, tag, label or other identification method authorized or required by rules and regulations promulgated under the provisions of this act.
(j) The using of any person to such person's own advantage, or revealing, other than to the administrator or officers or employees of the department of agriculture or to the courts where relevant in any jurisdictional proceeding under this act, any information acquired under authority of this act concerning any method or process which constitutes a trade secret under the uniform trade secrets act, K.S.A. 60-3320 et seq., and amendments thereto, and as a trade secret is entitled to protection.
(k) The using, on the labeling of any drug or in any advertisement relating to such drug, of any representation or suggestion that an application with respect to such drug is effective under K.S.A. 65-669a, and amendments thereto, or that such drug complies with the provisions of such section.
(l) In the case of a prescription drug distributed or offered for sale in this state, the failure of the manufacturer, packer or distributor thereof to maintain for transmittal, or to transmit, to any practitioner licensed by applicable law to administer such drug who makes written request for information as to such drug, true and correct copies of all printed matter which is required to be included in any package in which that drug is distributed or sold, or such other printed matter as is approved under the federal act. Nothing in this paragraph shall be construed to exempt any person from any labeling requirement imposed by or under other provisions of this act.
(m) (1) Placing or causing to be placed upon any drug or device or container thereof, with intent to defraud, the trade name or other identifying mark, or imprint of another or any likeness of any of the foregoing; (2) selling, dispensing, disposing of or causing to be sold, dispensed or disposed of or concealing or keeping in possession, control or custody, with intent to sell, dispense or dispose of, any drug, device or any container thereof, with knowledge that the trade name or other identifying mark or imprint of another or any likeness of any of the foregoing has been placed thereon in a manner prohibited by paragraph (1); or (3) making, selling, disposing of or causing to be made, sold or disposed of or keeping in possession, control or custody, or concealing, with intent to defraud, any punch, die, plate, or other thing designed to print, imprint or reproduce that trade name or other identifying mark or imprint of another or any likeness of any of the foregoing upon any drug, device or container thereof.
(n) Dispensing or causing to be dispensed a different drug or brand of drug in place of the drug or brand of drug ordered or prescribed without the express permission in each case of the person ordering or prescribing.
(o) Knowingly killing, selling, trading, exchanging or offering to sell, trade or exchange any diseased animal for human consumption, except immediate slaughter under state or federal meat and poultry inspection.
(p) Knowingly purchasing or otherwise obtaining possession of any diseased animal for the purpose and with the intent of disposing the same for food, except immediate slaughter under state or federal meat and poultry inspection.

(q) Offering or exposing for sale at retail, for human consumption, any slaughtered wild or domestic fowl, rabbit, squirrel or other small animal unless the entrails, crops and other offensive parts are properly drawn and removed and the carcass is cooled to 41 degrees fahrenheit or less within four hours of slaughter and held at such temperature until delivery to the end consumer.

(r) Failing to protect slaughtered fresh meats, fish, fowl or game for human consumption from dust, flies and other vermin or substance which may injuriously affect it. Protection shall be required at any wholesale or retail food establishment or food processing plant and for peddlers transporting such goods from place to place.


65-658. Same; injunction to restrain violation of 65-657.

In addition to the remedies provided by the food, drug and cosmetic act, the secretary of agriculture is hereby authorized to apply to the district court for, and the court may grant, a temporary or permanent injunction restraining, any person from violating any provision of the food, drug and cosmetic act; irrespective of whether or not there exists an adequate remedy at law.


65-660. Same; adulterated or misbranded food, drug, device or cosmetic; detaining or embargoing; condemnation proceedings; consolidation, when; samples and analyses of seized articles; destruction of certain perishable food.

(a) Whenever the secretary finds or has probable cause to believe, that any food, drug, device or cosmetic is adulterated, contains any substance injurious to public health, is offered in violation of any of the provisions of the food, drug and cosmetic act or rules and regulations adopted thereunder, or so misbranded as to be dangerous or fraudulent, within the meaning of this act, the secretary shall affix to such article a tag or other appropriate marking, giving notice that such article is, or is suspected of being, adulterated or misbranded and has been detained or embargoed. Such tag or marking shall warn all persons not to remove or dispose of such article by sale or otherwise until permission for removal or disposal is given by the secretary. It shall be unlawful for any person to remove such tag or marking from a detained or embargoed article or remove or dispose of such detained or embargoed article by sale or otherwise without the permission of the secretary.

(b) When an article detained or embargoed under subsection (a) has been found to be adulterated or misbranded, the secretary shall issue an order establishing measures to prevent further contamination or threat to the public health. The secretary may order the destruction of contaminated food, drugs, devices or cosmetics if no alternative assures that further contamination or health hazards are averted.

(c) If the secretary finds that an article so detained or embargoed is not adulterated or misbranded, the secretary shall remove the tag or other marking. Any order issued pursuant to subsection (b) or (c) shall be subject to review in accordance with the Kansas judicial review act. Nothing in this section shall be construed as limiting the right of the secretary to proceed as authorized by other sections of this act.


65-662. Same; minor violations; notice or warning.
Nothing in this act shall be construed as requiring the secretary to report for the institution of proceedings under this act, minor violations of this act, whenever the secretary believes that the public interest will be adequately served in the circumstances by a suitable written notice or warning.

**History:**  L. 1953, ch. 286, § 8; L. 1974, ch. 352, § 103; July 1.

### 65-668. Same; drugs or devices deemed adulterated, when.

A drug or device shall be deemed to be adulterated:

(a) (1) If it consists in whole or in part of any filthy, putrid, or decomposed substance; or

   (2)(A) if it has been produced, prepared, packed or held under insanitary conditions whereby it may have been contaminated with filth, or whereby it may have been rendered injurious to health; or

   (B) if it is a drug and the methods used in, or the facilities or controls used for, its manufacture, processing, packing, or holding do not conform to or are not operated or administered in conformity with current good manufacturing practice to assure that such drug meets the requirements of this act as to safety and has the identity and strength, and meets the quality and purity characteristics, which it purports or is represented to possess; or

(3) if it is a drug and its container is composed, in whole or in part, of any poisonous or deleterious substance which may render the contents injurious to health; or

(4) if (A) it is a drug and it bears or contains, for purposes of coloring only, a color additive which is unsafe within the meaning of K.S.A. 65-667, or

   (B) it is a color additive, the intended use of which in or on drugs is for purposes of coloring only, and is unsafe within the meaning of K.S.A. 65-667.

(b) If it purports to be or is represented as a drug the name of which is recognized in an official compendium, and its strength differs from, or its quality or purity falls below, the standard set forth in such compendium. Such determination as to strength, quality, or purity shall be made in accordance with the tests or methods of assay set forth in such compendium, or in the absence of or inadequacy of such tests or methods of assay, those prescribed under authority of the federal act. No drug defined in any official compendium shall be deemed to be adulterated under this paragraph because it differs from the standard of strength, quality, or purity therefor set forth in such compendium, if its difference in strength, quality, or purity from such standard is plainly stated on its label. Whenever a drug is recognized in both the United States pharmacopeia and the homeopathic pharmacopeia of the United States it shall be subject to the requirements of the United States pharmacopeia unless it is labeled and offered for sale as a homeopathic drug, in which case it shall be subject to the provisions of the homeopathic pharmacopeia of the United States and not to those of the United States pharmacopeia.

(c) If it is not subject to the provisions of paragraph (b) of this section and its strength differs from, or its purity or quality falls below, that which it purports or is represented to possess.

(d) If it is a drug and any substance has been (1) mixed or packed therewith so as to reduce its quality or strength; or (2) substituted wholly or in part therefor.

**History:**  L. 1953, ch. 286, § 14; L. 1965, ch. 377, § 5; July 1.

### 65-669. Same; drugs or devices deemed misbranded, when.

A drug or device shall be deemed to be misbranded:

(a) If its labeling is false or misleading in any particular.

(b) If in package form unless it bears a label containing:
(1) The name and place of business of the manufacturer, the packer or the distributor, except that in the case of a prescription drug it shall bear the name and place of business of the person responsible for the production of the finished dosage form of the drug, the packer and the distributor; except that nothing in this paragraph shall be construed to apply to wholesalers and the requirement of this paragraph shall be satisfied by stating such information on the label of the drug and filing a statement with such information with the secretary which shall be made available by the secretary on request to local, public and private health agencies, poison control centers, licentiates of the healing arts, the state board of pharmacy, consumers and others to promote the purposes of this act; in no event, however, shall the label contain less information than required under federal law; and

(2) an accurate statement of the quantity of the contents in terms of weight, measure, or numerical count, except that under this paragraph reasonable variations shall be permitted and exemptions as to small packages shall be allowed, in accordance with regulations prescribed by the secretary, or issued under the federal act.

(c) If any word, statement, or other information required by or under authority of this act to appear on the label or labeling is not prominently placed thereon with such conspicuousness, as compared with other words, statements, designs or devices, in the labeling, and in such terms as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use.

(d) If it is for use by human and contains any quantity of narcotic or hypnotic substance alpha-eucaine, barbituric acid, beta-eucaine, bromal, cannabis, carbromal, chloral, coca, cocaine, codeine, heroin, marijuana, morphine, opium, paraldehyde, peyote, or sulphonmethane, or any chemical derivative of such substance that has been by the secretary after investigation, found to be, and by regulations under this act, or by regulations issued pursuant to 21 U.S.C. § 352(d), designated as, habit forming, unless its label bears the name and quantity or proportion of such substance or derivative and in juxtaposition therewith the statement "warning-may be habit forming."

(e) (1) If it is a drug, unless its label bears, to the exclusion of any other nonproprietary name, except the applicable systematic chemical name or the chemical formula: (A) The established name, as defined in paragraph (2), of the drug, if such there be; and (B) in case it is fabricated from two or more ingredients, the established name of each active ingredient, including the kind and quantity of proportion of any alcohol, and also including, whether active or not, the established name and quantity or proportion of any bromides, ether, chloroform, acetanilid, acetphenetidin, amidopyrine, antipyrine, atropine, hyoscine, hyoscyamine, arsenic, digitalis, digitalis glucosides, mercury, ouabain, strophanthin, strychnine, thyroid, or any derivative or preparation of any such substances, contained therein. The requirements for stating the quantity of the active ingredients, other than the quantity of those specifically named in this paragraph, shall apply only to prescription drugs. To the extent that compliance with the requirements of subsection (e)(1)(B) is impracticable, exemptions shall be allowed under regulations promulgated by the secretary, or under the federal act.

(2) As used in this subsection, the term "established name," with respect to a drug or ingredient thereof, means: (A) The applicable official name designated pursuant to 21 U.S.C. § 358; (B) if there is no such name and such drug, or such ingredient, is an article recognized in an official compendium, then the official title thereof in such compendium; or (C) if neither subparagraph (A) nor subparagraph (B) applies, then the common or usual name, if any, of such drug or of such ingredient. Where subparagraph (B) applies to an article recognized in the United States pharmacopeia and in the homeopathic pharmacopoeia under different official titles, the official title used in the United States pharmacopeia shall apply unless it is labeled and offered for sale as a homeopathic drug, in which case the official title used in the homeopathic pharmacopoeia shall apply.

(f) Unless its labeling bears: (1) Adequate directions for use; and (2) such adequate warning against use in those pathological conditions or by children where its use may be dangerous to health, or against unsafe dosage or methods or duration of administration or application, in such manner and form as are
necessary for the protection of users. Where any requirement of paragraph (1), as applied to any drug or device, is not necessary for the protection of the public health, the secretary shall promulgate regulations exempting such drug or device from such requirements. Articles exempted under regulations issued under 21 U.S.C. § 352(f) may also be exempt.

(g) If it purports to be a drug the name of which is recognized in an official compendium, unless it is packaged and labeled as prescribed therein. The method of packing may be modified with the consent of the secretary, or if consent is obtained under the federal act. Whenever a drug is recognized in both the United States pharmacopeia and the homeopathic pharmacopoeia of the United States, it shall be subject to the requirements of the United States pharmacopeia with respect to the packaging and labeling unless it is labeled and offered for sale as a homeopathic drug, in which case it shall be subject to the provisions of the homeopathic pharmacopoeia of the United States, and not to those of the United States pharmacopeia. In the event of inconsistency between the requirements of this subsection and those of subsection (e) as to the name by which the drug or its ingredients shall be designated, the requirements of subsection (e) shall prevail.

(h) If it has been found by the secretary or under the federal act to be a drug liable to deterioration, unless it is packed in such form and manner and its label bears a statement of such precautions, as the regulations adopted by the secretary require as necessary for the protection of public health. No such regulations shall be established for any drug recognized in an official compendium until the secretary shall have informed the appropriate body charged with the revision of such compendium of the need for such packaging or labeling requirements and such body shall have failed within a reasonable time to prescribe such requirements.

(i) (1) If it is a drug and its container is so made, formed or filled as to be misleading; (2) if it is an imitation of another drug; or (3) if it is offered for sale under the name of another drug.

(j) If it is dangerous to health when used in the dosage, or with the frequency of duration prescribed, recommended or suggested in the labeling thereof.

(k) If it is, purports to be or is represented as a drug composed wholly or partly of insulin, unless: (1) It is from a batch with respect to which a certificate or release has been issued pursuant to 21 U.S.C. § 356; and (2) such certificate or release is in effect with respect to such drug.

(l) If it is, purports to be or is represented as a drug composed wholly or partly of any kind of penicillin, streptomycin, chlorotetracycline, chloramphenicol, bacitracin or any other antibiotic drug, or any derivative thereof, unless: (1) It is from a batch with respect to which a certificate or release has been issued pursuant to 21 U.S.C. § 357; and (2) such certificate or release is in effect with respect to such drug. This paragraph shall not apply to any drug or class of drugs exempted by regulations promulgated under 21 U.S.C. § 357(c) or (d). For the purpose of this subsection the term "antibiotic drug" means any drug intended for use by human containing any quantity of any chemical substance that is produced by a microorganism and which has the capacity to inhibit or destroy microorganisms in dilute solution, including the chemically synthesized equivalent of any such substance.

(m) If it is a color additive, the intended use of which in or on drugs is for the purpose of coloring only, unless its packaging and labeling are in conformity with such packaging and labeling requirements applicable to such color additive, prescribed under the provisions of K.S.A. 65-667, and amendments thereto, or of the federal act.

(n) In the case of any prescription drug distributed or offered for sale in this state, unless the manufacturer, packer, or distributor thereof includes in all advertisements and other descriptive printed matter issued or caused to be issued by the manufacturer, packer, or distributor with respect to that drug a true statement of: (1) The established name, as defined in subsection (e)(2); (2) the formula showing quantitatively each ingredient of such drug to the extent required for labels under 21 U.S.C. § 352(e); and (3) such other information in brief summary relating to side effects, contraindications, and effectiveness as shall be required in regulations issued under the federal act.
(o) If a trademark, trade name or other identifying mark, imprint or device of another or any likeness of the foregoing has been placed thereon or upon its container with intent to defraud.

(p) Drugs and devices that are, in accordance with the practice of the trade, to be processed, labeled or repacked in substantial quantities at establishments other than those where originally processed or packed shall be exempt from any labeling or packaging requirements of this act if such drugs and devices are being delivered, manufactured, processed, labeled, repacked or otherwise held in compliance with regulations issued by the secretary or under the federal act.

(q) A drug intended for use by human that: (1) Is a habit-forming drug to which K.S.A. 65-668, and amendments thereto, applies; or (2) because of its toxicity or other potentiality for harmful effect, or the method of its use, or the collateral measures necessary to its use, is not safe for use except under the supervision of a practitioner licensed by law to administer such drug; or (3) is limited by an approved application under 21 U.S.C. § 355 or K.S.A. 65-669a, and amendments thereto, to use under the professional supervision of a practitioner licensed by law to administer such drug, shall be dispensed only: (A) Upon a written prescription of a practitioner licensed by law to administer such drug or upon the written prescription of a mid-level practitioner as defined in K.S.A. 65-1626, and amendments thereto; (B) upon an oral prescription of such practitioner or mid-level practitioner which is reduced promptly to writing and filed by the pharmacist; or (C) by refilling, any such written or oral prescription if such refilling is authorized by the prescriber either in the original prescription or by oral order which is reduced promptly to writing and filed by the pharmacist. The act of dispensing a drug contrary to the provisions of this paragraph shall be deemed to be an act which results in a drug being misbranded while held for sale.

(r) Any drug dispensed by filling or refilling a written or oral prescription of a practitioner licensed by law to administer such drug or by filling or refilling a written or oral prescription of a mid-level practitioner as defined in K.S.A. 65-1626, and amendments thereto, shall be exempt from the requirements of this section, except subsections (a), (i)(2) and (3), (k) and (l), and the packaging requirements of subsections (g) and (h), if the drug bears a label containing the name and address of the dispenser, the serial number and date of the prescription or of its filling, the name of the prescriber and, if stated in the prescription, the name of the patient, and the directions for use and cautionary statements, if any, contained in such prescription. This exemption shall not apply to any drug dispensed in the course of the conduct of a business of dispensing drugs pursuant to diagnosis by mail, or to a drug dispensed in violation of subsection (q).

(s) The secretary may, by regulation, remove drugs subject to subsection (d) and K.S.A. 65-669a, and amendments thereto, from the requirements of subsection (q) when such requirements are not necessary for the protection of the public health. Drugs removed from the prescription requirements of the federal act by regulations issued thereunder may also, by regulations issued by the secretary, be removed from the requirements of subsection (q).

(t) A drug which is subject to subsection (q) shall be deemed to be misbranded if at any time prior to dispensing its label fails to bear the statement "caution: federal law prohibits dispensing without prescription," or "caution: state law prohibits dispensing without prescription." A drug to which subsection (q) does not apply shall be deemed to be misbranded if at any time prior to dispensing its label bears the caution statement quoted in the preceding sentence.

(u) Nothing in this section shall be construed to relieve any person from any requirement prescribed by or under authority of law with respect to drugs now included or that may hereafter be included within the classifications of narcotic drugs or marijuana as defined in the applicable federal and state laws relating to narcotic drugs and marijuana.

65-669a. New drugs; selling, offering or giving away, restrictions; investigational uses. 
(a) No person shall sell, deliver, offer for sale, hold for sale or give away any new drug unless:
(1) an application with respect thereto has been approved and such approval has not been withdrawn under 21 U.S.C.A. 355, or
(2) when not subject to the federal act, unless such drug has been tested and has been found to be safe for use and effective in use under the conditions prescribed, recommended, or suggested in the labeling thereof; and prior to selling or offering for sale such drug, there has been filed with the secretary an application setting forth
(A) full reports of investigations which have been made to show whether or not such drug is safe for use and whether such drug is effective in use;
(B) a full list of the articles used as components of such drug;
(C) a full statement of the composition of such drug;
(D) a full description of the methods used in, and the facilities and controls used for, the manufacture, processing and packing of such drug;
(E) such samples of such drug and of the articles used as components thereof as the secretary may require; and
(F) specimens of the labeling proposed to be used for such drug.
(b) An application provided for in subsection (a)(2) of this section shall become effective 180 days after the filing thereof, except that if the secretary finds, after due notice to the applicant and giving the applicant an opportunity for a hearing, that the drug is not safe or not effective for use under the conditions prescribed, recommended or suggested in the proposed labeling thereof, the secretary shall, prior to the effective date of the application, issue an order refusing to permit the application to become effective. Hearings under this subsection shall be conducted in accordance with the provisions of the Kansas administrative procedure act.
(c) An order refusing to permit an application under this section to become effective may be revoked by the secretary.
(d) This section shall not apply to:
(1) A drug intended solely for investigational use by experts qualified by scientific training and experience to investigate the safety and effectiveness of drugs, provided the drug is plainly labeled in compliance with regulations issued by the secretary or pursuant to 21 U.S.C.A. 355 or 21 U.S.C.A. 357; or
(2) a drug sold in this state at any time prior to the enactment of this act or introduced into interstate commerce at any time prior to the enactment of the federal act; or
(3) any drug which is licensed under the virus, serum, and toxin act of July 1, 1902 (U.S.C. 1958 ed. title 42, chapter 6A, sec. 262); or
(4) any drug which is subject to subsection (1) of K.S.A. 65-669 and amendments thereto.
(e) The provisions of subsection (n) of K.S.A. 65-656 and amendments thereto shall not apply to any drug which was, on October 9, 1962, or on the date immediately preceding the enactment of this subsection, (1) commercially sold or used in this state or in the United States, (2) not a new drug as defined by subsection (n) of K.S.A. 65-656 and amendments thereto as then in force, and (3) was not covered by an effective application under this section or under 21 U.S.C.A. 355, when such drug is intended solely for use under conditions prescribed, recommended or suggested in labeling with respect to such drug.

65-670. Same; cosmetic deemed adulterated, when.
A cosmetic shall be deemed to be adulterated:
(a) If it bears or contains any poisonous or deleterious substance which may render it injurious to users under the conditions of use prescribed in the labeling or advertisement thereof, or under such conditions of use as are customary or usual: Provided, That this provision shall not apply to coal-tar hair dye, the label of which bears the following legend conspicuously displayed thereon: "Caution-this product contains ingredients which may cause skin irritation on certain individuals and a preliminary test according to accompanying direction should first be made. This product must not be used for dyeing the eyelashes or eyebrows; to do so may cause blindness," and the labeling of which bears adequate direction for such preliminary testing. For the purposes of this paragraph and the paragraph (e) the term "hair dye" shall not include eyelash dyes or eyebrow dyes.  
(b) If it consists in whole or in part of any filthy, putrid, or decomposed substance.  
(c) If it has been produced, prepared, packed, or held under insanitary conditions whereby it may have become contaminated with filth, or whereby it may have been rendered injurious to health.  
(d) If its container is composed in whole or in part, of any poisonous or deleterious substance which may render the contents injurious to health.  
(e) If it is not a hair dye and it bears or contains a coal-tar color other than one from a batch which has been certified under authority of the federal act.  

History: L. 1953, ch. 286, § 16; June 30.  
65-671. Same; cosmetic deemed misbranded, when.  
A cosmetic shall be deemed to be misbranded:
(a) If its labeling is false or misleading in any particular.  
(b) If in package form unless it bears a label containing (1) the name and place of business of the manufacturer, packer, or distributor; and (2) an accurate statement of the quantity of the contents in terms of weight, measure, or numerical count: Provided, That under clause (2) of this paragraph reasonable variations shall be permitted, and exemptions as to small packages shall be established by regulations prescribed by the secretary.  
(c) If any word, statement or other information required by or under authority of this act to appear on the label or labeling is not prominently placed thereon with such conspicuousness (as compared with other words, statements, designs, or devices, in the labeling) and in such terms as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use.  
(d) If its container is so made, formed, or filled as to be misleading.  

65-672. Same; advertisements of food, drugs, devices or cosmetics deemed false, when.  
(a) An advertisement of a food, drug, device, or cosmetic shall be deemed to be false if it is false or misleading in any particular.  
(b) For the purpose of this act the advertisement of a drug or device representing it to have any effect in albuminuria, appendicitis, arteriosclerosis, blood poison, bone disease, Bright's disease, cancer, carbuncles, cholecystitis, diabetes, diphtheria, dropsy, erysipelas, gallstones, heart and vascular diseases, high blood pressure, mastoiditis, measels, meningitis, mumps, nephritis, otitis media, paralysis, pneumonia, poliomyelitis (infantile paralysis), prostate gland disorders, pyelitis, scarlet fever, sexual impotence, sinus infection, smallpox, tuberculosis, tumors, typhoid, uremia, venereal disease, shall also be deemed to be false, except that no advertisement not in
violation of subsection (a) shall be deemed to be false under this subsection if it is disseminated only to a physician, dentist or veterinarian, or appears only in the scientific periodicals of these professions, or is disseminated only for the purpose of public-health education by persons not commercially interested, directly or indirectly, in the sale of such drugs or devices: Provided, That whenever the secretary determines that an advance in medical science has made any type of self-medication safe as to any of the diseases named above, the secretary shall by regulation authorize the advertisement of drugs having curative or therapeutic effect for such disease, subject to such condition and restriction as the secretary may deem necessary in the interests of public health: Provided, That this subsection shall not be construed as indicating that self-medication for diseases other than those named herein is safe or efficacious.

**History:**  L. 1953, ch. 286, § 18; L. 1974, ch. 352, § 111; July 1.

### 65-674. Same; free access to establishments and vehicles for inspections and samples.

(a) The secretary shall have free access at all reasonable hours to any location in which foods, drugs, devices, or cosmetics are processed, stored, or distributed, or to enter any vehicle being used to transport or hold such foods, drugs, devices, or cosmetics in commerce, for the following purposes:

1. To inspect any location, products or equipment subject to the provisions of the food, drug and cosmetic act and rules and regulations adopted thereunder;
2. to inspect or sample food, drugs, devices or cosmetics reported to be adulterated or a threat to public health;
3. to inspect or investigate complaints of violations of the provisions of the food, drug and cosmetic act and rules and regulations adopted thereunder; or
4. to sample products.

(b) If the secretary is denied access to any location where such access is sought for the purposes as provided in subsection (a), the secretary may apply to any court of competent jurisdiction for a search warrant authorizing access to such location for such purpose. Upon such application and a showing of cause therefor, the court shall issue such search warrant.


### 65-675. Same; reports and dissemination of information.

(a) The secretary may cause to be published from time to time reports summarizing all judgments, decrees, and court orders which have been rendered under this act, including the nature of the charge and the disposition thereof.

(b) The secretary may also cause to be disseminated such information regarding food, drugs, devices, and cosmetics as the secretary deems necessary in the interest of public health and the protection of the consumer against fraud. Nothing in the section shall be construed to prohibit the secretary from collecting, reporting and illustrating the results of the investigations of the secretary.

**History:**  L. 1953, ch. 286, § 21; L. 1974, ch. 352, § 114; July 1.

### 65-678. Same; cooperation with federal food and drug administration.

The secretary is hereby authorized to confer and cooperate with the federal food and drug administration in the enforcement of the national food, drug and cosmetic act as it may apply to food, liquor, drugs, and cosmetic products received in this state from other states, territories or foreign countries.

**History:**  L. 1953, ch. 286, § 24; L. 1974, ch. 352, § 117; July 1.
65-679. Same; act not to limit authority established under certain other acts.
Nothing in this act shall be construed as limiting or abridging the authority of the secretary of agriculture established under the Kansas dairy law, K.S.A. 65-771 through 65-791, and amendments thereto; or the Kansas commercial feeding stuffs law, K.S.A. 2-1001 through 2-1013, and amendments thereto.

65-679a. Dimethyl sulfoxide; labeling and information requirements if sold other than by prescription.
(a) Any dimethyl sulfoxide (DMSO) sold in this state other than by prescription shall be labeled by the manufacturer and seller. The label shall contain a description of all of the contents in the solution, a statement of purity, the percent of dimethyl sulfoxide (DMSO) in the solution and the manufacturer's name and address. Whenever dimethyl sulfoxide (DMSO) is sold or otherwise supplied, the seller or supplier shall give additional printed material, approved by the secretary, to the person receiving the dimethyl sulfoxide (DMSO) that provides adequate warning against use that may be dangerous to the health of the user.
(b) The secretary of agriculture may adopt rules and regulations necessary to administer the provisions of this section.
(c) This section shall be part of and supplemental to the Kansas food, drug and cosmetic act.
History: L. 1982, ch. 255, § 1; L. 2010, ch. 72, § 11; July 1.

65-680. Same; invalidity of part.
If any provision of this act is declared unconstitutional or the applicability thereof to any person or circumstances is held invalid, the constitutionality of the remainder of the act and applicability thereof to other persons and circumstances shall not be affected thereby.
History: L. 1953, ch. 286, § 26; June 30.

65-682. Same; penalty.
(a) The secretary, after providing notice and an opportunity for a hearing in accordance with provisions of the Kansas administrative procedure act, may impose a civil penalty in an amount of not more than $1,000 per violation of the food, drug and cosmetic act or rule and regulation adopted, or order issued thereunder. In the case of a continuing violation, each day such violation continues shall be deemed a separate violation. Such civil penalty may be assessed in addition to any other penalty provided by law.
(b) Any party aggrieved by an order of the secretary as provided in subsection (a) may appeal such order to the district court in the manner provided by the Kansas judicial review act.
(c) Any penalty recovered pursuant to the provisions of subsection (a) shall be remitted to the state treasurer in accordance with the provisions of K.S.A. 75-4215, and amendments thereto. Upon receipt of each such remittance, the state treasurer shall deposit the entire amount in the state treasury to the credit of the state general fund.
(d) Any person who recklessly or intentionally violates the provisions of the food, drug and cosmetic act, or rules and regulations adopted thereunder, shall be guilty of a class A, nonperson misdemeanor.
65-685. Same; enforcement of criminal provisions.
The enforcement of the criminal provisions of this act shall be the duty of, and shall be implemented by, the county or district attorneys of the state. In the event a county or district attorney refuses to act, the attorney general shall so act.

VI. Chemical Control Act- Statutes

Article 70.—Chemical Control
Sheriff Matt Samuels Chemical Control Act

65-7001. Citation of act.
K.S.A. 65-7001 through 65-7015 and amendments thereto shall be known and may be cited as the sheriff Matt Samuels chemical control act.

65-7002. Purpose of act.
The purpose of the Kansas chemical control act is to prevent the illegal diversion of precursor chemicals by creating a system which will provide information regarding the distribution of regulated chemicals while protecting legitimate uses.
History: L. 1999, ch. 170, § 8; July 1.

65-7003. Definitions.
As used in K.S.A. 65-7001 through 65-7015, and amendments thereto:
(a) "Act" means the Kansas chemical control act;
(b) "administer" means the application of a regulated chemical whether by injection, inhalation, ingestion or any other means, directly into the body of a patient or research subject, such administration to be conducted by: (1) A practitioner, or in the practitioner's presence, by such practitioner's authorized agent; or
(2) the patient or research subject at the direction and in the presence of the practitioner;
(c) "agent or representative" means a person who is authorized to receive, possess, manufacture or distribute or in any other manner control or has access to a regulated chemical on behalf of another person;
(d) "bureau" means the Kansas bureau of investigation;
(e) "department" means the Kansas department of health and environment;
(f) "director" means the director of the Kansas bureau of investigation;
(g) "dispense" means to deliver a regulated chemical to an ultimate user, patient or research subject by, or pursuant to the lawful order of, a practitioner, including the prescribing, administering, packaging, labeling or compounding necessary to prepare the regulated chemical for that delivery;
(h) "distribute" means to deliver other than by administering or dispensing a regulated chemical;
(i) "manufacture" means to produce, prepare, propagate, compound, convert or process a regulated chemical directly or indirectly, by extraction from substances of natural origin, chemical synthesis or a combination of extraction and chemical synthesis, and includes packaging or repackaging of the substance or labeling or relabeling of its container. The term excludes the preparation, compounding, packaging, repackaging, labeling or relabeling of a regulated chemical:
(1) By a practitioner as an incident to the practitioner's administering or dispensing of a regulated chemical in the course of the practitioner's professional practice; or
(2) by a practitioner, or by the practitioner's authorized agent under the practitioner's supervision, for the purpose of, or as an incident to research, teaching or chemical analysis and not for sale;
(j) "person" means individual, corporation, business trust, estate, trust, partnership, association, joint venture, government, governmental subdivision or agency, or any other legal or commercial entity;
(k) "practitioner" means a person licensed to practice medicine and surgery, pharmacist, dentist, podiatrist, veterinarian, optometrist, or scientific investigator or other person authorized by law to use a controlled substance in teaching or chemical analysis or to conduct research with respect to a controlled substance;

(l) "regulated chemical" means a chemical that is used directly or indirectly to manufacture a controlled substance or other regulated chemical, or is used as a controlled substance analog, in violation of the state controlled substances act or this act. The fact that a chemical may be used for a purpose other than the manufacturing of a controlled substance or regulated chemical does not exempt it from the provisions of this act. Regulated chemical includes:

(1) Acetic anhydride (CAS No. 108-24-7);
(2) benzaldehyde (CAS No. 100-52-7);
(3) benzyl chloride (CAS No. 100-44-7);
(4) benzyl cyanide (CAS No. 140-29-4);
(5) diethylamine and its salts (CAS No. 109-89-7);
(6) ephedrine, its salts, optical isomers and salts of optical isomers (CAS No. 299-42-3), except products containing ephedra or ma huang, which do not contain any chemically synthesized ephedrine alkaloids, and are lawfully marketed as dietary supplements under federal law;
(7) hydriodic acid (CAS No. 10034-85-2);
(8) iodine (CAS No. 7553-56-2);
(9) lithium (CAS No. 7439-93-2);
(10) methylamine and its salts (CAS No. 74-89-5);
(11) nitroethane (CAS No. 79-24-3);
(12) chloroephedrine, its salts, optical isomers, and salts of optical isomers (CAS No. 30572-91-9);
(13) phenylacetic acid, its esters and salts (CAS No. 103-82-2);
(14) phenylpropanolamine, its salts, optical isomers, and salts of optical isomers (CAS No. 14838-15-4);
(15) piperidine and its salts (CAS No. 110-89-4);
(16) pseudoephedrine, its salts, optical isomers, and salts of optical isomers (CAS No. 90-82-4);
(17) red phosphorous (CAS No. 7723-14-0);
(18) sodium (CAS No. 7440-23-5); and
(19) thionylchloride (CAS No. 7719-09-7);
(20) gamma butyrolactone (GBL), including butyrolactone; butyrolactone gamma; 4-butyrolactone; 2(3H)-furanone dihydro; dihydro-2(3H)-furanone; tetrahydro-2-furanone; 1,2-butanolide; 1,4-butanolide; 4-butanolide; gamma-hydroxybutyric acid lactone; 3-hydroxybutyric acid lactone and 4-hydroxybutanoic acid lactone; CAS No. 96-48-0; and
(21) 1,4 butanediol, including butanediol; butane-1,4-diol; 1,4-butylen glycol; butylene glycol; 1,4-dihydroxybutane; 1,4-tetramethylene glycol; tetramethylene glycol; tetramethylene 1,4-diol; CAS No. 110-63-4;

(m) "regulated chemical distributor" means any person subject to the provisions of the Kansas chemical control act who manufactures or distributes a regulated chemical;

(n) "regulated chemical retailer" means any person who sells regulated chemicals directly to the public;

(o) "regulated chemical transaction" means the manufacture of a regulated chemical or the distribution, sale, exchange or other transfer of a regulated chemical within or into the state or from this state into another state; and

(p) "secretary" means the secretary of health and environment.

The provisions of this act shall not apply to: (a) A distribution of a regulated chemical to or by a common carrier for carriage in the lawful and usual course of the business of the common carrier, or to or by a warehouseman for storage in the lawful and usual course of the business of the warehouseman; (b) the lawful administering or dispensing of a regulated chemical by a licensed practitioner in the course of professional practice or research; (c) the purchase, distribution or possession of a regulated chemical by a local, state or federal law enforcement agency while in the discharge of official duties unless the Kansas bureau of investigation properly notifies the local law enforcement agency relying on the exclusion that its investigatory activities are contrary to the public interest; or (d) products containing ephedra or ma huang, which do not contain any chemically synthesized ephedrine alkaloids, and are lawfully marketed as dietary supplements under federal law.


65-7005. Secretary; powers and duties; director; powers and duties.
(a) The secretary is authorized and directed to:
(1) Adopt such rules and regulations, standards and procedures as may be necessary to carry out the purposes and provisions of this act;
(2) expend and authorize the expenditure of moneys from the chemical control act fund;
(3) report to the legislature on further assistance needed to administer the chemical control program;
(4) administer the chemical control program pursuant to provisions of this act;
(5) cooperate with appropriate federal, state, interstate and local units of government and with appropriate private organizations in carrying out the duties under this act;
(6) issue such orders necessary to implement the provisions of this act, and enforce the same by all appropriate administrative and judicial proceedings;
(7) collect and disseminate information and conduct educational and training programs relating to the chemical control program;
(8) accept, receive and administer grants or other funds or gifts from public and private entities, including the federal government, for the purpose of carrying out the provisions of this act;
(9) enter into contracts and agreements with the director of the Kansas bureau of investigation, other government agencies or private entities as necessary to carry out the provisions of this act; and
(10) examine and copy records and other information.
(b) The secretary may request the attorney general to bring an action in district court to seize property contaminated with chemicals for purposes of disposal or to enforce any other provision of this act.
(c) The director is authorized to:
(1) Provide investigative assistance to the department of health and environment when requested by the secretary or the secretary's duly authorized agent;
(2) conduct civil actions necessary to seize chemicals or chemical-contaminated materials from alleged illegal drug manufacturing sites or to gain access to illegal drug manufacturing sites;
(3) serve as the single point of contact for screening alleged illegal drug manufacturing sites to determine if clean up or evaluation by a local health officer or the secretary is necessary;
(4) serve as the contact agency for conducting any clean up action necessary at an alleged illegal drug manufacturing site where the removal of floors, walls, furniture or soil is not required and where the contamination of groundwater has not occurred; and
(5) enter into any agreements with the secretary necessary to carry out the provisions of this act.


65-7007. Regulated chemical distributor and retailer; submissions to bureau.
(a) Each regulated chemical distributor and retailer shall submit to the bureau:
(1) Any regulated transaction involving an extraordinary quantity of a regulated chemical, an uncommon method of payment or delivery, or any other circumstance that may indicate that the regulated chemical will be used in violation of this act.
(2) Any proposed regulated transaction with a person whose description or other identifying characteristic the bureau has previously furnished to the regulated chemical distributor or retailer.
(3) Any unusual or excessive loss or disappearance of a regulated chemical under the control of the regulated chemical distributor or retailer. The regulated person responsible for reporting a loss in-transit is the distributor.
(b) Each report submitted pursuant to subsection (a), whenever possible shall be made orally to the bureau at the earliest practicable opportunity after the regulated chemical distributor or retailer becomes aware of the circumstances involved and as much in advance of the conclusion of the transaction as possible. Written reports of these transactions shall subsequently be filed within 15 days after the regulated chemical distributor or retailer becomes aware of the circumstances of the event. A transaction may not be completed with a person whose description or identifying characteristics have previously been furnished to the regulated distributor by the bureau unless the transaction is approved by the bureau.
(c) This section shall not apply to any of the following:
(1) Any pharmacist, pharmacy or other authorized person who sells or furnishes a substance listed in K.S.A. 65-7003(1), and amendments thereto, upon the prescription or order of a practitioner as defined under K.S.A. 65-1626, and amendments thereto;
(2) any practitioner as defined under K.S.A. 65-1626, and amendments thereto, who administers, dispenses or furnishes a substance listed in K.S.A. 65-7003(1), and amendments thereto, to such patients within the scope of a practitioner's professional practice. Such administration or dispensing shall be in the patient record;
(3) any sale, transfer, furnishing or receipt of any drug that contains any substance listed in K.S.A. 65-7003(1), and amendments thereto, and that is lawfully sold, transferred or furnished over-the-counter without a prescription pursuant to the federal food, drug and cosmetic act or regulations adopted thereunder; and
(4) a regulated chemical retailer who only sells or distributes regulated chemicals that are nonprescription, over-the-counter medicines with less than three grams of base ingredient in the package in the following manner:
(A) Blister packs of not more than two dosage units per blister;
(B) liquid cold or cough medicines;
(C) liquid cold or cough gel capsules; and
(D) nasal drops or sprays.

**History:** L. 1999, ch. 170, § 13; L. 2017, ch. 34, § 23; Apr. 20.

**65-7008. Information program for retailers.**
The bureau shall develop and maintain a program to inform retailers about the methamphetamine problem in Kansas and devise procedures and forms for retailers to use in reporting to the bureau suspicious purchases, thefts or other transactions involving any products under the retailer's control which contain a regulated chemical under the provisions of this act including, but not limited to, nonprescription, over-the-counter medicines described in subsection (c)(4) of K.S.A. 65-7007 and amendments thereto. Reporting by retailers as required by this section shall be voluntary. Retailers reporting information to the bureau in good faith pursuant to this section shall be immune from civil liability.

**History:** L. 1999, ch. 170, § 14; July 1.

**65-7009. Orders subject to Kansas administrative procedure act; final action subject to Kansas judicial review act.**

(a) Any order of the secretary issued pursuant to this act is subject to the provisions of the Kansas administrative procedure act.

(b) Any final action of the secretary pursuant to this section is subject to review in accordance with the Kansas judicial review act.

**History:** L. 1999, ch. 170, § 15; L. 2010, ch. 17; § 169; July 1.

**65-7010. Civil penalties.**

(a) The secretary of the department of health and environment or the director of the division of environment, if designated by the secretary, upon a finding that a person has violated any provision of this act may impose a penalty not to exceed $25,000 which shall constitute an actual and substantial economic deterrent to the violation for which it is assessed and, in the case of a continuing violation, every day such violation continues shall be deemed a separate violation.

(b) No penalty shall be imposed pursuant to this section except after notice of violation and opportunity for hearing upon the written order of the secretary or the director of the division of environment, if designated by the secretary, to the person who committed the violation. The order shall state the violation, the penalty to be imposed and the right to appeal to the secretary for a hearing thereon. Any person may appeal an order by making a written request to the secretary for a hearing within 15 days of service of such order. Proceedings under this subsection shall be conducted in accordance with the provisions of the Kansas administrative procedure act.

(c) Any sum assessed under this section shall be deposited in the chemical control fund.

(d) Any final action of the secretary pursuant to this section is subject to review in accordance with the Kansas judicial review act.


**65-7011. Liability; cleanup.**

(a) A person who violates any provisions of this act, shall, in addition to any other penalty provided by law, be liable for detection and investigation costs, the costs of the actual cleanup or attempted cleanup and for damages for injury to, or both, or destruction of any natural resources caused by chemicals at the site.
(b) A civil action under this section may be commenced in the name of the state by the attorney general in the county in which the violation is alleged to have occurred.
(c) Any sum assessed under this section shall be deposited in the chemical control fund.


65-7012.   Chemical control fund; revenues; expenditures.
(a) There is established a fund in the treasury entitled the chemical control fund.
(b) Revenues from the following sources shall be deposited in the state treasury and credited to the fund:
    (1) Moneys received by the secretary in the form of grants, gifts, bequests, reimbursements, or appropriations from any source intended to be used for the purposes of the fund;
    (2) interest attributable to the investment of moneys in the fund; and
    (3) moneys collected under K.S.A. 65-7010 and 65-7011 and amendments thereto.
(c) Moneys in the chemical control fund can only be expended directly or through contracts for the costs of:
    (1) Administration and enforcement of the provisions of this act;
    (2) contracting for services needed to supplement the department's staff in alleged illegal drug manufacturing site clean ups;
    (3) consultation needed concerning alleged illegal drug manufacturing site clean ups;
    (4) activities to address immediate or emergency threats to human health or the environment related to alleged illegal drug manufacturing sites; and
    (5) development of educational materials and programs for informing the regulated community and the public about illegal drug manufacturing issues.
(d) On or before the 10th of each month following the month in which moneys are deposited into the chemical control fund, and thereafter on or before the 10th of each month, the director of accounts and reports shall transfer from the state general fund to the chemical control fund interest earnings based upon:
    (1) The average daily balance of moneys in the chemical control fund for the preceding month; and
    (2) the net earnings rate of the pooled money investment portfolio for the preceding month.
(e) All expenditures from the fund shall be made in accordance with appropriation acts upon warrants of the director of accounts and reports issued pursuant to vouchers approved by the secretary for the purposes set forth in this section.
(f) Moneys from the fund shall not supplant any other local, state or federal funds unless the secretary finds that it is in the best interests of the state to supplant such other funds and to make expenditures from the fund in a more timely manner to investigate or clean up chemicals, chemical-contaminated materials, soil or groundwater resulting from an alleged illegal drug manufacturing site or an arrest made pursuant to the Kansas chemical control act, to conduct any other clean up action necessary at an alleged illegal drug manufacturing site, or to abate any imminent and substantial danger to public health or safety or to the environment related to a release from an illegal drug manufacturing site.

65-7013. Secretary; investigation and cleanup; liability; inspections.

(a) The secretary is authorized to:

(1) Develop a contract with a hazardous waste response contractor for joint use by the Kansas department of health and environment and the Kansas bureau of investigation to conduct investigation and cleanup of chemicals, chemical-contaminated materials, soil, or groundwater resulting from an illegal drug manufacturing site or from an arrest made pursuant to the provisions of this act;

(2) authorize any person to carry out any cleanup action in accordance with the directions or requirements of the secretary, if the secretary determines that the person will commence and complete the cleanup properly and in a timely manner;

(3) undertake directly or by contract any cleanup action necessary at an alleged illegal drug manufacturing site including the cleanup, storage and disposal of chemicals and chemical contaminated materials located at an alleged illegal drug manufacturing site;

(4) to abate any imminent and substantial danger to the public health, safety or the environment related to a release from an illegal drug manufacturing site;

(5) direct or authorize a person responsible for creating an illegal drug manufacturing site as defined in subsection (b) to conduct a cleanup or perform any related actions;

(6) recover moneys expended by the state responding to alleged illegal drug manufacturing sites from persons responsible for creating such sites;

(7) examine and copy records and other information;

(8) enter into any agreements with the director necessary to carry out the provisions of this act; and

(9) request the attorney general to bring an action in any district court to seize property contaminated with chemicals for purposes of clean up, disposal or to enforce any other provision of this act.

(b) The following persons shall be considered responsible for creating an alleged illegal drug manufacturing site and shall be jointly and severally liable for those cleanup costs incurred by the state and for damages for injury to or destruction of any natural resources caused by chemicals at the site:

(1) Any person operating an alleged illegal drug manufacturing site;

(2) any owner or operator of an alleged illegal drug manufacturing site who obtained actual knowledge of the alleged illegal drug manufacturing site or damages caused by the site who failed to contact appropriate federal, state or local law enforcement authorities regarding the presence of the site; and

(3) any person who, by any acts or omissions, caused or contributed to the alleged illegal drug manufacturing site, unless the acts or omissions were in material compliance with applicable laws, standards, regulations, licenses or permits.

(c) Except as otherwise provided in subsection (d), the following persons shall not be considered responsible for creating an alleged illegal drug manufacturing site and shall not be liable for those cleanup costs incurred by the state:

(1) Any owner or operator who became the owner or operator after the creation of the alleged illegal drug manufacturing site who did not know and reasonably should not have known of the damages when the person first became the owner or operator;

(2) a unit of state or local government that acquired ownership or control of a site by virtue of tax delinquency, abandonment, exercise of eminent domain authority, forfeiture, purchase or condemnation;
(3) any person who is not otherwise responsible under subsection (b) who acquired a site by inheritance or bequest;

(4) a local government as a result of actions taken in response to an emergency created by the chemicals at or generated by or from an alleged illegal drug manufacturing site owned by another person; and

(5) manufacturers, distributors, and retailers who are registered with the state board of pharmacy and acted or failed to act without knowledge of the existence of an illegal drug manufacturing site or without the intent to furnish supplies to an illegal drug manufacturing site.

(d) Notwithstanding the exclusions provided in subsection (c) of this section, such persons shall be liable for cleanup costs incurred by the state to the extent that the person's acts or omissions constituted gross negligence or intentional misconduct.

(e) If any person who is liable under subsection (b) of this section fails without sufficient cause to conduct a cleanup action as required by an order of the secretary, the person shall be liable for the state's cleanup costs.

(f) A local health officer, upon notification by the department or the bureau of the existence of an alleged illegal drug manufacturing site, is authorized to cause an inspection of the property to be conducted to determine the extent of contamination. In those cases where the local health officer does not have the resources or expertise to conduct such an inspection, the secretary is authorized to conduct the inspection.

(g) If the local health officer or the secretary determines that the property where the alleged illegal drug manufacturing site exists is unfit for use due to the extent of contamination, the local health officer or the secretary is empowered to post an order prohibiting use of all or portions of the property. The posting shall be in a conspicuous place on the property.

(h) In those cases where a person responsible for creating an alleged illegal drug manufacturing site fails to conduct a cleanup of the site within 60 days of discovery of the site by federal, state or local law enforcement officials, the secretary is authorized to record, in accordance with Kansas law, a notice with the county register of deeds where the property is located that the land has been used to manufacture illegal drugs and that the property contains chemical contamination that may be harmful to the public health, safety or the environment. A notice of release shall be filed upon a showing to the department that the property is no longer harmful to the public health, safety and the environment.

(i) Notwithstanding any other provision of law, the State of Kansas, the department of health and environment and the Kansas bureau of investigation and their officers, employees and agents shall not be liable to a person possessing or owning chemicals located at an alleged illegal drug manufacturing site for any claims or actions arising from the identification, cleanup, storage or disposal of such chemicals by the department.

(j) Upon request of the law enforcement agency in charge after determination of the existence of an alleged illegal drug manufacturing site, any authorized officer, employee or agent of the department or any person under contract with the department may enter onto the premises of any alleged illegal drug manufacturing site, at reasonable times to review information, inspect, examine or gather data, conduct investigations, take remedial or other action where the secretary determines that such action is necessary to protect the public health or the environment.

65-7014. **Seizure and forfeiture.**
(a) All regulated chemicals which have been or are intended to be manufactured, provided, sold, furnished, transferred, delivered, or possessed in violation of this act shall be deemed contraband, and may be seized and summarily forfeited to the state.
(b) A violation of this act shall constitute conduct giving rise to forfeiture pursuant to the Kansas standard asset forfeiture act K.S.A. 60-4101 et seq. and amendments thereto. When property is forfeited pursuant to a violation of the Kansas chemical control act, the department shall sell all property not destroyed pursuant to subsection (a)(2) of K.S.A. 60-4117 and amendments thereto at public sale to the highest bidder for cash without appraisal. The proceeds of any sale shall be credited to the cleanup account which is hereby created in the chemical control fund. Moneys in such account can only be expended directly or through contracts for the costs of drug manufacturing site clean ups.

**History:** L. 1999, ch. 170, § 20; July 1.

65-7015. **Severability clause.**
If any provisions of this act or its application to any person or circumstances are held invalid, the invalidity shall not affect other provisions or applications of this act which can be given effect without the invalid provision or application, and to this end the provisions of this act are severable.

**History:** L. 1999, ch. 170, § 21; July 1.
VII. Drug Crimes—Statutes

KSA Chapter 21.—Crimes and Punishments
Article 57.—Crimes Involving Controlled Substances

21-5701. Definitions.
As used in K.S.A. 2022 Supp. 21-5701 through 21-5717, and amendments thereto:

(a) "Controlled substance" means any drug, substance or immediate precursor included in any of the schedules designated in K.S.A. 65-4105, 65-4107, 65-4109, 65-4111 and 65-4113, and amendments thereto.

(b) (1) "Controlled substance analog" means a substance that is intended for human consumption, and at least one of the following:

(A) The chemical structure of the substance is substantially similar to the chemical structure of a controlled substance listed in or added to the schedules designated in K.S.A. 65-4105 or 65-4107, and amendments thereto;

(B) the substance has a stimulant, depressant or hallucinogenic effect on the central nervous system substantially similar to the stimulant, depressant or hallucinogenic effect on the central nervous system of a controlled substance included in the schedules designated in K.S.A. 65-4105 or 65-4107, and amendments thereto; or

(C) with respect to a particular individual, such individual represents or intends the substance to have a stimulant, depressant or hallucinogenic effect on the central nervous system substantially similar to the stimulant, depressant or hallucinogenic effect on the central nervous system of a controlled substance included in the schedules designated in K.S.A. 65-4105 or 65-4107, and amendments thereto.

(2) "Controlled substance analog" does not include:

(A) A controlled substance;

(B) a substance for which there is an approved new drug application; or

(C) a substance with respect to which an exemption is in effect for investigational use by a particular person under section 505 of the federal food, drug, and cosmetic act, 21 U.S.C. § 355, to the extent conduct with respect to the substance is permitted by the exemption.

(c) "Cultivate" means the planting or promotion of growth of five or more plants that contain or can produce controlled substances.

(d) "Distribute" means the actual, constructive or attempted transfer from one person to another of some item whether or not there is an agency relationship. "Distribute" includes, but is not limited to, sale, offer for sale or any act that causes some item to be transferred from one person to another. "Distribute" does not include acts of administering, dispensing or prescribing a controlled substance as authorized by the pharmacy act of the state of Kansas, the uniform controlled substances act or otherwise authorized by law.

(e) (1) "Drug" means:

(A) Substances recognized as drugs in the official United States pharmacopeia, official homeopathic pharmacopoeia of the United States or official national formulary or any supplement to any of them;

(B) substances intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease in humans or animals;

(C) substances, other than food, intended to affect the structure or any function of the body of humans or animals; and
(D) substances intended for use as a component of any article specified in subparagraph (A), (B) or (C).

(2) "Drug" does not include devices or their components, parts or accessories.

(f)(1) "Drug paraphernalia" means all equipment and materials of any kind that are used, or primarily intended or designed for use in planting, propagating, cultivating, growing, harvesting, manufacturing, compounding, converting, producing, processing, preparing, testing, analyzing, packaging, repackaging, storing, containing, concealing, injecting, ingesting, inhaling or otherwise introducing into the human body a controlled substance and in violation of this act.

(2) "Drug paraphernalia" includes, but is not limited to:

(A) Kits used or intended for use in planting, propagating, cultivating, growing or harvesting any species of plant that is a controlled substance or from which a controlled substance can be derived;
(B) kits used or intended for use in manufacturing, compounding, converting, producing, processing or preparing controlled substances;
(C) isomerization devices used or intended for use in increasing the potency of any species of plant that is a controlled substance;
(D) testing equipment used or intended for use in identifying or in analyzing the strength, effectiveness or purity of controlled substances;
(E) scales and balances used or intended for use in weighing or measuring controlled substances;
(F) diluents and adulterants, including, but not limited to, quinine hydrochloride, mannitol, mannite, dextrose and lactose that are used or intended for use in cutting controlled substances;
(G) separation gins and sifters used or intended for use in removing twigs and seeds from or otherwise cleaning or refining marijuana;
(H) blenders, bowls, containers, spoons and mixing devices used or intended for use in compounding controlled substances;
(I) capsules, balloons, envelopes, bags and other containers used or intended for use in packaging small quantities of controlled substances;
(J) containers and other objects used or intended for use in storing or concealing controlled substances;
(K) hypodermic syringes, needles and other objects used or intended for use in parenterally injecting controlled substances into the human body;
(L) objects used or primarily intended or designed for use in ingesting, inhaling or otherwise introducing marijuana, cocaine, hashish, hashish oil, phencyclidine (PCP), methamphetamine or amphetamine into the human body, such as:
   (i) Metal, wooden, acrylic, glass, stone, plastic or ceramic pipes with or without screens, permanent screens, hashish heads or punctured metal bowls;
   (ii) water pipes, bongs or smoking pipes designed to draw smoke through water or another cooling device;
   (iii) carburetion pipes, glass or other heat-resistant tubes or any other device used, intended to be used or designed to be used to cause vaporization of a controlled substance for inhalation;
   (iv) smoking and carburetion masks;
   (v) roach clips, objects used to hold burning material, such as a marijuana cigarette, that has become too small or too short to be held in the hand;
   (vi) miniature cocaine spoons and cocaine vials;
   (vii) chamber smoking pipes;
   (viii) carburetor smoking pipes;
   (ix) electric smoking pipes;
   (x) air-driven smoking pipes;
(xi) chillums;
(xii) bongs;
(xiii) ice pipes or chillers;
(xiv) any smoking pipe manufactured to disguise its intended purpose;
(xv) wired cigarette papers; or
(xvi) cocaine freebase kits.

(3) "Drug paraphernalia" does not include:
(A) Any products, chemicals or materials described in K.S.A. 2022 Supp. 21-5709(a), and amendments thereto; or
(B) any materials used or intended for use to test a substance for the presence of fentanyl, a fentanyl analog, ketamine or gamma hydroxybutyric acid.

(g) "Fentanyl-related controlled substance" means any substance designated in K.S.A. 65-4105(b)(1), (b)(2), (b)(4), (b)(10), (b)(11), (b)(14), (b)(15), (b)(16), (b)(20), (b)(22), (b)(23), (b)(24), (b)(37), (b)(41), (b)(45), (b)(46), (b)(47), (b)(49), (b)(57), (b)(58), (b)(59), (b)(60), (b)(61), (b)(62), (b)(73), (b)(74), (b)(78), (g)(1) or (g)(2) or 65-4107(c)(1), (c)(6), (c)(9), (c)(26), (c)(28), (c)(30), (f)(3)(A) or (f)(3)(B), and amendments thereto, or any analog thereof.

(h) "Immediate precursor" means a substance that the state board of pharmacy has found to be and by rules and regulations designates as being the principal compound commonly used or produced primarily for use and that is an immediate chemical intermediary used or likely to be used in the manufacture of a controlled substance, the control of which is necessary to prevent, curtail or limit manufacture.

(i) "Isomer" means all enantiomers and diastereomers.

(j) "Manufacture" means the production, preparation, propagation, compounding, conversion or processing of a controlled substance either directly or indirectly or by extraction from substances of natural origin or independently by means of chemical synthesis or by a combination of extraction and chemical synthesis. "Manufacture" does not include:

(1) The preparation or compounding of a controlled substance by an individual for the individual's own lawful use or the preparation, compounding, packaging or labeling of a controlled substance:
   (A) By a practitioner or the practitioner's agent pursuant to a lawful order of a practitioner as an incident to the practitioner's administering or dispensing of a controlled substance in the course of the practitioner's professional practice; or
   (B) by a practitioner or by the practitioner's authorized agent under such practitioner's supervision for the purpose of or as an incident to research, teaching or chemical analysis or by a pharmacist or medical care facility as an incident to dispensing of a controlled substance; or
(2) the addition of diluents or adulterants, including, but not limited to, quinine hydrochloride, mannitol, mannite, dextrose or lactose that are intended for use in cutting a controlled substance.

(k) "Marijuana" means all parts of all varieties of the plant Cannabis whether growing or not, the seeds thereof, the resin extracted from any part of the plant and every compound, manufacture, salt, derivative, mixture or preparation of the plant, its seeds or resin. "Marijuana" does not include:

(1) The mature stalks of the plant, fiber produced from the stalks, oil or cake made from the seeds of the plant, any other compound, manufacture, salt, derivative, mixture or preparation of the mature stalks, except the resin extracted therefrom, fiber, oil or cake or the sterilized seed of the plant that is incapable of germination;
(2) any substance listed in schedules II through V of the uniform controlled substances act;
(3) drug products approved by the United States food and drug administration as of the effective date of this act;
(4) cannabidiol (other trade name: 2-[(3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl)-5-pentyl-1,3-benzenediol); or

(5) industrial hemp as defined in K.S.A. 2-3901, and amendments thereto, when cultivated, produced, possessed or used for activities authorized by the commercial industrial hemp act.

(l) "Minor" means a person under 18 years of age.

(m) "Narcotic drug" means any of the following whether produced directly or indirectly by extraction from substances of vegetable origin or independently by means of chemical synthesis or by a combination of extraction and chemical synthesis:

(1) Opium and opiate and any salt, compound, derivative or preparation of opium or opiate;

(2) any salt, compound, isomer, derivative or preparation thereof that is chemically equivalent or identical with any of the substances referred to in paragraph (1) but not including the isoquinoline alkaloids of opium;

(3) opium poppy and poppy straw;

(4) coca leaves and any salt, compound, derivative or preparation of coca leaves and any salt, compound, isomer, derivative or preparation thereof that is chemically equivalent or identical with any of these substances, but not including decocainized coca leaves or extractions of coca leaves that do not contain cocaine or ecgonine.

(n) "Opiate" means any substance having an addiction-forming or addiction-sustaining liability similar to morphine or being capable of conversion into a drug having addiction-forming or addiction-sustaining liability. "Opiate" does not include, unless specifically designated as controlled under K.S.A. 65-4102, and amendments thereto, the dextrorotatory isomer of 3-methoxy-n-methylmorphinan and its salts (dextromethorphan). "Opiate" does include its racemic and levorotatory forms.

(o) "Opium poppy" means the plant of the species Papaver somniferum l. except its seeds.

(p) "Person" means an individual, corporation, government or governmental subdivision or agency, business trust, estate, trust, partnership, association or any other legal entity.

(q) "Poppy straw" means all parts, except the seeds, of the opium poppy, after mowing.

(r) "School property" means property upon which is located a structure used by a unified school district or an accredited nonpublic school for student instruction or attendance or extracurricular activities of pupils enrolled in kindergarten or any of the grades one through 12. This definition shall not be construed as requiring that school be in session or that classes are actually being held at the time of the offense or that children must be present within the structure or on the property during the time of any alleged criminal act. If the structure or property meets the above definition, the actual use of that structure or property at the time alleged shall not be a defense to the crime charged or the sentence imposed.

(s) "Simulated controlled substance" means any product that identifies itself by a common name or slang term associated with a controlled substance and that indicates on its label or accompanying promotional material that the product simulates the effect of a controlled substance.


**21-5701b.**

**History:** L. 2009, ch. 32, § 1; L. 2010, ch. 109, § 13; L. 2012, ch. 150, § 7; L. 2017, ch. 57, § 1; L. 2018, ch. 101, § 4; L. 2019, ch. 37, § 10; L. 2022, ch. 76, § 3; Repealed L. 2023, ch. 94, § 8; July 1.

**21-5702. Effective date; scope of act.**
(a) Prosecutions for crimes committed prior to July 1, 2009, shall be governed by the law in effect at the time the crime was committed. For purposes of this section, a crime was committed prior to July 1, 2009, if any element of the crime occurred prior thereto.
(b) The prohibitions of this act shall apply unless the conduct prohibited is authorized by the pharmacy act of the state of Kansas, the uniform controlled substances act, the commercial industrial hemp act or otherwise authorized by law.


21-5703. Unlawful manufacturing of controlled substances.
(a) It shall be unlawful for any person to manufacture any controlled substance or controlled substance analog.
(b) Violation or attempted violation of subsection (a) is a:
(1) Drug severity level 2 felony, except as provided in subsections (b)(2) and (b)(3);
(2) drug severity level 1 felony if:
(A) The controlled substance is not methamphetamine, as defined by K.S.A. 65-4107(d)(3) or (f)(1), and amendments thereto, or an analog thereof;
(B) the controlled substance is not a fentanyl-related controlled substance; and
(C) the offender has a prior conviction for unlawful manufacturing of a controlled substance under this section, K.S.A. 65-4159, prior to its repeal, K.S.A. 2010 Supp. 21-36a03, prior to its transfer, or a substantially similar offense from another jurisdiction and the substance was not methamphetamine, as defined by K.S.A. 65-4107(d)(3) or (f)(1), and amendments thereto, or an analog thereof, in any such prior conviction; and
(3) drug severity level 1 felony if the controlled substance is methamphetamine, as defined by K.S.A. 65-4107(d)(3) or (f)(1), and amendments thereto, or an analog thereof, or is a fentanyl-related controlled substance.
(c) The provisions of K.S.A. 2022 Supp. 21-5301(d), and amendments thereto, shall not apply to a violation of attempting to unlawfully manufacture any controlled substance or controlled substance analog pursuant to this section.
(d) For persons arrested and charged under this section, bail shall be at least $50,000 cash or surety, and such person shall not be released upon the person's own recognizance pursuant to K.S.A. 22-2802, and amendments thereto, unless the court determines, on the record, that the defendant is not likely to re-offend, the court imposes pretrial supervision, or the defendant agrees to participate in a licensed or certified drug treatment program.
(e) The sentence of a person who violates this section shall not be subject to statutory provisions for suspended sentence, community service work or probation.
(f) The sentence of a person who violates this section, K.S.A. 65-4159, prior to its repeal or K.S.A. 2010 Supp. 21-36a03, prior to its transfer, shall not be reduced because these sections prohibit conduct identical to that prohibited by K.S.A. 65-4161 or 65-4163, prior to their repeal, K.S.A. 2010 Supp. 21-36a05, prior to its transfer, or K.S.A. 2016 Supp. 21-5705, and amendments thereto.

History: L. 2009, ch. 32, § 3; L. 2011, ch. 30, § 287; L. 2012, ch. 150, § 8; L. 2013, ch. 37, § 1; L. 2014, ch. 90, § 3; L. 2023, ch. 94, § 3; July 1.

21-5704. Same; costs and expenses.
All costs and expenses resulting from the seizure, disposition and decontamination of an unlawful manufacturing site shall be assessed as costs against the defendant.

21-5705. Unlawful cultivation or distribution of controlled substances.
(a) It shall be unlawful for any person to distribute or possess with the intent to distribute any of the following controlled substances or controlled substance analogs thereof:
   (1) Opiates, opium or narcotic drugs, or any stimulant designated in subsection (d)(1), (d)(3) or (f)(1) of K.S.A. 65-4107, and amendments thereto;
   (2) any depressant designated in subsection (e) of K.S.A. 65-4105, subsection (e) of K.S.A. 65-4107, subsection (b) or (c) of K.S.A. 65-4109 or subsection (b) of K.S.A. 65-4111, and amendments thereto;
   (3) any stimulant designated in subsection (f) of K.S.A. 65-4105, subsection (d)(2), (d)(4), (d)(5) or (f)(2) of K.S.A. 65-4107 or subsection (e) of K.S.A. 65-4109, and amendments thereto;
   (4) any hallucinogenic drug designated in subsection (d) of K.S.A. 65-4105, subsection (g) of K.S.A. 65-4107 or subsection (g) of K.S.A. 65-4109, and amendments thereto;
   (5) any substance designated in subsection (g) of K.S.A. 65-4105 and subsection (c), (d), (e), (f) or (g) of K.S.A. 65-4111, and amendments thereto;
   (6) any anabolic steroids as defined in subsection (f) of K.S.A. 65-4109, and amendments thereto; or
   (7) any substance designated in subsection (h) of K.S.A. 65-4105, and amendments thereto.
(b) It shall be unlawful for any person to distribute or possess with the intent to distribute a controlled substance or a controlled substance analog designated in K.S.A. 65-4113, and amendments thereto.
(c) It shall be unlawful for any person to cultivate any controlled substance or controlled substance analog listed in subsection (a).
(d) (1) Except as provided further, violation of subsection (a) is a:
   (A) Drug severity level 4 felony if the quantity of the material was less than 3.5 grams;
   (B) drug severity level 3 felony if the quantity of the material was at least 3.5 grams but less than 100 grams;
   (C) drug severity level 2 felony if the quantity of the material was at least 100 grams but less than 1 kilogram; and
   (D) drug severity level 1 felony if the quantity of the material was 1 kilogram or more.
   (2) Violation of subsection (a) with respect to material containing any quantity of marijuana, or an analog thereof, is a:
   (A) Drug severity level 4 felony if the quantity of the material was less than 25 grams;
   (B) drug severity level 3 felony if the quantity of the material was at least 25 grams but less than 450 grams;
   (C) drug severity level 2 felony if the quantity of the material was at least 450 grams but less than 30 kilograms; and
   (D) drug severity level 1 felony if the quantity of the material was 30 kilograms or more.
   (3) Violation of subsection (a) with respect to material containing any quantity of heroin, as defined by subsection (c)(1) of K.S.A. 65-4105, and amendments thereto, or methamphetamine, as defined by subsection (d)(3) or (f)(1) of K.S.A. 65-4107, and amendments thereto, or an analog thereof, is a:
   (A) Drug severity level 4 felony if the quantity of the material was less than 1 gram;
(B) drug severity level 3 felony if the quantity of the material was at least 1 gram but less than 3.5 grams;
(C) drug severity level 2 felony if the quantity of the material was at least 3.5 grams but less than 100 grams; and
(D) drug severity level 1 felony if the quantity of the material was 100 grams or more.

(4) Violation of subsection (a) with respect to material containing any quantity of a controlled substance designated in K.S.A. 65-4105, 65-4107, 65-4109 or 65-4111, and amendments thereto, or an analog thereof, distributed by dosage unit, is a:
   (A) Drug severity level 4 felony if the number of dosage units was fewer than 10;
   (B) drug severity level 3 felony if the number of dosage units was at least 10 but less than 100;
   (C) drug severity level 2 felony if the number of dosage units was at least 100 but less than 1,000; and
   (D) drug severity level 1 felony if the number of dosage units was 1,000 or more.

(5) For any violation of subsection (a), the severity level of the offense shall be increased one level if the controlled substance or controlled substance analog was distributed or possessed with the intent to distribute on or within 1,000 feet of any school property.

(6) Violation of subsection (b) is a:
   (A) Class A person misdemeanor, except as provided in subsection (d)(6)(B); and
   (B) nondrug severity level 7, person felony if the substance was distributed to or possessed with the intent to distribute to a minor.

(7) Violation of subsection (c) is a:
   (A) Drug severity level 3 felony if the number of plants cultivated was more than 4 but fewer than 50;
   (B) drug severity level 2 felony if the number of plants cultivated was at least 50 but fewer than 100; and
   (C) drug severity level 1 felony if the number of plants cultivated was 100 or more.

(e) In any prosecution under this section, there shall be a rebuttable presumption of an intent to distribute if any person possesses the following quantities of controlled substances or analogs thereof:
   (1) 450 grams or more of marijuana;
   (2) 3.5 grams or more of heroin or methamphetamine;
   (3) 100 dosage units or more containing a controlled substance; or
   (4) 100 grams or more of any other controlled substance.

(f) It shall not be a defense to charges arising under this section that the defendant:
   (1) Was acting in an agency relationship on behalf of any other party in a transaction involving a controlled substance or controlled substance analog;
   (2) did not know the quantity of the controlled substance or controlled substance analog; or
   (3) did not know the specific controlled substance or controlled substance analog contained in the material that was distributed or possessed with the intent to distribute.

(g) As used in this section:
   (1) "Material" means the total amount of any substance, including a compound or a mixture, which contains any quantity of a controlled substance or controlled substance analog.
   (2) "Dosage unit" means a controlled substance or controlled substance analog distributed or possessed with the intent to distribute as a discrete unit, including but not limited to, one pill, one capsule or one microdot, and not distributed by weight.
(A) For steroids, or controlled substances in liquid solution legally manufactured for prescription use, or an analog thereof, "dosage unit" means the smallest medically approved dosage unit, as determined by the label, materials provided by the manufacturer, a prescribing authority, licensed health care professional or other qualified health authority.

(B) For illegally manufactured controlled substances in liquid solution, or controlled substances in liquid products not intended for ingestion by human beings, or an analog thereof, "dosage unit" means 10 milligrams, including the liquid carrier medium, except as provided in subsection (g)(2)(C).

(C) For lysergic acid diethylamide (LSD) in liquid form, or an analog thereof, a dosage unit is defined as 0.4 milligrams, including the liquid medium.


21-5706. Unlawful possession of controlled substances.
(a) It shall be unlawful for any person to possess any opiates, opium or narcotic drugs, or any stimulant designated in K.S.A. 65-4107(d)(1), (d)(3) or (f)(1), and amendments thereto, or a controlled substance analog thereof.

(b) It shall be unlawful for any person to possess any of the following controlled substances or controlled substance analogs thereof:
   (1) Any depressant designated in K.S.A. 65-4105(e), 65-4107(e), 65-4109(b) or (c) or 65-4111(b), and amendments thereto;
   (2) any stimulant designated in K.S.A. 65-4105(f), 65-4107(d)(2), (d)(4), (d)(5) or (f)(2) or 65-4109(e), and amendments thereto;
   (3) any hallucinogenic drug designated in K.S.A. 65-4105(d), 65-4107(g) or 65-4109(g), and amendments thereto;
   (4) any substance designated in K.S.A. 65-4105(g) and 65-4111(c), (d), (e), (f) or (g), and amendments thereto;
   (5) any anabolic steroids as defined in K.S.A. 65-4109(f), and amendments thereto;
   (6) any substance designated in K.S.A. 65-4113, and amendments thereto; or
   (7) any substance designated in K.S.A. 65-4105(h), and amendments thereto.

(c) (1) Violation of subsection (a) is a drug severity level 5 felony.

(2) Except as provided in subsection (c)(3):
   (A) Violation of subsection (b) is a class A nonperson misdemeanor, except as provided in subparagraph (B); and
   (B) violation of subsection (b)(1) through (b)(5) or (b)(7) is a drug severity level 5 felony if that person has a prior conviction under such subsection, under K.S.A. 65-4162, prior to its repeal, under a substantially similar offense from another jurisdiction, or under any city ordinance or county resolution for a substantially similar offense if the substance involved was 3, 4-methylenedioxyamphetamine (MDMA), marijuana as designated in K.S.A. 65-4105(d), and amendments thereto, or any substance designated in K.S.A. 65-4105(h), and amendments thereto, or an analog thereof.

(3) If the substance involved is marijuana, as designated in K.S.A. 65-4105(d), and amendments thereto, or tetrahydrocannabinols, as designated in K.S.A. 65-4105(h), and amendments thereto, violation of subsection (b) is a:
   (A) Class B nonperson misdemeanor, except as provided in subparagraphs (B) and (C);
(B) class A nonperson misdemeanor if that person has a prior conviction under such subsection, under K.S.A. 65-4162, prior to its repeal, under a substantially similar offense from another jurisdiction, or under any city ordinance or county resolution for a substantially similar offense; and
(C) drug severity level 5 felony if that person has two or more prior convictions under such subsection, under K.S.A. 65-4162, prior to its repeal, under a substantially similar offense from another jurisdiction, or under any city ordinance or county resolution for a substantially similar offense.
(d) It shall be an affirmative defense to prosecution under this section arising out of a person's possession of any cannabidiol treatment preparation if the person:
(1) Has a debilitating medical condition, as defined in K.S.A. 2021 Supp. 65-6235, and amendments thereto, or is the parent or guardian of a minor child who has such debilitating medical condition;
(2) is possessing a cannabidiol treatment preparation, as defined in K.S.A. 2021 Supp. 65-6235, and amendments thereto, that is being used to treat such debilitating medical condition; and
(3) has possession of a letter, at all times while the person has possession of the cannabidiol treatment preparation, that:
(A) Shall be shown to a law enforcement officer on such officer's request;
(B) is dated within the preceding 15 months and signed by the physician licensed to practice medicine and surgery in Kansas who diagnosed the debilitating medical condition;
(C) is on such physician's letterhead; and
(D) identifies the person or the person's minor child as such physician's patient and identifies the patient's debilitating medical condition.
(e) It shall not be a defense to charges arising under this section that the defendant was acting in an agency relationship on behalf of any other party in a transaction involving a controlled substance or controlled substance analog.


21-5707. Unlawful manufacture, distribution, cultivation or possession of controlled substances using a communication facility.
(a) It shall be unlawful for any person to knowingly or intentionally use any communication facility:
(1) In committing, causing, or facilitating the commission of any felony under K.S.A. 2013 Supp. 21-5703, 21-5705 or 21-5706, and amendments thereto; or
(2) in any attempt to commit, any conspiracy to commit, or any criminal solicitation of any felony under K.S.A. 2013 Supp. 21-5703, 21-5705 or 21-5706, and amendments thereto. Each separate use of a communication facility may be charged as a separate offense under this subsection.
(b) Violation of subsection (a) is a nondrug severity level 8, nonperson felony.
(c) As used in this section, "communication facility" means any and all public and private instrumentalities used or useful in the transmission of writing, signs, signals, pictures or sounds of all kinds and includes telephone, wire, radio, computer, computer networks, beepers, pagers and all other means of communication.


21-5708. Unlawfully obtaining or selling a prescription-only drug.
(a) Unlawfully obtaining a prescription-only drug is:
(1) Making, altering or signing of a prescription order by a person other than a practitioner or a mid-level practitioner;
(2) distribution of a prescription order, knowing it to have been made, altered or signed by a person other than a practitioner or a mid-level practitioner;
(3) possession of a prescription order with intent to distribute it and knowing it to have been made, altered or signed by a person other than a practitioner or a mid-level practitioner;
(4) possession of a prescription-only drug knowing it to have been obtained pursuant to a prescription order made, altered or signed by a person other than a practitioner or a mid-level practitioner; or
(5) providing false information, with the intent to deceive, to a practitioner or mid-level practitioner for the purpose of obtaining a prescription-only drug.

(b) Unlawfully selling a prescription-only drug is unlawfully obtaining a prescription-only drug, as defined in subsection (a), and:

(1) Selling the prescription-only drug so obtained;
(2) offering for sale the prescription-only drug so obtained; or
(3) possessing with intent to sell the prescription-only drug so obtained.

(c) (1) Unlawfully obtaining a prescription-only drug is a:
(A) Class A nonperson misdemeanor, except as provided in subsection (c)(1)(B); and
(B) nondrug severity level 9, nonperson felony if that person has a prior conviction of under this section, K.S.A. 2010 Supp. 21-36a08, prior to its transfer, or K.S.A. 21-4214, prior to its repeal.

(2) Unlawfully selling a prescription-only drug is a nondrug severity level 6, nonperson felony.

(d) As used in this section:

(1) "Pharmacist," "practitioner," "mid-level practitioner" and "prescription-only drug" shall have the meanings ascribed thereto by K.S.A. 65-1626, and amendments thereto.

(2) "Prescription order" means an order transmitted in writing, orally, telephonically or by other means of communication for a prescription-only drug to be filled by a pharmacist. "Prescription order" does not mean a drug dispensed pursuant to such an order.

(e) The provisions of this section shall not be applicable to prosecutions involving prescription-only drugs which could be brought under K.S.A. 2013 Supp. 21-5705 or 21-5706, and amendments thereto.


21-5709. Unlawful possession of certain drug precursors and drug paraphernalia.
(a) It shall be unlawful for any person to possess ephedrine, pseudoephedrine, red phosphorus, lithium metal, sodium metal, iodine, anhydrous ammonia, pressurized ammonia or phenylpropanolamine, or their salts, isomers or salts of isomers with an intent to use the product to manufacture a controlled substance.

(b) It shall be unlawful for any person to use or possess with intent to use any drug paraphernalia to:
(1) Manufacture, cultivate, plant, propagate, harvest, test, analyze or distribute a controlled substance; or
(2) store, contain, conceal, inject, ingest, inhale or otherwise introduce a controlled substance into the human body.

(c) It shall be unlawful for any person to use or possess with intent to use anhydrous ammonia or pressurized ammonia in a container not approved for that chemical by the Kansas department of agriculture.
(d) It shall be unlawful for any person to purchase, receive or otherwise acquire at retail any compound, mixture or preparation containing more than 3.6 grams of pseudoephedrine base or ephedrine base in any single transaction or any compound, mixture or preparation containing more than nine grams of pseudoephedrine base or ephedrine base within any 30-day period.

(e) (1) Violation of subsection (a) is a drug severity level 3 felony;
(2) violation of subsection (b)(1) is a:
(A) Drug severity level 5 felony, except as provided in subsection (e)(2)(B); and
(B) class B nonperson misdemeanor if the drug paraphernalia was used to cultivate fewer than five marijuana plants;
(3) violation of subsection (b)(2) is a class B nonperson misdemeanor;
(4) violation of subsection (c) is a drug severity level 5 felony; and
(5) violation of subsection (d) is a class A nonperson misdemeanor.

(f) For persons arrested and charged under subsection (a) or (c), bail shall be at least $50,000 cash or surety, and such person shall not be released upon the person's own recognizance pursuant to K.S.A. 22-2802, and amendments thereto, unless the court determines, on the record, that the defendant is not likely to reoffend, the court imposes pretrial supervision or the defendant agrees to participate in a licensed or certified drug treatment program.


21-5710. Unlawful distribution of certain drug precursors and drug paraphernalia.
(a) It shall be unlawful for any person to advertise, market, label, distribute or possess with the intent to distribute:
(1) Any product containing ephedrine, pseudoephedrine, red phosphorus, lithium metal, sodium metal, iodine, anhydrous ammonia, pressurized ammonia or phenylpropanolamine or their salts, isomers or salts of isomers if the person knows or reasonably should know that the purchaser will use the product to manufacture a controlled substance or controlled substance analog; or
(2) Any product containing ephedrine, pseudoephedrine or phenylpropanolamine, or their salts, isomers or salts of isomers for indication of stimulation, mental alertness, weight loss, appetite control, energy or other indications not approved pursuant to the pertinent federal over-the-counter drug final monograph or tentative final monograph or approved new drug application.

(b) It shall be unlawful for any person to distribute, possess with the intent to distribute or manufacture with intent to distribute any drug paraphernalia, knowing or under circumstances where one reasonably should know that it will be used to manufacture or distribute a controlled substance or controlled substance analog in violation of K.S.A. 2016 Supp. 21-5701 through 21-5717, and amendments thereto.

(c) It shall be unlawful for any person to distribute, possess with intent to distribute or manufacture with intent to distribute any drug paraphernalia, knowing or under circumstances where one reasonably should know, that it will be used as such in violation of K.S.A. 2016 Supp. 21-5701 through 21-5717, and amendments thereto, except subsection (b) of K.S.A. 2016 Supp. 21-5706, and amendments thereto.

(d) It shall be unlawful for any person to distribute, possess with intent to distribute or manufacture with intent to distribute any drug paraphernalia, knowing, or under circumstances where one reasonably should know, that it will be used as such in violation of subsection (b) of K.S.A. 2016 Supp. 21-5706, and amendments thereto.
(e) (1) Violation of subsection (a) is a drug severity level 3 felony;
(2) violation of subsection (b) is a:
   (A) Drug severity level 5 felony, except as provided in subsection (e)(2)(B); and
   (B) drug severity level 4 felony if the trier of fact makes a finding that the offender
distributed or caused drug paraphernalia to be distributed to a minor or on or within 1,000
feet of any school property;
(3) violation of subsection (c) is a:
   (A) Nondrug severity level 9, nonperson felony, except as provided in subsection
   (e)(3)(B); and
   (B) drug severity level 5 felony if the trier of fact makes a finding that the offender
distributed or caused drug paraphernalia to be distributed to a minor or on or within 1,000
feet of any school property; and
(4) violation of subsection (d) is a:
   (A) Class A nonperson misdemeanor, except as provided in subsection (e)(4)(B); and
   (B) nondrug severity level 9, nonperson felony if the trier of fact makes a finding that
the offender distributed or caused drug paraphernalia to be distributed to a minor or on or
within 1,000 feet of any school property.

(f) For persons arrested and charged under subsection (a), bail shall be at least $50,000 cash or
surety, and such person shall not be released upon the person's own recognizance pursuant to
K.S.A. 22-2802, and amendments thereto, unless the court determines, on the record, that the
defendant is not likely to re-offend, the court imposes pretrial supervision or the defendant
agrees to participate in a licensed or certified drug treatment program.

(g) As used in this section, "or under circumstances where one reasonably should know" that
an item will be used in violation of this section, shall include, but not be limited to, the
following:
   (1) Actual knowledge from prior experience or statements by customers;
   (2) inappropriate or impractical design for alleged legitimate use;
   (3) receipt of packaging material, advertising information or other manufacturer supplied
information regarding the item's use as drug paraphernalia; or
   (4) receipt of a written warning from a law enforcement or prosecutorial agency having
jurisdiction that the item has been previously determined to have been designed specifically
for use as drug paraphernalia.

History:  L. 2009, ch. 32, § 10; L. 2010, ch. 74, § 5; L. 2010, ch. 155, § 5; L. 2012, ch. 150, §
14; L. 2014, ch. 90, § 5; July 1.

21-5711. Factors to consider when determining what is drug paraphernalia.
(a) In determining whether an object is drug paraphernalia, a court or other authority shall
consider, in addition to all other logically relevant factors, the following:
   (1) Statements by an owner or person in control of the object concerning its use;
   (2) prior convictions, if any, of an owner or person in control of the object, under any state
or federal law relating to any controlled substance;
   (3) the proximity of the object, in time and space, to a direct violation of K.S.A. 2013 Supp.
21-5701 through 21-5717, and amendments thereto;
   (4) the proximity of the object to controlled substances;
   (5) the existence of any residue of controlled substances on the object;
(6) direct or circumstantial evidence of the intent of an owner or person in control of the object, to deliver it to a person the owner or person in control of the object knows, or should reasonably know, intends to use the object to facilitate a violation of K.S.A. 2013 Supp. 21-5701 through 21-5717, and amendments thereto. The innocence of an owner or person in control of the object as to a direct violation of K.S.A. 2013 Supp. 21-5701 through 21-5717, and amendments thereto, shall not prevent a finding that the object is intended for use as drug paraphernalia;

(7) oral or written instructions provided with the object concerning its use;

(8) descriptive materials accompanying the object which explain or depict its use;

(9) national and local advertising concerning the object's use;

(10) the manner in which the object is displayed for sale;

(11) whether the owner or person in control of the object is a legitimate supplier of similar or related items to the community, such as a distributor or dealer of tobacco products;

(12) direct or circumstantial evidence of the ratio of sales of the object or objects to the total sales of the business enterprise;

(13) the existence and scope of legitimate uses for the object in the community;

(14) expert testimony concerning the object's use;

(15) any evidence that alleged paraphernalia can or has been used to store a controlled substance or to introduce a controlled substance into the human body as opposed to any legitimate use for the alleged paraphernalia; or

(16) advertising of the item in magazines or other means which specifically glorify, encourage or espouse the illegal use, manufacture, distribution or cultivation of controlled substances.

(b) The fact that an item has not yet been used or did not contain a controlled substance at the time of the seizure is not a defense to a charge that the item was possessed with the intention for use as drug paraphernalia.

**History:** L. 2009, ch. 32, § 11; July 1.

### 21-5712. Unlawful abuse of toxic vapors.

(a) Unlawful abuse of toxic vapors is possessing, buying, using, smelling or inhaling toxic vapors with the intent of causing a condition of euphoria, excitement, exhilaration, stupefaction or dulled senses of the nervous system.

(b) Unlawful abuse of toxic vapors is a class B nonperson misdemeanor.

(c) In addition to any sentence or fine imposed, the court shall enter an order which requires that the person enroll in and successfully complete an alcohol and drug safety action education program, treatment program or both such programs as provided in K.S.A. 8-1008, and amendments thereto.

(d) This section shall not apply to the inhalation of anesthesia or other substances for medical or dental purposes.

(e) For the purposes of this section, the term "toxic vapors" means vapors from the following substances or products containing such substances:

(1) Alcohols, including methyl, isopropyl, propyl or butyl;

(2) aliphatic acetates, including ethyl, methyl, propyl or methyl cellosolve acetate;

(3) acetone;

(4) benzene;

(5) carbon tetrachloride;
(6) cyclohexane;
(7) freons, including freon 11, freon 12 and other halogenated hydrocarbons;
(8) hexane;
(9) methyl ethyl ketone;
(10) methyl isobutyl ketone;
(11) naptha;
(12) perchlorethylene;
(13) toluene;
(14) trichloroethane; or
(15) xylene.

(f) In a prosecution for a violation of this section, evidence that a container lists one or more of
the substances described in subsection (e) as one of its ingredients shall be prima facie evidence
that the substance in such container contains toxic vapors.

History: L. 2009, ch. 32, § 12; L. 2015, ch. 20, § 1; July 1.

21-5713. Unlawful distribution or possession of a simulated controlled substance.
(a) It shall be unlawful for any person to distribute, possess with the intent to distribute, or
manufacture with the intent to distribute any simulated controlled substance.
(b) It shall be unlawful for any person to use or possess with intent to use any simulated
controlled substance.
(c) (1) Violation of subsection (a) is a:
       (A) nondrug severity level 9, non-person felony, except as provided in subsection
(c)(1)(B); and
       (B) nondrug severity level 7, nonperson felony if the trier of fact makes a finding that
the offender is 18 or more years of age and the violation occurred on or within 1,000 feet of any
school property; and
(2) violation of subsection (b) is a class A nonperson misdemeanor.


21-5714. Unlawful representation that noncontrolled substance is controlled substance.
(a) It shall be unlawful for any person to distribute or possess with the intent to distribute any
substance which is not a controlled substance:
       (1) Upon an express representation that the substance is a controlled substance or that the
substance is of such nature or appearance that the recipient will be able to distribute the
substance as a controlled substance; or
       (2) under circumstances which would give a reasonable person reason to believe that the
substance is a controlled substance.
(b) Violation of subsection (a) is a:
       (1) Class A nonperson misdemeanor, except as provided in subsection (b)(2); and
       (2) nondrug severity level 9, nonperson felony if the distributor is 18 or more years of age,
distributing to a minor and at least three years older than the minor to whom the distribution is
made.
(c) If any one of the following factors is established, there shall be a presumption that distribution of a substance was under circumstances which would give a reasonable person reason to believe that a substance is a controlled substance:
   (1) The substance was packaged in a manner normally used for the illegal distribution of controlled substances;
   (2) the distribution of the substance included an exchange of or demand for money or other consideration for distribution of the substance and the amount of the consideration was substantially in excess of the reasonable value of the substance; or
   (3) the physical appearance of the capsule or other material containing the substance is substantially identical to a specific controlled substance.
(d) A person who commits a violation of subsection (a) also may be prosecuted for, convicted of and punished for theft.


21-5715. Treatment of a controlled substance analog.
Within 10 days after the initiation of prosecution with respect to a controlled substance analog by indictment, complaint or information, the prosecuting attorney shall notify the board of pharmacy of information relevant to emergency scheduling as provided for in subsection (e) of K.S.A. 65-4102, and amendments thereto. After final determination that the controlled substance analog should not be scheduled, no prosecution relating to that substance as a controlled substance analog may be commenced or continued.


21-5716. Unlawful acts involving proceeds derived from violations of 21-5701 through 21-5717.
(a) It shall be unlawful for any person to receive or acquire proceeds or engage in transactions involving proceeds, known to be derived from a violation of K.S.A. 2013 Supp. 21-5701 through 21-5717, and amendments thereto, or any substantially similar offense from another jurisdiction. The provisions of this subsection do not apply to any transaction between an individual and that individual's counsel necessary to preserve that individual's right to representation, as guaranteed by section 10 of the bill of rights of the constitution of the state of Kansas and by the sixth amendment to the United States constitution. This exception does not create any presumption against or prohibition of the right of the state to seek and obtain forfeiture of any proceeds derived from a violation of K.S.A. 2013 Supp. 21-5701 through 21-5717, and amendments thereto.
(b) It shall be unlawful for any person to distribute, invest, conceal, transport or maintain an interest in or otherwise make available anything of value which that person knows is intended to be used for the purpose of committing or furthering the commission of any crime in K.S.A. 2013 Supp. 21-5701 through 21-5717, and amendments thereto, or any substantially similar offense from another jurisdiction.
(c) It shall be unlawful for any person to direct, plan, organize, initiate, finance, manage, supervise or facilitate the transportation or transfer of proceeds known to be derived from commission of any crime in K.S.A. 2013 Supp. 21-5701 through 21-5717, and amendments thereto, or any substantially similar offense from another jurisdiction.
(d) It shall be unlawful for any person to conduct a financial transaction involving proceeds derived from commission of any crime in K.S.A. 2013 Supp. 21-5701 through 21-5717, and
amendments thereto, or any substantially similar offense from another jurisdiction, when the transaction is designed in whole or in part to conceal or disguise the nature, location, source, ownership or control of the proceeds known to be derived from commission of any crime in K.S.A. 2013 Supp. 21-5701 through 21-5717, and amendments thereto, or any substantially similar offense from another jurisdiction, or to avoid a transaction reporting requirement under state or federal law.

(e) Violation of this section is a:
   (1) Drug severity level 5 felony if the value of the proceeds is less than $5,000;
   (2) drug severity level 4 felony if the value of the proceeds is at least $5,000 but less than $100,000;
   (3) drug severity level 3 felony if the value of the proceeds is at least $100,000 but less than $250,000;
   (4) drug severity level 2 felony if the value of the proceeds is at least $250,000 but less than $500,000; and
   (5) drug severity level 1 felony if the value of the proceeds is $500,000 or more.


21-5717. Uniformity of act.
The statutes listed below shall be applicable and uniform throughout this state and in all cities and counties therein. No city or county shall enact or enforce any law, ordinance, rule, regulation or resolution in conflict with, in addition to, or supplemental to, the provisions listed below unless expressly authorized by law to do so:
(a) Subsection (c) of K.S.A. 21-2501a, and amendments thereto;
(b) subsections (k) and (l) of K.S.A. 65-1643, and amendments thereto;
(c) subsections (e), (f) and (g) of K.S.A. 65-4113, and amendments thereto;
(d) subsection (c) of K.S.A. 2013 Supp. 21-5703, and amendments thereto;
(e) subsection (f) of K.S.A. 2013 Supp. 21-5709, and amendments thereto;
(f) subsection (f) of K.S.A. 2013 Supp. 21-5710, and amendments thereto.

History: L. 2009, ch. 32, § 17; July 1.
VIII. Kansas State Board of Pharmacy

Chapter 74.—State Boards, Commissions, and Authorities
Article 16.—Board of Pharmacy

74-1601.
History: L. 1885, ch. 150, § 2; L. 1887, ch. 174, § 1; R.S. 1923, 74-1601; Repealed, L. 1953, ch. 290, § 38; July 1.

74-1602.
History: L. 1885, ch. 150, § 9; L. 1887, ch. 174, § 3; R.S. 1923, 74-1602; L. 1927, ch. 290, § 1; Repealed, L. 1953, ch. 290, § 38; July 1.

74-1603. State board of pharmacy; creation, membership; vacancies; number of terms limited.
(a) There is hereby created a state board of pharmacy which shall consist of seven members, six of whom shall be licensed pharmacists, and one of whom shall be a representative of the general public.
(b) Vacancies occurring on the board other than by expiration of term shall be filled for the unexpired term in the same manner as the original appointment was made. No person who has been appointed to and qualified for two terms as a member of the board of pharmacy shall be eligible to be appointed as a member of the board. On July 1, 2009, the term of office of each existing board member shall be extended by one year.
(c) The office of the state board of pharmacy shall be located in the city of Topeka, Kansas.

74-1604. Same; appointment; terms; qualifications.
The governor shall appoint the members of the board and such members appointed on and after July 1, 2009, shall serve for terms of four years and until their successors are appointed and qualified.
No pharmacist shall be eligible for appointment as a member of the board unless such pharmacist has been a resident of the state and actively employed in or engaged in the practice of pharmacy in Kansas for at least five years immediately preceding the date of appointment.

74-1605. Same; names submitted by state pharmaceutical association for consideration; oaths. Upon the expiration of the term of any pharmacist, the state pharmaceutical association shall submit to the governor a list of pharmacists who meet the qualifications established by K.S.A. 74-1604 and amendments thereto, for membership on the board containing the names of not less than three times the number of registered pharmacists to be appointed to the board. In making appointments to the board, the governor shall give consideration to such list of persons. Within 30 days after their appointments, appointees to the board shall each take and subscribe to the oath prescribed by law for state officers, which shall be filed in the office of the secretary of state.
74-1606. Officers of board; executive secretary; compensation; employees.
(a) Annually, the board shall organize by electing a president and a vice-president and shall also
appoint a full-time executive secretary who shall not be a member of the board and whose
employment shall at all times be subject to the pleasure of the board. The executive secretary
shall be in the unclassified service of the Kansas civil service act and shall receive an annual
salary fixed by the board and approved by the state finance council.
(b) The board may employ, in accordance with the Kansas civil service act, such inspectors,
chemists, agents and clerical help as may be necessary for the purpose of administering and
enforcing the provisions of this act and may employ an attorney to assist in prosecutions under
this act and for such other purposes as the board may designate.
3; L. 2007, ch. 20, § 1; July 1.

74-1607. Same; compensation and expenses of board members.
Members of the state board of pharmacy attending meetings of such board, or attending a
subcommittee meeting thereof authorized by such board, shall be paid compensation, subsistence
allowances, mileage and other expenses as provided in K.S.A. 75-3223.
History: L. 1953, ch. 290, § 8; L. 1967, ch. 443, § 7; L. 1973, ch. 311, § 2; L. 1974, ch. 348, §
52; L. 1975, ch. 319, § 40; July 1.

74-1608. Same; meetings, notice; reports.
The board shall hold at least four meetings each year for the transaction of such business as may
legally come before it. Due notice of all meetings shall be given each member at least 10 days
prior to the date fixed for the meeting except that such notice shall not be required in those cases
where a member of the board shall file a written waiver of notice with the executive secretary.
The board shall make such reports of its activities as are required by K.S.A. 75-3044 to 75-3048,
and amendments thereto.
History: L. 1953, ch. 290, § 9; L. 1975, ch. 319, § 41; L. 1986, ch. 231, § 37; L. 2007, ch. 20, §
2; July 1.

74-1609. Same; executive secretary, duties; disposition of moneys received; pharmacy fee
fund.
The executive secretary of the board shall be the executive officer in charge of the office of the
board. Such secretary shall make, keep, and be in charge of all records and record books required
to be kept by such board, including a record of all registrations and permits required under this
act, and shall attend to the correspondence of the board and perform such other duties as the
board may require in carrying out and administering this act.
The executive secretary shall receive and receipt for all fees collected under this act. The
executive secretary of the board shall remit all moneys received by or for such secretary from
fees, charges or penalties to the state treasurer in accordance with the provisions of K.S.A. 75-
4215, and amendments thereto. Upon receipt of each such remittance, the state treasurer shall
deposit the entire amount in the state treasury. Ten percent of each such deposit shall be credited
to the state general fund and the balance shall be credited to the state board of pharmacy fee fund
which is hereby created. All expenditures from such fund shall be made in accordance with
appropriation acts upon warrants of the director of accounts and reports issued pursuant to
vouchers approved by the executive secretary or by the president of the board, or both, as the board shall determine.


**74-1610. Same; administration of oaths by president and executive secretary.**

Each member of the board and the executive secretary thereof shall have power to administer oaths in connection with the duties of the board.

**History:** L. 1953, ch. 290, § 11; L. 1975, ch. 319, § 43; July 1.

**74-1611. Same; records admissible in evidence.**

The books, registers and records of the board as made and kept by the executive secretary or under his or her supervision, subject to the direction of the board, or any portion thereof when certified by the executive secretary shall be prima facie evidence of the matter therein recorded and shall be deemed lawful evidence in any court of this state.

**History:** L. 1953, ch. 290, § 12; L. 1975, ch. 319, § 44; July 1.
IX. Related Laws/Useful Information

ANIMALS – SELECTED STATUTES

21-1213. Unlawful sale, purchase or injection of certain animal vaccines.
(a) It shall be unlawful:
(1) For any person, except an accredited veterinarian, to inject into any animal any live brucella abortus vaccine;
(2) for any person, except a licensed veterinarian or a person acting under the direct supervision of a licensed veterinarian, to inject any animal rabies vaccine into an animal;
(3) for any person, except a licensed veterinarian, to purchase any animal rabies vaccine;
(4) for any person to sell or offer for sale any animal rabies vaccine to any person except a licensed veterinarian;
(5) for any person to sell or offer for sale animal rabies vaccine to another unless the vendor is: (A) A manufacturer thereof; or (B) a licensed veterinarian; or
(6) for any person, except an accredited veterinarian, to purchase any live brucella abortus vaccine;
(7) for any person to sell or offer for sale any live brucella abortus vaccine to any person except an accredited veterinarian; or
(8) for any person to sell or offer for sale the live brucella abortus vaccine to another unless the vendor is: (A) A manufacturer thereof; or (B) an accredited veterinarian.
(b) As used in this section:
(1) "Direct supervision" means that an employee of a veterinarian or a student at a school of veterinary medicine shall be in personal contact with a veterinarian for each individual case.
(2) "Licensed veterinarian" has the meaning provided by K.S.A. 47-816, and amendments thereto.
(3) "Accredited veterinarian" means a veterinarian approved by the deputy administrator of veterinary services, animal and plant health inspection services, United States department of agriculture, in accordance with provisions of part 160 and 161, title 9, code of federal regulations. The veterinarian is accredited to perform certain functions of federal and cooperative state-federal programs. The accredited veterinarian is authorized to perform specified activities under the cooperative state-federal brucellosis eradication program.


21-1214. Same; penalties.
Any person who shall violate any of the provisions of this act shall be deemed guilty of a misdemeanor, and upon conviction shall be fined in a sum of not less than twenty-five ($25) nor more than five hundred dollars ($500), or shall be imprisoned in the county jail for not more than six (6) months, or by both such fine and imprisonment.

History: L. 1969, ch. 262, § 2; July 1.

SCHOOLS – SELECTED STATUTES

72-6283. Epinephrine kits; requirements.
Any accredited school may maintain an epinephrine kit. An epinephrine kit may consist of one or more doses of epinephrine. Epinephrine from an epinephrine kit shall be used only in emergency situations when the person administering the epinephrine reasonably believes that the signs and symptoms of an
anaphylactic reaction are occurring and if administered at school, on school property or at a school-sponsored event. A school may not maintain an epinephrine kit unless the school has consulted with a pharmacist licensed by the state board of pharmacy. The consultant pharmacist shall have supervisory responsibility for maintaining the epinephrine kit. The consultant pharmacist shall be responsible for developing procedures, proper control and accountability for the epinephrine kit. Periodic physical inventory of the epinephrine kit shall be required. An epinephrine kit shall be maintained under the control of the consultant pharmacist.

History: L. 2009, ch. 102, § 2; July 1.

MEDICAL CARE FACILITIES – SELECTED STATUTES

65-443. Termination of human pregnancy; performance, referral for, or participation in medical procedures not required; prescription or administration of any device or drug not required.

No person shall be required to perform, refer for, or participate in medical procedures or in the prescription or administration of any device or drug which result in the termination of a pregnancy or an effect of which the person reasonably believes may result in the termination of a pregnancy, and the refusal of any person to perform, refer for, or participate in those medical procedures, prescription or administration shall not be a basis for civil liability to any person. No medical care facility, medical care facility administrator or governing board of any medical care facility shall terminate the employment of, prevent or impair the practice or occupation of or impose any other sanction on any person because of such person's exercise of rights protected by this section.

History: L. 1969, ch. 182, § 1; L. 1975, ch. 313, § 1; L. 2012, ch. 112, § 1; July 1.

65-444. Same; medical care facility refusal to permit; establishment of criteria and procedures.

No medical care facility, medical care facility administrator or governing board of any medical care facility shall be required to permit the performance, referral for, or participation in medical procedures or in the prescription or administration of any device or drug which result in the termination of human pregnancies of an effect of which the medical care facility, administrator or board reasonably believes may result in the termination of human pregnancies within its facility and the refusal to permit such procedures, prescription or administration shall not be grounds for civil liability to any person. A medical care facility may establish criteria and procedures under which pregnancies may be terminated within its institution, in addition to those which may be prescribed by licensing, regulating or accrediting agencies.


CONTACT LENS PRESCRIPTIONS - SELECTED STATUTES

65-4966. Patient entitled to receive copy of contact lens prescription; disclosures; prescription limitations.

Each patient shall be entitled to receive a copy of such patient's contact lens prescription once the same prescription has been determined and the adaptation period has been completed. Any prescription for a specific brand of contact lenses available only from the licensed optometrist or person licensed to practice medicine and surgery, but which are generally marketed under an alternate brand, must disclose the name of the manufacturer and the trade name of the alternate
brand. No contact lens prescription may be limited by an expiration date or otherwise to a period of less than 12 months from either the date the prescription is first determined or the last date of the contact lens evaluation by a licensed optometrist or a person licensed to practice medicine and surgery, whichever date is later, unless a health related reason for the limitation is noted in the patient's medical record.


65-4967. Definition of person dispensing contact lenses for purposes of section; persons mailing or delivering contact lenses to patients in Kansas; registration requirements; fees; temporary suspension or limitation of registration; emergency proceedings; moneys remitted to state board of healing arts.

(a) For purposes of this section a person dispensing contact lenses means a person or entity not licensed under K.S.A. 65-1505, and amendments thereto, or licensed to practice medicine and surgery in Kansas who mails or delivers, using commercial courier or overnight or other delivery services, contact lenses to patients in Kansas pursuant to a contact lens prescription which such person or entity did not determine.

(b) No person dispensing contact lenses as defined under subsection (a) may dispense contact lenses to Kansas residents unless such person meets the criteria of this section, is registered under this section and pays the annual registration fee set by the state board of healing arts. Registration fees shall not exceed the annual fee for an initial or renewal permit to practice optometry in this state as provided in K.S.A. 65-1505, and amendments thereto.

(c) Approval of the registration for dispensing contact lenses shall be provided by the state board of healing arts upon certification by the person dispensing the contact lenses that such person:

(1) Is licensed or registered to dispense contact lenses in the state where the dispensing facility is located, if required to be licensed or registered in such state;

(2) provides the location, names and titles of all principal corporate officers and of the individual who is responsible for overseeing the dispensing of contact lenses in Kansas;

(3) complies with directions and appropriate requests for information from the regulating agency of each state where such person is licensed or registered;

(4) will respond directly and within a reasonable period of time, not to exceed 15 days, to all communications from the state board of healing arts concerning the dispensing of contact lenses in Kansas;

(5) maintains records of contact lenses and their corresponding valid, unexpired prescription dispensed in Kansas;

(6) agrees to cooperate with the state board of healing arts in providing information to the regulatory agency of any state where it is licensed or registered concerning matters related to the dispensing of contact lenses in Kansas;

(7) provides a toll-free telephone service for responding to questions and complaints from individuals in Kansas during such person's regular hours of operation and agrees to (a) include the toll-free number in literature provided with contact lenses and (b) refer all questions relating to eye care for the lenses prescribed to the licensee who determined the contact lens prescription;

(8) provides the following, or substantially equivalent, written notification to the patient whenever contact lenses are supplied:

**WARNING:** IF YOU ARE HAVING ANY OF THE FOLLOWING SYMPTOMS, REMOVE YOUR LENSES IMMEDIATELY AND CONSULT YOUR EYE CARE PRACTITIONER
BEFORE WEARING YOUR LENSES AGAIN: UNEXPLAINED EYE DISCOMFORT, WATERING, VISION CHANGE OR REDNESS;

(9) fills contact lens prescriptions according to the strict directions of a person licensed to practice optometry or person licensed to practice medicine and surgery in Kansas, without any deviation or substitution of lenses; and
(10) consents in writing to the personal and subject matter jurisdiction of the district courts of this state and the state board of healing arts for actions arising out of this act.

(d) The state board of healing arts may temporarily suspend or temporarily limit the registration of any person dispensing contact lenses to Kansas residents in accordance with the emergency adjudicative proceedings under the Kansas administrative procedure act if the board determines that there is cause to believe that any of the requirements of subsection (c) and that the registrant's continued dispensing of contact lenses to Kansas residents would constitute an imminent danger to the public health and safety.
(e) The state board of healing arts shall remit all moneys received under this section to the state treasurer in accordance with the provisions of K.S.A. 75-4215, and amendments thereto. Upon receipt of such remittance, the state treasurer shall deposit the entire amount in the state treasury to the credit of the healing arts fee fund.


SOCIAL WELFARE - DRUG FORMULARY - SELECTED STATUTES

39-7,121e. Limitation of reimbursement to multisource generic equivalent drugs, when; pharmacists not required to dispense certain drugs.
(a) Except where a prescriber has personally written "dispense as written" or "D.A.W.," or has signed the prescriber's name on the "dispense as written" signature line in accordance with K.S.A. 65-1637 and amendments thereto, the department of health and environment may limit reimbursement for a prescription under the medicaid program to the multisource generic equivalent drug.
(b) No pharmacist participating in the medical assistance program shall be required to dispense a prescription-only drug that will not be reimbursed by the medical assistance program.


LICENSURE OF ADULT CARE HOMES - SELECTED REGULATIONS

28-39-156. Pharmacy services.
The nursing facility shall provide pharmaceutical services including policies and procedures that assure the accurate acquisition, receipt, and administration of all drugs and biologicals to meet the needs of each resident.
(a) Supervision by a licensed pharmacist.
   (1) A pharmacist shall develop, coordinate, and supervise all pharmacy services.
   (2) The pharmacist shall perform a monthly review of the methods, procedures, storage, administration, disposal, and record-keeping of drugs and biologicals.
   (3) The pharmacist shall prepare a written report which includes recommendations for the administrator after each monthly review.
(b) Ordering and labeling.
(1) All drugs and biologicals shall be ordered pursuant to a written order issued by a licensed physician.

(2) The dispensing pharmacist shall label each prescription container in accordance with K.A.R. 68-7-14.

(3) Over-the-counter drugs. The facility shall ensure that any over-the-counter drug delivered to the facility is in the original, unbroken manufacturer’s package. The pharmacist or licensed nurse shall place the full name of the resident on the package. If over-the-counter drugs are removed from the original manufacturer’s package other than for administration, the pharmacist shall label the drug as required for prescription drugs.

(4) Physicians, advanced registered nurse practitioners, and physician assistants shall give verbal orders for drugs only to a licensed nurse, pharmacist or another physician. The licensed nurse, physician, or pharmacist shall immediately record the verbal order in the resident’s clinical record. The physician shall counter-sign all verbal orders within seven working days after receipt of the verbal order.

(c) Automatic stop orders. Drugs not specifically limited as to time or number of doses when ordered shall be controlled by automatic stop orders in accordance with written policies of the facility. A licensed nurse shall notify the physician of an automatic stop order before the administration of the last dose so that the physician may decide if additional drug is to be ordered.

(d) Storage.

(1) The licensed pharmacist shall ensure that all drugs and biologicals are stored according to state and federal laws.

(2) The nursing facility shall store all drugs and biologicals in a locked medication room or a locked medication cart located at the nurses’ station. Only the administrator and persons authorized to administer medications shall have keys to the medication room or the medication cart.

(3) The nursing facility shall store drugs and biologicals under sanitary conditions.

(4) The temperature of the medication room shall not exceed 85°F. The nursing facility shall store drugs and biologicals at the temperatures recommended by the manufacturer.

(e) The nursing facility shall develop and implement policies and procedures to assure that residents who self-administer drugs do so safely and accurately.

(f) Accountability and disposition. The nursing facility shall control and dispose of drugs and biologicals in a manner that ensures the safety of the resident.

(1) The nursing facility shall maintain records of receipt and disposition of all controlled substances in order that there can be an accurate reconciliation.

(2) The licensed pharmacist shall determine whether the records of drug and biological administration are in order and that an accurate account of all controlled substances was maintained and reconciled.

(3) The licensed pharmacist shall identify any deteriorated, outdated, or discontinued drugs and biologicals and any drugs or biologicals that are unused remaining from a discharged or deceased resident during the monthly pharmacy services review. The licensed pharmacist shall destroy, if appropriate, any deteriorated, outdated, unused, or discontinued drugs and biologicals at the nursing facility and in the presence of one witness who is a licensed nurse employed by the facility. A record shall be on file in the facility which contains the date, drug name, quantity of drugs and biologicals destroyed, and signatures of the pharmacist and licensed nurse.
(4) The nursing facility shall return to the dispensing pharmacy any drugs and biologicals which have been recalled and shall maintain documentation of this action in the facility.
(5) Staff members who have authority to administer drugs may provide drugs to residents or a responsible party during short-term absences from the facility.
   (A) A staff member who has the authority to administer drugs may transfer drugs to a suitable container.
   (B) The staff member preparing the drugs shall provide written instructions for the administration of the drugs to the resident or responsible party.
(6) The staff member preparing the drugs shall document the drugs provided and the instructions given in the resident’s clinical record.
(7) The nursing facility may send drugs with a resident at the time of discharge, if so ordered by the physician.
(g) Drug regimen review.
   (1) The licensed pharmacist shall review the drug regimen of each resident at least monthly.
   (2) The licensed pharmacist shall document in the resident’s clinical record that the drug regimen review has been performed.
   (3) The licensed pharmacist shall report any irregularities to the attending physician, the director of nursing, and the medical director. The pharmacist or a licensed nurse shall act upon any responses by the physician to the report.
   (4) The pharmacist shall document the drug regimen review in the resident’s clinical record or on a drug regimen report form. A copy of the drug regimen review shall be available to the department.
   (5) Any deviation between drugs ordered and drugs given shall be reported to the quality assessment and assurance committee.
(h) Emergency drug kits. A nursing facility may have an emergency drug kit available for use when needed.
   (1) The medical director, director of nursing, and licensed pharmacist shall determine the contents of the emergency drug kit. The contents of the kit shall be periodically reviewed and drugs added and deleted as appropriate. Written documentation of these determinations shall be available in the facility.
   (2) Policies and procedures shall be available for the use of the emergency drug kit.
   (3) The facility shall have a system in place which ensures that drugs used from the emergency drug kit are replaced in a timely manner.
   (4) The emergency drug kit shall be in compliance with K.A.R. 68-7-10 (d).
(Authorized by and implementing K.S.A. 39-932; effective Nov. 1, 1993; amended Feb. 21, 1997.)

HOSPITAL PHARMACY SERVICES - SELECTED REGULATIONS

28-34-10a. Pharmacy services.
(a) General provisions. Each hospital shall provide pharmaceutical services which are administered in accordance with accepted ethical and professional practices.
(b) Organization and staffing. The pharmaceutical service shall be directed by a licensed pharmacist. If the hospital has a pharmacy, it shall be directed by a licensed pharmacist. If the hospital does not have a pharmacy or a full-time staff pharmacist, a pharmacist employed on a part-time or consultant basis shall be responsible for control and dispensing of drugs and for
operation of the pharmacy or the pharmaceutical functions of nursing stations. In addition to meeting the standards in this regulation, services shall be provided in accordance with K.A.R. 68-7-11 and amendments thereto.

(c) Pharmacy facilities. Each hospital that maintains a pharmacy on its premises shall provide adequate equipment, supplies and facilities for the storage, safeguarding, preparation and dispensing of drugs. Drugs and biologicals must be kept in locked storage areas. Drugs requiring refrigeration shall be stored in conveniently located refrigerators which shall be used for drug storage only.

(d) Pharmacy and therapeutics committee. Each hospital shall establish a pharmacy and therapeutics committee or its equivalent. The committee shall consist of at least physicians, nurses and pharmacists. This committee shall assist in the formulation of broad professional policies regarding evaluation, appraisal, selection, procurement, storage, distribution and use of drugs and safety procedures and all other matters relating to drugs in the hospital. This committee shall meet at least quarterly, record its proceedings and report to the medical staff.

(e) Policies and procedures. The pharmaceutical service shall develop written policies and procedures. These policies shall be reviewed by the medical staff at least annually and shall be dated to indicate the date of last review. Procedures shall be established for the recording of all drug dispensations or other pharmacy transactions of the pharmacy or nursing stations.

(f) Medications dispensed. The hospital pharmacy shall dispense from a formulary of drugs approved by the medical staff through its appropriate committees. Any drug approved by the food and drug administration for use as an experimental drug may be used in accordance with standards established by the hospital's medical staff.

(g) Commercial pharmaceutical service. Each hospital using an outside pharmacist or pharmaceutical service shall have a contract with that pharmacist or service. As part of the contract, the pharmacist or service shall be required to maintain at least the standards for operation outlined in these regulations. (Authorized by and implementing K.S.A. 1991 Supp. 65-431; effective June 28, 1993.)

**EMERGENCY MEDICAL SERVICES – SELECTED STATUTES**

65-6149a. Automated external defibrillator; use by qualified persons and other entities, immunity from liability; notice of acquisition of unit; placement of units in state facilities.

(a) (1) Any person who in good faith renders emergency care or treatment by the use of or provision of an automated external defibrillator shall not be held liable for any civil damages as a result of such care or treatment or as a result of any act or failure to act in providing or arranging further medical treatment where the person acts as an ordinary reasonably prudent person would have acted under the same or similar circumstances.

(2) No person or entity which owns, leases, possesses or otherwise controls an automated external defibrillator and provides such automated external defibrillator to others for use shall be held liable for any civil damages as a result of such use where the person or entity which owns, leases, possesses or otherwise controls the automated external defibrillator has developed, implemented and follows guidelines to ensure proper maintenance and operation of the device.

(3) No person licensed to practice medicine and surgery who pursuant to a prescription order authorizes the acquisition of an automated external defibrillator or participates in the development of usual and customary protocols for an automated external defibrillator by a person or entity which owns, leases, possesses or otherwise controls such automated external
defibrillator and provides such automated external defibrillator for use by others shall be held liable for any civil damages as a result of such use.

(4) No person or entity which teaches or provides a training program for cardiopulmonary resuscitation that includes training in the use of automated external defibrillators shall be held liable for any civil damages as a result of such training or use if such person or entity has provided such training in a manner consistent with the usual and customary standards for the providing of such training.

(b) Pursuant to the provisions of this subsection, persons or entities which purchase or otherwise acquire an automated external defibrillator shall notify the emergency medical service which operates in the geographic area of the location of the automated external defibrillator. Persons or entities acquiring an automatic electronic defibrillator shall notify the emergency medical service providing local service on forms developed and provided by the emergency medical services board.

(c) The secretary of administration, in conjunction with the Kansas highway patrol, shall develop guidelines for the placement of automated external defibrillators in state owned or occupied facilities. The guidelines shall include, but not be limited to:

(1) Which state owned or occupied facilities should have automated external defibrillators readily available for use;

(2) recommendations for appropriate training courses in cardiopulmonary resuscitation and automated external defibrillators use;

(3) integration with existing emergency response plans;

(4) proper maintenance and testing of the devices;

(5) coordination with appropriate professionals in the oversight of training; and

(6) coordination with local emergency medical services regarding placement and conditions of use.

Nothing in this subsection shall be construed to require the state to purchase automated external defibrillators.


KANSAS RETAILERS' SALES TAX - SELECTED STATUTES

79-3606. Exempt sales. The following shall be exempt from the tax imposed by this act:

***

(p) all sales of drugs dispensed pursuant to a prescription order by a licensed practitioner or a mid-level practitioner as defined by K.S.A. 65-1626, and amendments thereto. As used in this subsection, "drug" means a compound, substance or preparation and any component of a compound, substance or preparation, other than food and food ingredients, dietary supplements or alcoholic beverages, recognized in the official United States pharmacopeia, official homeopathic pharmacopoeia of the United States or official national formulary, and supplement to any of them, intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease or intended to affect the structure or any function of the body, except that for taxable years commencing after December 31, 2013, this subsection shall not apply to any sales of drugs used in the performance or induction of an abortion, as defined in K.S.A. 65-6701, and amendments thereto;
(q) all sales of insulin dispensed by a person licensed by the state board of pharmacy to a person for treatment of diabetes at the direction of a person licensed to practice medicine by the state board of healing arts;

(r) all sales of oxygen delivery equipment, kidney dialysis equipment, enteral feeding systems, prosthetic devices and mobility enhancing equipment prescribed in writing by a person licensed to practice the healing arts, dentistry or optometry, and in addition to such sales, all sales of hearing aids, as defined by K.S.A. 74-5807(c), and amendments thereto, and repair and replacement parts therefor, including batteries, by a person licensed in the practice of dispensing and fitting hearing aids pursuant to the provisions of K.S.A. 74-5808, and amendments thereto. For the purposes of this subsection: (1) "Mobility enhancing equipment" means equipment including repair and replacement parts to same, but does not include durable medical equipment, which is primarily and customarily used to provide or increase the ability to move from one place to another and which is appropriate for use either in a home or a motor vehicle; is not generally used by persons with normal mobility; and does not include any motor vehicle or equipment on a motor vehicle normally provided by a motor vehicle manufacturer; and (2) "prosthetic device" means a replacement, corrective or supportive device including repair and replacement parts for same worn on or in the body to artificially replace a missing portion of the body, prevent or correct physical deformity or malfunction or support a weak or deformed portion of the body;

(hh) all sales of medical supplies and equipment, including durable medical equipment, purchased directly by a nonprofit skilled nursing home or nonprofit intermediate nursing care home, as defined by K.S.A. 39-923, and amendments thereto, for the purpose of providing medical services to residents thereof. This exemption shall not apply to tangible personal property customarily used for human habitation purposes. As used in this subsection, "durable medical equipment" means equipment including repair and replacement parts for such equipment, that can withstand repeated use, is primarily and customarily used to serve a medical purpose, generally is not useful to a person in the absence of illness or injury and is not worn in or on the body, but does not include mobility enhancing equipment as defined in subsection (r), oxygen delivery equipment, kidney dialysis equipment or enteral feeding systems;

***

40-2,211. Kansas telemedicine act; definitions.
(a) For purposes of Kansas telemedicine act:
(1) "Distant site" means a site at which a healthcare provider is located while providing healthcare services by means of telemedicine.
(2) "Healthcare provider" means a physician, licensed physician assistant, licensed advanced practice registered nurse or person licensed, registered, certified or otherwise authorized to practice by the behavioral sciences regulatory board.
(3) "Originating site" means a site at which a patient is located at the time healthcare services are provided by means of telemedicine.
(4) "Physician" means a person licensed to practice medicine and surgery by the state board of healing arts.
(5) "Telemedicine," including "telehealth," means the delivery of healthcare services or consultations while the patient is at an originating site and the healthcare provider is at a distant site. Telemedicine shall be provided by means of real-time two-way interactive audio, visual, or audio-visual communications, including the application of secure video conferencing or store-and-forward technology to provide or support healthcare delivery, that facilitate the assessment, diagnosis, consultation, treatment, education and care management of a patient's healthcare. "Telemedicine" does not include communication between:
(A) Healthcare providers that consist solely of a telephone voice-only conversation, email or facsimile transmission; or
(B) a physician and a patient that consists solely of an email or facsimile transmission.
(b) This section shall take effect on and after January 1, 2019.
History: L. 2018, ch. 98, § 2; July 1.

40-2,212. Same; confidentiality.
(a) The same requirements for patient privacy and confidentiality under the health insurance portability and accountability act of 1996 and 42 C.F.R. § 2.13, as applicable, that apply to healthcare services delivered via in-person contact shall also apply to healthcare services delivered via telemedicine. Nothing in this section shall supersede the provisions of any state law relating to the confidentiality, privacy, security or privileged status of protected health information.
(b) Telemedicine may be used to establish a valid provider-patient relationship.
(c) The same standards of practice and conduct that apply to healthcare services delivered via in-person contact shall also apply to healthcare services delivered via telemedicine.
(d) (1) A person authorized by law to provide and who provides telemedicine services to a patient shall provide the patient with guidance on appropriate follow-up care.
(2) (A) Except when otherwise prohibited by any other provision of law, when the patient consents and the patient has a primary care or other treating physician, the person providing telemedicine services shall send within three business days a report to such primary care or other treating physician of the treatment and services rendered to the patient in the telemedicine encounter.
(B) A person licensed, registered, certified or otherwise authorized to practice by the behavioral sciences regulatory board shall not be required to comply with the provisions of subparagraph (A).
(e) This section shall take effect on and after January 1, 2019.
History: L. 2018, ch. 98, § 3; July 1.
40-3821. Pharmacy benefits manager registration act; citation of act; licensure required; applicability.

(a) K.S.A. 40-3821 through 40-3828, and amendments thereto, and K.S.A. 2022 Supp. 40-3828a, and amendments thereto, shall be known and may be cited as the pharmacy benefits manager licensure act.

(b) On and after January 1, 2023, a person shall not perform, act or do business in this state as a pharmacy benefits manager unless such person has a valid license issued by the commissioner pursuant to this act.

(c) This act shall apply to any pharmacy benefits manager that provides claims processing services, other prescription drug or device services, or both, to covered persons who are residents of this state.

(d) This act shall not apply to any pharmacy benefits manager that holds a certificate of registration as an administrator pursuant to K.S.A. 40-3810, and amendments thereto.

(e) A license issued in accordance with the pharmacy benefits manager licensure act shall be nontransferrable.

History: L. 2006, ch. 154, § 1; L. 2022, ch. 44, § 2; July 1.

40-3822. Same; definitions.

As used in this act:

(a) "Act" means the pharmacy benefits manager licensure act.

(b) "Commissioner" means the commissioner of insurance as defined by K.S.A. 40-102, and amendments thereto.

(c) (1) "Covered entity" means:

(A) A nonprofit hospital or medical service corporation, health insurer, health benefit plan or health maintenance organization;

(B) a health program administered by a department or the state in the capacity of provider of health coverage; or

(C) an employer, labor union or other group of persons organized in the state that provides health coverage to covered individuals who are employed or reside in the state.

(2) "Covered entity" does not include any:

(A) Self-funded plan that is exempt from state regulation pursuant to ERISA;

(B) plan issued for coverage for federal employees; or

(C) health plan that provides coverage only for accidental injury, specified disease, hospital indemnity, medicare supplement, disability income, long-term care or other limited benefit health insurance policies and contracts.

(d) "Covered person" means a member, policyholder, subscriber, enrollee, beneficiary, dependent or other individual participating in a health benefit plan.

(e) "Department" means the insurance department.

(f) "ERISA" means the federal employee retirement income security act of 1974.

(g) "Health benefit plan" means the same as defined in K.S.A. 40-4602, and amendments thereto.

(h) "Health insurer" means the same as defined in K.S.A. 40-4602, and amendments thereto.

(i) "Maximum allowable cost" or "MAC" means any term or methodology that a pharmacy benefits manager or a healthcare insurer may use to establish the maximum amount that a pharmacy benefits manager will reimburse a pharmacy or a pharmacist for generic drugs.
(j) "Pharmacy benefits management" means:
   (1) Any of the following services provided with regard to the administration of the following pharmacy benefits:
      (A) Mail service pharmacy;
      (B) claims processing, retail network management and payment of claims to pharmacies for prescription drugs dispensed to covered individuals;
      (C) clinical formulary development and management services;
      (D) rebate contracting and administration;
      (E) certain patient compliance, therapeutic intervention and generic substitution programs; or
      (F) disease management programs involving prescription drug utilization; and
   (2) (A) the procurement of prescription drugs by a prescription benefits manager at a negotiated rate for dispensation to covered individuals within this state; or
      (B) the administration or management of prescription drug benefits provided by a covered insurance entity for the benefit of covered individuals.

(k) "Pharmacy benefits manager" means a person, business or other entity that performs pharmacy benefits management. "Pharmacy benefits manager" includes any person or entity acting in a contractual or employment relationship for a pharmacy benefits manager in the performance of pharmacy benefits management for a covered entity. "Pharmacy benefits manager" does not include a covered insurance entity.

(l) "Person" means an individual, partnership, corporation, organization or other business entity.

History: L. 2006, ch. 154, § 2; L. 2022, ch. 44, § 3; July 1.

40-3823. Same; licensure; application; required information; fee; material changes in information; confidentiality of documents.
   (a) No person shall act or operate as a pharmacy benefits manager without first obtaining a valid license issued by the commissioner.
   (b) Each person seeking a license to act as a pharmacy benefits manager shall file with the commissioner an application for a license upon a form to be furnished by the commissioner. At a minimum, the application form shall include the following information:
      (1) The name, address and telephone number of the pharmacy benefits manager.
      (2) The name, address, official position and professional qualifications of each individual who is responsible for the conduct of the affairs of the pharmacy benefits manager, including all members of the board of directors, board of trustees, executive committee, other governing board or committee, the principal officers in the case of a corporation, the partners or members in the case of a partnership or association.
      (3) The name and address of the applicant's agent for service of process in the state.
      (4) The name, address, phone number, email address and official position of the employee who will serve as the primary contact for the department.
      (5) A copy of the pharmacy benefits manager's corporate charter, articles of incorporation or other charter document.
      (6) A template contract, which shall include a dispute resolution process, that ultimately involves an independent fact finder between:
         (A) The pharmacy benefits manager and the health insurer; or
         (B) the pharmacy benefits manager and the pharmacy or a pharmacy's contracting agent.
      (7) A network adequacy report on a form prescribed by the department through rules and regulations.
   (c) A nonrefundable application fee of $2,500.
(d) The licensee shall inform the commissioner, by any means acceptable to the commissioner, of any material change in the information required by this subsection within 90 days of such change. Failure to timely inform the commissioner of a material change may result in a penalty against the licensee in the amount of $500.

(e) Within 90 days after receipt of a completed application, the network adequacy report and the applicable license fee, the commissioner shall review the application and issue a license if the applicant is deemed qualified under this section. If the commissioner determines that the applicant is not qualified, the commissioner shall notify the applicant and shall specify the reason for the denial.

(f) (1) All documents, materials or other information and copies thereof in the possession or control of the department or any other governmental entity that are obtained by or disclosed to the commissioner or any other person in the course of an application, examination or investigation made pursuant to this act shall be confidential by law and privileged, shall not be subject to any open records, freedom of information, sunshine or other public record disclosure laws, and shall not be subject to subpoena or discovery.

(2) The provisions of paragraph (1) shall only apply to the disclosure of the confidential documents described in paragraph (1) by the department or any other governmental entity and shall not be construed to create any privilege in favor of any other party.

(3) The provisions of this subsection shall expire on July 1, 2027, unless the legislature reviews and reenacts this provision pursuant to K.S.A. 45-229, and amendments thereto, prior to July 1, 2027.


40-3824. Same; renewal of license, application; fees.

(a) Each pharmacy benefits manager license shall expire on March 31 each year and may be renewed annually on the request of the licensee. The application for renewal shall be submitted on a form furnished by the commissioner and accompanied by a renewal fee of $2,500. The application for renewal shall be in such form and contain such matters as the commissioner prescribes.

(b) If a license renewal fee is not paid by the prescribed date, the amount of the fee, plus a penalty fee of $2,500 shall be paid. The pharmacy benefits manager's license may be revoked or suspended by the commissioner until the renewal fee and any penalty assessed has been paid.

(c) Any person who performs or is performing any pharmacy benefits management service shall be required to obtain a license as a pharmacy benefits manager from the commissioner not later than January 1, 2023, in order to continue to do business in Kansas.


40-3825. Same; rules and regulations.

(a) In accordance with the provisions of the rules and regulations filing act, K.S.A. 77-415 et seq., and amendments thereto, the commissioner may adopt, amend and revoke rules and regulations governing the administration and enforcement of this act, limited to:

(1) The content of the application form;

(2) the content of any other form or report required to implement this act; and

(3) such other rules and regulations as the commissioner may deem necessary to carry out the provisions of this act.

(b) The commissioner shall adopt, amend and revoke all such necessary rules and regulations not later than July 1, 2023.

40-3826. Same; statement of charges, hearing; violation; penalty.
   (a) If the commissioner has reason to believe that a pharmacy benefits manager has been engaged
   in this state or is engaging in this state in activity that violates the pharmacy benefits manager licensure
   act, the commissioner shall issue and serve upon such pharmacy benefits manager a statement of the
   charges of any such violation and conduct a hearing thereon in accordance with the provisions of the
   Kansas administrative procedure act.

   (b) If, after such a hearing, the commissioner determines that the pharmacy benefits manager
   charged has violated the act, the commissioner may, in the exercise of discretion, order any one or
   more of the following:

   (1) (A) Payment of a monetary penalty of not more than $1,000 for each and every act or violation.
       The total of the monetary penalties for such violations shall not exceed $10,000;

       (B) if the pharmacy benefits manager knew or reasonably should have known that such manager
       was in violation of this act, payment of a monetary penalty of not more than $5,000 for each and every
       act or violation. The total of the monetary penalties for such violations shall not exceed $50,000 in any
       six-month period;

   (2) if such manager knew or reasonably should have known such person was in violation of this
       act, the suspension or revocation of the pharmacy benefits manager's license; or

   (3) the assessment of any costs incurred as a result of conducting the administrative hearing
       authorized by the provisions of this section against the pharmacy benefits manager.

   (c) As used in this section, "costs" includes witness fees, mileage allowances, any costs associated
       with reproduction of documents that become a part of the hearing record and expenses of making a
       record of the hearing.

   (d) (1) If the deadline for filing a petition for review has expired and no such petition has been
       filed, the commissioner may reopen and modify or set aside any portion or the entirety of any
       administrative order issued under this section.

       (2) The reopening of any such order may occur if, in the commissioner's opinion, the conditions
           of fact or law have changed to warrant such an action or if such an action is warranted in the public
           interest.

   (e) Any person who acts as a pharmacy benefits manager without being licensed as required by
       this act shall be subject to a fine of $5,000 for the period in which the pharmacy benefits manager is
       found to be in violation.


40-3827. Same; pharmacy benefits manager licensure fund.
   (a) There is hereby established in the state treasury the pharmacy benefits manager licensure fund.
   Such fund shall be administered by the commissioner for costs related to administering the pharmacy
   benefits manager licensing act. All expenditures from the pharmacy benefits manager licensure fund
   shall be made in accordance with appropriation acts upon warrants of the director of accounts and
   reports issued pursuant to vouchers approved by the commissioner or by the commissioner's designee.

   (b) The commissioner shall remit all moneys received by or for the commissioner under the
   provisions of this act to the state treasurer in accordance with the provisions of K.S.A. 75-4215, and
   amendments thereto. Upon receipt of each such remittance, the state treasurer shall deposit the entire
   amount thereof in the state treasury and such amount shall be credited to the pharmacy benefits
   manager licensure fund.


40-3828. Same; severability.
If any provision of this act or the application thereof to any person or circumstance is held invalid, the invalidity does not affect other provisions or applications of the act which can be given effect without the invalid provision or application, and to this end the provisions of this act are severable.

**History:** L. 2006, ch. 154, § 8; Apr. 27.

### 40-3828a. Pharmacy benefits manager licensure act; denial, revocation or limitation of license.

(a) A pharmacy benefits manager's license may be revoked, suspended or limited, the licensee may be censured or placed under probationary conditions or an application for a license or for reinstatement of a license may be denied upon a finding that the:

1. Applicant or licensee committed fraud or misrepresentation in applying for or securing an original, renewal or reinstated license;
2. Licensee has violated any lawful rule or regulation promulgated by the commissioner or violated any lawful order or directive of the commissioner previously entered by the commissioner;
3. Pharmacy benefits manager has engaged in fraudulent activity that constitutes a violation of state or federal law;
4. Licensee has failed to furnish any information legally requested by the commissioner to the commissioner or the commissioner's investigators or representatives;
5. Pharmacy benefits manager has been determined by the commissioner to be in violation of or noncompliance with state or federal law; or
6. Pharmacy benefits manager has failed to timely submit a renewal application and the information required under K.S.A. 40-3824, and amendments thereto. In lieu of a denial of a renewal application, the commissioner may permit the pharmacy benefits manager to submit to the commissioner a corrective action plan to correct or cure any deficiencies.

(b) This section shall be a part of and supplemental to the pharmacy benefits manager licensure act.

**History:** L. 2022, ch. 44, § 1; July 1.

### 40-3829. Pharmacy benefits managers; maximum allowable cost pricing; definitions.

As used in K.S.A. 40-3829 and 40-3830, and amendments thereto:

(a) "List" means the list of drugs for which maximum allowable costs have been established;
(b) "maximum allowable cost" or "MAC" means the same as defined in K.S.A. 40-3822, and amendments thereto;
(c) "network pharmacy" means a pharmacy that contracts with a pharmacy benefits manager;
(d) "pharmacy benefits manager" means the same as defined in K.S.A. 40-3822, and amendments thereto;
(e) "pharmacy benefits plan or pharmacy benefits program" means a plan or program that pays for, reimburses, covers the cost of or otherwise provides for pharmacist services to individuals who reside in or are employed in this state; and
(f) "wholesaler" means a person or entity that sells and distributes prescription pharmaceutical products, including, but not limited to, a full line of brand name, generic and over-the-counter pharmaceuticals and that offers regular and private delivery to a pharmacy.

**History:** L. 2016, ch. 13, § 1; L. 2022, ch. 44, § 9; July 1.

### 40-3830. Same; MAC list requirements; frequency of updates; appeals process.
A pharmacy benefits manager, including the pharmacy benefits manager for the state healthcare benefits program, shall:

(a) Not place a drug on a MAC list unless there are at least two therapeutically equivalent multi-source generic drugs, or at least one generic drug available from at least one manufacturer, generally available for purchase by network pharmacies from national or regional wholesalers and the national drug code for the drug is not obsolete;

(b) provide to each network pharmacy at the beginning of the term of a contract and upon request thereafter, the sources utilized to determine the maximum allowable cost price;

(c) provide a process for each network pharmacy provider to readily access the maximum allowable price specific to that provider;

(d) review and update each applicable maximum allowable cost list every seven business days and apply the updates to reimbursements not later than one business day;

(e) ensure that dispensing fees are not included in the calculation of maximum allowable cost;

(f) establish a reasonable administrative appeal procedure to allow a pharmacy or pharmacy’s contracting agent to challenge MAC for a specific drug as:

1. Not meeting the requirements of this section;
2. being below the cost at which the pharmacy may obtain the drug;
3. include in any administrative appeals procedure the following:
   1. A dedicated telephone number and email address or website for the purpose of submitting administrative appeals; and
   2. the ability to submit an administrative appeal directly to the pharmacy benefits manager regarding the pharmacy benefits plan or program or through a pharmacy service administrative organization;

(h) permit a network pharmacy or a network pharmacy’s contracting agent to file an administrative appeal not later than 10 business days after the fill date;

(i) require that the pharmacy benefits manager only request the following information to determine a MAC administrative appeal:

1. The prescription number;
2. the provider’s name;
3. the national drug code used during the filing of the claim;
4. the date of the fill;
5. the reimbursement amount; and
6. such other information related to the appealed claim as required by contract;

(j) (1) provide a response to the appealing network pharmacy not later than 10 business days after receiving an appeal request containing information sufficient for the pharmacy benefits manager to process the appeal as specified by the contract.

2. If the appeal is upheld, the pharmacy benefits manager:

(A) Shall make the adjustment in the drug price effective not later than one business day after the appeal is resolved;

(B) shall make the adjustment applicable to all similarly situated network pharmacy providers, as determined by the plan sponsor or pharmacy benefits manager, as appropriate; and

(C) permit the appealing pharmacy to reverse and rebill the appealed claim.

3. If the appeal is denied, the pharmacy benefits manager shall provide the appealing pharmacy the reason for the denial and the national drug code number from a national or regional wholesaler operating in Kansas where the drug is generally available for purchase at a price equal to or less than the maximum allowable cost, and when applicable, may be substituted lawfully.

History: L. 2016, ch. 13, § 2; L. 2022, ch. 44, § 10; July 1.
(a) This section shall be known and may be cited as the Kansas pharmacy patients fair practices act.
(b) As used in this section:
(1) "Covered person" means the same as defined in K.S.A. 2019 Supp. 40-3822, and amendments thereto.
(2) "Health carrier" means the same as defined in K.S.A. 2019 Supp. 40-2,195, and amendments thereto.
(3) "Pharmacy benefits manager" means the same as defined in K.S.A. 2019 Supp. 40-3822, and amendments thereto.
(c) (1) Co-payments applied by a health carrier for a prescription drug may not exceed the total submitted charges by the network pharmacy.
(2) A pharmacy or pharmacist shall have the right to provide a covered person with information regarding the amount of the covered person's cost share for a prescription drug. Neither a pharmacy nor a pharmacist shall be proscribed by a pharmacy benefits manager from discussing any such information or for selling a more affordable alternative to the covered person if such an alternative is available.
(d) (1) This section applies to any contract between a pharmacy benefits manager and a pharmacy, a pharmacy services administration organization or a group purchasing organization that is entered into or renewed on and after January 1, 2019.
(2) The provisions of this section shall not apply to any policy or certificate that provides coverage for any specified disease, specified accident or accident only coverage, credit, dental, disability income, hospital indemnity, long-term care insurance as defined by K.S.A. 40-2227, and amendments thereto, vision care or any other limited supplemental benefit nor to any medicare supplement policy of insurance as defined by the commissioner of insurance by rule and regulation, any coverage issued as a supplement to liability insurance, workers compensation or similar insurance, automobile medical-payment insurance or any insurance under which benefits are payable with or without regard to fault, whether written on a group, blanket or individual basis.
History: L. 2018, ch. 23, § 1; July 1.

HEALTHCARE PROVIDER INSURANCE - SELECTED STATUTES

40-3401. Definitions.
(a) "Applicant" means any healthcare provider.
(b) "Basic coverage" means a policy of professional liability insurance required to be maintained by each healthcare provider pursuant to the provisions of K.S.A. 40-3402(a) or (b), and amendments thereto.
(c) "Commissioner" means the commissioner of insurance.
(d) "Fiscal year" means the year commencing on the effective date of this act and each year, commencing on the first day of July thereafter.
(e) "Fund" means the healthcare stabilization fund established pursuant to K.S.A. 40-3403(a), and amendments thereto.
(f) "Healthcare provider" means a person licensed to practice any branch of the healing arts by the state board of healing arts, a person who holds a temporary permit to practice any branch of the healing arts
issued by the state board of healing arts, a person engaged in a postgraduate training program approved
by the state board of healing arts, a medical care facility licensed by the state of Kansas, a podiatrist
licensed by the state board of healing arts, a health maintenance organization issued a certificate of
authority by the commissioner, an optometrist licensed by the board of examiners in optometry, a
pharmacist licensed by the state board of pharmacy, a licensed professional nurse who is authorized to
practice as a registered nurse anesthetist, a licensed professional nurse who has been granted a
temporary authorization to practice nurse anesthesia under K.S.A. 65-1153, and amendments thereto,
a professional corporation organized pursuant to the professional corporation law of Kansas by persons
who are authorized by such law to form such a corporation and who are healthcare providers as defined
by this subsection, a Kansas limited liability company organized for the purpose of rendering
professional services by its members who are healthcare providers as defined by this subsection and
who are legally authorized to render the professional services for which the limited liability company
is organized, a partnership of persons who are healthcare providers under this subsection, a Kansas
not-for-profit corporation organized for the purpose of rendering professional services by persons who
are healthcare providers as defined by this subsection, a nonprofit corporation organized to administer
the graduate medical education programs of community hospitals or medical care facilities affiliated
with the university of Kansas school of medicine, a dentist certified by the state board of healing arts
to administer anesthetics under K.S.A. 65-2899, and amendments thereto, a psychiatric hospital
licensed prior to January 1, 1988, and continuously thereafter under K.S.A. 2015 Supp. 75-3307b, prior
to its repeal, and K.S.A. 2021 Supp. 39-2001 et seq., and amendments thereto, or a mental health center
or mental health clinic licensed by the state of Kansas. On and after January 1, 2015, "healthcare
provider" also means a physician assistant licensed by the state board of healing arts, a licensed
advanced practice registered nurse who is authorized by the board of nursing to practice as an advanced
practice registered nurse in the classification of a nurse-midwife, a licensed advanced practice
registered nurse who has been granted a temporary authorization by the board of nursing to practice as
an advanced practice registered nurse in the classification of a nurse-midwife, a nursing facility
licensed by the state of Kansas, an assisted living facility licensed by the state of Kansas or a residential
healthcare facility licensed by the state of Kansas. "Healthcare provider" does not include: (1) Any
state institution for people with intellectual disability; (2) any state psychiatric hospital; (3) any person
holding an exempt license issued by the state board of healing arts or the board of nursing; (4) any
person holding a visiting clinical professor license from the state board of healing arts; (5) any person
holding an inactive license issued by the state board of healing arts; (6) any person holding a federally
active license issued by the state board of healing arts; (7) an advanced practice registered nurse who
is authorized by the board of nursing to practice as an advanced practice registered nurse in the
classification of nurse-midwife or nurse anesthetist and who practices solely in the course of
employment or active duty in the United States government or any of its departments, bureaus or
agencies or who provides professional services as a charitable healthcare provider as defined under
K.S.A. 75-6102, and amendments thereto; or (8) a physician assistant licensed by the state board of
healing arts who practices solely in the course of employment or active duty in the United States
government or any of its departments, bureaus or agencies or who provides professional services as a
charitable healthcare provider as defined under K.S.A. 75-6102, and amendments thereto.

(g) "Inactive healthcare provider" means a person or other entity who purchased basic coverage or
qualified as a self-insurer on or subsequent to the effective date of this act but who, at the time a claim
is made for personal injury or death arising out of the rendering of or the failure to render professional
services by such healthcare provider, does not have basic coverage or self-insurance in effect solely
because such person is no longer engaged in rendering professional service as a healthcare provider.

(h) "Insurer" means any corporation, association, reciprocal exchange, inter-insurer and any other legal
entity authorized to write bodily injury or property damage liability insurance in this state, including
workers compensation and automobile liability insurance, pursuant to the provisions of the acts contained in article 9, 11, 12 or 16 of chapter 40 of the Kansas Statutes Annotated, and amendments thereto.

(i) "Plan" means the operating and administrative rules and procedures developed by insurers and rating organizations or the commissioner to make professional liability insurance available to healthcare providers.

(j) "Professional liability insurance" means insurance providing coverage for legal liability arising out of the performance of professional services rendered or that should have been rendered by a healthcare provider.

(k) "Rating organization" means a corporation, an unincorporated association, a partnership or an individual licensed pursuant to K.S.A. 40-956, and amendments thereto, to make rates for professional liability insurance.

(l) "Self-insurer" means a healthcare provider who qualifies as a self-insurer pursuant to K.S.A. 40-3414, and amendments thereto.

(m) "Medical care facility" means the same when used in the healthcare provider insurance availability act as defined in K.S.A. 65-425, and amendments thereto, except that as used in the healthcare provider insurance availability act such term, as it relates to insurance coverage under the healthcare provider insurance availability act, also includes any director, trustee, officer or administrator of a medical care facility.

(n) "Mental health center" means a mental health center licensed by the state of Kansas under K.S.A. 2021 Supp. 39-2001 et seq., and amendments thereto, except that as used in the healthcare provider insurance availability act such term, as it relates to insurance coverage under the healthcare provider insurance availability act, also includes any director, trustee, officer or administrator of a mental health center.

(o) "Mental health clinic" means a mental health clinic licensed by the state of Kansas under K.S.A. 2021 Supp. 39-2001 et seq., and amendments thereto, except that as used in the healthcare provider insurance availability act such term, as it relates to insurance coverage under the healthcare provider insurance availability act, also includes any director, trustee, officer or administrator of a mental health clinic.

(p) "State institution for people with intellectual disability" means Winfield state hospital and training center, Parsons state hospital and training center and the Kansas neurological institute.

(q) "State psychiatric hospital" means Larned state hospital, Osawatomie state hospital and Rainbow mental health facility.

(r) "Person engaged in residency training" means:

1. A person engaged in a postgraduate training program approved by the state board of healing arts who is employed by and is studying at the university of Kansas medical center only when such person is engaged in medical activities that do not include extracurricular, extra-institutional medical service for which such person receives extra compensation and that have not been approved by the dean of the school of medicine and the executive vice-chancellor of the university of Kansas medical center. Persons engaged in residency training shall be considered resident healthcare providers for purposes of K.S.A. 40-3401 et seq., and amendments thereto; and

2. a person engaged in a postgraduate training program approved by the state board of healing arts who is employed by a nonprofit corporation organized to administer the graduate medical education programs of community hospitals or medical care facilities affiliated with the university of Kansas school of medicine or who is employed by an affiliate of the university of Kansas school of medicine as defined in K.S.A. 76-367, and amendments thereto, only when such person is engaged in medical activities that do not include extracurricular, extra-institutional medical service for which such person
receives extra compensation and that have not been approved by the chief operating officer of the nonprofit corporation or the chief operating officer of the affiliate and the executive vice-chancellor of the university of Kansas medical center.

(s) "Full-time physician faculty employed by the university of Kansas medical center" means a person licensed to practice medicine and surgery who holds a full-time appointment at the university of Kansas medical center when such person is providing healthcare. A person licensed to practice medicine and surgery who holds a full-time appointment at the university of Kansas medical center may also be employed part-time by the United States department of veterans affairs if such employment is approved by the executive vice-chancellor of the university of Kansas medical center.

(t) "Sexual act" or "sexual activity" means that sexual conduct that constitutes a criminal or tortious act under the laws of the state of Kansas.

(u) "Board" means the board of governors created by K.S.A. 40-3403, and amendments thereto.

(v) "Board of directors" means the governing board created by K.S.A. 40-3413, and amendments thereto.

(w) "Locum tenens contract" means a temporary agreement not exceeding 182 days per calendar year that employs a healthcare provider to actively render professional services in this state.

(x) "Professional services" means patient care or other services authorized under the act governing licensure of a healthcare provider.

(y) "Healthcare facility" means a nursing facility, an assisted living facility or a residential healthcare facility as all such terms are defined in K.S.A. 39-923, and amendments thereto.

(z) "Charitable healthcare provider" means the same as defined in K.S.A. 75-6102, and amendments thereto.

History:

40-3402. Professional liability insurance to be maintained by health care providers as condition of active licensure to render services in state, exception, limits of coverage; information to be furnished by insurer; termination of coverage, notice; contents of policies issued in state; duties of certain insurance companies; surcharge and information required of certain health care providers; occurrence form policy as alternative to required claims made policy for certain persons.

(a) Prior to January 1, 2022, a policy of professional liability insurance approved by the commissioner and issued by an insurer duly authorized to transact business in this state in which the limit of the insurer's liability is not less than $200,000 per claim, subject to not less than a $600,000 annual aggregate for all claims made during the policy period, shall be maintained in effect by each resident healthcare provider as a condition of active licensure or other statutory authorization to render professional service as a healthcare provider in this state, unless such healthcare provider is a self-insurer. For all new policies and policies that renew on and after January 1, 2022, a policy of professional liability insurance approved by the commissioner and issued by an insurer duly authorized to transact business in this state in which the limit of the insurer's liability is not less than $500,000 per claim, subject to not less than a $1,500,000 annual aggregate for all claims made during the policy
period, shall be maintained by each resident healthcare provider as a condition of active licensure or other statutory authorization to render professional service as a healthcare provider in this state, unless such healthcare provider is a self-insurer. This provision shall not apply to optometrists and pharmacists on and after July 1, 1991, to physical therapists on and after July 1, 1995, or to health maintenance organizations on and after July 1, 1997. Such policy shall provide as a minimum coverage for claims made during the term of the policy that were incurred during the term of such policy or during the prior term of a similar policy. Any insurer offering such policy of professional liability insurance to any healthcare provider may offer to such healthcare provider a policy as prescribed in this section with deductible options. Such deductible shall be within such policy limits.

(1) Each insurer providing basic coverage shall, within 30 days after the effective date of any policy issued in accordance with this subsection, notify the board of governors that such coverage is or will be in effect. Such notification shall be on a form approved by the board of governors and shall include information identifying the professional liability policy issued or to be issued, the name and address of all healthcare providers covered by the policy, the amount of the annual premium, the effective and expiration dates of the coverage and such other information as the board of governors shall require. A copy of the notice required by this subsection shall be furnished to the named insured.

(2) In the event of termination of basic coverage by cancellation, nonrenewal, expiration or otherwise by either the insurer or named insured, notice of such termination shall be furnished by the insurer to the board of governors, the state agency which licenses, registers or certifies the named insured and the named insured. Such notice shall be provided no less than 30 days prior to the effective date of any termination initiated by the insurer or within 10 business days after the date coverage is terminated at the request of the named insured and shall include the name and address of the healthcare provider or providers for whom basic coverage is terminated and the date basic coverage will cease to be in effect. No basic coverage shall be terminated by cancellation or failure to renew by the insurer unless such insurer provides a notice of termination as required by this subsection.

(3) Any professional liability insurance policy issued, delivered or in effect in this state on and after July 1, 1976, shall contain or be endorsed to provide basic coverage as required by subsection (a). Notwithstanding any omitted or inconsistent language, any contract of professional liability insurance shall be construed to obligate the insurer to meet all the mandatory requirements and obligations of this act. The liability of an insurer for claims made prior to July 1, 1984, shall not exceed those limits of insurance provided by such policy prior to July 1, 1984.

(b) A nonresident healthcare provider shall not be licensed to actively render professional service as a healthcare provider in this state unless such healthcare provider maintains continuous coverage in effect as prescribed by subsection (a), except such coverage may be provided by a nonadmitted insurer who has filed the form required by subsection (b)(1). This provision shall not apply to optometrists and pharmacists on and after July 1, 1991, or to physical therapists on and after July 1, 1995.

(1) Every insurance company authorized to transact business in this state, that is authorized to issue professional liability insurance in any jurisdiction, shall file with the commissioner, as a condition of its continued transaction of business within this state, a form prescribed by the commissioner declaring that its professional liability insurance policies, wherever issued, shall be deemed to provide at least the insurance required by this subsection when the insured is rendering professional services as a nonresident healthcare provider in this state. Any nonadmitted insurer may file such a form.

(2) Every nonresident healthcare provider that is required to maintain basic coverage pursuant to this subsection shall pay the surcharge levied by the board of governors pursuant to K.S.A. 40-3404(a), and amendments thereto, directly to the board of governors and shall furnish to the board of governors the information required in subsection (a)(1).

(c) Every healthcare provider that is a self-insurer, the university of Kansas medical center for persons engaged in residency training, as described in K.S.A. 40-3401(r)(1), and amendments thereto, the
employers of persons engaged in residency training, as described in K.S.A. 40-3401(r)(2), and amendments thereto, the private practice corporations or foundations and their full-time physician faculty employed by the university of Kansas medical center or a medical care facility or mental health center for self-insurers under K.S.A. 40-3414(e), and amendments thereto, shall pay the surcharge levied by the board of governors pursuant to K.S.A. 40-3404(a), and amendments thereto, directly to the board of governors and shall furnish to the board of governors the information required in subsections (a)(1) and (a)(2).

(d) In lieu of a claims made policy otherwise required under this section, a person engaged in residency training who is providing services as a healthcare provider but, while providing such services, is not covered by the self-insurance provisions of K.S.A. 40-3414(d), and amendments thereto, may obtain basic coverage under an occurrence form policy, if such policy provides professional liability insurance coverage and limits that are substantially the same as the professional liability insurance coverage and limits required by K.S.A. 40-3402(a), and amendments thereto. Where such occurrence form policy is in effect, the provisions of the healthcare provider insurance availability act referring to claims made policies shall be construed to mean occurrence form policies.

(e) In lieu of a claims made policy otherwise required under this section, a nonresident healthcare provider employed pursuant to a locum tenens contract to provide services in this state as a healthcare provider may obtain basic coverage under an occurrence form policy, if such policy provides professional liability insurance coverage and limits that are substantially the same as the professional liability insurance coverage and limits required by K.S.A. 40-3402, and amendments thereto. Where such occurrence form policy is in effect, the provisions of the healthcare provider insurance availability act referring to claims made policies shall be construed to mean occurrence form policies.

19-2243. Flea markets; prohibition of sale of certain baby products or drugs.
(a) No person at a flea market shall sell, offer for sale or knowingly permit the sale of baby food, infant formula or similar products or any drugs. The provisions of this section shall not apply to a person who keeps available for public inspection an identification card identifying such person as an authorized representative of the manufacturer or distributor of over-the-counter drugs or baby food, infant formula or similar products, as long as the card is not false, fraudulent or fraudulently obtained.
(b) For purposes of this section:
   (1) "Flea market" means any location, other than a permanent retail store, at which space is rented or otherwise made available to others for the conduct of business as a transient merchant as defined in K.S.A. 29-2232 and amendments thereto.
   (2) "Drug" shall have the meaning ascribed to such term under K.S.A. 65-1626 and amendments thereto.
(c) The provisions of this section shall be part of and supplemental to the transient merchant licensing act.
History: L. 1998, ch. 72, § 1; July 1.

JURORS - SELECTED STATUTES

43-159. Same; exclusions from jury service by court. In addition to the persons excused from jury service in K.S.A. 43-158, and amendments thereto, the following persons may be excused from jury service by the court: (a) Persons so physically or mentally infirm as to be unequal to the task of ordinary jury duty;
(b) persons whose presence elsewhere is required for the public welfare, health or safety;
(c) persons for whom jury service would cause extraordinary or compelling personal hardship; and
(d) persons whose personal relationship to the parties or whose information or interest in the case to be tried is such that there is a probability such persons would find it difficult to be impartial.
X. Other Healthcare Provider Statutes and Regulations

HEALING ARTS - SELECTED STATUTES

65-2837a. Restrictions on prescribing, ordering, dispensing, administering, selling, supplying or giving certain amphetamine or sympathomimetic amine controlled substances; unprofessional conduct.

(a) It shall be unlawful for any person licensed to practice medicine and surgery to prescribe, order, dispense, administer, sell, supply or give or for a mid-level practitioner as defined in K.S.A. 65-1626, and amendments thereto, to prescribe, administer, supply or give any amphetamine or sympathomimetic amine designated in schedule II, III or IV under the uniform controlled substances act, except as provided in this section. Failure to comply with this section by a licensee shall constitute unprofessional conduct under K.S.A. 65-2837, and amendments thereto.

(b) When any licensee prescribes, orders, dispenses, administers, sells, supplies or gives or when any mid-level practitioner as defined in K.S.A. 65-1626, and amendments thereto, prescribes, administers, sells, supplies or gives any amphetamine or sympathomimetic amine designated in schedule II, III or IV under the uniform controlled substances act, the patient's medical record shall adequately document the purpose for which the drug is being given. Such purpose shall be restricted to one or more of the following:

1. The treatment of narcolepsy.
2. The treatment of drug-induced brain dysfunction.
3. The treatment of attention-deficit/hyperactivity disorder.
4. The differential diagnostic psychiatric evaluation of depression.
5. The treatment of depression shown by adequate medical records and documentation to be unresponsive to other forms of treatment.
6. The clinical investigation of the effects of such drugs or compounds, in which case, before the investigation is begun, the licensee shall, in addition to other requirements of applicable laws, apply for and obtain approval of the investigation from the state board of healing arts.
7. The treatment of obesity with controlled substances, as may be defined by rules and regulations adopted by the board of healing arts.
8. The treatment of binge eating disorder.
9. The treatment of any other disorder or disease for which such drugs or compounds have been found to be safe and effective by competent scientific research that has been generally accepted by the scientific community, in which case, the licensee before prescribing, ordering, dispensing, administering, selling, supplying or giving the drug or compound for a particular condition, or the licensee before authorizing a mid-level practitioner to prescribe the drug or compound for a particular condition, shall obtain a determination from the board of healing arts that the drug or compound can be used for that particular condition.


For the purpose of this act the following persons shall be deemed to be engaged in the practice of medicine and surgery:

(a) Persons who publicly profess to be physicians or surgeons, or publicly profess to assume the duties incident to the practice of medicine or surgery or any of their branches.
(b) Persons who prescribe, recommend or furnish medicine or drugs, or perform any surgical operation of whatever nature by the use of any surgical instrument, procedure, equipment or mechanical device for the diagnosis, cure or relief of any wounds, fractures, bodily injury, infirmity, disease, physical or mental illness or psychological disorder, of human beings.
(c) Persons who attach to their name the title M.D., surgeon, physician, physician and surgeon, or any other word or abbreviation indicating that they are engaged in the treatment or diagnosis of ailments, diseases or injuries of human beings.


For the purpose of this act the following persons shall be deemed to be engaged in the practice of osteopathy or to be osteopathic physicians and surgeons:
(a) Persons who publicly profess to be osteopathic physicians, or publicly profess to assume the duties incident to the practice of osteopathy, as heretofore interpreted by the supreme court of this state, shall be deemed to be engaged in the practice of osteopathy.
(b) Osteopathic physicians and surgeons shall mean and include those persons who receive a license to practice medicine and surgery pursuant to the provisions of this act.


65-2871. Persons deemed engaged in practice of chiropractic.
For the purpose of this act the following persons shall be deemed to be engaged in the practice of chiropractic:
(a) Persons who examine, analyze and diagnose the human living body, and its diseases by the use of any physical, thermal or manual method and use the X-ray diagnosis and analysis taught in any accredited chiropractic school or college; and
(b) persons who adjust any misplaced tissue of any kind or nature, manipulate or treat the human body by manual, mechanical, electrical or natural methods or by the use of physical means, physiotherapy (including light, heat, water or exercise), or by the use of foods, food concentrates, or food extract, or who apply first aid and hygiene, but chiropractors are expressly prohibited from prescribing or administering to any person medicine or drugs in materia medica, or from performing any surgery, as hereinabove stated, or from practicing obstetrics.


65-2872. Persons not engaged in the practice of the healing arts.
The practice of the healing arts shall not be construed to include the following persons:
(a) Persons rendering gratuitous services in the case of an emergency.
(b) Persons gratuitously administering ordinary household remedies.
(c) The members of any church practicing their religious tenets provided they shall not be exempt from complying with all public health regulations of the state.
(d) Students while in actual classroom attendance in an accredited healing arts school who after completing one year's study treat diseases under the supervision of a licensed instructor.
(e) Students upon the completion of at least three years study in an accredited healing arts school and who, as a part of their academic requirements for a degree, serve a preceptorship not to exceed 180 days under the supervision of a licensed practitioner.
(f) Persons who massage for the purpose of relaxation, muscle conditioning, or figure improvement, provided no drugs are used and such persons do not hold themselves out to be physicians or healers.

(g) Persons whose professional services are performed under the supervision or by order of or referral from a practitioner who is licensed under this act.

(h) Persons in the general fields of psychology, education and social work, dealing with the social, psychological and moral well-being of individuals or groups, or both, provided they do not use drugs and do not hold themselves out to be the physicians, surgeons, osteopathic physicians or chiropractors.

(i) Practitioners of the healing arts in the United States army, navy, air force, public health service, and coast guard or other military service when acting in the line of duty in this state.

(j) Practitioners of the healing arts licensed in another state when and while incidentally called into this state in consultation with practitioners licensed in this state.

(k) Dentists practicing their professions, when licensed and practicing in accordance with the provisions of article 14 of chapter 65 of the Kansas Statutes Annotated, and amendments thereto, and any interpretation thereof by the supreme court of this state.

(l) Optometrists practicing their professions, when licensed and practicing under and in accordance with the provisions of article 15 of chapter 65 of the Kansas Statutes Annotated, and amendments thereto, and any interpretation thereof by the supreme court of this state.

(m) Nurses practicing their profession when licensed and practicing under and in accordance with the provisions of article 11 of chapter 65 of the Kansas Statutes Annotated, and amendments thereto, and any interpretation thereof by the supreme court of this state.

(n) Podiatrists practicing their profession, when licensed and practicing under and in accordance with the provisions of article 20 of chapter 65 of the Kansas Statutes Annotated, and amendments thereto, and any interpretation thereof by the supreme court of this state.

(o) Every act or practice falling in the field of the healing arts, not specifically excepted herein, shall constitute the practice thereof.

(p) Pharmacists practicing their profession, when licensed and practicing under and in accordance with the provisions of article 16 of chapter 65 of the Kansas Statutes Annotated, and amendments thereto, and any interpretation thereof by the supreme court of this state.

(q) A dentist licensed in accordance with the provisions of article 14 of chapter 65 of the Kansas Statutes Annotated, and amendments thereto, who administers general and local anesthetics to facilitate medical procedures conducted by a person licensed to practice medicine and surgery if such dentist is certified by the board of healing arts under K.S.A. 65-2899, and amendments thereto, to administer such general and local anesthetics.

(r) Practitioners of the healing arts duly licensed under the laws of another state who do not open an office or maintain or appoint a place to regularly meet patients or to receive calls within this state, but who order services which are performed in this state in accordance with rules and regulations of the board. The board shall adopt rules and regulations identifying circumstances in which professional services may be performed in this state based upon an order by a practitioner of the healing arts licensed under the laws of another state.

(s) Acupuncturists, when licensed and practicing in accordance with K.S.A. 65-7601 through 65-7624, and amendments thereto, rules and regulations adopted [pursuant] thereto, and interpretations thereof by the supreme court of this state.

(t) Persons licensed by the state board of cosmetology practicing their professions, when licensed and practicing under and in accordance with the provisions of article 19 of chapter 65 of the Kansas Statutes Annotated, and amendments thereto, and any interpretation thereof by the supreme court of this state.

Historical and other Notes:
65-2872b. Same; administration of epinephrine; limitation of liability.
(a) The practice of the healing arts shall not be construed to include any person administering epinephrine in emergency situations to a student or a member of a school staff if:
   (1) The person administering the epinephrine reasonably believes that the student or staff member is exhibiting the signs and symptoms of an anaphylactic reaction;
   (2) a physician has authorized, in writing, the school to maintain a stock supply of epinephrine; and
   (3) the epinephrine is administered at school, on school property or at a school-sponsored event.
(b) Any person who gratuitously and in good faith renders emergency care or treatment through the administration of epinephrine to a student or a member of a school staff at school, on school property or at a school-sponsored event shall not be held liable for any civil damages as a result of such care or administration or as a result of any act or failure to act in providing or arranging further medical treatment where the person acts as an ordinary reasonably prudent person would have acted under the same or similar circumstances.
History: L. 2009, ch. 102, § 1; July 1.

65-28,127. Licensees who direct, supervise, order, refer, accept responsibility for, enter into practice protocols with or delegate acts which constitute practice of healing arts to others; requirements and limitations; construction of section.
(a) Every supervising or responsible licensee who directs, supervises, orders, refers, accepts responsibility for, enters into written agreements or practice protocols with, or who delegates acts which constitute the practice of the healing arts to other persons shall:
   (1) Be actively engaged in the practice of the healing arts in Kansas;
   (2) review and keep current any required written agreements or practice protocols between the supervising or responsible licensee and such persons, as may be determined by the board;
   (3) direct, supervise, order, refer, enter into a written agreement or practice protocol with, or delegate to such persons only those acts and functions which the supervising or responsible licensee knows or has reason to believe can be competently performed by such person and is not in violation of any other statute or regulation;
   (4) direct, supervise, order, refer, enter into a written agreement or practice protocol with, or delegate to other persons only those acts and functions which are within the normal and customary specialty, competence and lawful practice of the supervising or responsible licensee;
   (5) provide for a qualified, substitute licensee who accepts responsibility for the direction, supervision, delegation and written agreements or practice protocols with such persons when the supervising or responsible licensee is temporarily absent; and
   (6) comply with all rules and regulations of the board establishing limits and conditions on the delegation and supervision of services constituting the practice of medicine and surgery.
(b) "Responsible licensee" means a person licensed by the state board of healing arts to practice medicine and surgery or chiropractic who has accepted responsibility for the actions of persons who perform acts pursuant to written agreements or practice protocols with, or at the order of, or referral, direction, supervision or delegation from such responsible licensee.
(c) Except as otherwise provided by rules and regulations of the board implementing this section, the physician assistant licensure act shall govern the direction and supervision of physician assistants by persons licensed by the state board of healing arts to practice medicine and surgery.
(d) Nothing in subsection (a)(4) shall be construed to prohibit a person licensed to practice medicine and surgery from ordering, authorizing or directing anesthesia care by a registered nurse anesthetist pursuant to K.S.A. 65-1158, and amendments thereto.

(e) Nothing in this section shall be construed to prohibit a person licensed to practice medicine and surgery from ordering, authorizing or directing physical therapy services pursuant to K.S.A. 65-2901 et seq., and amendments thereto.

(f) Nothing in this section shall be construed to prohibit a person licensed to practice medicine and surgery from entering into a co-management relationship with an optometrist pursuant to K.S.A. 65-1501 et seq., and amendments thereto.

(g) The board may adopt rules and regulations establishing limits and conditions on the delegation and supervision of services constituting the practice of medicine and surgery.

(h) As used in this section, "supervising physician" shall have the meaning ascribed thereto in K.S.A. 65-28a02, and amendments thereto.

(i) This section shall be part of and supplemental to the Kansas healing arts act.


65-28,135. Telemedicine; out-of-state physician practice; requirements and limitations; waiver application and fee; other healthcare professionals.

(a) Notwithstanding any other provision of law, a physician holding a license issued by the applicable licensing agency of another state or who otherwise meets the requirements of this section may practice telemedicine to treat patients located in the state of Kansas, if such physician receives a telemedicine waiver issued by the state board of healing arts. The state board of healing arts shall issue such a waiver within 15 days from receipt of a complete application, if the physician:

(1) Submits a complete application that may include evidence in the form of an affidavit from an authorized third party that the applicant meets the requirements of this section in a manner determined by the state board of healing arts and pays a fee not to exceed $100; and

(2) holds an unrestricted license to practice medicine and surgery in another state or meets the qualifications required under Kansas law for a license to practice medicine and surgery and is not the subject of any investigation or disciplinary action by the applicable licensing agency.

(b) A physician practicing telemedicine in accordance with this subsection shall conduct an appropriate assessment and evaluation of the patient's current condition and document the appropriate medical indication for any prescription issued.

(c) Nothing in this section shall supersede or otherwise affect the provisions of K.S.A. 65-4a10, and amendments thereto, or K.S.A. 40-2,210 et seq., and amendments thereto.

(d) Any person who receives a telemedicine waiver under the provisions of this section shall be subject to all rules and regulations pertaining to the practice of the licensed profession in this state and shall be considered a licensee for the purposes of the professional practice acts administered by the state board of healing arts.

(e) A waiver issued under this section shall expire on the date of expiration established by the state board of healing arts unless renewed in the manner established by the state board of healing arts, including payment of an annual renewal fee not to exceed $100 and evidence that the applicant continues to meet the qualifications described in this section.

(f) Notwithstanding any other provision of law to the contrary, a physician holding a license issued by the applicable licensing agency of another state may provide, without limitation, consultation through remote technology to a physician licensed in the state of Kansas.
(g) An applicable healthcare licensing agency of this state may adopt procedures consistent with this section to allow other healthcare professionals licensed and regulated by such licensing agency to practice telemedicine within the scope of practice defined by Kansas law for such healthcare profession as deemed by such licensing agency to be consistent with ensuring patient safety.

(h) Nothing in this section shall be construed to prohibit a licensing agency from denying an application for a waiver under this section if the licensing body determines that granting the application may endanger the health and safety of the public.

(i) As used in this subsection, "telemedicine" means the delivery of healthcare services by a healthcare provider while the patient is at a different physical location.

History: L. 2021, ch. 88, § 10; May 6.

HEALING ARTS - SELECTED REGULATIONS

100-10a-4. Criteria.
(a) Exempt licenses may be issued to qualified applicants if the professional activities of the applicant will be limited to the following:
   (1) Performing administrative functions, including peer review, disability determinations, utilization review and expert opinions;
   (2) providing direct patient care services gratuitously or providing supervision, direction or consultation for no compensation. Nothing in this subsection shall prohibit an exempt license holder from receiving payment for subsistence allowances or actual and necessary expenses incurred in providing such services;
   (3) rendering professional services as a "charitable health care provider" as defined in K.S.A. 1990 Supp. 75-6102 and amendments thereto; and
   (4) providing services as a district coroner or deputy coroner.
(b) Applications describing professional activities not included in (a) shall be reviewed by the board on a case-by-case basis to determine eligibility for an exempt license.


100-21-1. Definition of dispensing physician.
"Dispensing physician" means a person licensed to practice medicine and surgery who purchases and keeps drugs and compounds his or her own prescriptions for the purpose of supplying such drugs to his or her patients.

(Authorized by K.S.A. 65-2865; effective, E-81-11, May 14, 1980; effective May 1, 1981.)

100-21-2. Drug label.
A dispensing physician shall clearly label each drug dispensed. The label shall be typed or machine printed and shall include the following:
(a) The name, address and telephone number of the dispensing physician.
(b) The full name of the patient.
(c) The identification number assigned to the prescription order by the dispensing physician.
(d) The date the prescription was filled or refilled.
(e) Adequate directions for use.
(f) The expiration date of the drug dispensed, if applicable.
(g) The brand name or corresponding generic name and manufacturer or distributors name and the strength, at the discretion of the physician.
(Authorized by K.S.A. 65-2865; effective, E-81-11, May 14, 1980; effective May 1, 1981.)

100-21-3. Packaging.
All oral medications shall be dispensed in child resistant containers in accordance with the poison prevention packaging act of 1970 and in light resistant air-tight containers as required by the United States pharmacopeia. In those cases where a bona fide circumstance exists to make it undesirable to use safety closures, medication may be dispensed in a nonchild resistant container.
(Authorized by K.S.A. 65-2865; effective, E-81-11, May 14, 1980; effective May 1, 1981.)

100-21-4. Record keeping and inventories.
(a) There shall be kept in the office of every dispensing physician a suitable book or file in which shall be preserved for a period of not less than three (3) years, every prescription order filled or refilled by such dispensing physician, and said book or file of prescription orders shall at all times be open to inspection to proper authorities.
(b) Each dispensing physician shall maintain the inventories and records of controlled substances as follows:
   (1) Inventories and records of all controlled substances listed in schedules I and II shall be maintained separately from all other records and prescriptions for such substances shall be maintained in a separate prescription file:
   (2) Inventories and records of controlled substances listed in schedules III, IV, and V shall be maintained either separately from all other records or in such form that the information required is readily retrievable from ordinary business records and prescriptions for such substances shall be maintained either in a separate prescription file for controlled substances listed in schedules III, IV, and V only, or in such form that they are readily retrievable from the other prescription records. Prescriptions will be deemed readily retrievable if, at the time they are initially filled the face of the prescription is stamped in red ink in the lower right corner with the letter “C” no less than 1-inch high and filed either in the prescription file for controlled substances listed in schedules I and II or in the usual consecutively numbered prescription file for non-controlled substances.
(c) Inventory requirements. An initial inventory of all controlled substances shall be taken and recorded. Every two years on May 1, a new inventory shall be taken and recorded. The records of these inventories shall be maintained for a period of three years.
(Authorized by K.S.A. 65-2865; effective, E-81-11, May 14, 1980; effective May 1, 1981.)

100-21-5. Storage and security.
(a) All dispensing physicians shall provide effective controls and procedures to guard against theft and diversion of controlled substances.
(b) All drugs shall be stored under conditions proper and suitable to maintain their integrity.
(Authorized by K.S.A. 65-2865; effective, E-81-11, May 14, 1980; effective May 1, 1981.)

100-23-1. Treatment of obesity.
A person shall not dispense or prescribe controlled substances to treat obesity, as defined by this regulation, except in conformity with the following minimal requirements.
(a) Amphetamines shall not be dispensed or prescribed to treat obesity.
(b) The treating physician shall personally examine the patient. The physical examination shall include checking the blood pressure and pulse, examining the heart and lungs, recording weight and height, and administering any other appropriate diagnostic tests. The examination and patient history shall determine if controlled substances are indicated and if any co-morbidity exists. The treating physician shall enter each of these findings in the patient’s record.
(c) The treating physician shall prescribe nutritional counseling, including behavior modification and appropriate exercise for weight loss, and record these parameters on the patient record.
(d) The treating physician shall not dispense or prescribe more than a 30-day supply of controlled substances, at one time, to treat obesity.
(e) Except as provided by subsection (f) of this regulation, the treating physician may continuously dispense or prescribe controlled substances to treat obesity when the physician observes and records that the patient significantly benefits from the controlled substances and has no serious adverse effects related to the drug regimen. A patient significantly benefits from the controlled substances when weight is reduced, or when weight loss is maintained and any existing co-morbidity is reduced. At the time of each return patient visit, the treating physician shall monitor progress of the patient; the treating physician or a person acting at the treating physician’s order shall check the patient’s weight, blood pressure, pulse, heart, and lungs. The findings shall be entered in the patient’s record.
(f) The treating physician shall not dispense or prescribe additional controlled substances to treat obesity for a patient who has not achieved a weight loss of at least 5% of the patient’s initial weight, during the initial 90 days of treatment using controlled substances to treat obesity.
(g) As used in this regulation, the term “controlled substance” means any drug included in any schedule of the Kansas uniform controlled substances act.
(h) As used in this regulation, the term “obesity” means a documented diagnosis of excess adipose tissue, resulting in body mass index of 30 or higher (BMI > 30kg/m2), or a body mass index of 27 or higher in the presence of other risk factors (BMI > 27kg/m2). Body mass index is calculated by dividing measured body weight in kilograms by body height in meters squared (kg/m2); expected body mass index is 20-25 kg/m2.


HEALTHCARE PROVIDERS - SELECTED STATUTES

65-4909. Limited liability for certain associations of health care providers, review organizations, committee members and individuals or entities acting at request thereof; good faith requirement; "health care provider" defined.
(a) There shall be no liability on the part of and no action for damages shall arise against any: (1) State, regional or local association of health care providers; (2) state, regional or local association of licensed
adult care home administrators; (3) organization delegated review functions by law, and the individual members of any committee thereof (whether or not such individual members are health care providers or licensed adult care home administrators); or (4) individual or entity acting at the request of any committee, association or organization listed in subsections (1) through (3), which in good faith investigates or communicates information regarding the quality, quantity or cost of care being given patients by health care providers or being furnished residents of adult care homes for any act, statement or proceeding undertaken or performed within the scope of the functions and within the course of the performance of the duties of any such association, organization or committee if such association, organization or committee or such individual member thereof acted in good faith and without malice.

(b) As used in this section, "health care provider" means a person licensed to practice any branch of the healing arts or engaged in a postgraduate training program approved by the state board of healing arts, mid-level practitioner as defined under K.S.A. 65-468, and amendments thereto, licensed dentist, licensed professional nurse, licensed practical nurse, licensed optometrist, licensed podiatrist, licensed pharmacist, physical therapist or respiratory therapist.


65-4915. Peer review; healthcare providers, services and costs; definitions; authority of peer review officer or committee; records and testimony of information contained therein privileged; licensing agency disciplinary proceedings; exceptions.

(a) As used in this section:

(1) "Healthcare provider" means: (A) Those persons and entities defined as a healthcare provider under K.S.A. 40-3401, and amendments thereto; and (B) a dentist licensed by the Kansas dental board, a dental hygienist licensed by the Kansas dental board, a professional nurse licensed by the board of nursing, a practical nurse licensed by the board of nursing, a mental health technician licensed by the board of nursing, a physical therapist licensed by the state board of healing arts, a physical therapist assistant certified by the state board of healing arts, an occupational therapist licensed by the state board of healing arts, an occupational therapy assistant licensed by the state board of healing arts, a respiratory therapist licensed by the state board of healing arts, a physician assistant licensed by the state board of healing arts and emergency medical service provider and ambulance services certified by the emergency medical services board.

(2) "Healthcare provider group" means:

(A) A state or local association of healthcare providers or one or more committees thereof;
(B) the board of governors created under K.S.A. 40-3403, and amendments thereto;
(C) an organization of healthcare providers formed pursuant to state or federal law and authorized to evaluate medical and healthcare services;
(D) a review committee operating pursuant to K.S.A. 65-2840c, and amendments thereto;
(E) an organized medical staff of a licensed medical care facility as defined by K.S.A. 65-425, and amendments thereto, an organized medical staff of a private psychiatric hospital licensed under K.S.A. 2021 Supp. 39-2001 et seq., and amendments thereto, or an organized medical staff of a state psychiatric hospital or state institution for people with intellectual disability, as follows: Larned state hospital, Osawatomie state hospital, Rainbow mental health facility, Kansas neurological institute and Parsons state hospital and training center;
(F) a healthcare provider;
(G) a professional society of healthcare providers or one or more committees thereof;
(H) a Kansas corporation whose stockholders or members are healthcare providers or an association of healthcare providers, which corporation evaluates medical and healthcare services;
(I) an insurance company, health maintenance organization or administrator of a health benefits plan that engages in any of the functions defined as peer review under this section; or

(J) the university of Kansas medical center.

(3) "Peer review" means any of the following functions:

(A) Evaluate and improve the quality of healthcare services rendered by healthcare providers;

(B) determine that health services rendered were professionally indicated or were performed in compliance with the applicable standard of care;

(C) determine that the cost of healthcare rendered was considered reasonable by the providers of professional health services in this area;

(D) evaluate the qualifications, competence and performance of the providers of healthcare or to act upon matters relating to the discipline of any individual provider of healthcare;

(E) reduce morbidity or mortality;

(F) establish and enforce guidelines designed to keep within reasonable bounds the cost of healthcare;

(G) conduct of research;

(H) determine if a hospital's facilities are being properly utilized;

(I) supervise, discipline, admit, determine privileges or control members of a hospital's medical staff;

(J) review the professional qualifications or activities of healthcare providers;

(K) evaluate the quantity, quality and timeliness of healthcare services rendered to patients in the facility;

(L) evaluate, review or improve methods, procedures or treatments being utilized by the medical care facility or by healthcare providers in a facility rendering healthcare.

(4) "Peer review officer or committee" means:

(A) An individual employed, designated or appointed by, or a committee of or employed, designated or appointed by, a healthcare provider group and authorized to perform peer review; or

(B) a healthcare provider monitoring the delivery of healthcare at correctional institutions under the jurisdiction of the secretary of corrections.

(b) Except as provided by K.S.A. 60-437, and amendments thereto, and by subsections (c) and (d), the reports, statements, memoranda, proceedings, findings and other records submitted to or generated by peer review committees or officers shall be privileged and shall not be subject to discovery, subpoena or other means of legal compulsion for their release to any person or entity or be admissible in evidence in any judicial or administrative proceeding. Information contained in such records shall not be discoverable or admissible at trial in the form of testimony by an individual who participated in the peer review process. The peer review officer or committee creating or initially receiving the record is the holder of the privilege established by this section. This privilege may be claimed by the legal entity creating the peer review committee or officer, or by the commissioner of insurance for any records or proceedings of the board of governors.

(c) Subsection (b) shall not apply to proceedings in which a healthcare provider contests the revocation, denial, restriction or termination of staff privileges or the license, registration, certification or other authorization to practice of the healthcare provider. A licensing agency in conducting a disciplinary proceeding in which admission of any peer review committee report, record or testimony is proposed shall hold the hearing in closed session when any such report, record or testimony is disclosed. Unless otherwise provided by law, a licensing agency conducting a disciplinary proceeding may close only that portion of the hearing in which disclosure of a report or record privileged under this section is proposed. In closing a portion of a hearing as provided by this section, the presiding officer may exclude any person from the hearing location except the licensee, the licensee's attorney, the agency's attorney, the witness, the court reporter and appropriate staff support for either counsel. The licensing agency shall make the portions of the agency record in which such report or record is disclosed subject
to a protective order prohibiting further disclosure of such report or record. Such report or record shall not be subject to discovery, subpoena or other means of legal compulsion for their release to any person or entity. No person in attendance at a closed portion of a disciplinary proceeding shall at a subsequent civil, criminal or administrative hearing, be required to testify regarding the existence or content of a report or record privileged under this section that was disclosed in a closed portion of a hearing, nor shall such testimony be admitted into evidence in any subsequent civil, criminal or administrative hearing. A licensing agency conducting a disciplinary proceeding may review peer review committee records, testimony or reports but must prove its findings with independently obtained testimony or records that shall be presented as part of the disciplinary proceeding in open meeting of the licensing agency. Offering such testimony or records in an open public hearing shall not be deemed a waiver of the peer review privilege relating to any peer review committee testimony, records or report.

(d) Nothing in this section shall limit the authority that may otherwise be provided by law of the commissioner of insurance, the state board of healing arts or other healthcare provider licensing or disciplinary boards of this state to require a peer review committee or officer to report to it any disciplinary action or recommendation of such committee or officer; to transfer to it records of such committee's or officer's proceedings or actions to restrict or revoke the license, registration, certification or other authorization to practice of a healthcare provider; or to terminate the liability of the fund for all claims against a specific healthcare provider for damages for death or personal injury pursuant to K.S.A. 40-3403(i), and amendments thereto. Reports and records so furnished shall not be subject to discovery, subpoena or other means of legal compulsion for their release to any person or entity and shall not be admissible in evidence in any judicial or administrative proceeding other than a disciplinary proceeding by the state board of healing arts or other healthcare provider licensing or disciplinary boards of this state.

(e) A peer review committee or officer may report to and discuss its activities, information and findings to other peer review committees or officers or to a board of directors or an administrative officer of a healthcare provider without waiver of the privilege provided by subsection (b) and the records of all such committees or officers relating to such report shall be privileged as provided by subsection (b).

(f) Nothing in this section shall be construed to prevent an insured from obtaining information pertaining to payment of benefits under a contract with an insurance company, a health maintenance organization or an administrator of a health benefits plan.


65-4921. Definitions.
As used in K.S.A. 65-4921 through 65-4930, and amendments thereto:
(a) "Appropriate licensing agency" means the agency that issued the license to the individual or health care provider who is the subject of a report under this act.
(b) "Department" means the department of health and environment.
(c) "Health care provider" means: (1) Those persons and entities defined as a health care provider under K.S.A. 40-3401, and amendments thereto; and (2) a dentist licensed by the Kansas dental board, a dental hygienist licensed by the Kansas dental board, a professional nurse licensed by the board of nursing, a practical nurse licensed by the board of nursing, a mental health technician licensed by the board of nursing, a physical therapist licensed by the state board of healing arts, a physical therapist assistant certified by the state board of healing arts, an occupational therapist licensed by the state board of healing arts, an occupational therapy assistant licensed by the state board of healing arts and a respiratory therapist licensed by the state board of healing arts.
(d) "License," "licensee" and "licensing" include comparable terms that relate to regulation similar to licensure, such as registration.

(e) "Medical care facility" means: (1) A medical care facility licensed under K.S.A. 65-425 et seq., and amendments thereto; (2) a private psychiatric hospital licensed under K.S.A. 39-2001 et seq., and amendments thereto; and (3) state psychiatric hospitals and state institutions for people with intellectual disability, as follows: Larned state hospital, Osawatomie state hospital, Rainbow mental health facility, Kansas neurological institute and Parsons state hospital and training center.

(f) "Reportable incident" means an act by a health care provider that: (1) Is or may be below the applicable standard of care and has a reasonable probability of causing injury to a patient; or (2) may be grounds for disciplinary action by the appropriate licensing agency.

(g) "Risk manager" means the individual designated by a medical care facility to administer its internal risk management program and to receive reports of reportable incidents within the facility.

(h) "Secretary" means the secretary of health and environment.


### 65-4922. Medical care facilities; risk management program required; submission of plan; inspections and investigations; approval of plan; reports and records confidential.

(a) Each medical care facility shall establish and maintain an internal risk management program which shall consist of:

1. A system for investigation and analysis of the frequency and causes of reportable incidents within the facility;
2. Measures to minimize the occurrence of reportable incidents and the resulting injuries within the facility; and
3. A reporting system based upon the duty of all health care providers staffing the facility and all agents and employees of the facility directly involved in the delivery of health care services to report reportable incidents to the chief of the medical staff, chief administrative officer or risk manager of the facility.

(b) Not less than 60 days before the time for renewal of its license in 1987, each medical care facility shall submit to the department its plan for establishing and implementing an internal risk management program. Such plan may rely upon policies and procedures adopted by the medical care facility and its departments and committees. Failure to submit such a plan shall result in denial of the renewal of the facility's license.

(c) The department shall make or cause to be made such inspections and investigations as it deems necessary to reasonably assure that each medical care facility is implementing the internal risk management program required by this section. In making such inspections and investigations, the department may review and copy the reports and records of all executive committees designated to investigate reportable incidents under this act.

(d) Upon review of a plan submitted pursuant to subsection (b), the department shall determine whether the plan meets criteria of this section. If the plan does not meet such criteria, the department shall disapprove the plan and return it to the facility, along with the reasons for disapproval. Within 60 days, the facility shall submit to the department a revised plan which meets the requirements of this section and any rules and regulations adopted hereunder. No medical care facility shall be granted renewal of its license in 1988 unless its plan has been approved by the department.

(e) A medical care facility shall not be liable for compliance with or failure to comply with the provisions of this section or any rules and regulations adopted hereunder, except as provided in K.S.A. 65-430 and amendments thereto.
The secretary shall adopt such rules and regulations as necessary to administer and enforce the provisions of this section.

Any reports and records reviewed or obtained by the department and in the department's possession, pursuant to subsection (a) of K.S.A. 65-4925, and amendments thereto, shall be confidential and privileged and not subject to discovery, subpoena or legal compulsion for their release to any person or entity, nor shall they be admissible in any civil or administrative action other than a disciplinary proceeding by the department.

History: L. 1986, ch. 229, § 3; L. 1987, ch. 176, § 9; L. 1989, ch. 201, § 1; April 27.

65-4923. Reporting requirements.

(a) If a health care provider, or a medical care facility agent or employee who is directly involved in the delivery of health care services, has knowledge that a health care provider has committed a reportable incident, such health care provider, agent or employee shall report such knowledge as follows:

(1) If the reportable incident did not occur in a medical care facility, the report shall be made to the appropriate state or county professional society or organization, which shall refer the matter to a professional practices review committee duly constituted pursuant to the society's or organization's bylaws. The committee shall investigate all such reports and take appropriate action. The committee shall have the duty to report to the appropriate state licensing agency any finding by the committee that a health care provider acted below the applicable standard of care which action had a reasonable probability of causing injury to a patient, or in a manner which may be grounds for disciplinary action by the appropriate licensing agency, so that the agency may take appropriate disciplinary measures.

(2) If the reportable incident occurred within a medical care facility, the report shall be made to the chief of the medical staff, chief administrative officer or risk manager of the facility. The chief of the medical staff, chief administrative officer or risk manager shall refer the report to the appropriate executive committee or professional practices peer review committee which is duly constituted pursuant to the bylaws of the facility. The committee shall investigate all such reports and take appropriate action, including recommendation of a restriction of privileges at the appropriate medical care facility. In making its investigation, the committee may also consider treatment rendered by the health care provider outside the facility. The committee shall have the duty to report to the appropriate state licensing agency any finding by the committee that a health care provider acted below the applicable standard of care which action had a reasonable probability of causing injury to a patient, or in a manner which may be grounds for disciplinary action by the appropriate licensing agency, so that the agency may take appropriate disciplinary measures.

(3) If the health care provider involved in the reportable incident is a medical care facility, the report shall be made to the chief of the medical staff, chief administrative officer or risk manager of the facility. The chief of the medical staff, chief administrative officer or risk manager shall refer the report to the appropriate executive committee which is duly constituted pursuant to the bylaws of the facility. The executive committee shall investigate all such reports and take appropriate action. The committee shall have the duty to report to the department of health and environment any finding that the facility acted in a manner which is below the applicable standard of care and which has a reasonable probability of causing injury to a patient, so that appropriate disciplinary measures may be taken.

(4) As used in this subsection (a), "knowledge" means familiarity because of direct involvement or observation of the incident.
(5) This subsection (a) shall not be construed to modify or negate the physician-patient privilege, the psychologist-client privilege or the social worker-client privilege as codified by Kansas statutes.

(b) If a reportable incident is reported to a state agency which licenses health care providers, the agency may investigate the report or may refer the report to a review or executive committee to which the report could have been made under subsection (a) for investigation by such committee.

(c) When a report is made under this section, the person making the report shall not be required to report the reportable incident pursuant to K.S.A. 65-28,122 or 65-4216, and amendments to such sections. When a report made under this section is investigated pursuant to the procedure set forth under this section, the person or entity to which the report is made shall not be required to report the reportable incident pursuant to K.S.A. 65-28,121, 65-28,122 or 65-4216, and amendments to such sections.

(d) Each review and executive committee referred to in subsection (a) shall submit to the secretary of health and environment, on a form promulgated by such agency, at least once every three months, a report summarizing the reports received pursuant to subsections (a)(2) and (a)(3) of this section. The report shall include the number of reportable incidents reported, whether an investigation was conducted and any action taken.

(e) If a state agency that licenses health care providers determines that a review or executive committee referred to in subsection (a) is not fulfilling its duties under this section, the agency, upon notice and an opportunity to be heard, may require all reports pursuant to this section to be made directly to the agency.

(f) The provisions of this section shall not apply to a health care provider acting solely as a consultant or providing review at the request of any person or party.


65-4924. Reports relating to impaired providers; procedures.

(a) If a report to a state licensing agency pursuant to subsection (a)(1) or (2) of K.S.A. 65-4923 or any other report or complaint filed with such agency relates to a health care provider's inability to practice the provider's profession with reasonable skill and safety due to physical or mental disabilities, including deterioration through the aging process, loss of motor skill or abuse of drugs or alcohol, the agency may refer the matter to an impaired provider committee of the appropriate state or county professional society or organization.

(b) The state licensing agency shall have the authority to enter into an agreement with the impaired provider committee of the appropriate state or county professional society or organization to undertake those functions and responsibilities specified in the agreement and to provide for payment therefor from moneys appropriated to the agency for that purpose. Such functions and responsibilities may include any or all of the following:

1. Contracting with providers of treatment programs;
2. Receiving and evaluating reports of suspected impairment from any source;
3. Intervening in cases of verified impairment;
4. Referring impaired providers to treatment programs;
5. Monitoring the treatment and rehabilitation of impaired health care providers;
6. Providing posttreatment monitoring and support of rehabilitated impaired health care providers; and
(7) Performing such other activities as agreed upon by the licensing agency and the impaired provider committee.

c) The impaired provider committee shall develop procedures in consultation with the licensing agency for:
   (1) Periodic reporting of statistical information regarding impaired provider program activity;
   (2) Periodic disclosure and joint review of such information as the licensing agency considers appropriate regarding reports received, contacts or investigations made and the disposition of each report;
   (3) Immediate reporting to the licensing agency of the name and results of any contact or investigation regarding any impaired provider who is believed to constitute an imminent danger to the public or to self;
   (4) Reporting to the licensing agency, in a timely fashion, any impaired provider who refuses to cooperate with the committee or refuses to submit to treatment, or whose impairment is not substantially alleviated through treatment, and who in the opinion of the committee exhibits professional incompetence; and
   (5) Informing each participant of the impaired provider committee of the procedures, the responsibilities of participants and the possible consequences of noncompliance.

d) If the licensing agency has reasonable cause to believe that a health care provider is impaired, the licensing agency may cause an evaluation of such health care provider to be conducted by the impaired provider committee or its designee for the purpose of determining if there is an impairment. The impaired provider committee or its designee shall report the findings of its evaluation to the licensing agency.

e) An impaired health care provider may submit a written request to the licensing agency for a restriction of the provider's license. The agency may grant such request for restriction and shall have authority to attach conditions to the licensure of the provider to practice within specified limitations. Removal of a voluntary restriction on licensure to practice shall be subject to the statutory procedure for reinstatement of license.

(f) A report to the impaired provider committee shall be deemed to be a report to the licensing agency for the purposes of any mandated reporting of provider impairment otherwise provided for by the law of this state.

g) An impaired provider who is participating in, or has successfully completed, a treatment program pursuant to this section shall not be excluded from any medical care facility staff solely because of such participation. However, the medical care facility may consider any impairment in determining the extent of privileges granted to a health care provider.

(h) Notwithstanding any other provision of law, a state or county professional society or organization and the members thereof shall not be liable to any person for any acts, omissions or recommendations made in good faith while acting within the scope of the responsibilities imposed pursuant to this section.


65-4926. Immunity from civil liability for report or investigation, limits.
Any person or entity which, in good faith, reports or provides information or investigates any health care provider as authorized by K.S.A. 65-4923 or 65-4924 shall not be liable in a civil action for damages or other relief arising from the reporting, providing of information or investigation except upon clear and convincing evidence that the report or information was
completely false, or that the investigation was based on false information, and that the falsity was actually known to the person making the report, providing the information or conducting the investigation at the time thereof.

**History:** L. 1986, ch. 229, § 7; July 1.

65-4977. **Persons suffering from pain; use of controlled substances for pain treatment.**

(a) A person suffering from pain:

(1) Should be an active participant in decisions about the assessment, diagnosis and treatment of their pain.

(2) May accept or reject the use of any or all diagnostic and therapeutic modalities which may be recommended to treat such person's pain.

(3) Should accurately, completely, and honestly report all symptoms and concerns to physicians and other health care professionals conducting assessment and treatment of such person's pain.

(b) Nothing in this act shall be construed to prevent, restrict or limit a physician or other person authorized to prescribe drugs from prescribing, dispensing, administering, or distributing a controlled substance to a patient for the treatment of pain, when it is for a valid medical purpose and based on appropriate clinical indications.

(c) Nothing in this act shall be construed to require a physician or other person authorized to prescribe drugs to prescribe, dispense, administer, or distribute a controlled substance to a patient for the treatment of pain if in the judgment of the prescriber the use of a controlled substance is not clinically indicated or the most appropriate therapeutic modality.

**History:** L. 2006, ch. 110, § 3; July 1.

DENTAL ACT - SELECTED STATUTES

65-1422. **Persons deemed to be practicing dentistry.**

A person shall be deemed to be practicing dentistry:

(a) Who performs, or attempts or professes to perform, any dental operation or oral surgery or dental service of any kind, gratuitously or for a salary, fee, money or other remuneration paid, or to be paid directly or indirectly, to such person or to any other person or agency who is a proprietor of a place where dental operations, oral surgery or dental services are performed; or

(b) who directly or indirectly, by any means or method, takes impression of the human tooth, teeth, jaws or performs any phase of any operation incident to the replacement of a part of a tooth; or

(c) who supplies artificial substitutes for the natural teeth, or who furnishes, supplies, constructs, reproduces or repairs any prosthetic denture, bridge, appliance or any other structure to be worn in the human mouth, except on the written prescription of a licensed dentist; or

(d) who places such appliance or structure in the human mouth, or adjusts or attempts or professes to adjust the same, or delivers the same to any person other than the dentist upon whose prescription the work was performed; or

(e) who professes to the public by any method to furnish, supply, construct, reproduce or repair any prosthetic denture, bridge, appliance or other structure to be worn in the human mouth; or

(f) who diagnoses, or professes to diagnose, prescribe for, or professes to prescribe for, treats, or professes to treat, disease, pain, deformity, deficiency, injury or physical condition of the human teeth or jaws, or adjacent structure; or
(g) who extracts, or attempts to extract, human teeth, or corrects or attempts to correct, malformations of teeth or of the jaws; or
(h) who repairs or fills cavities in the human teeth; or
(i) who diagnoses, makes and adjusts appliances to artificial casts or malposed teeth for treatment of the malposed teeth in the human mouth, with or without instruction; or
(j) who uses a roentgen or x-ray machine for the purpose of taking dental x-rays or roentgenograms; or
(k) who gives, or professes to give, interpretations or readings of dental x-rays or roentgenograms; or
(l) who administers an anesthetic of any nature in connection with a dental operation; or
(m) who uses the words dentist, dental surgeon, oral surgeon, or the letters D.D.S., D.M.D., or any other words, letters, title or descriptive matter which in any way represents oneself as being able to diagnose, treat, prescribe or operate for any disease, pain, deformity, deficiency, injury or physical condition of the teeth or jaws or adjacent structures; or
(n) who states, or professes, or permits to be stated or professed by any means or method whatsoever that such person can perform or will attempt to perform dental operations or render a diagnosis connected therewith.

History: L. 1943, ch. 221, § 5; L. 2000, ch. 169, § 2; July 1.

65-1438. Using services of unlicensed person; written prescription; misdemeanors; suspension or revocation of license.
(a) Any dentist who shall use the services of any person (which word when used in this section shall include all legal entities) not licensed to practice dentistry in this state, to construct, alter, repair or duplicate any denture, plate, partial plate, bridge, splint, orthodontic or prosthetic appliance, shall first furnish such unlicensed person with a written prescription, on forms prescribed by the board, which shall contain:
   (1) The name and address of such unlicensed person.
   (2) The patient's name or number. In event such number is used, the name of the patient shall be written upon the duplicate copy of such prescription retained by the dentist.
   (3) The date on which it was written.
   (4) A prescription [description] of the work to be done, with diagrams if necessary.
   (5) A specification of the type and quality of materials to be used.
   (6) The signature of the dentist, and the number of his Kansas license. Such unlicensed person shall retain the original prescription and the dentist shall retain a duplicate copy thereof for inspection by the board, or its agent, for two years.
(b) Any dentist who shall:
   (1) Use any such service of any such licensed [unlicensed] person without first having furnished him such prescription; or
   (2) fail to retain a duplicate copy thereof for two years; or
   (3) refuse to allow the board, or its agent, to inspect it during such time, shall be guilty of a misdemeanor, and the board may revoke or suspend his license therefor.
(c) Any such unlicensed person who shall:
   (1) Perform any such service without first having obtained such prescription; or
   (2) fail to retain the original thereof for two years; or
   (3) refuse to allow the board, or its agent, to inspect it during such time shall be guilty of a misdemeanor.
65-1444. Drugs; surgery; anesthetics; appliances; qualifications for administering intravenous sedation and general anesthetics; sedation permits; rules and regulations; assistant administering and monitoring nitrous oxide or oxygen, requirements; denial, revocation, suspension or limitation of sedation permit.

(a) A dentist shall have the right to prescribe drugs or medicine, perform such surgical operations, administer analgesia, local anesthetics and use such appliances as may be necessary to the proper practice of dentistry. Dentists may be authorized by the board to administer sedation and general anesthetics subject to rules and regulations concerning qualifications of such dentists as may be adopted by the board. The board shall have authority to issue sedation permits to administer sedation and general anesthetics. The board may establish different requirements and qualifications based upon the type of sedation or general anesthetics the dentist is authorized by the board to use. The board may also establish by rules and regulations the requirement that the authorization to administer sedation and general anesthetics be periodically renewed and the requirements that must be met to obtain such renewal. Any office of a dentist who is authorized by the board to administer sedation or general anesthetics shall be subject to inspection by the board for purposes of determining if the dentist is in compliance with the board's rules and regulations.

(b) A dentist may utilize an assistant not licensed by the board in the administration and monitoring of nitrous oxide or oxygen, or both, if that person is certified in cardiopulmonary resuscitation and has satisfactorily completed a course of instruction which has been approved by the board. To be approved by the board, the course of instruction shall include a minimum of six hours of instruction at a teaching institution accredited by the American dental association and include satisfactory completion of courses which offer both didactic and clinical instruction in:
   (A) Theory of pain control;
   (B) anatomy;
   (C) medical history;
   (D) pharmacology; and
   (E) emergencies and complications.

(c) The board may deny, revoke, suspend or limit a sedation permit for violation by the permit holder of the requirements established by the board by rules and regulations or in lieu thereof or in addition thereto may assess a fine in accordance with K.S.A. 65-1436, and amendments thereto.

History:  L. 1943, ch. 221, § 22; June 28.

OPTOMETRY ACT - SELECTED STATUTES

65-1501. Practice of optometry defined; exclusions; standard of care in diagnosis and treatment of glaucoma; low vision rehabilitation services.

(a) The practice of optometry means:
   (1) The examination of the human eye and its adnexae and the employment of objective or subjective means or methods (including the administering, prescribing or dispensing, of topical
pharmaceutical drugs) for the purpose of diagnosing the refractive, muscular, or pathological condition thereof;

(2) the prescribing, dispensing or adapting of lenses (including any ophthalmic lenses which are classified as drugs by any law of the United States or of this state), prisms, low vision rehabilitation services, orthoptic exercises and visual training therapy for the relief of any insufficiencies or abnormal conditions of the human eye and its adnexae; and

(3) the prescribing, administering or dispensing of topical pharmaceutical drugs and oral drugs for the examination, diagnosis and treatment of ocular conditions and any insufficiencies or abnormal conditions of the human eye and its adnexae including adult open angle glaucoma.

(b) The practice of optometry shall not include: (1) The management and treatment of glaucoma, except as provided in subsection (a); (2) the performance of surgery, including the use of lasers for surgical purposes, except that licensees may remove non-perforating foreign bodies from the cornea, conjunctiva, or eyelids; remove eyelashes; scrape the cornea for diagnostic tests, smears or cultures; dilate, probe, irrigate or close by punctual plug the tear drainage structures of the eye; express conjunctival follicles or cysts; debridement of the corneal epithelium and co-management of post-operative care; or (3) the performance of procedures requiring anesthesia administered by injection or general anesthesia.

(c) A licensee shall be held to a standard of care in the diagnosis and treatment of adult open-angle glaucoma commensurate to that of a person licensed to practice medicine and surgery, who exercises that degree of skill and proficiency commonly exercised by an ordinary, skillful, careful and prudent person licensed to practice medicine and surgery.

(d) Under the direction and supervision of a licensee, a licensed professional nurse, licensed practical nurse, licensed physical therapist and licensed occupational therapist may assist in the provision of low vision rehabilitation services in addition to such other services which such licensed professional nurse, licensed practical nurse, licensed physical therapist and licensed occupational therapist is authorized by law to provide under subsection (d) of K.S.A. 65-1113, subsection (h) of K.S.A. 65-1124, subsection (b) of K.S.A. 65-2901 and subsection (b) of K.S.A. 65-5402, and amendments thereto.


For the purposes of this act the following terms shall have the meanings respectively ascribed to them unless the context requires otherwise:

(a) "Board" means the board of examiners in optometry established under K.S.A. 74-1501 and amendments thereto.

(b) "License" means a license to practice optometry granted under the optometry law.

(c) "Licensee" means a person licensed under the optometry law to practice optometry.

(d) "Adapt" means the determination, selection, fitting or use of lenses, prisms, orthoptic exercises or visual training therapy for the aid of any insufficiencies or abnormal conditions of the eyes after or by examination or testing.

(e) "Lenses" means any type of ophthalmic lenses, which are lenses prescribed or used for the aid of any insufficiencies or abnormal conditions of the eyes.

(f) "Prescription" means a verbal, written or electronic order transmitted directly or by electronic means from a licensee giving or containing the name and address of the prescriber, the license
registration number of the licensee, the name and address of the patient, the specifications and directions for lenses, prisms, orthoptic exercises, low vision rehabilitation services or visual training therapy to be used for the aid of any insufficiencies or abnormal conditions of the eyes, including instructions necessary for the fabrication or use thereof and the date of issue.

(g) "Prescription for topical pharmaceutical drugs or oral drugs" means a verbal, written or electronic order transmitted directly or by electronic means from a licensee giving or containing the name and address of the prescriber, the license registration number of the licensee, the name and address of the patient, the name and quantity of the drug prescribed, directions for use, the number of refills permitted, the date of issue and expiration date.

(h) "Topical pharmaceutical drugs" means drugs administered topically and not by other means.

(i) "Dispense" means to deliver prescription-only medication or ophthalmic lenses to the ultimate user pursuant to the lawful prescription of a licensee and dispensing of prescription-only medication by a licensee shall be limited to a twenty-four hour supply or minimal quantity necessary until a prescription can be filled by a licensed pharmacist, except that the twenty-four hour supply or minimal quantity shall not apply to lenses described in subsection (a)(2) of K.S.A. 65-1501, and amendments thereto.

(j) "False advertisement" means any advertisement which is false, misleading or deceptive in a material respect. In determining whether any advertisement is misleading, there shall be taken into account not only representations made or suggested by statement, word, design, device, sound or any combination thereof, but also the extent to which the advertisement fails to reveal facts material in the light of such representations made.

(k) "Advertisement" means all representations disseminated in any manner or by any means, for the purpose of inducing, or which are likely to induce, directly or indirectly, the purchase of professional services or ophthalmic goods.

(l) "Health care provider" shall have the meaning ascribed to that term in subsection (f) of K.S.A. 40-3401 and amendments thereto.

(m) "Medical facility" shall have the meaning ascribed to that term in subsection (c) of K.S.A. 65-411 and amendments thereto.

(n) "Medical care facility" shall have the meaning ascribed to that term in K.S.A. 65-425 and amendments thereto.

(o) "Ophthalmologist" means a person licensed to practice medicine and surgery by the state board of healing arts who specializes in the diagnosis and medical and surgical treatment of diseases and defects of the human eye and related structures.

(p) "Low vision rehabilitation services" means the evaluation, diagnosis, management and care of the low vision patient including low vision rehabilitation therapy, education and interdisciplinary consultation under the direction and supervision of an ophthalmologist or optometrist.

(q) "Oral drugs" means oral antibacterial drugs, oral antiviral drugs, oral antihistamines, oral analgesic drugs, oral steroids, oral antiglaucoma drugs and other oral drugs with clinically accepted ocular uses.

**History:** L. 1975, ch. 318, § 1; L. 1987, ch. 235, § 2; L. 1990, ch. 223, § 1; L. 1996, ch. 95, § 2; L. 1999, ch. 23, § 2; L. 2005, ch. 93, § 3; L. 2010, ch. 31, § 2; L. 2012, ch 8, § 2; July 1.
65-2002.  License required; scope of practice; applicability of act; surgical treatment of the ankle.
(a) It shall be unlawful for any person to profess to be a podiatrist, to practice or assume the duties incidental to podiatry, to advertise or hold oneself out to the public as a podiatrist, or to use any sign or advertisement with the word or words podiatrist, foot specialist, foot correctionist, foot expert, practapedist or chiropodist, or any other term or terms indicating that such person is a podiatrist or that such person practices or holds oneself out as practicing podiatry or foot correction in any manner, without first obtaining from the board a license authorizing the practice of podiatry in this state, except as hereinafter provided.

(b) A licensed podiatrist shall be authorized to prescribe such drugs or medicine, and to perform such surgery on the human foot, ankle and tendons that insert into the foot, including amputation of the toes or part of the foot, as may be necessary to the proper practice of podiatry, but no podiatrist shall amputate the human foot or administer any anesthetic other than local.

(c) This act shall not prohibit the recommendation, advertising, fitting or sale of corrective shoes, arch supports, or similar mechanical appliances, or foot remedies by manufacturers, wholesalers or retail dealers.

(d) No podiatrist shall perform surgery on the ankle unless such person has completed a two-year post-doctoral surgical residency program prior to July 1, 2007, or a three-year post-doctoral surgical residency program on or after July 1, 2007, in reconstructive rearfoot/ankle surgery and is either board-certified or board qualified progressing to board certification in reconstructive rearfoot/ankle surgery by a nationally recognized certifying organization acceptable to the board. Surgical treatment of the ankle by a podiatrist shall be performed only in a medical care facility, as defined in K.S.A. 65-425, and amendments thereto.

History: L. 1927, ch. 246, § 2; L. 1951, ch. 362, § 1; L. 1975, ch. 323, § 1; L. 1979, ch. 197, § 2; L. 1988, ch. 246, § 1; L. 1997, ch. 88, § 1; L. 2014, ch. 131, § 61; L. 2019, ch. 68, § 3; July 1.

PODIATRY - SELECTED REGULATIONS

100-49-10. Definition of human foot.
As utilized in the podiatry act, K.S.A. 65-2001 through 65-2013 and amendments thereto, “human foot” shall mean that part of the human anatomy that consists of the tarsus, metatarsus, phalanges, cartilage, muscles, tendons, ligaments, skin, vasculature, and the other tissues distal to and including the articulating cartilaginous surfaces of the ankle joint.


NATUROPATHIC ACT - SELECTED STATUTES

65-7201.  Citation of act.
K.S.A. 65-7201 to 65-7218, inclusive, and amendments thereto shall be known and may be cited as the naturopathic doctor licensure act.

History: L. 2002, ch. 203, § 20; L. 2010, ch. 126, § 1; July 1, 2011

65-7202. Definitions.
As used in K.S.A. 65-7201 through 65-7218, and amendments thereto:
(a) "Naturopathic doctor" means a doctor of naturopathic medicine who is authorized and licensed pursuant to this act.

(b) (1) "Naturopathic medicine," or "naturopathy" means a system of health care practiced by naturopathic doctors for the prevention, diagnosis and treatment of human health conditions, injuries and diseases, that uses education, natural medicines and therapies to support and stimulate the individual's intrinsic self-healing processes, and includes: (A) Prescribing, recommending or administering: (i) Food, food extracts, vitamins, minerals, enzymes, whole gland thyroid, botanicals, homeopathic preparations, nonprescription drugs, plant substances that are not designated as prescription drugs or controlled substances, topical drugs as defined in subsection (i); (ii) health care counseling, nutritional counseling and dietary therapy, naturopathic physical applications, barrier contraceptive devices; (iii) substances on the naturopathic formulary that are authorized for intramuscular or intravenous administration pursuant to a written protocol entered into with a physician who has entered into a written protocol with a naturopathic doctor licensed under the naturopathic doctor licensure act; (iv) noninvasive physical examinations, venipuncture to obtain blood for clinical laboratory tests and orofacial examinations, excluding endoscopies; (v) minor office procedures; and (vi) naturopathic acupuncture; and (B) ordering diagnostic imaging studies, including, but not limited to, x-ray, ultrasound, mammogram, bone densitometry, computed tomography, magnetic resonance imaging and electrocardiograms, except that naturopathic doctors shall refer patients to an appropriately licensed and qualified healthcare professional to conduct diagnostic imaging studies and interpret the results of such studies.

(2) A naturopathic doctor may not perform surgery, obstetrics, administer ionizing radiation, or prescribe, dispense or administer any controlled substances as defined in K.S.A. 65-4101, and amendments thereto, or any prescription-only drugs except those listed on the naturopathic formulary adopted by the board pursuant to this act.

c) "Board" means the state board of healing arts.

d) "Approved naturopathic medical college" means a college and program granting the degree of doctor of naturopathy or naturopathic medicine that has been approved by the board under this act and which college and program requires at a minimum a four-year, full-time resident program of academic and clinical study.

e) "Homeopathic preparations" means substances and drugs prepared according to the official homeopathic pharmacopoeia recognized by the United States food and drug administration.

(f) "Naturopathic acupuncture" means the insertion of fine metal needles through the skin at specific points on or near the surface of the body with or without the palpation of specific points on the body and with or without the application of electric current or heat to the needles or skin or both to treat human disease and impairment and to relieve pain.

g) "Minor office procedures" means care incidental to superficial lacerations and abrasions, superficial lesions and the removal of foreign bodies located in the superficial tissues, except eyes, and not involving blood vessels, tendons, ligaments or nerves. "Minor office procedures" includes use of antiseptics, but shall not include the suturing, repairing, alteration or removal of tissue or the use of general or spinal anesthesia. Minor office procedures does not include anesthetics or surgery.

(h) "Naturopathic physical applications" means the therapeutic use by naturopathic doctors of the actions or devices of electrical muscle stimulation, galvanic, diathermy, ultrasound, ultraviolet light, constitutional hydrotherapy, naturopathic musculoskeletal technique and therapeutic exercise.

(i) "Topical drugs" means topical analgesics, antiseptics, scabicides, antifungals and antibacterials but does not include prescription only drugs.

(j) "Physician" means a person licensed to practice medicine and surgery.
(k) "Written protocol" means a formal written agreement between a naturopathic doctor licensed under this act and a person licensed to practice medicine and surgery. Any licensee of the board entering into a written protocol with a licensed naturopathic doctor shall notify the board in writing of such relationship by providing such information as the board may require.

**History:** L. 2002, ch. 203, § 21; L. 2010, ch. 126, § 2; L. 2019, ch. 55, § 38; May 9.

---

**65-7211. Authorized representations; unlawful representations; authority not conferred upon naturopathic doctors to engage in activities not conferred by act.**

(a) A person licensed under this act as a naturopathic doctor shall:

(1) use the letters “N.D.”, when using the letters or term “Dr.” or “Doctor” to identify themselves to patients or to the public; and

(2) be authorized to use the words “naturopathic doctor”, “doctor of naturopathy”, “doctor of naturopathic medicine”, or “naturopath”, to indicate that such a person is a naturopathic doctor licensed under this act. A person licensed under this act may not advertise, hold themselves out to the public, refer to themselves, or use the terms “naturopathic physician”, “physician”, or “naturopathic medical doctor” in conjunction with such licensee’s name. A violation of this subsection (a) shall constitute a class B misdemeanor.

(b) It shall be unlawful for any person who is not licensed under this act as a naturopathic doctor or whose license has been suspended or revoked to hold oneself out to the public in any manner as a licensed naturopathic doctor, or use the abbreviation of "N.D." or the words "naturopathic doctor," "doctor of naturopathy," "doctor of naturopathic medicine," "naturopath," "naturopathic medical doctor" or any other words, letters, abbreviations or insignia indicating or implying that such person is a naturopathic doctor. A violation of this subsection (b) shall constitute a class B person misdemeanor.

(c) No statute granting authority to persons licensed or registered by the state board of healing arts shall be construed to confer authority upon naturopathic doctors to engage in any activity not conferred by this act.

**History:** L. 2002, ch. 203, § 30; L. 2010, ch. 126, § 10; Jan. 1, 2011

---

**NATUROPATHIC - SELECTED REGULATIONS**

**100-72-8. Naturopathic formulary.**

The following list shall constitute the naturopathic formulary for drugs and substances that are approved for intramuscular (IM) or intravenous (IV) administration, or both, by a naturopathic doctor pursuant to a written protocol entered into with a physician:

(a) Electrolytes and carrier solutions:

(1) Sterile water (IV, IM);
(2) electrolyte solution (IV);
(3) lactated ringers (IV);
(4) saline solution (IV); and
(5) half normal saline (IV);

(b) vitamins:

(1) Vitamin C (IV);
(2) B complex (IV, IM);
(3) folic acid (IV, IM);
(4) vitamin D (IV);
(5) vitamin E (IV);
(6) vitamin K (IV, IM);
(7) vitamin A (IV, IM); and
(8) vitamin B₁₂ (IV, IM);
(c) minerals:
(1) Calcium (IV, IM);
(2) chromium (IV, IM);
(3) copper (IV, IM);
(4) iron (IV, IM);
(5) zinc (IV, IM);
(6) iodine (IV, IM);
(7) magnesium (IV, IM);
(8) selenium (IV, IM);
(9) molybdenum (IV, IM);
(10) vanadium (IV, IM);
(11) phosphorus (IV, IM); and
(12) manganese (IV, IM);
(d) amino acids:
(1) Amino acids, singular or in combination (IV);
(2) glutathione (IV, IM);
(3) tryptophan (IV); and
(4) 5 hydroxy tryptophan (IV);
(e) botanicals:
(1) Glycyrrhizin (IV, IM); and
(2) thujone-free artemisia (IV, IM); and
(f) the following miscellaneous drugs and substances:
(1) Lipids (IV);
(2) co-enzyme Q 10 (also known as ubiquinone or Co-Q 10) (IV, IM);
(3) alpha lipoic acid (IV, IM);
(4) hydrochloric acid (IV);
(5) epinephrine (IM);
(6) chelators, only with prior board approval:
   (A) EDTA (IV); and
   (B) DMPS (IV);
(7) diphenhydramine hydrochloride (IV, IM); and
(8) atropine sulfate (IV).

(Authorized by K.S.A. 65-7203; implementing K.S.A. 65-7212; effective Jan. 21, 2005.)

100-72-9. Written protocol.
(a) Each physician entering into a written protocol with a registered naturopathic doctor shall be
    licensed to practice medicine and surgery in the state of Kansas and shall provide a copy of the
    protocol to the board within 10 days of entering into the protocol.
(b) Each written protocol between a physician and a naturopathic doctor shall contain the
    following information:
    (1) The date on which the protocol was signed and the signatures of the physician and the
        naturopathic doctor;
(2) the license number of the physician and the registration number of the naturopathic doctor;
(3) the names of the drugs and substances from the naturopathic formulary, which is specified in K.A.R. 100-72-8, that the naturopathic doctor will be allowed to administer and the method of administration of each drug and substance;
(4) the usage and dosage authorized for each drug and substance;
(5) any warning or precaution associated with the administration of each drug and substance;
(6) a statement that a current copy of the protocol will be maintained at each practice location of the physician and the naturopathic doctor and that any change made to the protocol will be provided to the board within 10 days of making the change;
(7) a statement that the physician is professionally competent to order each drug and substance that the protocol authorizes the naturopathic doctor to administer and that treating the conditions identified in the protocol is within the lawful and customary practice of the physician;
(8) a statement that the authority to administer any drug or substance intravenously is limited to times when the physician either is physically present in the same building or can be present within five minutes at the location where the service is performed;
(9) the identification of any task or service that the physician delegates to any unlicensed person working with the naturopathic doctor;
(10) a statement that emergency procedures have been established by the physician and adopted by the naturopathic doctor to protect the patient in the absence of the physician and that the naturopathic doctor is competent to carry out those emergency procedures; and
(11) any conditions imposed by the physician on the naturopathic doctor before the administration of any of the drugs and substances listed in the protocol.

c) Each written protocol shall be reviewed by the physician and naturopathic doctor at least annually, and each review shall be signed and dated on the current copy of the protocol.


NURSING ACT - SELECTED STATUTES

65-1130. Advanced practice registered nurse; standards and requirements for licensure; rules and regulations; roles, titles and abbreviations; prescription of drugs authorized; licensure of currently registered individuals; malpractice insurance coverage required, exceptions.

(a) No professional nurse shall announce or represent to the public that such person is an advanced practice registered nurse unless such professional nurse has complied with requirements established by the board and holds a valid license as an advanced practice registered nurse in accordance with the provisions of this section.

(b)(1) The board shall establish standards and requirements for any professional nurse who desires to obtain licensure as an advanced practice registered nurse. Such standards and requirements shall include, but not be limited to, standards and requirements relating to the education of advanced practice registered nurses. The board may give such examinations and secure such assistance as it deems necessary to determine the qualifications of applicants.

(2) (A) On and after July 1, 2023, an applicant for initial licensure as an advanced practice registered nurse shall have a current advanced practice registered nurse certification in such applicant's specific role and population focus that has been granted by a national certifying organization recognized by the board and whose certification standards are approved by the board as equal to or greater than the corresponding standards established by the board; and
(B) an advanced practice registered nurse whose initial licensure is prior to July 1, 2023, may submit evidence of such certification to the board upon renewal.

c) The board shall adopt rules and regulations consistent with the Kansas nurse practice act applicable to advanced practice registered nurses that:

1) Establish roles and identify titles and abbreviations of advanced practice registered nurses that are consistent with nursing practice specialties recognized by the nursing profession.

2) Establish education and qualifications necessary for licensure for each role of advanced practice registered nurse established by the board at a level adequate to assure the competent performance by advanced practice registered nurses of functions and procedures which advanced practice registered nurses are authorized to perform. Advanced practice registered nursing is based on knowledge and skills acquired in basic nursing education, licensure as a registered nurse and graduation from or completion of a master's or higher degree in one of the advanced practice registered nurse roles approved by the board of nursing.

3) Define the role of advanced practice registered nurses and establish limitations and restrictions on such role. The board shall adopt a definition of the role under this paragraph that is consistent with the education and qualifications required to obtain a license as an advanced practice registered nurse that protects the public from persons performing functions and procedures as advanced practice registered nurses for which they lack adequate education and qualifications and that authorizes advanced practice registered nurses to perform acts generally recognized by the profession of nursing as capable of being performed, in a manner consistent with the public health and safety, by persons with postbasic education in nursing. In defining such role the board shall consider:

   A) The education required for a licensure as an advanced practice registered nurse;
   B) the type of nursing practice and preparation in specialized advanced practice skills involved in each role of advanced practice registered nurse established by the board;
   C) the scope and limitations of advanced practice nursing prescribed by national advanced practice organizations in accordance with the laws of this state; and
   D) acts recognized by the nursing profession as appropriate to be performed by persons with postbasic education in nursing.

4) An advanced practice registered nurse may prescribe durable medical equipment and prescribe, procure and administer any drug consistent with such licensee's specific role and population focus, except an advanced practice registered nurse shall not prescribe any drug that is intended to cause an abortion. Any drug that is a controlled substance shall be prescribed, procured or administered in accordance with the uniform controlled substances act.

5) A prescription order shall include the name, address and telephone number of the advanced practice registered nurse. An advanced practice registered nurse may not dispense drugs but may request, receive and sign for professional samples and may distribute professional samples to patients.

6) In order to prescribe controlled substances, the advanced practice registered nurse shall:

   A) Register with the federal drug enforcement administration; and
   B) comply with federal drug enforcement administration requirements related to controlled substances.

7) An advanced practice registered nurse certified in the role of registered nurse anesthetist while functioning as a registered nurse anesthetist under K.S.A. 65-1151 through 65-1164, and amendments thereto, shall be subject to the provisions of K.S.A. 65-1151 through 65-1164, and amendments thereto, with respect to drugs and anesthetic agents and shall not be subject to the provisions of this subsection.

8) An advanced practice registered nurse shall maintain malpractice insurance coverage as a condition of rendering professional clinical services as an advanced practice registered nurse in this
state and shall provide proof of insurance at the time of licensure and renewal of license. The requirements of this subsection shall not apply to an advanced practice registered nurse who:

(i) Practices solely in employment for which the advanced practice registered nurse is covered under the federal tort claims act or the Kansas tort claims act;

(ii) practices solely as a charitable healthcare provider under K.S.A. 75-6102, and amendments thereto; or

(iii) is serving on active duty in the armed forces of the United States.

(c) As used in this section, "drug" means those articles and substances defined as drugs in K.S.A. 65-1626 and 65-4101, and amendments thereto.

(f) A person registered to practice as an advanced registered nurse practitioner in the state of Kansas immediately prior to the effective date of this act shall be deemed to be licensed to practice as an advanced practice registered nurse under this act and such person shall not be required to file an original application for licensure under this act. Any application for registration filed which has not been granted prior to the effective date of this act shall be processed as an application for licensure under this act.

(g) An advanced practice registered nurse certified in the role of certified nurse-midwife and engaging in the independent practice of midwifery under the independent practice of midwifery act with respect to prescribing drugs shall be subject to the provisions of the independent practice of midwifery act and shall not be subject to the provisions of this section.

(h) This section shall not supersede the requirements outlined in K.S.A. 65-4a08(b), and amendments thereto.


65-1158. Duties of registered nurse anesthetists.

(a) Upon the order of a physician or dentist requesting anesthesia or analgesia care, each registered nurse anesthetist shall be authorized to:

(1) Conduct a pre- and post-anesthesia and pre- and post-analgesia visit and assessment with appropriate documentation;
(2) develop a general plan of anesthesia care with the physician or dentist;
(3) select the method for administration of anesthesia or analgesia;
(4) select or administer appropriate medications and anesthetic agents during the peri-anesthetic or peri-analgesic period;
(5) order necessary medications and tests in the peri-anesthetic or peri-analgesic period;
(6) induce and maintain anesthesia or analgesia at the required levels;
(7) support life functions during the peri-anesthetic or peri-analgesic period;
(8) recognize and take appropriate action with respect to patient responses during the peri-anesthetic or peri-analgesic period;
(9) manage the patient's emergence from anesthesia or analgesia; and
(10) participate in the life support of the patient.

(b) Each registered nurse anesthetist may participate in periodic and joint evaluation of services rendered, including, but not limited to, chart reviews, case reviews, patient evaluation and outcome of case statistics.

(c) A registered nurse anesthetist shall perform duties and functions in an interdependent role as a member of a physician or dentist directed health care team.

60-11-102. Roles of advanced practice registered nurses.
The four roles of advanced practice registered nurses licensed by the board of nursing shall be
the following:
(a) Clinical nurse specialist;
(b) nurse anesthetist;
(c) nurse-midwife; and
(d) nurse practitioner.
(Authorized by and implementing K.S.A. 65-1113, as amended by L. 2011, ch. 114, sec. 39, and
K.S.A. 65-1130, as amended by L. 2011, ch. 114, sec. 44; effective May 1, 1984; amended Sept.
4, 2009; amended May 18, 2012.)

60-11-104a. Prescription orders.
(a) Any advanced practice registered nurse may perform the following:
(1) Prescribe durable medical equipment;
(2) prescribe, procure, and administer any drug consistent with the licensee's specific role and
population focus, except any drug that is intended to cause an abortion; and
(3) prescribe, procure, or administer any drug that is a controlled substance in accordance with
the uniform controlled substances act as specified in K.S.A. 65-4101, and amendments thereto.
(b) Each prescription order in written form shall meet the following requirements:
(1) Include the name, address, and telephone number of the practice location of the advanced
practice registered nurse;
(2) be signed by the advanced practice registered nurse with the letters A.P.R.N.; and
(3) contain the D.E.A. registration number issued to the advanced practice registered nurse when
a controlled substance, as defined in K.S.A. 65-4101 and amendments thereto, is prescribed.
(c) Nothing in this regulation shall be construed to prohibit any registered nurse or licensed
practical nurse or advanced practice registered nurse from conveying a prescription order orally
or administering a drug if acting under the lawful direction of a person licensed to practice either
medicine and surgery or dentistry or licensed as an advanced practice registered nurse.
(d) When used in this regulation, terms shall be construed to have the meanings specified in
K.S.A. 65-1626, and amendments thereto.
(Authorized by and implementing K.S.A. 65-1130, as amended by 2022 S Sub for HB 2279, sec.
1; effective, T-60-9-12-88, Sept. 12, 1988; effective Feb. 13, 1989; amended May 7, 1990;
amended Jan. 3, 1995; amended March 31, 2000; amended May 18, 2012; amended, T-60-6-30-
22, July 1, 2022; amended Oct. 14, 2022.)

60-11-105. Functions of the advanced practice registered nurse in the role of nurse-
midwife.
Each advanced practice registered nurse in the role of nurse-midwife shall function in an
advanced role through the application of advanced skills and knowledge of women's health care
through the life span and shall be authorized to perform the following:
(a) Provide independent nursing diagnosis, as defined in K.S.A. 65-1113 and amendments
thereo, and treatment, as defined in K.S.A. 65-1113 and amendments thereto;
(b) develop and manage the medical plan of care for patients or clients;
(c) provide health care services for which the nurse-midwife is educationally prepared and for which competency has been established and maintained. Educational preparation may include academic coursework, workshops, institutes, and seminars if theory or clinical experience, or both, are included;
(d) in a manner consistent with subsection (c), provide health care for women, focusing on gynecological needs, pregnancy, childbirth, the postpartum period, care of the newborn, and family planning, including indicated partner evaluation, treatment, and referral for infertility and sexually transmitted diseases; and
(e) provide innovation in evidence-based nursing practice based upon advanced clinical expertise, decision making, and leadership skills and serve as a consultant, researcher, and patient advocate for individuals, families, groups, and communities to achieve quality, cost-effective patient outcomes and solutions.


60-11-106. Functions of the advanced practice registered nurse; nurse anesthetist.
The functions that may be performed by any advanced practice registered nurse functioning in the advanced role of registered nurse anesthetist shall be those functions defined in K.S.A. 65-1158, and amendments thereto.


60-11-107. Functions of the advanced practice registered nurse in the role of clinical nurse specialist.
Each advanced practice registered nurse in the role of clinical nurse specialist shall function in an advanced role to provide evidence-based nursing practice within a specialty area focused on specific patients or clients, populations, settings, and types of care. Each clinical nurse specialist shall be authorized to perform the following:
(a) Provide independent nursing diagnosis, as defined in K.S.A. 65-1113 and amendments thereto, and treatment, as defined in K.S.A. 65-1113 and amendments thereto;
(b) develop and manage the medical plan of care for patients or clients;
(c) provide health care services for which the clinical nurse specialist is educationally prepared and for which competency has been established and maintained. Educational preparation may include academic coursework, workshops, institutes, and seminars if theory or clinical experience, or both, are included;
(d) provide care for specific patients or clients or specific populations, or both, utilizing a broad base of advanced scientific knowledge, nursing theory, and skills in assessing, planning, implementing, and evaluating health and nursing care; and
(e) provide innovation in evidence-based nursing practice based upon advanced clinical expertise, decision making, and leadership skills and serve as a consultant, researcher, and patient advocate for individuals, families, groups, and communities to achieve quality, cost-effective patient outcomes and solutions. (Authorized by and implementing K.S.A. 2021 Supp. 65-1113 and K.S.A. 65-1130, as amended by 2022 S Sub for HB 2279, sec. 1; effective May 1,
PHYSICIAN ASSISTANT LICENSURE ACT - SELECTED STATUTES

65-28a02. Definitions.
(a) The following words and phrases when used in the physician assistant licensure act shall have the meanings respectively ascribed to them in this section:
(1) "Board" means the state board of healing arts.
(2) "Direction and supervision" means the guidance, direction and coordination of activities of a physician assistant by such physician assistant's supervising physician, whether written or verbal, whether immediate or by prior arrangement, in accordance with standards established by the board by rules and regulations, which standards shall be designed to ensure adequate direction and supervision by the supervising physician of the physician assistant. The term "direction and supervision" shall not be construed to mean that the immediate or physical presence of the supervising physician is required during the performance of the physician assistant.
(3) "Physician" means any person licensed by the state board of healing arts to practice medicine and surgery.
(4) "Physician assistant" means a person who is licensed in accordance with the provisions of K.S.A. 65-28a04, and amendments thereto, and who provides patient services under the direction and supervision of a supervising physician.
(5) "Supervising physician" means prior to January 11, 2016, a responsible physician and on and after January 11, 2016, a physician who has accepted responsibility for the medical services rendered and actions of the physician assistant while performing under the direction and supervision of the supervising physician.
(6) "Responsible physician" means a physician who has accepted continuous and ultimate responsibility for the medical services rendered and actions of the physician assistant while performing under the direction and supervision of the responsible physician.
(7) "Licensee," for purposes of the physician assistant licensure act, means all persons issued a license or temporary license pursuant to the physician assistant licensure act.
(8) "License," for purposes of the physician assistant licensure act, means any license or temporary license granted by the physician assistant licensure act.
(9) "Agreement" means, prior to January 11, 2016, protocol and on and after January 11, 2016, agreement.
(b) Prior to January 11, 2016, wherever the term "supervising physician" in connection with the term "physician assistant," or words of like effect, appears in any statute, contract or other document, it shall mean responsible physician as defined in subsection (a)(6). On and after January 11, 2016, such term shall mean supervising physician as defined in subsection (a)(5).

65-28a08. Practice of physician assistant; direction and supervision of physician; prescription of drugs; identification to patient of physician assistant; rules and regulations; "drug" defined.
(a) The practice of a physician assistant shall include medical services within the education, training and experience of the physician assistant that are delegated by the supervising physician. Physician assistants practice in a dependent role with a supervising physician, and may perform those duties and
responsibilities through delegated authority or written agreement. Medical services rendered by physician assistants may be performed in any setting authorized by the supervising physician, including, but not limited to, clinics, hospitals, ambulatory surgical centers, patient homes, nursing homes and other medical institutions.

(b) (1) A person licensed as a physician assistant may perform, only under the direction and supervision of a physician, acts which constitute the practice of medicine and surgery to the extent and in the manner authorized by the physician responsible for the physician assistant and only to the extent such acts are consistent with rules and regulations adopted by the board which relate to acts performed by a physician assistant under the supervising physician's direction and supervision. A physician assistant may prescribe drugs pursuant to a written agreement as authorized by the supervising physician.

(2) On and after January 11, 2016, a physician assistant, when authorized by a supervising physician, may dispense prescription-only drugs:

(A) In accordance with rules and regulations adopted by the board governing prescription-only drugs;
(B) when dispensing such prescription-only drugs is in the best interests of the patient and pharmacy services are not readily available; and
(C) if such prescription-only drugs do not exceed the quantity necessary for a 72-hour supply.

(c) Before a physician assistant shall perform under the direction and supervision of a supervising physician, such physician assistant shall be identified to the patient and others involved in providing the patient services as a physician assistant to the supervising physician. Physician assistants licensed under the provisions of this act shall keep such person's license available for inspection at their primary place of business. A physician assistant may not perform any act or procedure performed in the practice of optometry except as provided in K.S.A. 65-1508 and 65-2887, and amendments thereto.

(d) (1) The board shall adopt rules and regulations to be effective January 11, 2016, governing the practice of physician assistants, including the delegation, direction and supervision responsibilities of a supervising physician. Such rules and regulations shall establish conditions and limitations as the board determines to be necessary to protect the public health and safety, and may include a limit upon the number of physician assistants that a supervising physician is able to safely and properly supervise. In developing rules and regulations relating to the practice of physician assistants, the board shall take into consideration the amount of training and capabilities of physician assistants, the different practice settings in which physician assistants and supervising physicians practice, the needs of the geographic area of the state in which the physician assistant and the supervising physician practice and the differing degrees of direction and supervision by a supervising physician appropriate for such settings and areas.

(2) The board shall adopt rules and regulations governing the prescribing of drugs by physician assistants and the responsibilities of the supervising physician with respect thereto. Such rules and regulations shall establish such conditions and limitations as the board determines to be necessary to protect the public health and safety. In developing rules and regulations relating to the prescribing of drugs by physician assistants, the board shall take into consideration the amount of training and capabilities of physician assistants, the different practice settings in which physician assistants and supervising physicians practice, the degree of direction and supervision to be provided by a supervising physician and the needs of the geographic area of the state in which the supervising physician's physician assistant and the supervising physician practice. In all cases in which a physician assistant is authorized to prescribe drugs by a supervising physician, a written agreement between the supervising physician and the physician assistant containing the essential terms of such authorization shall be in effect. Any written prescription order shall include the name, address and telephone number of the supervising physician. In no case shall the scope of the authority of the physician assistant to prescribe drugs exceed the normal and customary practice of the supervising physician in the prescribing of drugs.
(e) The physician assistant may request, receive and sign for professional samples and may distribute professional samples to patients pursuant to a written agreement as authorized by the supervising physician. In order to prescribe or dispense controlled substances, the physician assistant shall register with the federal drug enforcement administration.

(f) As used in this section, "drug" means those articles and substances defined as drugs in K.S.A. 65-1626 and 65-4101, and amendments thereto.

(g) Prior to January 11, 2016, the board shall limit the number of physician assistants a responsible physician may supervise at any one time to the equivalent of two full-time physician assistants as approved in each case by the board. Any limitation on the number of physician assistants in this subsection shall not apply to services performed in a medical care facility, as defined in K.S.A. 65-425, and amendments thereto. The provisions of this subsection shall expire on January 11, 2016.  


65-28a09. Responsible and designated physician; notice to board when supervision and direction terminated; forms.

(a) If a supervising physician temporarily leaves such physician's customary location of practice, the supervising physician shall, by prior arrangement, name another supervising physician who shall provide direction and supervision to the physician assistant.

(b) A physician assistant shall not perform professional services unless the name, address and signature of each supervising physician and the form required under subsection (a)(2) of K.S.A. 65-28a03, and amendments thereto, have been provided to the board. A supervising physician and physician assistant shall notify the board when supervision and direction of the physician assistant has terminated. The board shall provide forms for identifying each supervising physician and for giving notice that direction and supervision has terminated. These forms may direct that additional information be provided, including a copy of any written agreements, as required by rules and regulations adopted by the board.


PHYSICIAN ASSISTANT - SELECTED REGULATIONS

100-28a-6. Scope of practice.
Any physician assistant may perform acts that constitute the practice of medicine and surgery as follows:

(a) When directly ordered, authorized, and coordinated by the supervising physician or substitute supervising physician through that individual's physical presence;

(b) when directly ordered, authorized, and coordinated by the supervising physician or substitute supervising physician through verbal or electronic communication;

(c) when authorized by the active practice request form submitted to, the board by the physician assistant and the supervising physician as required by K.A.R. 100-28a-9; or


100-28a-9. Physician request form; content.
The active practice request form submitted by each physician assistant shall contain the following:

(a) The name and license number of the physician assistant;
(b) the name and license number of the supervising physician;
(c) the name and license number of each substitute supervising physician;
(d) information about each practice location, including hospitals and other facilities, which shall include the following:
   (1) The street address and telephone number;
   (2) a description of the type of medical services provided to patients;
   (3) specification of whether the location is a different practice location and, if so, whether the physician assistant has spent at least 80 hours since being licensed under the direct supervision of a physician licensed in this state; and
   (4) the name of each substitute supervising physician who shall provide supervision to the physician assistant at the practice location if the supervising physician is temporarily unavailable;
(e) the written agreement, which shall contain the following information:
   (1) A description of the medical services and procedures that the physician assistant may perform at each practice location;
   (2) a list of any medical services and procedures that the physician assistant is prohibited from performing;
   (3) any types of supervision required for specified medical services and procedures;
   (4) the prescription-only drugs, including controlled substances and professional samples, that the physician assistant is authorized to prescribe, administer, dispense, or distribute;
   (5) any specific exceptions to the physician assistant's authority to prescribe, administer, dispense, or distribute prescription-only drugs, including controlled substances and professional samples;
   (6) a description of the procedure for communication between the supervising physician and the physician assistant if the physician assistant is at a different practice location; and
   (7) a description of the procedure for notifying a substitute supervising physician if the supervising physician is unavailable;
(f) an acknowledgment that the supervising physician or a substitute supervising physician shall be available for communication with the physician assistant at all times during which the physician assistant could reasonably be expected to provide professional services;
(g) an acknowledgment that a current copy of the active practice request form shall be maintained at each practice location and that any amendments to the active practice request form shall be provided to the board within 10 days of being made;
(h) confirmation that the supervising physician has established and implemented a method for the initial, periodic, and annual evaluation of the professional competency of the physician assistant required by K.A.R. 100-28a-10;
(i) confirmation that the medical services and procedures that the physician assistant is authorized to perform are within the clinical competence and customary practice of the supervising physician and all substitute supervising physicians; and
(j) the dated signatures of the physician assistant, supervising physician, and all substitute supervising physicians. (Authorized by and implementing K.S.A. 2015 Supp. 65-28a03 and 65-28a08; effective, T-100-2-13-01, Feb. 13, 2001; effective June 1, 2001; amended, T-100-12-10-15, Jan. 11, 2016; amended May 6, 2016.)

100-28a-13. Prescription-only drugs.
(a) Any physician assistant may administer, prescribe, distribute, or dispense a prescription-only drug pursuant to K.S.A. 65-28a08, and amendments thereto, as authorized by the written agreement required by K.A.R. 100-28a-9 and as authorized by this regulation.

(b) As used in this regulation, "emergency situation" shall have the meaning specified in K.A.R. 68-20-19.

(c) Any physician assistant may directly administer a prescription-only drug as follows:
(1) If directly ordered or authorized by the supervising physician or substitute supervising physician;
(2) if authorized by a written agreement between the supervising physician and the physician assistant; or
(3) if an emergency situation exists.

(d)(1) Any physician assistant may prescribe a schedule II controlled substance in the same manner as that in which the physician assistant may perform acts that constitute the practice of medicine and surgery as specified in K.A.R. 100-28a-6. Except as specified in paragraph (d)(2), each prescription for a schedule II controlled substance shall be in writing.
(2) Any physician assistant may, by oral or telephonic communication, authorize a schedule II controlled substance in an emergency situation. Within seven days after authorizing an emergency prescription order, the physician assistant shall cause a written prescription, completed in accordance with appropriate federal and state laws, to be delivered to the dispenser of the drug.

(e) Any physician assistant may orally, telephonically, electronically, or in writing prescribe a controlled substance listed in schedule III, IV, or V, or a prescription-only drug not listed in any schedule as a controlled substance in the same manner as that in which the physician assistant may perform acts that constitute the practice of medicine and surgery as specified in K.A.R. 100-28a-6.

(f) Each written prescription order by a physician assistant shall meet the following requirements:
(1) Contain the name, address, and telephone number of the supervising physician;
(2) contain the name, address, and telephone number of the physician assistant;
(3) be signed by the physician assistant with the letters "P.A." following the signature; and
(4) contain any DEA registration number issued to the physician assistant if a controlled substance is prescribed.

(g) Any physician assistant may distribute a prescription-only drug to a patient only if all of the following conditions are met:
(1) The drug is distributed under the same conditions as those in which a physician assistant may directly administer a prescription-only drug, as described in subsection (b).
(2) The drug has been provided to the physician assistant or the physician assistant's supervising physician or employer at no cost.
(3) The drug is commercially labeled and is distributed to the patient in the original prepackaged unit-dose container.
(4) The drug is distributed to the patient at no cost.

(h) Any physician assistant may dispense a prescription-only drug to a patient under the limited circumstances specified in K.S.A. 65-28a08, and amendments thereto, in the same manner as that in which the physician assistant may perform acts that constitute the practice of medicine and surgery specified in K.A.R. 100-28a-6.
(i) A physician assistant shall not administer, prescribe, distribute, or dispense a prescription-only drug for any quantity or strength in excess of the normal and customary practice of the supervising physician. (Authorized by K.S.A. 2015 Supp. 65-28a03 and 65-28a08; implementing K.S.A. 2015 Supp. 65-28a08; effective, T-100-2-13-01, Feb. 13, 2001; effective June 1, 2001; amended, T-100-12-10-15, Jan. 11, 2016; amended May 6, 2016.)

100-28a-14. Different practice location.
Any physician assistant may perform acts that constitute the practice of medicine and surgery at a different practice location if all of the following requirements are met:
(a) Before providing any services at the different practice location, the physician assistant shall have spent at least 80 hours since being licensed under the direct supervision of a physician licensed in this state.
(b) The supervising physician or substitute supervising physician shall remain available to provide guidance, direction, and coordination of the activities of the physician assistant. This availability may be provided by electronic means.
(c) The different practice location shall be listed on the active practice request form required by K.A.R. 100-28a-9.
(d) Written notice that the different practice location is staffed primarily by a physician assistant shall be posted in a location where the notice is likely to be seen by patients. (Authorized by K.S.A. 65-28a03 and 65-28a08; implementing K.S.A. 65-28a08; effective, T-100-2-13-01, Feb. 13, 2001; effective June 1, 2001; amended July 22, 2005; amended, T-100-12-10-15, Jan. 11, 2016; amended May 6, 2016; amended March 8, 2019.)

INDEPENDENT PRACTICE OF MIDWIFERY ACT - SELECTED STATUTES

65-28b02. Definitions.
As used in the independent practice of midwifery act:
(a) "Board" means the state board of healing arts.
(b) "Certified nurse-midwife" means an individual who:
(1) Is educated in the two disciplines of nursing and midwifery;
(2) is currently certified by a certifying board approved by the state board of nursing; and
(3) is currently licensed under the Kansas nurse practice act.
(c) "Independent practice of midwifery" means the provision of clinical services by a certified nurse-midwife without the requirement of a collaborative practice agreement with a person licensed to practice medicine and surgery when such clinical services are limited to those associated with a normal, uncomplicated pregnancy and delivery, including:
(1) The prescription of drugs and diagnostic tests;
(2) the performance of episiotomy or repair of a minor vaginal laceration;
(3) the initial care of the normal newborn; and
(4) family planning services, including treatment or referral of male partners for sexually-transmitted infections.
(d) The provisions of this section shall become effective on January 1, 2017.
History: L. 2016, ch. 92, § 89; July 1.

65-28b07. Same; rules and regulations; standards of care.
(a) The board, in consultation with the state board of nursing, shall adopt rules and regulations pertaining to certified nurse-midwives engaging in the independent practice of midwifery and governing the ordering of tests, diagnostic services and prescribing of drugs and referral or transfer to physicians in the event of complications or emergencies. Such rules and regulations shall not be adopted until the state board of nursing and the board have consulted and concurred on the content of each rule and regulation. Such rules and regulations shall be adopted no later than January 1, 2017.

(b) A certified nurse midwife engaging in the independent practice of midwifery shall be subject to the provisions of the independent practice of midwifery act with respect to the ordering of tests, diagnostic services and prescribing of drugs, and shall not be subject to the provisions of K.S.A. 65-1130, and amendments thereto.

(c) The standards of care for certified nurse-midwives in the ordering of tests, diagnostic services and the prescribing of drugs shall be those standards which protect patients and shall be standards comparable to persons licensed to practice medicine and surgery providing the same services.

(d) The board is hereby authorized to solely adopt those rules and regulations necessary to administer the administrative provisions of this act.

History: L. 2016, ch. 92, § 94; July 1.

65-28b10. Same; abortion not authorized.
(a) Nothing in the independent practice of midwifery act should be construed to authorize a certified nurse-midwife engaging in the independent practice of midwifery under such act to perform, induce or prescribe drugs for an abortion.

(b) The provisions of this section shall become effective on January 1, 2017.

History: L. 2016, ch. 92, § 97; July 1.

MIDWIFE - SELECTED REGULATIONS

100-28b-1. Definitions.
As used in this article of the board's regulations, each of the following terms shall have the meaning specified in this regulation:
(a) "Abortion" has the meaning specified in K.S.A. 65-6701, and amendments thereto.
(b) "Antepartum" means occurring in the period that commences when a pregnant woman presents herself to a licensee during pregnancy and ends at the onset of labor.
(c) "Approved national certification" means certification as a certified nurse-midwife by the American midwifery certification board.
(d) "Birthing center" means a facility that provides delivery services for normal, uncomplicated pregnancies. This term shall not include a medical care facility as defined by K.S.A. 65-425, and amendments thereto.
(e) "Family planning services" means the provision of contraceptive methods, preconception health services, and sexually transmitted infection screening and treatment to patients.
(f) "Formal consult" means the process whereby a licensee formally requests a physician's written recommendations for the care and treatment of a patient's identifiable risks.
(g) "Home birth" means an attended birth at a private residence or a location other than a birthing center or hospital.
(h) "Hospital" has the meaning specified in K.S.A. 65-425, and amendments thereto.
(i) "Identifiable risk" means medical history or clinical signs or symptoms that could require clinical services other than those associated with a normal, uncomplicated pregnancy and a normal, uncomplicated delivery.
(j) "Informal consult" means the process whereby a licensee who maintains management responsibility for the patient's care informally requests the advice or opinion of a physician.
(k) "Initial care of a normal newborn" means the clinical services provided to a normal newborn during the first 28 days of life. This term shall include lactation services.
(l) "Intrapartum" means occurring in the period commencing with the onset of labor and ending after the delivery of the placenta.
(m) "Licensee" means an individual licensed by the board to engage in the independent practice of midwifery as defined in K.S.A. 65-28b02, and amendments thereto.
(n) "Minor vaginal laceration" means a tear that extends beyond the fourchette, perineal skin, and vaginal mucosa to perineal muscles and fascia, but not the anal sphincter.
(o) "Newborn" means an infant during the first 28 days of life after birth.
(p) "Normal newborn" means a newborn who has been clinically determined to have no complications or to be at low risk of developing complications.
(q) "Normal, uncomplicated delivery" means delivery of a singleton cephalic vaginal birth that has been clinically determined to be at low risk for complications.
(r) "Normal, uncomplicated pregnancy" means a pregnancy that is initially determined to be at a low risk for a poor pregnancy outcome and that remains at a low risk throughout the pregnancy.
(s) "Patient" means a woman to whom an independent certified nurse-midwife provides clinical services.
(t) "Physician" means an individual licensed to actively practice medicine and surgery or osteopathic medicine and surgery in Kansas.
(u) "Poor pregnancy outcome" means any outcome other than a live, healthy patient.
(v) "Postpartum" means occurring in the period commencing with the delivery of the placenta and ending six weeks after birth.
(w) "Referral" means the process whereby a licensee requests a physician to assume management responsibility for a patient's care.
(x) "Transfer" means the process whereby a licensee or physician accepts management responsibility for a patient's care.
(y) "Transport" means the process whereby a patient is moved from one location to another.

(Authorized by K.S.A. 65-28b07(d); implementing K.S.A. 65-28b02 and 65-28b07(d); effective Jan. 10, 2020.)

VETERINARY MEDICINE - SELECTED REGULATIONS

70-7-1. The practice of veterinary medicine.
Each veterinarian shall meet the following minimum standards in the practice of veterinary medicine:
(a) Storage compartments. Each veterinarian shall maintain clean, orderly, and protective storage compartments for drugs, supplies, and equipment. Refrigeration shall be available for drugs that require it.
(b) Field sterilization. Each veterinarian shall provide a means of sterilizing instruments when practicing veterinary medicine away from a veterinary premises.
(c) Conflict of interest. When representing conflicting interests, including representation of both the buyer and the seller of an animal to be inspected for soundness, the veterinarian shall make full disclosure of the dual relationship and shall obtain documented consent from all parties to the transaction.
(d) Certificates of veterinary inspection. A veterinarian shall not issue a certificate of veterinary inspection unless the veterinarian has personal knowledge, obtained through actual inspection and appropriate tests of the animal, that the animal meets the requirements of the certificate.

(e) Patient acceptance. Each veterinarian shall decide which medical cases will be accepted in the veterinarian's professional capacity and what course of treatment will be followed once a patient has been accepted. The veterinarian shall be responsible for advising the client as to the treatment to be provided.

(f) Control of services. A veterinarian shall not allow any professional services to be controlled or exploited by any lay entity, personal or corporate, that intervenes between the client and the veterinarian. A veterinarian shall not allow a nonlicensed person or entity to interfere with or intervene in the veterinarian's practice of veterinary medicine. Each veterinarian shall be responsible for the veterinarian's own actions and shall be directly responsible to the client for the care and treatment of the patient.

(g) Anesthesia and anesthetic equipment. Each veterinarian shall provide anesthetic services as needed. Each anesthetic agent shall be administered only by a veterinarian or a person trained in its administration under the direct supervision of a licensed veterinarian. Each veterinarian shall use disinfectants capable of eliminating harmful viruses and bacteria for cleaning anesthetic equipment.

(h) Patient records.

(1) Length of maintenance. Each veterinarian shall maintain a patient record for three years from the date of the last visit.

(2) Necessary elements. Each veterinarian shall ensure that all patient records are legible and made contemporaneously with treatment or services rendered. All records shall include the following elements:

(A) Patient identification. Patient identification shall include the patient's name, species, breed, age or date of birth, sex, color, and markings;

(B) Client identification. Client identification shall include the owner's name, home address, and telephone number;

(C) A vaccination record; and

(D) A complete record of the physical examination findings and treatment or services rendered.

(i) Manner of maintenance. Each veterinarian shall maintain records in a manner that will permit any authorized veterinarian to proceed with the care and treatment of the animal, if required, by reading the medical record of that particular patient.

(i) Medication records. The veterinarian shall ensure that each dose of a medication administered is properly recorded on the patient's medical record. All drugs shall be administered and dispensed only upon the order of a licensed veterinarian.

(j) Controlled drugs. The veterinarian shall ensure that a separate written ledger that includes the current quantity on hand is maintained when a controlled drug is administered or dispensed.

(k) Locked area. If controlled drugs are used, the veterinarian shall ensure that a locked area for the storage of controlled substances is provided.

(l) Dispensation of medications for companion animals.

(1) All prescription drugs to be dispensed for use by a companion animal may be dispensed only on the order of a licensed veterinarian who has an existing veterinary-client-patient relationship as defined by the Kansas veterinary practice act. The veterinarian shall ensure that labels will be affixed to any unlabeled container containing any medication dispensed and to each factory-labeled container that contains prescription drugs or controlled substances dispensed for
companion animals. The label shall be affixed to the immediate container and shall include the following information:
(A) The name and address of the veterinarian and, if the drug is a controlled substance, the veterinarian's telephone number;
(B) the date of delivery or dispensing;
(C) the name of the patient, the client's name, and, if the drug is a controlled substance, the client's address;
(D) the species of the animal;
(E) the name, active ingredient, strength, and quantity of the drug dispensed;
(F) directions for use specified by the practitioner, including dosage, frequency, route of administration, and duration of therapy; and
(G) any cautionary statements required by law, including statements indicating that the drug is not for human consumption, is poisonous, or has withdrawal periods associated with the drug. If the size of the immediate container is insufficient to be labeled, the container shall be enclosed within another container large enough to be labeled.
(2) Upon request of a client, each licensed veterinarian shall provide a written prescription for a prescription drug to a client instead of dispensing the prescription drug.
(m) Dispensation of medications for food or commercial animals. All prescription drugs to be dispensed for food used by a food animal or used by a commercial animal may be dispensed only on a written order of a licensed veterinarian with an existing veterinary-client-patient relationship as defined by the Kansas veterinary practice act. That veterinarian shall maintain the original written order on file in the veterinarian's office. A copy of the written order shall be on file with the distributor, and a second copy shall be maintained on the premises of the patient-client. The written order shall include the following information:
(1) The name and address of the veterinarian and, if the drug is a controlled substance, the veterinarian's telephone number;
(2) the date of delivery or dispensing;
(3) the name of the patient, the client's name, and, if the drug is a controlled substance, the client's address;
(4) the species or breed, or both, of the animal;
(5)(A) The established name or active ingredient of each drug or, if formulated from more than one ingredient, the established name of each ingredient; and
(B) the strength and quantity of each drug dispensed; and
(6) directions for use specified by the practitioner, including the following:
(A) The class or species of the animal or animals receiving the drug or some other identification of the animals; and
(B) the dosage, the frequency and route of administration, and duration of therapy; and
(C) any cautionary statements required by law, including statements indicating whether the drug is not for human consumption or is poisonous or whether there are withdrawal periods associated with the drug.
(n) Supervision.
(1) Each veterinarian shall provide direct supervision of any employee or associate of the veterinarian who participates in the practice of veterinary medicine, except that a veterinarian may provide indirect supervision to any person who meets either of the following conditions:
(A) Is following the written instructions for treatment of the animal patient on the veterinary premises; or
(B) has completed three or more years of study in a school of veterinary medicine.

(2) A veterinarian may delegate to an employee or associate of the veterinarian only those activities within the practice of veterinary medicine that are consistent with that person's training, experience, and professional competence. A veterinarian shall not delegate any of the following:
   (A) The activities of diagnosis;
   (B) performance of any surgical procedure; or
   (C) prescription of any drug, medicine, biologic, apparatus, application, anesthesia, or other therapeutic or diagnostic substance or technique.